US11788089B2 - Compositions and methods for modulating MECP2 expression - Google Patents

Compositions and methods for modulating MECP2 expression Download PDF

Info

Publication number
US11788089B2
US11788089B2 US16/876,271 US202016876271A US11788089B2 US 11788089 B2 US11788089 B2 US 11788089B2 US 202016876271 A US202016876271 A US 202016876271A US 11788089 B2 US11788089 B2 US 11788089B2
Authority
US
United States
Prior art keywords
mecp2
oligonucleotide
nucleotide
nucleotides
single stranded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/876,271
Other versions
US20210102203A1 (en
Inventor
Arthur M. Krieg
Romesh R. Subramanian
James McSwiggen
Jeannie T. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Howard Hughes Medical Institute
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/876,271 priority Critical patent/US11788089B2/en
Application filed by General Hospital Corp filed Critical General Hospital Corp
Assigned to RANA THERAPEUTICS, INC. reassignment RANA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KRIEG, ARTHUR M., MCSWIGGEN, JAMES, SUBRAMANIAN, ROMESH
Assigned to HOWARD HUGHES MEDICAL INSTITUTE reassignment HOWARD HUGHES MEDICAL INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEE, JEANNIE T.
Assigned to THE GENERAL HOSPITAL CORPORATION D/B/A/ MASSACHUSETTS GENERAL HOSPITAL reassignment THE GENERAL HOSPITAL CORPORATION D/B/A/ MASSACHUSETTS GENERAL HOSPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOWARD HUGHES MEDICAL INSTITUTE
Assigned to THE GENERAL HOSPITAL CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Translate Bio MA, Inc
Publication of US20210102203A1 publication Critical patent/US20210102203A1/en
Assigned to RANA DEVELOPMENT, INC. reassignment RANA DEVELOPMENT, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: RANA THERAPEUTICS, INC.
Assigned to TRANSLATE BIO MA, INC. reassignment TRANSLATE BIO MA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RANA DEVELOPMENT, INC.
Publication of US11788089B2 publication Critical patent/US11788089B2/en
Application granted granted Critical
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl

Definitions

  • the invention relates to oligonucleotide based compositions, as well as methods of using oligonucleotide based compositions for treating disease.
  • Rett syndrome is a developmental disorder of the brain occurring mostly in females characterized by normal early development, followed by a slowing of development resulting in loss of control of the hands, loss of speech, breathing problems, slowed brain and head growth, ambulatory problems, seizures, and mental retardation. Rett syndrome affects approximately 1 in 10,000 live female births. Most cases of Rett syndrome are caused by a mutation in the methyl CpG binding protein 2, or MECP2 gene, on the X chromosome that causes reduced activity or inactivation of MECP2.
  • MECP2 is a transcriptional repressor that binds to methylated DNA and is present in large quantities in mature nerve cells.
  • MECP2 represses transcription from methylated gene promoters through interaction with histone deacetylase and the corepressor SIN3A.
  • Many of the genes that are known to be regulated by the MECP2 protein play a role in normal brain function, particularly the maintenance of synapses.
  • Mouse studies have demonstrated MECP2 mutations cause defects in synaptic function, especially in synaptic plasticity.
  • single stranded oligonucleotides are provided that target a PRC2-associated region of a MECP2 gene (e.g., human MECP2) and thereby cause upregulation of the gene.
  • single stranded oligonucleotides are provided that target a PRC2-associated region of the gene encoding MECP2.
  • these single stranded oligonucleotides activate or enhance expression of MECP2 by relieving or preventing PRC2 mediated repression of MECP2.
  • Upregulation of MECP2 offers a treatment for diseases associated with decreased MECP2 activity.
  • Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 for the treatment and/or prevention of Rett Syndrome.
  • MECP2 is also associated with MECP2-related severe neonatal encephalopathy, Angelman syndrome, and PPM-X syndrome. Accordingly, certain aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 for the treatment and/or prevention of MECP2-related severe neonatal encephalopathy, Angelman syndrome, and PPM-X syndrome.
  • Further aspects of the invention provide methods for selecting oligonucleotides for activating or enhancing expression of MECP2.
  • methods are provided for selecting a set of oligonucleotides that is enriched in candidates (e.g., compared with a random selection of oligonucleotides) for activating or enhancing expression of MECP2. Accordingly, the methods may be used to establish sets of clinical candidates that are enriched in oligonucleotides that activate or enhance expression of MECP2.
  • Such libraries may be utilized, for example, to identify lead oligonucleotides for developing therapeutics to treat MECP2.
  • oligonucleotide chemistries are provided that are useful for controlling the pharmacokinetics, biodistribution, bioavailability and/or efficacy of the single stranded oligonucleotides for activating expression of MECP2.
  • single stranded oligonucleotides that have a region of complementarity that is complementarity with (e.g., at least 8 consecutive nucleotides of) a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2.
  • the oligonucleotide has at least one of the following features: a) a sequence that is 5′X-Y-Z, in which X is any nucleotide and in which X is at the 5′ end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length; b) a sequence that does not comprise three or more consecutive guanosine nucleotides; c) a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length to the second nucleotide sequence, that are between 50 kilobases upstream of a 5′-end of an off-target gene and 50 kilobases downstream of a 3′-end of the off-target gene; d) a sequence that is complementary to a PRC2-
  • the single stranded oligonucleotide has at least two of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least three of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least four of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has each of features a), b), c), d), and e). In certain embodiments, the oligonucleotide has the sequence 5′X-Y-Z, in which the oligonucleotide is 8-50 nucleotides in length.
  • single stranded oligonucleotides have a sequence X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2.
  • single stranded oligonucleotides have a sequence 5′-X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2.
  • Y is a sequence selected from Table 1.
  • the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 5 to 118.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660, or a fragment thereof that is at least 8 nucleotides.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660, in which the 5′ end of the nucleotide sequence provided is the 5′ end of the oligonucleotide.
  • the region of complementarity e.g., the at least 8 consecutive nucleotides is also present within the nucleotide sequence set forth as SEQ ID NO: 3 or 4.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660.
  • the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 5 to 84.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 47653 or a fragment thereof that is at least 8 nucleotides.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 47653, wherein the 5′ end of the nucleotide sequence provided in any one of SEQ ID NOS: 119 to 47653 is the 5′ end of the oligonucleotide.
  • the at least 8 consecutive nucleotides are also present within the nucleotide sequence set forth as SEQ ID NO: 3.
  • the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 85 to 118.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 47462 to 83660 or a fragment thereof that is at least 8 nucleotides.
  • the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 47462 to 83660, wherein the 5′ end of the nucleotide sequence provided in any one of SEQ ID NOS: 47462 to 83660 is the 5′ end of the oligonucleotide.
  • the at least 8 consecutive nucleotides are present within the nucleotide sequence set forth as SEQ ID NO: 4.
  • a single stranded oligonucleotide comprises a nucleotide sequence as set forth in Table 3. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in Table 3. In some embodiments, a single stranded oligonucleotide consists of a nucleotide sequence as set forth in Table 3.
  • the single stranded oligonucleotide does not comprise three or more consecutive guanosine nucleotides. In some embodiments, the single stranded oligonucleotide does not comprise four or more consecutive guanosine nucleotides.
  • the single stranded oligonucleotide is 8 to 30 nucleotides in length. In some embodiments, the single stranded oligonucleotide is up to 50 nucleotides in length. In some embodiments, the single stranded oligonucleotide is 8 to 10 nucleotides in length and all but 1, 2, or 3 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides.
  • the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of a nucleotide sequence set forth as SEQ ID NO: 1 or 2, in which the nucleotide sequence of the single stranded oligonucleotide comprises one or more of a nucleotide sequence selected from the group consisting of
  • At least one nucleotide of the oligonucleotide is a nucleotide analogue.
  • the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
  • At least one nucleotide of the oligonucleotide comprises a 2′ O-methyl. In some embodiments, each nucleotide of the oligonucleotide comprises a 2′ O-methyl. In some embodiments, the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide. In some embodiments, the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide. In some embodiments, each nucleotide of the oligonucleotide is a LNA nucleotide.
  • the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′-O-methyl nucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and ENA nucleotide analogues. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and LNA nucleotides.
  • the 5′ nucleotide of the oligonucleotide is a deoxyribonucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise alternating LNA nucleotides and 2′-O-methyl nucleotides. In some embodiments, the 5′ nucleotide of the oligonucleotide is a LNA nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one LNA nucleotide on each of the 5′ and 3′ ends of the deoxyribonucleotides.
  • the single stranded oligonucleotide comprises modified internucleotide linkages (e.g., phosphorothioate internucleotide linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleotides. In some embodiments, the single stranded oligonucleotide comprises modified internucleotide linkages (e.g., phosphorothioate internucleotide linkages or other linkages) between all nucleotides.
  • modified internucleotide linkages e.g., phosphorothioate internucleotide linkages or other linkages
  • the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group. In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ thiophosphate. In some embodiments, the single stranded oligonucleotide has a biotin moiety or other moiety conjugated to its 5′ or 3′ nucleotide.
  • the single stranded oligonucleotide has cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5′ or 3′ end.
  • compositions are provided that comprise any of the oligonucleotides disclosed herein, and a carrier.
  • compositions are provided that comprise any of the oligonucleotides in a buffered solution.
  • the oligonucleotide is conjugated to the carrier.
  • the carrier is a peptide.
  • the carrier is a steroid.
  • pharmaceutical compositions are provided that comprise any of the oligonucleotides disclosed herein, and a pharmaceutically acceptable carrier.
  • kits that comprise a container housing any of the compositions disclosed herein.
  • methods of increasing expression of MECP2 in a cell involve delivering any one or more of the single stranded oligonucleotides disclosed herein into the cell.
  • delivery of the single stranded oligonucleotide into the cell results in a level of expression of MECP2 that is greater (e.g., at least 50% greater) than a level of expression of MECP2 in a control cell that does not comprise the single stranded oligonucleotide.
  • methods of increasing levels of MECP2 in a subject are provided.
  • methods of treating a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
  • the methods involve administering any one or more of the single stranded oligonucleotides disclosed herein to the subject.
  • Table 3 Formatted oligonucleotide sequences made for testing showing nucleotide modifications.
  • the table shows the sequence of the modified nucleotides, where InaX represents an LNA nucleotide with 3′ phosphorothioate linkage, omeX is a 2′-O-methyl nucleotide, dX is a deoxy nucleotide.
  • An s at the end of a nucleotide code indicates that the nucleotide had a 3′ phosphorothioate linkage.
  • the “ ⁇ Sup” at the end of the sequence marks the fact that the 3′ end lacks either a phosphate or thiophosphate on the 3′ linkage.
  • the Formatted Sequence column shows the sequence of the oligonucleotide, including modified nucleotides.
  • Polycomb repressive complex 2 (PRC2) is a histone methyltransferase and a known epigenetic regulator involved in silencing of genomic regions through methylation of histone H3.
  • PRC2 interacts with long noncoding RNAs (lncRNAs), such as RepA, Xist, and Tsix, to catalyze trimethylation of histone H3-lysine27.
  • lncRNAs long noncoding RNAs
  • RepA long noncoding RNAs
  • Xist Xist
  • Tsix long noncoding RNAs
  • PRC2 contains four subunits, Eed, Suz12, RbAp48, and Ezh2.
  • aspects of the invention relate to the recognition that single stranded oligonucleotides that bind to PRC2-associated regions of RNAs (e.g., lncRNAs) that are expressed from within a genomic region that encompasses or that is in functional proximity to the MECP2 gene can induce or enhance expression of MECP2. In some embodiments, this upregulation is believed to result from inhibition of PRC2 mediated repression of MECP2.
  • RNAs e.g., lncRNAs
  • PRC2-associated region refers to a region of a nucleic acid that comprises or encodes a sequence of nucleotides that interact directly or indirectly with a component of PRC2.
  • a PRC2-associated region may be present in a RNA (e.g., a long non-coding RNA (lncRNA)) that that interacts with a PRC2.
  • lncRNA long non-coding RNA
  • a PRC2-associated region may be present in a DNA that encodes an RNA that interacts with PRC2. In some cases, the PRC2-associated region is equivalently referred to as a PRC2-interacting region.
  • a PRC2-associated region is a region of an RNA that crosslinks to a component of PRC2 in response to in situ ultraviolet irradiation of a cell that expresses the RNA, or a region of genomic DNA that encodes that RNA region.
  • a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region.
  • a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4 (which as noted above are components of PRC2), or a region of genomic DNA that encodes that RNA region.
  • a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g., RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that protected RNA region.
  • a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g., RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region.
  • a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region.
  • a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region.
  • the PRC2-associated region may be referred to as a “peak.”
  • a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that interact with PRC2 complex. In some embodiments, a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that encode an RNA that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5 kb in length that comprises a sequence (e.g., of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5 kb in length within which an RNA is encoded that has a sequence (e.g., of 40 to 60 nucleotides) that is known to interact with PRC2.
  • a PRC2-associated region comprises a sequence of about 4 kb in length that comprise a sequence (e.g., of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of about 4 kb in length within which an RNA is encoded that includes a sequence (e.g., of 40 to 60 nucleotides) that is known to interact with PRC2. In some embodiments, a PRC2-associated region has a sequence as set forth in any one of SEQ ID NOS: 5 to 118.
  • single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region in a genomic region that encompasses or that is in proximity to the MECP2 gene. In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 5 to 118.
  • single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 5 to 118 combined with up to 2 kb, up to 5 kb, or up to 10 kb of flanking sequences from a corresponding genomic region to which these SEQ IDs map (e.g., in a human genome).
  • single stranded oligonucleotides have a sequence as set forth in any one of SEQ ID NOS: 119 to 83660.
  • single stranded oligonucleotides have a sequence as set forth in Table 3.
  • these oligonucleotides are able to interfere with the binding of and function of PRC2, by preventing recruitment of PRC2 to a specific chromosomal locus.
  • a single administration of single stranded oligonucleotides designed to specifically bind a PRC2-associated region lncRNA can stably displace not only the lncRNA, but also the PRC2 that binds to the lncRNA, from binding chromatin. After displacement, the full complement of PRC2 is not recovered for up to 24 hours.
  • lncRNA can recruit PRC2 in a cis fashion, repressing gene expression at or near the specific chromosomal locus from which the lncRNA was transcribed.
  • Methods of modulating gene expression are provided, in some embodiments, that may be carried out in vitro, ex vivo, or in vivo. It is understood that any reference to uses of compounds throughout the description contemplates use of the compound in preparation of a pharmaceutical composition or medicament for use in the treatment of condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels or activity of MECP2.
  • condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
  • this aspect of the invention includes use of such single stranded oligonucleotides in the preparation of a medicament for use in the treatment of disease, wherein the treatment involves upregulating expression of MECP2.
  • methods are provided for selecting a candidate oligonucleotide for activating expression of MECP2.
  • the methods generally involve selecting as a candidate oligonucleotide, a single stranded oligonucleotide comprising a nucleotide sequence that is complementary to a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 5 to 118).
  • sets of oligonucleotides may be selected that are enriched (e.g., compared with a random selection of oligonucleotides) in oligonucleotides that activate expression of MECP2.
  • single stranded oligonucleotides complementary to the PRC2-associated regions are provided for modulating expression of MECP2 in a cell.
  • expression of MECP2 is upregulated or increased.
  • single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts such that gene expression is upregulated or increased.
  • single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts, resulting in reduced methylation of histone H3 and reduced gene inactivation, such that gene expression is upregulated or increased.
  • this interaction may be disrupted or inhibited due to a change in the structure of the long RNA that prevents or reduces binding to PRC2.
  • the oligonucleotide may be selected using any of the methods disclosed herein for selecting a candidate oligonucleotide for activating expression of MECP2.
  • the single stranded oligonucleotide may comprise a region of complementarity that is complementary with a PRC2-associated region of a nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4.
  • the region of complementarity of the single stranded oligonucleotide may be complementary with at least 6, e.g., at least 7, at least 8, at least 9, at least 10, at least 15 or more consecutive nucleotides of the PRC2-associated region.
  • the PRC2-associated region may map to a position in a chromosome between 50 kilobases upstream of a 5′-end of the MECP2 gene and 50 kilobases downstream of a 3′-end of the MECP2 gene.
  • the PRC2-associated region may map to a position in a chromosome between 25 kilobases upstream of a 5′-end of the MECP2 gene and 25 kilobases downstream of a 3′-end of the MECP2 gene.
  • the PRC2-associated region may map to a position in a chromosome between 12 kilobases upstream of a 5′-end of the MECP2 gene and 12 kilobases downstream of a 3′-end of the MECP2 gene.
  • the PRC2-associated region may map to a position in a chromosome between 5 kilobases upstream of a 5′-end of the MECP2 gene and 5 kilobases downstream of a 3′-end of the ME
  • the genomic position of the selected PRC2-associated region relative to the MECP2 gene may vary.
  • the PRC2-associated region may be upstream of the 5′ end of the MECP2 gene.
  • the PRC2-associated region may be downstream of the 3′ end of the MECP2 gene.
  • the PRC2-associated region may be within an intron of the MECP2 gene.
  • the PRC2-associated region may be within an exon of the MECP2 gene.
  • the PRC2-associated region may traverse an intron-exon junction, a 5′-UTR-exon junction or a 3′-UTR-exon junction of the MECP2 gene.
  • the single stranded oligonucleotide may comprise a sequence having the formula X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of varying length.
  • X is the 5′ nucleotide of the oligonucleotide.
  • the oligonucleotide when X is anchored at the 5′ end of the oligonucleotide, the oligonucleotide does not have any nucleotides or nucleotide analogs linked 5′ to X.
  • the single stranded oligonucleotide has a sequence 5′X-Y-Z and is 8-50 nucleotides in length. Oligonucleotides that have these sequence characteristics are predicted to avoid the miRNA pathway. Therefore, in some embodiments, oligonucleotides having these sequence characteristics are unlikely to have an unintended consequence of functioning in a cell as a miRNA molecule.
  • the Y sequence may be a nucleotide sequence of 6 nucleotides in length set forth in Table 1.
  • the single stranded oligonucleotide may have a sequence that does not contain guanosine nucleotide stretches (e.g., 3 or more, 4 or more, 5 or more, 6 or more consecutive guanosine nucleotides).
  • guanosine nucleotide stretches e.g., 3 or more, 4 or more, 5 or more, 6 or more consecutive guanosine nucleotides.
  • oligonucleotides having guanosine nucleotide stretches have increased non-specific binding and/or off-target effects, compared with oligonucleotides that do not have guanosine nucleotide stretches.
  • the single stranded oligonucleotide may have a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length, that map to a genomic position encompassing or in proximity to an off-target gene.
  • a threshold level of sequence identity may be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity.
  • the single stranded oligonucleotide may have a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops.
  • oligonucleotides that are complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising one or more single stranded loops e.g., at least two single stranded loops
  • have a greater likelihood of being active e.g., of being capable of activating or enhancing expression of a target gene than a randomly selected oligonucleotide.
  • the secondary structure may comprise a double stranded stem between the at least two single stranded loops.
  • the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of at least one of the loops.
  • the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2-associated region that encodes at least a portion of at least two of the loops.
  • the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of the double stranded stem.
  • a PRC2-associated region e.g., of an lncRNA
  • the predicted secondary structure RNA (e.g., lncRNA) containing the PRC2-associated region is determined using RNA secondary structure prediction algorithms, e.g., RNAfold, mfold.
  • oligonucleotides are designed to target a region of the RNA that forms a secondary structure comprising one or more single stranded loop (e.g., at least two single stranded loops) structures which may comprise a double stranded stem between the at least two single stranded loops.
  • a single stranded loop e.g., at least two single stranded loops
  • the single stranded oligonucleotide may have a sequence that is has greater than 30% G-C content, greater than 40% G-C content, greater than 50% G-C content, greater than 60% G-C content, greater than 70% G-C content, or greater than 80% G-C content.
  • the single stranded oligonucleotide may have a sequence that has up to 100% G-C content, up to 95% G-C content, up to 90% G-C content, or up to 80% G-C content.
  • the oligonucleotide is 8 to 10 nucleotides in length, all but 1, 2, 3, 4, or 5 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides.
  • the sequence of the PRC2-associated region to which the single stranded oligonucleotide is complementary comprises no more than 3 nucleotides selected from adenine and uracil.
  • the single stranded oligonucleotide may be complementary to a chromosome of a different species (e.g., a mouse, rat, rabbit, goat, monkey, etc.) at a position that encompasses or that is in proximity to that species' homolog of MECP2.
  • the single stranded oligonucleotide may be complementary to a human genomic region encompassing or in proximity to the MECP2 gene and also be complementary to a mouse genomic region encompassing or in proximity to the mouse homolog of MECP2.
  • the single stranded oligonucleotide may be complementary to a sequence as set forth in SEQ ID NO: 1 or 2, which is a human genomic region encompassing or in proximity to the MECP2 gene, and also be complementary to a sequence as set forth in SEQ ID NO: 3 or 4, which is a mouse genomic region encompassing or in proximity to the mouse homolog of the MECP2 gene. Oligonucleotides having these characteristics may be tested in vivo or in vitro for efficacy in multiple species (e.g., human and mouse). This approach also facilitates development of clinical candidates for treating human disease by selecting a species in which an appropriate animal exists for the disease.
  • the region of complementarity of the single stranded oligonucleotide is complementary with at least 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 bases, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides of a PRC2-associated region.
  • the region of complementarity is complementary with at least 8 consecutive nucleotides of a PRC2-associated region.
  • sequence of the single stranded oligonucleotide is based on an RNA sequence that binds to PRC2, or a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 bases, or about 5 to 15, or about 5 to 30, or about 5 to 40 bases, or about 5 to 50 bases.
  • Complementary refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of PRC2-associated region, then the single stranded nucleotide and PRC2-associated region are considered to be complementary to each other at that position.
  • the single stranded nucleotide and PRC2-associated region are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases.
  • complementary is a term which is used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the single stranded nucleotide and PRC2-associated region. For example, if a base at one position of a single stranded nucleotide is capable of hydrogen bonding with a base at the corresponding position of a PRC2-associated region, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.
  • the single stranded oligonucleotide may be at least 80% complementary to (optionally one of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the consecutive nucleotides of a PRC2-associated region.
  • the single stranded oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of a PRC2-associated region.
  • the single stranded oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.
  • a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable.
  • a complementary nucleic acid sequence for purposes of the present disclosure is specifically hybridizable when binding of the sequence to the target molecule (e.g., lncRNA) interferes with the normal function of the target (e.g., lncRNA) to cause a loss of activity (e.g., inhibiting PRC2-associated repression with consequent up-regulation of gene expression) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency.
  • the single stranded oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or more nucleotides in length. In a preferred embodiment, the oligonucleotide is 8 to 30 nucleotides in length.
  • the PRC2-associated region occurs on the same DNA strand as a gene sequence (sense). In some embodiments, the PRC2-associated region occurs on the opposite DNA strand as a gene sequence (anti-sense). Oligonucleotides complementary to a PRC2-associated region can bind either sense or anti-sense sequences.
  • Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing).
  • adenosine-type bases are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T.
  • Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.
  • any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be replaced with any other nucleotide suitable for base pairing (e.g., via a Watson-Crick base pair) with an adenosine nucleotide.
  • any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be suitably replaced with a different pyrimidine nucleotide or vice versa.
  • any one or more thymidine (T) nucleotides (or modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing may be suitably replaced with a uridine (U) nucleotide (or a modified nucleotide thereof) or vice versa.
  • GC content of the single stranded oligonucleotide is preferably between about 30-60%. Contiguous runs of three or more Gs or Cs may not be preferable in some embodiments. Accordingly, in some embodiments, the oligonucleotide does not comprise a stretch of three or more guanosine nucleotides.
  • the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome) as a single contiguous transcript (e.g., a non-spliced RNA).
  • a genome e.g., a human genome
  • a single contiguous transcript e.g., a non-spliced RNA
  • the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome), in which the distance in the genome between the 5′end of the coding region of the RNA and the 3′ end of the coding region of the RNA is less than 1 kb, less than 2 kb, less than 3 kb, less than 4 kb, less than 5 kb, less than 7 kb, less than 8 kb, less than 9 kb, less than 10 kb, or less than 20 kb.
  • a genome e.g., a human genome
  • any oligonucleotide provided herein can be excluded.
  • single stranded oligonucleotides disclosed herein may increase expression of mRNA corresponding to the gene by at least about 50% (i.e. 150% of normal or 1.5 fold), or by about 2 fold to about 5 fold.
  • expression may be increased by at least about 15 fold, 20 fold, 30 fold, 40 fold, 50 fold or 100 fold, or any range between any of the foregoing numbers. It has also been found that increased mRNA expression has been shown to correlate to increased protein expression.
  • the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to the PRC2 binding RNA that is transcribed from the same strand as a protein coding reference gene.
  • the oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein coding sense strand of a reference gene (refGene).
  • the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to a PRC2 binding RNA that transcribed from the opposite strand (the antisense strand) of a protein coding reference gene.
  • the oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein coding antisense strand of a reference gene
  • the oligonucleotides described herein may be modified, e.g., comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof.
  • the oligonucleotides can exhibit one or more of the following properties: do not induce substantial cleavage or degradation of the target RNA; do not cause substantially complete cleavage or degradation of the target RNA; do not activate the RNAse H pathway; do not activate RISC; do not recruit any Argonaute family protein; are not cleaved by Dicer; do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; may have improved endosomal exit; do interfere with interaction of lncRNA with PRC2, preferably the Ezh2 subunit but optionally the Suz12, Eed, RbAp46/48 sub
  • Oligonucleotides that are designed to interact with RNA to modulate gene expression are a distinct subset of base sequences from those that are designed to bind a DNA target (e.g., are complementary to the underlying genomic DNA sequence from which the RNA is transcribed).
  • oligonucleotides disclosed herein may be linked to one or more other oligonucleotides disclosed herein by a linker, e.g., a cleavable linker.
  • a linker e.g., a cleavable linker.
  • the target selection methods may generally involve steps for selecting single stranded oligonucleotides having any of the structural and functional characteristics disclosed herein.
  • the methods involve one or more steps aimed at identifying oligonucleotides that target a PRC2-associated region that is functionally related to MECP2, for example a PRC2-associated region of a lncRNA that regulates expression of MECP2 by facilitating (e.g., in a cis-regulatory manner) the recruitment of PRC2 to the MECP2 gene.
  • Such oligonucleotides are expected to be candidates for activating expression of MECP2 because of their ability to hybridize with the PRC2-associated region of a nucleic acid (e.g., a lncRNA).
  • this hybridization event is understood to disrupt interaction of PRC2 with the nucleic acid (e.g., a lncRNA) and as a result disrupt recruitment of PRC2 and its associated co-repressors (e.g., chromatin remodeling factors) to the MECP2 gene locus.
  • Methods of selecting a candidate oligonucleotide may involve selecting a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 5 to 118) that maps to a chromosomal position encompassing or in proximity to the MECP2 gene (e.g., a chromosomal position having a sequence as set forth in any one of SEQ ID NOS: 1 to 4).
  • the PRC2-associated region may map to the strand of the chromosome comprising the sense strand of the MECP2 gene, in which case the candidate oligonucleotide is complementary to the sense strand of the MECP2 gene (i.e., is antisense to the MECP2 gene).
  • the PRC2-associated region may map to the strand of the first chromosome comprising the antisense strand of the MECP2 gene, in which case the oligonucleotide is complementary to the antisense strand (the template strand) of the MECP2 gene (i.e., is sense to the MECP2 gene).
  • Methods for selecting a set of candidate oligonucleotides that is enriched in oligonucleotides that activate expression of MECP2 may involve selecting one or more PRC2-associated regions that map to a chromosomal position that encompasses or that is in proximity to the MECP2 gene and selecting a set of oligonucleotides, in which each oligonucleotide in the set comprises a nucleotide sequence that is complementary with the one or more PRC2-associated regions.
  • a set of oligonucleotides that is enriched in oligonucleotides that activate expression of refers to a set of oligonucleotides that has a greater number of oligonucleotides that activate expression of a target gene (e.g., MECP2) compared with a random selection of oligonucleotides of the same physicochemical properties (e.g., the same GC content, T m , length etc.) as the enriched set.
  • design and/or synthesis of a single stranded oligonucleotide involves design and/or synthesis of a sequence that is complementary to a nucleic acid or PRC2-associated region described by such sequence information
  • the skilled person is readily able to determine the complementary sequence, e.g., through understanding of Watson Crick base pairing rules which form part of the common general knowledge in the field.
  • design and/or synthesis of a single stranded oligonucleotide involves manufacture of an oligonucleotide from starting materials by techniques known to those of skill in the art, where the synthesis may be based on a sequence of a PRC2-associated region, or portion thereof.
  • Methods of design and/or synthesis of a single stranded oligonucleotide may involve one or more of the steps of:
  • Single stranded oligonucleotides so designed and/or synthesized may be useful in method of modulating gene expression as described herein.
  • oligonucleotides of the invention are synthesized chemically.
  • Oligonucleotides used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques.
  • Oligonucleotides of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification.
  • nucleic acid sequences of the invention include a phosphorothioate at least the first, second, or third internucleotide linkage at the 5′ or 3′ end of the nucleotide sequence.
  • the nucleic acid sequence can include a 2′-modified nucleotide, e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or 2′-O—N-methylacetamido (2′-O-NMA).
  • a 2′-modified nucleotide e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MO
  • the nucleic acid sequence can include at least one 2′-O-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2′-O-methyl modification.
  • the nucleic acids are “locked,” i.e., comprise nucleic acid analogues in which the ribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom.
  • the method may further comprise the steps of amplifying the synthesized single stranded oligonucleotide, and/or purifying the single stranded oligonucleotide (or amplified single stranded oligonucleotide), and/or sequencing the single stranded oligonucleotide so obtained.
  • the process of preparing a single stranded oligonucleotide may be a process that is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene associated with a PRC2-associated region.
  • a PRC2-associated region may be, or have been, identified, or obtained, by a method that involves identifying RNA that binds to PRC2.
  • Such methods may involve the following steps: providing a sample containing nuclear ribonucleic acids, contacting the sample with an agent that binds specifically to PRC2 or a subunit thereof, allowing complexes to form between the agent and protein in the sample, partitioning the complexes, synthesizing nucleic acid that is complementary to nucleic acid present in the complexes.
  • single stranded oligonucleotide is based on a PRC2-associated region, or a portion of such a sequence, it may be based on information about that sequence, e.g., sequence information available in written or electronic form, which may include sequence information contained in publicly available scientific publications or sequence databases.
  • the oligonucleotide may comprise at least one ribonucleotide, at least one deoxyribonucleotide, and/or at least one bridged nucleotide.
  • the oligonucleotide may comprise a bridged nucleotide, such as a locked nucleic acid (LNA) nucleotide, a constrained ethyl (cEt) nucleotide, or an ethylene bridged nucleic acid (ENA) nucleotide. Examples of such nucleotides are disclosed herein and known in the art.
  • the oligonucleotide comprises a nucleotide analog disclosed in one of the following United States Patent or Patent Application Publications: U.S. Pat. Nos. 7,399,845, 7,741,457, 8,022,193, 7,569,686, 7,335,765, 7,314,923, 7,335,765, and U.S. Pat. No. 7,816,333, US 20110009471, the entire contents of each of which are incorporated herein by reference for all purposes.
  • the oligonucleotide may have one or more 2′ O-methyl nucleotides.
  • the oligonucleotide may consist entirely of 2′ O-methyl nucleotides.
  • the single stranded oligonucleotide has one or more nucleotide analogues.
  • the single stranded oligonucleotide may have at least one nucleotide analogue that results in an increase in T m of the oligonucleotide in a range of 1° C., 2° C., 3° C., 4° C., or 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
  • the single stranded oligonucleotide may have a plurality of nucleotide analogues that results in a total increase in T m of the oligonucleotide in a range of 2° C., 3° C., 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 15° C., 20° C., 25° C., 30° C., 35° C., 40° C., 45° C. or more compared with an oligonucleotide that does not have the nucleotide analogue.
  • the oligonucleotide may be of up to 50 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides of the oligonucleotide are nucleotide analogues.
  • the oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides of the oligonucleotide are nucleotide analogues.
  • the oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides of the oligonucleotide are nucleotide analogues.
  • the oligonucleotides may have every nucleotide except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides modified.
  • the oligonucleotide may consist entirely of bridged nucleotides (e.g., LNA nucleotides, cEt nucleotides, ENA nucleotides).
  • the oligonucleotide may comprise alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides.
  • the oligonucleotide may comprise alternating deoxyribonucleotides and 2′-O-methyl nucleotides.
  • the oligonucleotide may comprise alternating deoxyribonucleotides and ENA nucleotide analogues.
  • the oligonucleotide may comprise alternating deoxyribonucleotides and LNA nucleotides.
  • the oligonucleotide may comprise alternating LNA nucleotides and 2′-O-methyl nucleotides.
  • the oligonucleotide may have a 5′ nucleotide that is a bridged nucleotide (e.g., a LNA nucleotide, cEt nucleotide, ENA nucleotide).
  • the oligonucleotide may have a 5′ nucleotide that is a deoxyribonucleotide.
  • the oligonucleotide may comprise deoxyribonucleotides flanked by at least one bridged nucleotide (e.g., a LNA nucleotide, cEt nucleotide, ENA nucleotide) on each of the 5′ and 3′ ends of the deoxyribonucleotides.
  • the oligonucleotide may comprise deoxyribonucleotides flanked by 1, 2, 3, 4, 5, 6, 7, 8 or more bridged nucleotides (e.g., LNA nucleotides, cEt nucleotides, ENA nucleotides) on each of the 5′ and 3′ ends of the deoxyribonucleotides.
  • the 3′ position of the oligonucleotide may have a 3′ hydroxyl group.
  • the 3′ position of the oligonucleotide may have a 3′ thiophosphate.
  • the oligonucleotide may be conjugated with a label.
  • the oligonucleotide may be conjugated with a biotin moiety, cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5′ or 3′ end.
  • the single stranded oligonucleotide comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.
  • the single stranded oligonucleotides are chimeric oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide.
  • These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
  • Chimeric single stranded oligonucleotides of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, U.S. Pat. Nos.
  • the single stranded oligonucleotide comprises at least one nucleotide modified at the 2′ position of the sugar, most preferably a 2′-O-alkyl, 2′-O-alkyl-O-alkyl or 2′-fluoro-modified nucleotide.
  • RNA modifications include 2′-fluoro, 2′-amino and 2′ O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3′ end of the RNA.
  • modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages.
  • oligonucleotides with phosphorothioate backbones and those with heteroatom backbones particularly CH 2 —NH—O—CH 2 , CH, ⁇ N(CH 3 ) ⁇ O ⁇ CH 2 (known as a methylene(methylimino) or MMI backbone, CH 2 —O—N (CH 3 )—CH 2 , CH 2 —N (CH 3 )—N (CH 3 )—CH 2 and O—N (CH 3 )—CH 2 —CH 2 backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH); amide backbones (see De Mesmaeker et al. Ace. Chem. Res.
  • PNA peptide nucleic acid
  • Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3′alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′; see U.S.
  • Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991.
  • the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).
  • PMO phosphorodiamidate morpholino oligomer
  • Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 2000, 122, 8595-8602.
  • Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
  • These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts; see U.S. Pat. Nos.
  • Modified oligonucleotides are also known that include oligonucleotides that are based on or constructed from arabinonucleotide or modified arabinonucleotide residues.
  • Arabinonucleosides are stereoisomers of ribonucleosides, differing only in the configuration at the 2′-position of the sugar ring.
  • a 2′-arabino modification is 2′-F arabino.
  • the modified oligonucleotide is 2′-fluoro-D-arabinonucleic acid (FANA) (as described in, for example, Lon et al., Biochem., 41:3457-3467, 2002 and Min et al., Bioorg. Med. Chem. Lett., 12:2651-2654, 2002; the disclosures of which are incorporated herein by reference in their entireties). Similar modifications can also be made at other positions on the sugar, particularly the 3′ position of the sugar on a 3′ terminal nucleoside or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide.
  • FANA 2′-fluoro-D-arabinonucleic acid
  • WO 99/67378 discloses arabinonucleic acids (ANA) oligomers and their analogues for improved sequence specific inhibition of gene expression via association to complementary messenger RNA.
  • ENAs ethylene-bridged nucleic acids
  • Preferred ENAs include, but are not limited to, 2′-O,4′-C-ethylene-bridged nucleic acids.
  • LNAs examples include compounds of the following general formula.
  • R is selected from hydrogen and C 1-4 -alkyl
  • Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group
  • B constitutes a natural or non-natural nucleotide base moiety
  • the asymmetric groups may be found in either orientation.
  • the LNA used in the oligonucleotides described herein comprises at least one LNA unit according any of the formulas
  • Y is —O—, —S—, —NH—, or N(R H );
  • Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group;
  • B constitutes a natural or non-natural nucleotide base moiety, and
  • RH is selected from hydrogen and C 1-4 -alkyl.
  • the Locked Nucleic Acid (LNA) used in the oligonucleotides described herein comprises at least one Locked Nucleic Acid (LNA) unit according any of the formulas shown in Scheme 2 of PCT/DK2006/000512.
  • the LNA used in the oligomer of the invention comprises internucleoside linkages selected from -0-P(O) 2 —O—, —O—P(O,S)—O—, —O—P(S) 2 —O—, —S—P(O) 2 —O—, —S—P(O,S)—O—, —S—P(S) 2 —O—, -0-P(O) 2 —S—, —O—P(O,S)—S—, —S—P(O) 2 —S—, —O—PO(R H )—O—, O—PO(OCH 3 )—O—, —O—PO(NR H )—O—, -0-PO(OCH 2 CH 2 S—R)—O—, —O—PO(BH 3 )—O—, —O—PO(NHR H )—O—, —O—P(O) 2 —NR H —
  • thio-LNA comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from S or —CH 2 —S—.
  • Thio-LNA can be in both beta-D and alpha-L-configuration.
  • amino-LNA comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from —N(H)—, N(R)—, CH 2 —N(H)—, and —CH 2 —N(R)— where R is selected from hydrogen and C 1-4 -alkyl.
  • Amino-LNA can be in both beta-D and alpha-L-configuration.
  • Oxy-LNA comprises a locked nucleotide in which at least one of X or Y in the general formula above represents —O— or —CH 2 —O—. Oxy-LNA can be in both beta-D and alpha-L-configuration.
  • ena-LNA comprises a locked nucleotide in which Y in the general formula above is —CH 2 —O— (where the oxygen atom of —CH 2 —O— is attached to the 2′-position relative to the base B).
  • LNAs are described in additional detail herein.
  • One or more substituted sugar moieties can also be included, e.g., one of the following at the 2′ position: OH, SH, SCH 3 , F, OCN, OCH 3 OCH 3 , OCH 3 O(CH 2 )n CH 3 , O(CH 2 )n NH 2 or O(CH 2 )n CH 3 where n is from 1 to about 10; C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF 3 ; OCF 3 ; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH 3 ; SO 2 CH 3 ; ONO 2 ; NO 2 ; N 3 ; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercal
  • a preferred modification includes 2′-methoxyethoxy [2′-O—CH 2 CH 2 OCH 3 , also known as 2′-O-(2-methoxyethyl)] (Martin et al, HeIv. Chim. Acta, 1995, 78, 486).
  • Other preferred modifications include 2′-methoxy (2′-O—CH 3 ), 2′-propoxy (2′-OCH 2 CH 2 CH 3 ) and 2′-fluoro (2′-F).
  • Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide and the 5′ position of 5′ terminal nucleotide.
  • Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.
  • Single stranded oligonucleotides can also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
  • nucleobase often referred to in the art simply as “base”
  • “unmodified” or “natural” nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U).
  • Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2′ deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, isocytosine, pseudoisocytosine, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 5-propynyluracil, 8-azaguanine,
  • both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
  • the base units are maintained for hybridization with an appropriate nucleic acid target compound.
  • an oligomeric compound an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA).
  • PNA peptide nucleic acid
  • the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone.
  • the nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
  • PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, Science, 1991, 254, 1497-1500.
  • Single stranded oligonucleotides can also include one or more nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
  • base any nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
  • “unmodified” or “natural” nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
  • Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substi
  • nucleobases comprise those disclosed in U.S. Pat. No. 3,687,808, those disclosed in “The Concise Encyclopedia of Polymer Science And Engineering”, pages 858-859, Kroschwitz, ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandle Chemie, International Edition, 1991, 30, page 613, and those disclosed by Sanghvi, Chapter 15, Antisense Research and Applications,” pages 289-302, Crooke, and Lebleu, eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention.
  • 5-substituted pyrimidines 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
  • 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 ⁇ 0>C (Sanghvi, et al., eds, “Antisense Research and Applications,” CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications. Modified nucleobases are described in U.S. Pat. No.
  • the single stranded oligonucleotides are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.
  • one or more single stranded oligonucleotides, of the same or different types can be conjugated to each other; or single stranded oligonucleotides can be conjugated to targeting moieties with enhanced specificity for a cell type or tissue type.
  • moieties include, but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci.
  • Acids Res., 1992, 20, 533-538 an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl.
  • a phospholipid e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-
  • Acids Res., 1990, 18, 3777-3783 a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp.
  • conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers.
  • Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.
  • Groups that enhance the pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid.
  • Groups that enhance the pharmacokinetic properties include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference.
  • Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety.
  • lipid moieties such as a cholesterol moiety, cholic acid, a thioether,
  • single stranded oligonucleotide modification include modification of the 5′ or 3′ end of the oligonucleotide.
  • the 3′ end of the oligonucleotide comprises a hydroxyl group or a thiophosphate.
  • additional molecules e.g. a biotin moiety or a fluorophor
  • the single stranded oligonucleotide comprises a biotin moiety conjugated to the 5′ nucleotide.
  • the single stranded oligonucleotide comprises locked nucleic acids (LNA), ENA modified nucleotides, 2′-O-methyl nucleotides, or 2′-fluoro-deoxyribonucleotides.
  • LNA locked nucleic acids
  • ENA ENA modified nucleotides
  • 2′-O-methyl nucleotides or 2′-fluoro-deoxyribonucleotides.
  • the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides.
  • the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2′-O-methyl nucleotides.
  • the single stranded oligonucleotide comprises alternating deoxyribonucleotides and ENA modified nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and locked nucleic acid nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating locked nucleic acid nucleotides and 2′-O-methyl nucleotides.
  • the 5′ nucleotide of the oligonucleotide is a deoxyribonucleotide. In some embodiments, the 5′ nucleotide of the oligonucleotide is a locked nucleic acid nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one locked nucleic acid nucleotide on each of the 5′ and 3′ ends of the deoxyribonucleotides. In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group or a 3′ thiophosphate.
  • the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between at least two nucleotides. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between all nucleotides.
  • the single stranded oligonucleotide can have any combination of modifications as described herein.
  • the oligonucleotide may comprise a nucleotide sequence having one or more of the following modification patterns.
  • the invention relates to methods for modulating gene expression in a cell (e.g., a cell for which MECP2 levels are reduced) for research purposes (e.g., to study the function of the gene in the cell).
  • the invention relates to methods for modulating gene expression in a cell (e.g., a cell for which MECP2 levels are reduced) for gene or epigenetic therapy.
  • the cells can be in vitro, ex vivo, or in vivo (e.g., in a subject who has a disease resulting from reduced expression or activity of MECP2.
  • methods for modulating gene expression in a cell comprise delivering a single stranded oligonucleotide as described herein.
  • delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered.
  • delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 50% greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered.
  • methods comprise administering to a subject (e.g. a human) a composition comprising a single stranded oligonucleotide as described herein to increase protein levels in the subject.
  • a subject e.g. a human
  • the increase in protein levels is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or more, higher than the amount of a protein in the subject before administering.
  • the methods include introducing into the cell a single stranded oligonucleotide that is sufficiently complementary to a PRC2-associated region (e.g., of a long non-coding RNA) that maps to a genomic position encompassing or in proximity to the MECP2 gene.
  • a PRC2-associated region e.g., of a long non-coding RNA
  • a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
  • a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
  • administering a single stranded oligonucleotide as described herein.
  • a subject can include a non-human mammal, e.g. mouse, rat, guinea pig, rabbit, cat, dog, goat, cow, or horse.
  • a subject is a human.
  • Single stranded oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals, including humans.
  • Single stranded oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.
  • an animal preferably a human, suspected of having Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, or PPM-X syndrome is treated by administering single stranded oligonucleotide in accordance with this invention.
  • the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a single stranded oligonucleotide as described herein.
  • oligonucleotides described herein can be formulated for administration to a subject for treating a condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels of MECP2. It should be understood that the formulations, compositions and methods can be practiced with any of the oligonucleotides disclosed herein.
  • a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient e.g., an oligonucleotide or compound of the invention
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g. tumor regression.
  • compositions of this invention can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such formulations can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixtured with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.
  • a formulated single stranded oligonucleotide composition can assume a variety of states.
  • the composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g., less than 80, 50, 30, 20, or 10% water).
  • the single stranded oligonucleotide is in an aqueous phase, e.g., in a solution that includes water.
  • the aqueous phase or the crystalline compositions can, e.g., be incorporated into a delivery vehicle, e.g., a liposome (particularly for the aqueous phase) or a particle (e.g., a microparticle as can be appropriate for a crystalline composition).
  • the single stranded oligonucleotide composition is formulated in a manner that is compatible with the intended method of administration.
  • the composition is prepared by at least one of the following methods: spray drying, lyophilization, vacuum drying, evaporation, fluid bed drying, or a combination of these techniques; or sonication with a lipid, freeze-drying, condensation and other self-assembly.
  • a single stranded oligonucleotide preparation can be formulated or administered (together or separately) in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes a single stranded oligonucleotide, e.g., a protein that complexes with single stranded oligonucleotide.
  • another agent e.g., another therapeutic agent or an agent that stabilizes a single stranded oligonucleotide, e.g., a protein that complexes with single stranded oligonucleotide.
  • Still other agents include chelators, e.g., EDTA (e.g., to remove divalent cations such as Mg 2+ ), salts, RNAse inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.
  • the single stranded oligonucleotide preparation includes another single stranded oligonucleotide, e.g., a second single stranded oligonucleotide that modulates expression of a second gene or a second single stranded oligonucleotide that modulates expression of the first gene. Still other preparation can include at least 3, 5, ten, twenty, fifty, or a hundred or more different single stranded oligonucleotide species. Such single stranded oligonucleotides can mediated gene expression with respect to a similar number of different genes.
  • the single stranded oligonucleotide preparation includes at least a second therapeutic agent (e.g., an agent other than an oligonucleotide).
  • a composition that includes a single stranded oligonucleotide can be delivered to a subject by a variety of routes.
  • routes include: intravenous, intradermal, topical, rectal, parenteral, anal, intravaginal, intranasal, pulmonary, ocular.
  • therapeutically effective amount is the amount of oligonucleotide present in the composition that is needed to provide the desired level of MECP2 expression in the subject to be treated to give the anticipated physiological response.
  • physiologically effective amount is that amount delivered to a subject to give the desired palliative or curative effect.
  • pharmaceutically acceptable carrier means that the carrier can be administered to a subject with no significant adverse toxicological effects to the subject.
  • compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration.
  • Such compositions typically include one or more species of single stranded oligonucleotide and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
  • the route and site of administration may be chosen to enhance targeting.
  • intramuscular injection into the muscles of interest would be a logical choice.
  • Lung cells might be targeted by administering the single stranded oligonucleotide in aerosol form.
  • the vascular endothelial cells could be targeted by coating a balloon catheter with the single stranded oligonucleotide and mechanically introducing the oligonucleotide.
  • Topical administration refers to the delivery to a subject by contacting the formulation directly to a surface of the subject.
  • the most common form of topical delivery is to the skin, but a composition disclosed herein can also be directly applied to other surfaces of the body, e.g., to the eye, a mucous membrane, to surfaces of a body cavity or to an internal surface.
  • the most common topical delivery is to the skin.
  • the term encompasses several routes of administration including, but not limited to, topical and transdermal. These modes of administration typically include penetration of the skin's permeability barrier and efficient delivery to the target tissue or stratum.
  • Topical administration can be used as a means to penetrate the epidermis and dermis and ultimately achieve systemic delivery of the composition.
  • Topical administration can also be used as a means to selectively deliver oligonucleotides to the epidermis or dermis of a subject, or to specific strata thereof, or to an underlying tissue.
  • Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • Coated condoms, gloves and the like may also be useful.
  • Transdermal delivery is a valuable route for the administration of lipid soluble therapeutics.
  • the dermis is more permeable than the epidermis and therefore absorption is much more rapid through abraded, burned or denuded skin.
  • Inflammation and other physiologic conditions that increase blood flow to the skin also enhance transdermal adsorption. Absorption via this route may be enhanced by the use of an oily vehicle (inunction) or through the use of one or more penetration enhancers.
  • Other effective ways to deliver a composition disclosed herein via the transdermal route include hydration of the skin and the use of controlled release topical patches.
  • the transdermal route provides a potentially effective means to deliver a composition disclosed herein for systemic and/or local therapy.
  • iontophoresis transfer of ionic solutes through biological membranes under the influence of an electric field
  • phonophoresis or sonophoresis use of ultrasound to enhance the absorption of various therapeutic agents across biological membranes, notably the skin and the cornea
  • optimization of vehicle characteristics relative to dose position and retention at the site of administration may be useful methods for enhancing the transport of topically applied compositions across skin and mucosal sites.
  • oligonucleotides administered through these membranes may have a rapid onset of action, provide therapeutic plasma levels, avoid first pass effect of hepatic metabolism, and avoid exposure of the oligonucleotides to the hostile gastrointestinal (GI) environment. Additional advantages include easy access to the membrane sites so that the oligonucleotide can be applied, localized and removed easily.
  • GI gastrointestinal
  • compositions can be targeted to a surface of the oral cavity, e.g., to sublingual mucosa which includes the membrane of ventral surface of the tongue and the floor of the mouth or the buccal mucosa which constitutes the lining of the cheek.
  • the sublingual mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many agents. Further, the sublingual mucosa is convenient, acceptable and easily accessible.
  • a pharmaceutical composition of single stranded oligonucleotide may also be administered to the buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar pharmaceutical formulation as described above and a propellant.
  • the dispenser is first shaken prior to spraying the pharmaceutical formulation and propellant into the buccal cavity.
  • compositions for oral administration include powders or granules, suspensions or solutions in water, syrups, slurries, emulsions, elixirs or non-aqueous media, tablets, capsules, lozenges, or troches.
  • carriers that can be used include lactose, sodium citrate and salts of phosphoric acid.
  • Various disintegrants such as starch, and lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets.
  • useful diluents are lactose and high molecular weight polyethylene glycols.
  • the nucleic acid compositions can be combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added.
  • Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, intrathecal or intraventricular administration.
  • parental administration involves administration directly to the site of disease (e.g. injection into a tumor).
  • Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
  • Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir.
  • the total concentration of solutes should be controlled to render the preparation isotonic.
  • any of the single stranded oligonucleotides described herein can be administered to ocular tissue.
  • the compositions can be applied to the surface of the eye or nearby tissue, e.g., the inside of the eyelid.
  • ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers.
  • Such compositions can include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA or benzylchronium chloride, and the usual quantities of diluents and/or carriers.
  • the single stranded oligonucleotide can also be administered to the interior of the eye, and can be introduced by a needle or other delivery device which can introduce it to a selected area or structure.
  • Pulmonary delivery compositions can be delivered by inhalation by the patient of a dispersion so that the composition, preferably single stranded oligonucleotides, within the dispersion can reach the lung where it can be readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.
  • Pulmonary delivery can be achieved by different approaches, including the use of nebulized, aerosolized, micellular and dry powder-based formulations. Delivery can be achieved with liquid nebulizers, aerosol-based inhalers, and dry powder dispersion devices. Metered-dose devices are preferred. One of the benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self-contained. Dry powder dispersion devices, for example, deliver agents that may be readily formulated as dry powders. A single stranded oligonucleotide composition may be stably stored as lyophilized or spray-dried powders by itself or in combination with suitable powder carriers.
  • the delivery of a composition for inhalation can be mediated by a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.
  • a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.
  • the term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli.
  • the powder is said to be “respirable.”
  • the average particle size is less than about 10 ⁇ m in diameter preferably with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 ⁇ m and most preferably less than about 5.0 ⁇ m.
  • the particle size distribution is between about 0.1 ⁇ m and about 5 ⁇ m in diameter, particularly about 0.3 ⁇ m to about 5 ⁇ m.
  • dry means that the composition has a moisture content below about 10% by weight (% w) water, usually below about 5% w and preferably less it than about 3% w.
  • a dry composition can be such that the particles are readily dispersible in an inhalation device to form an aerosol.
  • the types of pharmaceutical excipients that are useful as carrier include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.
  • HSA human serum albumin
  • bulking agents such as carbohydrates, amino acids and polypeptides
  • pH adjusters or buffers such as sodium chloride
  • salts such as sodium chloride
  • Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
  • Pulmonary administration of a micellar single stranded oligonucleotide formulation may be achieved through metered dose spray devices with propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants.
  • Exemplary devices include devices which are introduced into the vasculature, e.g., devices inserted into the lumen of a vascular tissue, or which devices themselves form a part of the vasculature, including stents, catheters, heart valves, and other vascular devices. These devices, e.g., catheters or stents, can be placed in the vasculature of the lung, heart, or leg.
  • Other devices include non-vascular devices, e.g., devices implanted in the peritoneum, or in organ or glandular tissue, e.g., artificial organs.
  • the device can release a therapeutic substance in addition to a single stranded oligonucleotide, e.g., a device can release insulin.
  • unit doses or measured doses of a composition that includes single stranded oligonucleotide are dispensed by an implanted device.
  • the device can include a sensor that monitors a parameter within a subject.
  • the device can include pump, e.g., and, optionally, associated electronics.
  • Tissue e.g., cells or organs can be treated with a single stranded oligonucleotide, ex vivo and then administered or implanted in a subject.
  • the tissue can be autologous, allogeneic, or xenogeneic tissue.
  • tissue can be treated to reduce graft v. host disease.
  • the tissue is allogeneic and the tissue is treated to treat a disorder characterized by unwanted gene expression in that tissue.
  • tissue e.g., hematopoietic cells, e.g., bone marrow hematopoietic cells, can be treated to inhibit unwanted cell proliferation.
  • Introduction of treated tissue, whether autologous or transplant can be combined with other therapies.
  • the single stranded oligonucleotide treated cells are insulated from other cells, e.g., by a semi-permeable porous barrier that prevents the cells from leaving the implant, but enables molecules from the body to reach the cells and molecules produced by the cells to enter the body.
  • the porous barrier is formed from alginate.
  • a contraceptive device is coated with or contains a single stranded oligonucleotide.
  • exemplary devices include condoms, diaphragms, IUD (implantable uterine devices, sponges, vaginal sheaths, and birth control devices.
  • the invention features a method of administering a single stranded oligonucleotide (e.g., as a compound or as a component of a composition) to a subject (e.g., a human subject).
  • a subject e.g., a human subject.
  • the unit dose is between about 10 mg and 25 mg per kg of bodyweight. In one embodiment, the unit dose is between about 1 mg and 100 mg per kg of bodyweight. In one embodiment, the unit dose is between about 0.1 mg and 500 mg per kg of bodyweight. In some embodiments, the unit dose is more than 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 25, 50 or 100 mg per kg of bodyweight.
  • the defined amount can be an amount effective to treat or prevent a disease or disorder, e.g., a disease or disorder associated with the MECP2.
  • the unit dose for example, can be administered by injection (e.g., intravenous or intramuscular), an inhaled dose, or a topical application.
  • the unit dose is administered daily. In some embodiments, less frequently than once a day, e.g., less than every 2, 4, 8 or 30 days. In another embodiment, the unit dose is not administered with a frequency (e.g., not a regular frequency). For example, the unit dose may be administered a single time. In some embodiments, the unit dose is administered more than once a day, e.g., once an hour, two hours, four hours, eight hours, twelve hours, etc.
  • a subject is administered an initial dose and one or more maintenance doses of a single stranded oligonucleotide.
  • the maintenance dose or doses are generally lower than the initial dose, e.g., one-half less of the initial dose.
  • a maintenance regimen can include treating the subject with a dose or doses ranging from 0.0001 to 100 mg/kg of body weight per day, e.g., 100, 10, 1, 0.1, 0.01, 0.001, or 0.0001 mg per kg of bodyweight per day.
  • the maintenance doses may be administered no more than once every 1, 5, 10, or 30 days. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient.
  • the dosage may be delivered no more than once per day, e.g., no more than once per 24, 36, 48, or more hours, e.g., no more than once for every 5 or 8 days.
  • the patient can be monitored for changes in his condition and for alleviation of the symptoms of the disease state.
  • the dosage of the oligonucleotide may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, if the disease state has been ablated, or if undesired side-effects are observed.
  • the effective dose can be administered in a single dose or in two or more doses, as desired or considered appropriate under the specific circumstances. If desired to facilitate repeated or frequent infusions, implantation of a delivery device, e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable.
  • a delivery device e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable.
  • the oligonucleotide pharmaceutical composition includes a plurality of single stranded oligonucleotide species.
  • the single stranded oligonucleotide species has sequences that are non-overlapping and non-adjacent to another species with respect to a naturally occurring target sequence (e.g., a PRC2-associated region).
  • the plurality of single stranded oligonucleotide species is specific for different PRC2-associated regions.
  • the single stranded oligonucleotide is allele specific. In some cases, a patient is treated with a single stranded oligonucleotide in conjunction with other therapeutic modalities.
  • the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the compound of the invention is administered in maintenance doses, ranging from 0.0001 mg to 100 mg per kg of body weight.
  • the concentration of the single stranded oligonucleotide composition is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in humans.
  • concentration or amount of single stranded oligonucleotide administered will depend on the parameters determined for the agent and the method of administration, e.g. nasal, buccal, pulmonary.
  • nasal formulations may tend to require much lower concentrations of some ingredients in order to avoid irritation or burning of the nasal passages. It is sometimes desirable to dilute an oral formulation up to 10-100 times in order to provide a suitable nasal formulation.
  • treatment of a subject with a therapeutically effective amount of a single stranded oligonucleotide can include a single treatment or, preferably, can include a series of treatments.
  • the effective dosage of a single stranded oligonucleotide used for treatment may increase or decrease over the course of a particular treatment.
  • the subject can be monitored after administering a single stranded oligonucleotide composition. Based on information from the monitoring, an additional amount of the single stranded oligonucleotide composition can be administered.
  • Dosing is dependent on severity and responsiveness of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved.
  • Optimal dosing schedules can be calculated from measurements of MECP2 expression levels in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models.
  • the animal models include transgenic animals that express a human MECP2.
  • the composition for testing includes a single stranded oligonucleotide that is complementary, at least in an internal region, to a sequence that is conserved between MECP2 in the animal model and the MECP2 in a human.
  • the administration of the single stranded oligonucleotide composition is parenteral, e.g. intravenous (e.g., as a bolus or as a diffusible infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral or ocular.
  • Administration can be provided by the subject or by another person, e.g., a health care provider.
  • the composition can be provided in measured doses or in a dispenser which delivers a metered dose. Selected modes of delivery are discussed in more detail below.
  • kits comprising a container housing a composition comprising a single stranded oligonucleotide.
  • the composition is a pharmaceutical composition comprising a single stranded oligonucleotide and a pharmaceutically acceptable carrier.
  • the individual components of the pharmaceutical composition may be provided in one container. Alternatively, it may be desirable to provide the components of the pharmaceutical composition separately in two or more containers, e.g., one container for single stranded oligonucleotides, and at least another for a carrier compound.
  • the kit may be packaged in a number of different configurations such as one or more containers in a single box.
  • the different components can be combined, e.g., according to instructions provided with the kit.
  • the components can be combined according to a method described herein, e.g., to prepare and administer a pharmaceutical composition.
  • the kit can also include a delivery device.
  • RNA is harvested from the cells using Promega SV 96 Total RNA Isolation system or Trizol omitting the DNAse step. RNA harvested from cells is normalized so that equal RNA is input to each reverse transcription reaction. Reverse transcriptase reactions are performed using the Superscript II kit and real time PCR performed on cDNA samples using icycler SYBR green chemistry (Biorad). A baseline level of mRNA expression for MECP2 is determined through quantitative PCR as outlined above. Baseline levels are also determined for mRNA of various housekeeping genes which are constitutively expressed. A “control” housekeeping gene with approximately the same level of baseline expression as the target gene is chosen for comparison purposes.
  • Human hepatocyte Hep3B, human hepatocyte HepG2 cells, mouse hepatoma Hepa1-6 cells, and human renal proximal tubule epithelial cells (RPTEC) are cultured using conditions known in the art (see, e.g. Current Protocols in Cell Biology).
  • Oligonucleotides were designed within PRC2-interacting regions in order to upregulate MECP2.
  • the sequence and structure of each oligonucleotide is shown in Table 3.
  • the following table provides a description of the nucleotide analogs, modifications and intranucleotide linkages used for certain oligonucleotides tested and described in Table 2.
  • Oligonucleotides are designed within PRC2-interacting regions in order to upregulate MECP2.
  • Cells are seeded into each well of 24-well plates at a density of 25,000 cells per 500 uL and transfections are performed with Lipofectamine and the single stranded oligonucleotides.
  • Control wells contain Lipofectamine alone.
  • approximately 200 uL of cell culture supernatants are stored at ⁇ 80 C for ELISA.
  • RNA is harvested from the cells and quantitative PCR is carried out as outlined above.
  • the percent induction of target mRNA expression by each oligonucleotide is determined by normalizing mRNA levels in the presence of the oligonucleotide to the mRNA levels in the presence of control (Lipofectamine alone). This is compared side-by-side with the increase in mRNA expression of the “control” housekeeping gene.
  • Oligonucleotides are designed as candidates for upregulating MECP2 expression.
  • the single stranded oligonucleotides are designed to be complementary to a PRC2-interacting region within a sequence as set forth in SEQ ID NO: 1 or 2.
  • the oligonucleotides are tested in at least duplicate. Briefly, cells are transfected in vitro with each of the oligonucleotides as described above. MECP2 expression in cells following treatment is evaluated by qRT-PCR. Oligonucleotides that upregulate MECP2 expression are identified.

Abstract

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation which claims the benefit under 35 U.S.C. § 120 of U.S. application Ser. No. 15/787,876, entitled “COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION” filed on Oct. 19, 2017, which is a continuation which claims the benefit under 35 U.S.C. § 120 of U.S. application Ser. No. 14/401,237, entitled “COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION” filed on Nov. 14, 2014, which is a national stage filing under U.S.C. § 371 of PCT International Application PCT/US2013/041394, with an international filing date of May 16, 2013, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/648,051, entitled “COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION”, filed May 16, 2012, the contents of each of which are incorporated herein by reference in their entireties.
FIELD OF THE INVENTION
The invention relates to oligonucleotide based compositions, as well as methods of using oligonucleotide based compositions for treating disease.
BACKGROUND OF THE INVENTION
Rett syndrome is a developmental disorder of the brain occurring mostly in females characterized by normal early development, followed by a slowing of development resulting in loss of control of the hands, loss of speech, breathing problems, slowed brain and head growth, ambulatory problems, seizures, and mental retardation. Rett syndrome affects approximately 1 in 10,000 live female births. Most cases of Rett syndrome are caused by a mutation in the methyl CpG binding protein 2, or MECP2 gene, on the X chromosome that causes reduced activity or inactivation of MECP2.
MECP2 is a transcriptional repressor that binds to methylated DNA and is present in large quantities in mature nerve cells. MECP2 represses transcription from methylated gene promoters through interaction with histone deacetylase and the corepressor SIN3A. Many of the genes that are known to be regulated by the MECP2 protein play a role in normal brain function, particularly the maintenance of synapses. Mouse studies have demonstrated MECP2 mutations cause defects in synaptic function, especially in synaptic plasticity.
SUMMARY OF THE INVENTION
Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 in cells. In some embodiments, single stranded oligonucleotides are provided that target a PRC2-associated region of a MECP2 gene (e.g., human MECP2) and thereby cause upregulation of the gene. In some embodiments, single stranded oligonucleotides are provided that target a PRC2-associated region of the gene encoding MECP2. In some embodiments, these single stranded oligonucleotides activate or enhance expression of MECP2 by relieving or preventing PRC2 mediated repression of MECP2.
Upregulation of MECP2 offers a treatment for diseases associated with decreased MECP2 activity. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 for the treatment and/or prevention of Rett Syndrome. MECP2 is also associated with MECP2-related severe neonatal encephalopathy, Angelman syndrome, and PPM-X syndrome. Accordingly, certain aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 for the treatment and/or prevention of MECP2-related severe neonatal encephalopathy, Angelman syndrome, and PPM-X syndrome.
Further aspects of the invention provide methods for selecting oligonucleotides for activating or enhancing expression of MECP2. In some embodiments, methods are provided for selecting a set of oligonucleotides that is enriched in candidates (e.g., compared with a random selection of oligonucleotides) for activating or enhancing expression of MECP2. Accordingly, the methods may be used to establish sets of clinical candidates that are enriched in oligonucleotides that activate or enhance expression of MECP2. Such libraries may be utilized, for example, to identify lead oligonucleotides for developing therapeutics to treat MECP2. Furthermore, in some embodiments, oligonucleotide chemistries are provided that are useful for controlling the pharmacokinetics, biodistribution, bioavailability and/or efficacy of the single stranded oligonucleotides for activating expression of MECP2.
According to some aspects of the invention single stranded oligonucleotides are provided that have a region of complementarity that is complementarity with (e.g., at least 8 consecutive nucleotides of) a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2. In some embodiments, the oligonucleotide has at least one of the following features: a) a sequence that is 5′X-Y-Z, in which X is any nucleotide and in which X is at the 5′ end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length; b) a sequence that does not comprise three or more consecutive guanosine nucleotides; c) a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length to the second nucleotide sequence, that are between 50 kilobases upstream of a 5′-end of an off-target gene and 50 kilobases downstream of a 3′-end of the off-target gene; d) a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops; and e) a sequence that has greater than 60% G-C content. In some embodiments, the single stranded oligonucleotide has at least two of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least three of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least four of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has each of features a), b), c), d), and e). In certain embodiments, the oligonucleotide has the sequence 5′X-Y-Z, in which the oligonucleotide is 8-50 nucleotides in length.
According to some aspects of the invention, single stranded oligonucleotides are provided that have a sequence X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2. In some aspects of the invention, single stranded oligonucleotides are provided that have a sequence 5′-X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2. In some embodiments, Y is a sequence selected from Table 1. In some embodiments, the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 5 to 118.
In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660, or a fragment thereof that is at least 8 nucleotides. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660, in which the 5′ end of the nucleotide sequence provided is the 5′ end of the oligonucleotide. In some embodiments, the region of complementarity (e.g., the at least 8 consecutive nucleotides) is also present within the nucleotide sequence set forth as SEQ ID NO: 3 or 4.
In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660.
In some embodiments, the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 5 to 84. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 47653 or a fragment thereof that is at least 8 nucleotides. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 47653, wherein the 5′ end of the nucleotide sequence provided in any one of SEQ ID NOS: 119 to 47653 is the 5′ end of the oligonucleotide. In some embodiments, the at least 8 consecutive nucleotides are also present within the nucleotide sequence set forth as SEQ ID NO: 3.
In some embodiments, the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 85 to 118. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 47462 to 83660 or a fragment thereof that is at least 8 nucleotides. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 47462 to 83660, wherein the 5′ end of the nucleotide sequence provided in any one of SEQ ID NOS: 47462 to 83660 is the 5′ end of the oligonucleotide. In some embodiments, the at least 8 consecutive nucleotides are present within the nucleotide sequence set forth as SEQ ID NO: 4.
In some embodiments, a single stranded oligonucleotide comprises a nucleotide sequence as set forth in Table 3. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in Table 3. In some embodiments, a single stranded oligonucleotide consists of a nucleotide sequence as set forth in Table 3.
In some embodiments, the single stranded oligonucleotide does not comprise three or more consecutive guanosine nucleotides. In some embodiments, the single stranded oligonucleotide does not comprise four or more consecutive guanosine nucleotides.
In some embodiments, the single stranded oligonucleotide is 8 to 30 nucleotides in length. In some embodiments, the single stranded oligonucleotide is up to 50 nucleotides in length. In some embodiments, the single stranded oligonucleotide is 8 to 10 nucleotides in length and all but 1, 2, or 3 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides.
In some embodiments, the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of a nucleotide sequence set forth as SEQ ID NO: 1 or 2, in which the nucleotide sequence of the single stranded oligonucleotide comprises one or more of a nucleotide sequence selected from the group consisting of
(a) (X)Xxxxxx, (X)xXxxxx, (X)xxXxxx, (X)xxxXxx, (X)xxxxXx and (X)xxxxxX,
(b) (X)XXxxxx, (X)XxXxxx, (X)XxxXxx, (X)XxxxXx, (X)XxxxxX, (X)xXXxxx, (X)xXxXxx, (X)xXxxXx, (X)xXxxxX, (X)xxXXxx, (X)xxXxXx, (X)xxXxxX, (X)xxxXXx, (X)xxxXxX and (X)xxxxXX,
(c) (X)XXXxxx, (X)xXXXxx, (X)xxXXXx, (X)xxxXXX, (X)XXxXxx, (X)XXxxXx, (X)XXxxxX, (X)xXXxXx, (X)xXXxxX, (X)xxXXxX, (X)XxXXxx, (X)XxxXXx (X)XxxxXX, (X)xXxXXx, (X)xXxxXX, (X)xxXxXX, (X)xXxXxX and (X)XxXxXx,
(d) (X)xxXXX, (X)xXxXXX, (X)xXXxXX, (X)xXXXxX, (X)xXXXXx, (X)XxxXXXX, (X)XxXxXX, (X)XxXXxX, (X)XxXXx, (X)XXxxXX, (X)XXxXxX, (X)XXxXXx, (X)XXXxxX, (X)XXXxXx, and (X)XXXXxx,
(e) (X)xXXXXX, (X)XxXXXX, (X)XXxXXX, (X)XXXxXX, (X)XXXXxX and (X)XXXXXx, and
(f) XXXXXX, XxXXXXX, XXxXXXX, XXXxXXX, XXXXxXX, XXXXXxX and XXXXXXx, wherein “X” denotes a nucleotide analogue, (X) denotes an optional nucleotide analogue, and “x” denotes a DNA or RNA nucleotide unit.
In some embodiments, at least one nucleotide of the oligonucleotide is a nucleotide analogue. In some embodiments, the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
In some embodiments, at least one nucleotide of the oligonucleotide comprises a 2′ O-methyl. In some embodiments, each nucleotide of the oligonucleotide comprises a 2′ O-methyl. In some embodiments, the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide. In some embodiments, the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide. In some embodiments, each nucleotide of the oligonucleotide is a LNA nucleotide.
In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′-O-methyl nucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and ENA nucleotide analogues. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and LNA nucleotides. In some embodiments, the 5′ nucleotide of the oligonucleotide is a deoxyribonucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise alternating LNA nucleotides and 2′-O-methyl nucleotides. In some embodiments, the 5′ nucleotide of the oligonucleotide is a LNA nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one LNA nucleotide on each of the 5′ and 3′ ends of the deoxyribonucleotides.
In some embodiments, the single stranded oligonucleotide comprises modified internucleotide linkages (e.g., phosphorothioate internucleotide linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleotides. In some embodiments, the single stranded oligonucleotide comprises modified internucleotide linkages (e.g., phosphorothioate internucleotide linkages or other linkages) between all nucleotides.
In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group. In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ thiophosphate. In some embodiments, the single stranded oligonucleotide has a biotin moiety or other moiety conjugated to its 5′ or 3′ nucleotide. In some embodiments, the single stranded oligonucleotide has cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5′ or 3′ end.
According to some aspects of the invention compositions are provided that comprise any of the oligonucleotides disclosed herein, and a carrier. In some embodiments, compositions are provided that comprise any of the oligonucleotides in a buffered solution. In some embodiments, the oligonucleotide is conjugated to the carrier. In some embodiments, the carrier is a peptide. In some embodiments, the carrier is a steroid. According to some aspects of the invention pharmaceutical compositions are provided that comprise any of the oligonucleotides disclosed herein, and a pharmaceutically acceptable carrier.
According to other aspects of the invention, kits are provided that comprise a container housing any of the compositions disclosed herein.
According to some aspects of the invention, methods of increasing expression of MECP2 in a cell are provided. In some embodiments, the methods involve delivering any one or more of the single stranded oligonucleotides disclosed herein into the cell. In some embodiments, delivery of the single stranded oligonucleotide into the cell results in a level of expression of MECP2 that is greater (e.g., at least 50% greater) than a level of expression of MECP2 in a control cell that does not comprise the single stranded oligonucleotide.
According to some aspects of the invention, methods of increasing levels of MECP2 in a subject are provided. According to some aspects of the invention, methods of treating a condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels of MECP2 in a subject are provided. In some embodiments, the methods involve administering any one or more of the single stranded oligonucleotides disclosed herein to the subject.
BRIEF DESCRIPTION OF TABLES
Table 1: Hexamers that are not seed sequences of human miRNAs
Table 2: A listing of oligonucleotide modifications
Table 3: Formatted oligonucleotide sequences made for testing showing nucleotide modifications. The table shows the sequence of the modified nucleotides, where InaX represents an LNA nucleotide with 3′ phosphorothioate linkage, omeX is a 2′-O-methyl nucleotide, dX is a deoxy nucleotide. An s at the end of a nucleotide code indicates that the nucleotide had a 3′ phosphorothioate linkage. The “−Sup” at the end of the sequence marks the fact that the 3′ end lacks either a phosphate or thiophosphate on the 3′ linkage. The Formatted Sequence column shows the sequence of the oligonucleotide, including modified nucleotides.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
Aspects of the invention provided herein relate to the discovery of polycomb repressive complex 2 (PRC2)-interacting RNAs. Polycomb repressive complex 2 (PRC2) is a histone methyltransferase and a known epigenetic regulator involved in silencing of genomic regions through methylation of histone H3. Among other functions, PRC2 interacts with long noncoding RNAs (lncRNAs), such as RepA, Xist, and Tsix, to catalyze trimethylation of histone H3-lysine27. PRC2 contains four subunits, Eed, Suz12, RbAp48, and Ezh2. Aspects of the invention relate to the recognition that single stranded oligonucleotides that bind to PRC2-associated regions of RNAs (e.g., lncRNAs) that are expressed from within a genomic region that encompasses or that is in functional proximity to the MECP2 gene can induce or enhance expression of MECP2. In some embodiments, this upregulation is believed to result from inhibition of PRC2 mediated repression of MECP2.
As used herein, the term “PRC2-associated region” refers to a region of a nucleic acid that comprises or encodes a sequence of nucleotides that interact directly or indirectly with a component of PRC2. A PRC2-associated region may be present in a RNA (e.g., a long non-coding RNA (lncRNA)) that that interacts with a PRC2. A PRC2-associated region may be present in a DNA that encodes an RNA that interacts with PRC2. In some cases, the PRC2-associated region is equivalently referred to as a PRC2-interacting region.
In some embodiments, a PRC2-associated region is a region of an RNA that crosslinks to a component of PRC2 in response to in situ ultraviolet irradiation of a cell that expresses the RNA, or a region of genomic DNA that encodes that RNA region. In some embodiments, a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region. In some embodiments, a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4 (which as noted above are components of PRC2), or a region of genomic DNA that encodes that RNA region.
In some embodiments, a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g., RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that protected RNA region. In some embodiments, a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g., RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region.
In some embodiments, a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region. In some embodiments, a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region. In such embodiments, the PRC2-associated region may be referred to as a “peak.”
In some embodiments, a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that interact with PRC2 complex. In some embodiments, a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that encode an RNA that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5 kb in length that comprises a sequence (e.g., of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5 kb in length within which an RNA is encoded that has a sequence (e.g., of 40 to 60 nucleotides) that is known to interact with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of about 4 kb in length that comprise a sequence (e.g., of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of about 4 kb in length within which an RNA is encoded that includes a sequence (e.g., of 40 to 60 nucleotides) that is known to interact with PRC2. In some embodiments, a PRC2-associated region has a sequence as set forth in any one of SEQ ID NOS: 5 to 118.
In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region in a genomic region that encompasses or that is in proximity to the MECP2 gene. In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 5 to 118. In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 5 to 118 combined with up to 2 kb, up to 5 kb, or up to 10 kb of flanking sequences from a corresponding genomic region to which these SEQ IDs map (e.g., in a human genome). In some embodiments, single stranded oligonucleotides have a sequence as set forth in any one of SEQ ID NOS: 119 to 83660. In some embodiments, single stranded oligonucleotides have a sequence as set forth in Table 3.
Without being bound by a theory of invention, these oligonucleotides are able to interfere with the binding of and function of PRC2, by preventing recruitment of PRC2 to a specific chromosomal locus. For example, a single administration of single stranded oligonucleotides designed to specifically bind a PRC2-associated region lncRNA can stably displace not only the lncRNA, but also the PRC2 that binds to the lncRNA, from binding chromatin. After displacement, the full complement of PRC2 is not recovered for up to 24 hours. Further, lncRNA can recruit PRC2 in a cis fashion, repressing gene expression at or near the specific chromosomal locus from which the lncRNA was transcribed.
Methods of modulating gene expression are provided, in some embodiments, that may be carried out in vitro, ex vivo, or in vivo. It is understood that any reference to uses of compounds throughout the description contemplates use of the compound in preparation of a pharmaceutical composition or medicament for use in the treatment of condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels or activity of MECP2. Thus, as one nonlimiting example, this aspect of the invention includes use of such single stranded oligonucleotides in the preparation of a medicament for use in the treatment of disease, wherein the treatment involves upregulating expression of MECP2.
In further aspects of the invention, methods are provided for selecting a candidate oligonucleotide for activating expression of MECP2. The methods generally involve selecting as a candidate oligonucleotide, a single stranded oligonucleotide comprising a nucleotide sequence that is complementary to a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 5 to 118). In some embodiments, sets of oligonucleotides may be selected that are enriched (e.g., compared with a random selection of oligonucleotides) in oligonucleotides that activate expression of MECP2.
Single Stranded Oligonucleotides for Modulating Expression of MECP2
In one aspect of the invention, single stranded oligonucleotides complementary to the PRC2-associated regions are provided for modulating expression of MECP2 in a cell. In some embodiments, expression of MECP2 is upregulated or increased. In some embodiments, single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts such that gene expression is upregulated or increased. In some embodiments, single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts, resulting in reduced methylation of histone H3 and reduced gene inactivation, such that gene expression is upregulated or increased. In some embodiments, this interaction may be disrupted or inhibited due to a change in the structure of the long RNA that prevents or reduces binding to PRC2. The oligonucleotide may be selected using any of the methods disclosed herein for selecting a candidate oligonucleotide for activating expression of MECP2.
The single stranded oligonucleotide may comprise a region of complementarity that is complementary with a PRC2-associated region of a nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4. The region of complementarity of the single stranded oligonucleotide may be complementary with at least 6, e.g., at least 7, at least 8, at least 9, at least 10, at least 15 or more consecutive nucleotides of the PRC2-associated region.
The PRC2-associated region may map to a position in a chromosome between 50 kilobases upstream of a 5′-end of the MECP2 gene and 50 kilobases downstream of a 3′-end of the MECP2 gene. The PRC2-associated region may map to a position in a chromosome between 25 kilobases upstream of a 5′-end of the MECP2 gene and 25 kilobases downstream of a 3′-end of the MECP2 gene. The PRC2-associated region may map to a position in a chromosome between 12 kilobases upstream of a 5′-end of the MECP2 gene and 12 kilobases downstream of a 3′-end of the MECP2 gene. The PRC2-associated region may map to a position in a chromosome between 5 kilobases upstream of a 5′-end of the MECP2 gene and 5 kilobases downstream of a 3′-end of the MECP2 gene.
The genomic position of the selected PRC2-associated region relative to the MECP2 gene may vary. For example, the PRC2-associated region may be upstream of the 5′ end of the MECP2 gene. The PRC2-associated region may be downstream of the 3′ end of the MECP2 gene. The PRC2-associated region may be within an intron of the MECP2 gene. The PRC2-associated region may be within an exon of the MECP2 gene. The PRC2-associated region may traverse an intron-exon junction, a 5′-UTR-exon junction or a 3′-UTR-exon junction of the MECP2 gene.
The single stranded oligonucleotide may comprise a sequence having the formula X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of varying length. In some embodiments X is the 5′ nucleotide of the oligonucleotide. In some embodiments, when X is anchored at the 5′ end of the oligonucleotide, the oligonucleotide does not have any nucleotides or nucleotide analogs linked 5′ to X. In some embodiments, other compounds such as peptides or sterols may be linked at the 5′ end in this embodiment as long as they are not nucleotides or nucleotide analogs. In some embodiments, the single stranded oligonucleotide has a sequence 5′X-Y-Z and is 8-50 nucleotides in length. Oligonucleotides that have these sequence characteristics are predicted to avoid the miRNA pathway. Therefore, in some embodiments, oligonucleotides having these sequence characteristics are unlikely to have an unintended consequence of functioning in a cell as a miRNA molecule. The Y sequence may be a nucleotide sequence of 6 nucleotides in length set forth in Table 1.
The single stranded oligonucleotide may have a sequence that does not contain guanosine nucleotide stretches (e.g., 3 or more, 4 or more, 5 or more, 6 or more consecutive guanosine nucleotides). In some embodiments, oligonucleotides having guanosine nucleotide stretches have increased non-specific binding and/or off-target effects, compared with oligonucleotides that do not have guanosine nucleotide stretches.
The single stranded oligonucleotide may have a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length, that map to a genomic position encompassing or in proximity to an off-target gene. For example, an oligonucleotide may be designed to ensure that it does not have a sequence that maps to genomic positions encompassing or in proximity with all known genes (e.g., all known protein coding genes) other than MECP2. In a similar embodiment, an oligonucleotide may be designed to ensure that it does not have a sequence that maps to any other known PRC2-associated region, particularly PRC2-associated regions that are functionally related to any other known gene (e.g., any other known protein coding gene). In either case, the oligonucleotide is expected to have a reduced likelihood of having off-target effects. The threshold level of sequence identity may be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity.
The single stranded oligonucleotide may have a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops. In has been discovered that, in some embodiments, oligonucleotides that are complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising one or more single stranded loops (e.g., at least two single stranded loops) have a greater likelihood of being active (e.g., of being capable of activating or enhancing expression of a target gene) than a randomly selected oligonucleotide. In some cases, the secondary structure may comprise a double stranded stem between the at least two single stranded loops. Accordingly, the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of at least one of the loops. In some cases, the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2-associated region that encodes at least a portion of at least two of the loops. In some cases, the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of the double stranded stem. In some embodiments, a PRC2-associated region (e.g., of an lncRNA) is identified (e.g., using RIP-Seq methodology or information derived therefrom). In some embodiments, the predicted secondary structure RNA (e.g., lncRNA) containing the PRC2-associated region is determined using RNA secondary structure prediction algorithms, e.g., RNAfold, mfold. In some embodiments, oligonucleotides are designed to target a region of the RNA that forms a secondary structure comprising one or more single stranded loop (e.g., at least two single stranded loops) structures which may comprise a double stranded stem between the at least two single stranded loops.
The single stranded oligonucleotide may have a sequence that is has greater than 30% G-C content, greater than 40% G-C content, greater than 50% G-C content, greater than 60% G-C content, greater than 70% G-C content, or greater than 80% G-C content. The single stranded oligonucleotide may have a sequence that has up to 100% G-C content, up to 95% G-C content, up to 90% G-C content, or up to 80% G-C content. In some embodiments in which the oligonucleotide is 8 to 10 nucleotides in length, all but 1, 2, 3, 4, or 5 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides. In some embodiments, the sequence of the PRC2-associated region to which the single stranded oligonucleotide is complementary comprises no more than 3 nucleotides selected from adenine and uracil.
The single stranded oligonucleotide may be complementary to a chromosome of a different species (e.g., a mouse, rat, rabbit, goat, monkey, etc.) at a position that encompasses or that is in proximity to that species' homolog of MECP2. The single stranded oligonucleotide may be complementary to a human genomic region encompassing or in proximity to the MECP2 gene and also be complementary to a mouse genomic region encompassing or in proximity to the mouse homolog of MECP2. For example, the single stranded oligonucleotide may be complementary to a sequence as set forth in SEQ ID NO: 1 or 2, which is a human genomic region encompassing or in proximity to the MECP2 gene, and also be complementary to a sequence as set forth in SEQ ID NO: 3 or 4, which is a mouse genomic region encompassing or in proximity to the mouse homolog of the MECP2 gene. Oligonucleotides having these characteristics may be tested in vivo or in vitro for efficacy in multiple species (e.g., human and mouse). This approach also facilitates development of clinical candidates for treating human disease by selecting a species in which an appropriate animal exists for the disease.
In some embodiments, the region of complementarity of the single stranded oligonucleotide is complementary with at least 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 bases, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides of a PRC2-associated region. In some embodiments, the region of complementarity is complementary with at least 8 consecutive nucleotides of a PRC2-associated region. In some embodiments the sequence of the single stranded oligonucleotide is based on an RNA sequence that binds to PRC2, or a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 bases, or about 5 to 15, or about 5 to 30, or about 5 to 40 bases, or about 5 to 50 bases.
Complementary, as the term is used in the art, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of PRC2-associated region, then the single stranded nucleotide and PRC2-associated region are considered to be complementary to each other at that position. The single stranded nucleotide and PRC2-associated region are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases. Thus, “complementary” is a term which is used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the single stranded nucleotide and PRC2-associated region. For example, if a base at one position of a single stranded nucleotide is capable of hydrogen bonding with a base at the corresponding position of a PRC2-associated region, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.
The single stranded oligonucleotide may be at least 80% complementary to (optionally one of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the consecutive nucleotides of a PRC2-associated region. In some embodiments the single stranded oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of a PRC2-associated region. In some embodiments the single stranded oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.
It is understood in the art that a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable. In some embodiments, a complementary nucleic acid sequence for purposes of the present disclosure is specifically hybridizable when binding of the sequence to the target molecule (e.g., lncRNA) interferes with the normal function of the target (e.g., lncRNA) to cause a loss of activity (e.g., inhibiting PRC2-associated repression with consequent up-regulation of gene expression) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency.
In some embodiments, the single stranded oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or more nucleotides in length. In a preferred embodiment, the oligonucleotide is 8 to 30 nucleotides in length.
In some embodiments, the PRC2-associated region occurs on the same DNA strand as a gene sequence (sense). In some embodiments, the PRC2-associated region occurs on the opposite DNA strand as a gene sequence (anti-sense). Oligonucleotides complementary to a PRC2-associated region can bind either sense or anti-sense sequences. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). It is understood that for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.
In some embodiments, any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be replaced with any other nucleotide suitable for base pairing (e.g., via a Watson-Crick base pair) with an adenosine nucleotide. In some embodiments, any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be suitably replaced with a different pyrimidine nucleotide or vice versa. In some embodiments, any one or more thymidine (T) nucleotides (or modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be suitably replaced with a uridine (U) nucleotide (or a modified nucleotide thereof) or vice versa. In some embodiments, GC content of the single stranded oligonucleotide is preferably between about 30-60%. Contiguous runs of three or more Gs or Cs may not be preferable in some embodiments. Accordingly, in some embodiments, the oligonucleotide does not comprise a stretch of three or more guanosine nucleotides.
In some embodiments, the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome) as a single contiguous transcript (e.g., a non-spliced RNA). In some embodiments, the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome), in which the distance in the genome between the 5′end of the coding region of the RNA and the 3′ end of the coding region of the RNA is less than 1 kb, less than 2 kb, less than 3 kb, less than 4 kb, less than 5 kb, less than 7 kb, less than 8 kb, less than 9 kb, less than 10 kb, or less than 20 kb.
It is to be understood that any oligonucleotide provided herein can be excluded. In some embodiments, it has been found that single stranded oligonucleotides disclosed herein may increase expression of mRNA corresponding to the gene by at least about 50% (i.e. 150% of normal or 1.5 fold), or by about 2 fold to about 5 fold. In some embodiments, expression may be increased by at least about 15 fold, 20 fold, 30 fold, 40 fold, 50 fold or 100 fold, or any range between any of the foregoing numbers. It has also been found that increased mRNA expression has been shown to correlate to increased protein expression.
In some or any of the embodiments of the oligonucleotides described herein, or processes for designing or synthesizing them, the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to the PRC2 binding RNA that is transcribed from the same strand as a protein coding reference gene. The oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein coding sense strand of a reference gene (refGene).
In some or any of the embodiments of oligonucleotides described herein, or processes for designing or synthesizing them, the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to a PRC2 binding RNA that transcribed from the opposite strand (the antisense strand) of a protein coding reference gene. The oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein coding antisense strand of a reference gene
The oligonucleotides described herein may be modified, e.g., comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof. In addition, the oligonucleotides can exhibit one or more of the following properties: do not induce substantial cleavage or degradation of the target RNA; do not cause substantially complete cleavage or degradation of the target RNA; do not activate the RNAse H pathway; do not activate RISC; do not recruit any Argonaute family protein; are not cleaved by Dicer; do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; may have improved endosomal exit; do interfere with interaction of lncRNA with PRC2, preferably the Ezh2 subunit but optionally the Suz12, Eed, RbAp46/48 subunits or accessory factors such as Jarid2; do decrease histone H3 lysine27 methylation and/or do upregulate gene expression.
Oligonucleotides that are designed to interact with RNA to modulate gene expression are a distinct subset of base sequences from those that are designed to bind a DNA target (e.g., are complementary to the underlying genomic DNA sequence from which the RNA is transcribed).
Any of the oligonucleotides disclosed herein may be linked to one or more other oligonucleotides disclosed herein by a linker, e.g., a cleavable linker.
Method for Selecting Candidate Oligonucleotides for Activating Expression of MECP2
Methods are provided herein for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2. The target selection methods may generally involve steps for selecting single stranded oligonucleotides having any of the structural and functional characteristics disclosed herein. Typically, the methods involve one or more steps aimed at identifying oligonucleotides that target a PRC2-associated region that is functionally related to MECP2, for example a PRC2-associated region of a lncRNA that regulates expression of MECP2 by facilitating (e.g., in a cis-regulatory manner) the recruitment of PRC2 to the MECP2 gene. Such oligonucleotides are expected to be candidates for activating expression of MECP2 because of their ability to hybridize with the PRC2-associated region of a nucleic acid (e.g., a lncRNA). In some embodiments, this hybridization event is understood to disrupt interaction of PRC2 with the nucleic acid (e.g., a lncRNA) and as a result disrupt recruitment of PRC2 and its associated co-repressors (e.g., chromatin remodeling factors) to the MECP2 gene locus.
Methods of selecting a candidate oligonucleotide may involve selecting a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 5 to 118) that maps to a chromosomal position encompassing or in proximity to the MECP2 gene (e.g., a chromosomal position having a sequence as set forth in any one of SEQ ID NOS: 1 to 4). The PRC2-associated region may map to the strand of the chromosome comprising the sense strand of the MECP2 gene, in which case the candidate oligonucleotide is complementary to the sense strand of the MECP2 gene (i.e., is antisense to the MECP2 gene). Alternatively, the PRC2-associated region may map to the strand of the first chromosome comprising the antisense strand of the MECP2 gene, in which case the oligonucleotide is complementary to the antisense strand (the template strand) of the MECP2 gene (i.e., is sense to the MECP2 gene).
Methods for selecting a set of candidate oligonucleotides that is enriched in oligonucleotides that activate expression of MECP2 may involve selecting one or more PRC2-associated regions that map to a chromosomal position that encompasses or that is in proximity to the MECP2 gene and selecting a set of oligonucleotides, in which each oligonucleotide in the set comprises a nucleotide sequence that is complementary with the one or more PRC2-associated regions. As used herein, the phrase, “a set of oligonucleotides that is enriched in oligonucleotides that activate expression of” refers to a set of oligonucleotides that has a greater number of oligonucleotides that activate expression of a target gene (e.g., MECP2) compared with a random selection of oligonucleotides of the same physicochemical properties (e.g., the same GC content, Tm, length etc.) as the enriched set.
Where the design and/or synthesis of a single stranded oligonucleotide involves design and/or synthesis of a sequence that is complementary to a nucleic acid or PRC2-associated region described by such sequence information, the skilled person is readily able to determine the complementary sequence, e.g., through understanding of Watson Crick base pairing rules which form part of the common general knowledge in the field.
In some embodiments design and/or synthesis of a single stranded oligonucleotide involves manufacture of an oligonucleotide from starting materials by techniques known to those of skill in the art, where the synthesis may be based on a sequence of a PRC2-associated region, or portion thereof.
Methods of design and/or synthesis of a single stranded oligonucleotide may involve one or more of the steps of:
Identifying and/or selecting PRC2-associated region;
Designing a nucleic acid sequence having a desired degree of sequence identity or complementarity to a PRC2-associated region or a portion thereof;
Synthesizing a single stranded oligonucleotide to the designed sequence;
Purifying the synthesized single stranded oligonucleotide; and
Optionally mixing the synthesized single stranded oligonucleotide with at least one pharmaceutically acceptable diluent, carrier or excipient to form a pharmaceutical composition or medicament.
Single stranded oligonucleotides so designed and/or synthesized may be useful in method of modulating gene expression as described herein.
Preferably, single stranded oligonucleotides of the invention are synthesized chemically. Oligonucleotides used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques.
Oligonucleotides of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification. For example, nucleic acid sequences of the invention include a phosphorothioate at least the first, second, or third internucleotide linkage at the 5′ or 3′ end of the nucleotide sequence. As another example, the nucleic acid sequence can include a 2′-modified nucleotide, e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or 2′-O—N-methylacetamido (2′-O-NMA). As another example, the nucleic acid sequence can include at least one 2′-O-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2′-O-methyl modification. In some embodiments, the nucleic acids are “locked,” i.e., comprise nucleic acid analogues in which the ribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom.
It is understood that any of the modified chemistries or formats of single stranded oligonucleotides described herein can be combined with each other, and that one, two, three, four, five, or more different types of modifications can be included within the same molecule. In some embodiments, the method may further comprise the steps of amplifying the synthesized single stranded oligonucleotide, and/or purifying the single stranded oligonucleotide (or amplified single stranded oligonucleotide), and/or sequencing the single stranded oligonucleotide so obtained.
As such, the process of preparing a single stranded oligonucleotide may be a process that is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene associated with a PRC2-associated region.
In the methods described above a PRC2-associated region may be, or have been, identified, or obtained, by a method that involves identifying RNA that binds to PRC2.
Such methods may involve the following steps: providing a sample containing nuclear ribonucleic acids, contacting the sample with an agent that binds specifically to PRC2 or a subunit thereof, allowing complexes to form between the agent and protein in the sample, partitioning the complexes, synthesizing nucleic acid that is complementary to nucleic acid present in the complexes.
Where the single stranded oligonucleotide is based on a PRC2-associated region, or a portion of such a sequence, it may be based on information about that sequence, e.g., sequence information available in written or electronic form, which may include sequence information contained in publicly available scientific publications or sequence databases.
Nucleotide Analogues
In some embodiments, the oligonucleotide may comprise at least one ribonucleotide, at least one deoxyribonucleotide, and/or at least one bridged nucleotide. In some embodiments, the oligonucleotide may comprise a bridged nucleotide, such as a locked nucleic acid (LNA) nucleotide, a constrained ethyl (cEt) nucleotide, or an ethylene bridged nucleic acid (ENA) nucleotide. Examples of such nucleotides are disclosed herein and known in the art. In some embodiments, the oligonucleotide comprises a nucleotide analog disclosed in one of the following United States Patent or Patent Application Publications: U.S. Pat. Nos. 7,399,845, 7,741,457, 8,022,193, 7,569,686, 7,335,765, 7,314,923, 7,335,765, and U.S. Pat. No. 7,816,333, US 20110009471, the entire contents of each of which are incorporated herein by reference for all purposes. The oligonucleotide may have one or more 2′ O-methyl nucleotides. The oligonucleotide may consist entirely of 2′ O-methyl nucleotides.
Often the single stranded oligonucleotide has one or more nucleotide analogues. For example, the single stranded oligonucleotide may have at least one nucleotide analogue that results in an increase in Tm of the oligonucleotide in a range of 1° C., 2° C., 3° C., 4° C., or 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue. The single stranded oligonucleotide may have a plurality of nucleotide analogues that results in a total increase in Tm of the oligonucleotide in a range of 2° C., 3° C., 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 15° C., 20° C., 25° C., 30° C., 35° C., 40° C., 45° C. or more compared with an oligonucleotide that does not have the nucleotide analogue.
The oligonucleotide may be of up to 50 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides of the oligonucleotide are nucleotide analogues. The oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides of the oligonucleotide are nucleotide analogues. The oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides of the oligonucleotide are nucleotide analogues. Optionally, the oligonucleotides may have every nucleotide except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides modified.
The oligonucleotide may consist entirely of bridged nucleotides (e.g., LNA nucleotides, cEt nucleotides, ENA nucleotides). The oligonucleotide may comprise alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides. The oligonucleotide may comprise alternating deoxyribonucleotides and 2′-O-methyl nucleotides. The oligonucleotide may comprise alternating deoxyribonucleotides and ENA nucleotide analogues. The oligonucleotide may comprise alternating deoxyribonucleotides and LNA nucleotides. The oligonucleotide may comprise alternating LNA nucleotides and 2′-O-methyl nucleotides. The oligonucleotide may have a 5′ nucleotide that is a bridged nucleotide (e.g., a LNA nucleotide, cEt nucleotide, ENA nucleotide). The oligonucleotide may have a 5′ nucleotide that is a deoxyribonucleotide.
The oligonucleotide may comprise deoxyribonucleotides flanked by at least one bridged nucleotide (e.g., a LNA nucleotide, cEt nucleotide, ENA nucleotide) on each of the 5′ and 3′ ends of the deoxyribonucleotides. The oligonucleotide may comprise deoxyribonucleotides flanked by 1, 2, 3, 4, 5, 6, 7, 8 or more bridged nucleotides (e.g., LNA nucleotides, cEt nucleotides, ENA nucleotides) on each of the 5′ and 3′ ends of the deoxyribonucleotides. The 3′ position of the oligonucleotide may have a 3′ hydroxyl group. The 3′ position of the oligonucleotide may have a 3′ thiophosphate.
The oligonucleotide may be conjugated with a label. For example, the oligonucleotide may be conjugated with a biotin moiety, cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5′ or 3′ end.
Preferably the single stranded oligonucleotide comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.
In some embodiments, the single stranded oligonucleotides are chimeric oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. Chimeric single stranded oligonucleotides of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5, 220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.
In some embodiments, the single stranded oligonucleotide comprises at least one nucleotide modified at the 2′ position of the sugar, most preferably a 2′-O-alkyl, 2′-O-alkyl-O-alkyl or 2′-fluoro-modified nucleotide. In other preferred embodiments, RNA modifications include 2′-fluoro, 2′-amino and 2′ O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3′ end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher Tm (i.e., higher target binding affinity) than 2′-deoxyoligonucleotides against a given target.
A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide; these modified oligos survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly CH2 —NH—O—CH2, CH,˜N(CH3)˜O˜CH2 (known as a methylene(methylimino) or MMI backbone, CH2—O—N (CH3)—CH2, CH2 —N (CH3)—N (CH3)—CH2 and O—N (CH3)—CH2 —CH2 backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH); amide backbones (see De Mesmaeker et al. Ace. Chem. Res. 1995, 28:366-374); morpholino backbone structures (see Summerton and Weller, U.S. Pat. No. 5,034,506); peptide nucleic acid (PNA) backbone (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., Science 1991, 254, 1497). Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3′alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′; see U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.
Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).
Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 2000, 122, 8595-8602.
Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts; see U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.
Modified oligonucleotides are also known that include oligonucleotides that are based on or constructed from arabinonucleotide or modified arabinonucleotide residues. Arabinonucleosides are stereoisomers of ribonucleosides, differing only in the configuration at the 2′-position of the sugar ring. In some embodiments, a 2′-arabino modification is 2′-F arabino. In some embodiments, the modified oligonucleotide is 2′-fluoro-D-arabinonucleic acid (FANA) (as described in, for example, Lon et al., Biochem., 41:3457-3467, 2002 and Min et al., Bioorg. Med. Chem. Lett., 12:2651-2654, 2002; the disclosures of which are incorporated herein by reference in their entireties). Similar modifications can also be made at other positions on the sugar, particularly the 3′ position of the sugar on a 3′ terminal nucleoside or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide.
PCT Publication No. WO 99/67378 discloses arabinonucleic acids (ANA) oligomers and their analogues for improved sequence specific inhibition of gene expression via association to complementary messenger RNA.
Other preferred modifications include ethylene-bridged nucleic acids (ENAs) (e.g., International Patent Publication No. WO 2005/042777, Morita et al., Nucleic Acid Res., Suppl 1:241-242, 2001; Surono et al., Hum. Gene Ther., 15:749-757, 2004; Koizumi, Curr. Opin. Mol. Ther., 8:144-149, 2006 and Horie et al., Nucleic Acids Symp. Ser (Oxf), 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties). Preferred ENAs include, but are not limited to, 2′-O,4′-C-ethylene-bridged nucleic acids.
Examples of LNAs are described in WO/2008/043753 and include compounds of the following general formula.
Figure US11788089-20231017-C00001
where X and Y are independently selected among the groups —O—,
—S—, —N(H)—, N(R)—, —CH2— or —CH— (if part of a double bond),
—CH2—O—, —CH2—S—, —CH2—N(H)—, —CH2—N(R)—, —CH2—CH2— or —CH2—CH— (if part of a double bond),
—CH═CH—, where R is selected from hydrogen and C1-4-alkyl; Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety; and the asymmetric groups may be found in either orientation.
Preferably, the LNA used in the oligonucleotides described herein comprises at least one LNA unit according any of the formulas
Figure US11788089-20231017-C00002
wherein Y is —O—, —S—, —NH—, or N(RH); Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety, and RH is selected from hydrogen and C1-4-alkyl.
In some embodiments, the Locked Nucleic Acid (LNA) used in the oligonucleotides described herein comprises at least one Locked Nucleic Acid (LNA) unit according any of the formulas shown in Scheme 2 of PCT/DK2006/000512.
In some embodiments, the LNA used in the oligomer of the invention comprises internucleoside linkages selected from -0-P(O)2—O—, —O—P(O,S)—O—, —O—P(S)2—O—, —S—P(O)2—O—, —S—P(O,S)—O—, —S—P(S)2—O—, -0-P(O)2—S—, —O—P(O,S)—S—, —S—P(O)2—S—, —O—PO(RH)—O—, O—PO(OCH3)—O—, —O—PO(NRH)—O—, -0-PO(OCH2CH2S—R)—O—, —O—PO(BH3)—O—, —O—PO(NHRH)—O—, —O—P(O)2—NRH—, —NRH—P(O)2—O—, —NRH—CO—O—, where RH is selected from hydrogen and C1-4-alkyl.
Specifically preferred LNA units are shown in scheme 2:
Figure US11788089-20231017-C00003
The term “thio-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from S or —CH2—S—. Thio-LNA can be in both beta-D and alpha-L-configuration.
The term “amino-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from —N(H)—, N(R)—, CH2—N(H)—, and —CH2—N(R)— where R is selected from hydrogen and C1-4-alkyl. Amino-LNA can be in both beta-D and alpha-L-configuration.
The term “oxy-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above represents —O— or —CH2—O—. Oxy-LNA can be in both beta-D and alpha-L-configuration.
The term “ena-LNA” comprises a locked nucleotide in which Y in the general formula above is —CH2—O— (where the oxygen atom of —CH2—O— is attached to the 2′-position relative to the base B).
LNAs are described in additional detail herein.
One or more substituted sugar moieties can also be included, e.g., one of the following at the 2′ position: OH, SH, SCH3, F, OCN, OCH3 OCH3, OCH3 O(CH2)n CH3, O(CH2)n NH2 or O(CH2)n CH3 where n is from 1 to about 10; C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF3; OCF3; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH3; SO2 CH3; ONO2; NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy [2′-O—CH2CH2OCH3, also known as 2′-O-(2-methoxyethyl)] (Martin et al, HeIv. Chim. Acta, 1995, 78, 486). Other preferred modifications include 2′-methoxy (2′-O—CH3), 2′-propoxy (2′-OCH2 CH2CH3) and 2′-fluoro (2′-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.
Single stranded oligonucleotides can also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2′ deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, isocytosine, pseudoisocytosine, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 5-propynyluracil, 8-azaguanine, 7-deazaguanine, N6 (6-aminohexyl)adenine, 6-aminopurine, 2-aminopurine, 2-chloro-6-aminopurine and 2,6-diaminopurine or other diaminopurines. See, e.g., Kornberg, “DNA Replication,” W. H. Freeman & Co., San Francisco, 1980, pp 75-77; and Gebeyehu, G., et al. Nucl. Acids Res., 15:4513 (1987)). A “universal” base known in the art, e.g., inosine, can also be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, in Crooke, and Lebleu, eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and may be used as base substitutions.
It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.
In some embodiments, both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, Science, 1991, 254, 1497-1500.
Single stranded oligonucleotides can also include one or more nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.
Further, nucleobases comprise those disclosed in U.S. Pat. No. 3,687,808, those disclosed in “The Concise Encyclopedia of Polymer Science And Engineering”, pages 858-859, Kroschwitz, ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandle Chemie, International Edition, 1991, 30, page 613, and those disclosed by Sanghvi, Chapter 15, Antisense Research and Applications,” pages 289-302, Crooke, and Lebleu, eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2<0>C (Sanghvi, et al., eds, “Antisense Research and Applications,” CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications. Modified nucleobases are described in U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175, 273; 5, 367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.
In some embodiments, the single stranded oligonucleotides are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. For example, one or more single stranded oligonucleotides, of the same or different types, can be conjugated to each other; or single stranded oligonucleotides can be conjugated to targeting moieties with enhanced specificity for a cell type or tissue type. Such moieties include, but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al, Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). See also U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552, 538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.
These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety. See, e.g., U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.
In some embodiments, single stranded oligonucleotide modification include modification of the 5′ or 3′ end of the oligonucleotide. In some embodiments, the 3′ end of the oligonucleotide comprises a hydroxyl group or a thiophosphate. It should be appreciated that additional molecules (e.g. a biotin moiety or a fluorophor) can be conjugated to the 5′ or 3′ end of the single stranded oligonucleotide. In some embodiments, the single stranded oligonucleotide comprises a biotin moiety conjugated to the 5′ nucleotide.
In some embodiments, the single stranded oligonucleotide comprises locked nucleic acids (LNA), ENA modified nucleotides, 2′-O-methyl nucleotides, or 2′-fluoro-deoxyribonucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2′-O-methyl nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and ENA modified nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and locked nucleic acid nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating locked nucleic acid nucleotides and 2′-O-methyl nucleotides.
In some embodiments, the 5′ nucleotide of the oligonucleotide is a deoxyribonucleotide. In some embodiments, the 5′ nucleotide of the oligonucleotide is a locked nucleic acid nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one locked nucleic acid nucleotide on each of the 5′ and 3′ ends of the deoxyribonucleotides. In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group or a 3′ thiophosphate.
In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between at least two nucleotides. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between all nucleotides.
It should be appreciated that the single stranded oligonucleotide can have any combination of modifications as described herein.
The oligonucleotide may comprise a nucleotide sequence having one or more of the following modification patterns.
(a) (X)Xxxxxx, (X)xXxxxx, (X)xxXxxx, (X)xxxXxx, (X)xxxxXx and (X)xxxxxX,
(b) (X)XXxxxx, (X)XxXxxx, (X)XxxXxx, (X)XxxxXx, (X)XxxxxX, (X)xXXxxx, (X)xXxXxx, (X)xXxxXx, (X)xXxxxX, (X)xxXXxx, (X)xxXxXx, (X)xxXxxX, (X)xxxXXx, (X)xxxXxX and (X)xxxxXX,
(c) (X)XXXxxx, (X)xXXXxx, (X)xxXXXx, (X)xxxXXX, (X)XXxXxx, (X)XXxxXx, (X)XXxxxX, (X)xXXxXx, (X)xXXxxX, (X)xxXXxX, (X)XxXXxx, (X)XxxXXx (X)XxxxXX, (X)xXxXXx, (X)xXxxXX, (X)xxXxXX, (X)xXxXxX and (X)XxXxXx,
(d) (X)xxXXX, (X)xXxXXX, (X)xXXxXX, (X)xXXXxX, (X)xXXXXx, (X)XxxXXXX, (X)XxXxXX, (X)XxXXxX, (X)XxXXx, (X)XXxxXX, (X)XXxXxX, (X)XXxXXx, (X)XXXxxX, (X)XXXxXx, and (X)XXXXxx,
(e) (X)xXXXXX, (X)XxXXXX, (X)XXxXXX, (X)XXXxXX, (X)XXXXxX and (X)XXXXXx, and
(f) XXXXXX, XxXXXXX, XXxXXXX, XXXxXXX, XXXXxXX, XXXXXxX and XXXXXXx, in which “X” denotes a nucleotide analogue, (X) denotes an optional nucleotide analogue, and “x” denotes a DNA or RNA nucleotide unit. Each of the above listed patterns may appear one or more times within an oligonucleotide, alone or in combination with any of the other disclosed modification patterns.
Methods for Modulating Gene Expression
In one aspect, the invention relates to methods for modulating gene expression in a cell (e.g., a cell for which MECP2 levels are reduced) for research purposes (e.g., to study the function of the gene in the cell). In another aspect, the invention relates to methods for modulating gene expression in a cell (e.g., a cell for which MECP2 levels are reduced) for gene or epigenetic therapy. The cells can be in vitro, ex vivo, or in vivo (e.g., in a subject who has a disease resulting from reduced expression or activity of MECP2. In some embodiments, methods for modulating gene expression in a cell comprise delivering a single stranded oligonucleotide as described herein. In some embodiments, delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered. In certain embodiments, delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 50% greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered.
In another aspect of the invention, methods comprise administering to a subject (e.g. a human) a composition comprising a single stranded oligonucleotide as described herein to increase protein levels in the subject. In some embodiments, the increase in protein levels is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or more, higher than the amount of a protein in the subject before administering.
As another example, to increase expression of MECP2 in a cell, the methods include introducing into the cell a single stranded oligonucleotide that is sufficiently complementary to a PRC2-associated region (e.g., of a long non-coding RNA) that maps to a genomic position encompassing or in proximity to the MECP2 gene.
In another aspect of the invention provides methods of treating a condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels of expression of MECP2 in a subject, the method comprising administering a single stranded oligonucleotide as described herein.
A subject can include a non-human mammal, e.g. mouse, rat, guinea pig, rabbit, cat, dog, goat, cow, or horse. In preferred embodiments, a subject is a human. Single stranded oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Single stranded oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.
For therapeutics, an animal, preferably a human, suspected of having Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, or PPM-X syndrome is treated by administering single stranded oligonucleotide in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a single stranded oligonucleotide as described herein.
Formulation, Delivery, And Dosing
The oligonucleotides described herein can be formulated for administration to a subject for treating a condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels of MECP2. It should be understood that the formulations, compositions and methods can be practiced with any of the oligonucleotides disclosed herein.
The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient (e.g., an oligonucleotide or compound of the invention) which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g. tumor regression.
Pharmaceutical formulations of this invention can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such formulations can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixtured with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.
A formulated single stranded oligonucleotide composition can assume a variety of states. In some examples, the composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g., less than 80, 50, 30, 20, or 10% water). In another example, the single stranded oligonucleotide is in an aqueous phase, e.g., in a solution that includes water. The aqueous phase or the crystalline compositions can, e.g., be incorporated into a delivery vehicle, e.g., a liposome (particularly for the aqueous phase) or a particle (e.g., a microparticle as can be appropriate for a crystalline composition). Generally, the single stranded oligonucleotide composition is formulated in a manner that is compatible with the intended method of administration.
In some embodiments, the composition is prepared by at least one of the following methods: spray drying, lyophilization, vacuum drying, evaporation, fluid bed drying, or a combination of these techniques; or sonication with a lipid, freeze-drying, condensation and other self-assembly.
A single stranded oligonucleotide preparation can be formulated or administered (together or separately) in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes a single stranded oligonucleotide, e.g., a protein that complexes with single stranded oligonucleotide. Still other agents include chelators, e.g., EDTA (e.g., to remove divalent cations such as Mg2+), salts, RNAse inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.
In one embodiment, the single stranded oligonucleotide preparation includes another single stranded oligonucleotide, e.g., a second single stranded oligonucleotide that modulates expression of a second gene or a second single stranded oligonucleotide that modulates expression of the first gene. Still other preparation can include at least 3, 5, ten, twenty, fifty, or a hundred or more different single stranded oligonucleotide species. Such single stranded oligonucleotides can mediated gene expression with respect to a similar number of different genes. In one embodiment, the single stranded oligonucleotide preparation includes at least a second therapeutic agent (e.g., an agent other than an oligonucleotide).
Route of Delivery
A composition that includes a single stranded oligonucleotide can be delivered to a subject by a variety of routes. Exemplary routes include: intravenous, intradermal, topical, rectal, parenteral, anal, intravaginal, intranasal, pulmonary, ocular. The term “therapeutically effective amount” is the amount of oligonucleotide present in the composition that is needed to provide the desired level of MECP2 expression in the subject to be treated to give the anticipated physiological response. The term “physiologically effective amount” is that amount delivered to a subject to give the desired palliative or curative effect. The term “pharmaceutically acceptable carrier” means that the carrier can be administered to a subject with no significant adverse toxicological effects to the subject.
The single stranded oligonucleotide molecules of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically include one or more species of single stranded oligonucleotide and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
The route and site of administration may be chosen to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscles of interest would be a logical choice. Lung cells might be targeted by administering the single stranded oligonucleotide in aerosol form. The vascular endothelial cells could be targeted by coating a balloon catheter with the single stranded oligonucleotide and mechanically introducing the oligonucleotide.
Topical administration refers to the delivery to a subject by contacting the formulation directly to a surface of the subject. The most common form of topical delivery is to the skin, but a composition disclosed herein can also be directly applied to other surfaces of the body, e.g., to the eye, a mucous membrane, to surfaces of a body cavity or to an internal surface. As mentioned above, the most common topical delivery is to the skin. The term encompasses several routes of administration including, but not limited to, topical and transdermal. These modes of administration typically include penetration of the skin's permeability barrier and efficient delivery to the target tissue or stratum. Topical administration can be used as a means to penetrate the epidermis and dermis and ultimately achieve systemic delivery of the composition. Topical administration can also be used as a means to selectively deliver oligonucleotides to the epidermis or dermis of a subject, or to specific strata thereof, or to an underlying tissue.
Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.
Transdermal delivery is a valuable route for the administration of lipid soluble therapeutics. The dermis is more permeable than the epidermis and therefore absorption is much more rapid through abraded, burned or denuded skin. Inflammation and other physiologic conditions that increase blood flow to the skin also enhance transdermal adsorption. Absorption via this route may be enhanced by the use of an oily vehicle (inunction) or through the use of one or more penetration enhancers. Other effective ways to deliver a composition disclosed herein via the transdermal route include hydration of the skin and the use of controlled release topical patches. The transdermal route provides a potentially effective means to deliver a composition disclosed herein for systemic and/or local therapy. In addition, iontophoresis (transfer of ionic solutes through biological membranes under the influence of an electric field), phonophoresis or sonophoresis (use of ultrasound to enhance the absorption of various therapeutic agents across biological membranes, notably the skin and the cornea), and optimization of vehicle characteristics relative to dose position and retention at the site of administration may be useful methods for enhancing the transport of topically applied compositions across skin and mucosal sites.
Both the oral and nasal membranes offer advantages over other routes of administration. For example, oligonucleotides administered through these membranes may have a rapid onset of action, provide therapeutic plasma levels, avoid first pass effect of hepatic metabolism, and avoid exposure of the oligonucleotides to the hostile gastrointestinal (GI) environment. Additional advantages include easy access to the membrane sites so that the oligonucleotide can be applied, localized and removed easily.
In oral delivery, compositions can be targeted to a surface of the oral cavity, e.g., to sublingual mucosa which includes the membrane of ventral surface of the tongue and the floor of the mouth or the buccal mucosa which constitutes the lining of the cheek. The sublingual mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many agents. Further, the sublingual mucosa is convenient, acceptable and easily accessible.
A pharmaceutical composition of single stranded oligonucleotide may also be administered to the buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar pharmaceutical formulation as described above and a propellant. In one embodiment, the dispenser is first shaken prior to spraying the pharmaceutical formulation and propellant into the buccal cavity.
Compositions for oral administration include powders or granules, suspensions or solutions in water, syrups, slurries, emulsions, elixirs or non-aqueous media, tablets, capsules, lozenges, or troches. In the case of tablets, carriers that can be used include lactose, sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, and lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular weight polyethylene glycols. When aqueous suspensions are required for oral use, the nucleic acid compositions can be combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added.
Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, intrathecal or intraventricular administration. In some embodiments, parental administration involves administration directly to the site of disease (e.g. injection into a tumor).
Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic.
Any of the single stranded oligonucleotides described herein can be administered to ocular tissue. For example, the compositions can be applied to the surface of the eye or nearby tissue, e.g., the inside of the eyelid. For ocular administration, ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers. Such compositions can include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA or benzylchronium chloride, and the usual quantities of diluents and/or carriers. The single stranded oligonucleotide can also be administered to the interior of the eye, and can be introduced by a needle or other delivery device which can introduce it to a selected area or structure.
Pulmonary delivery compositions can be delivered by inhalation by the patient of a dispersion so that the composition, preferably single stranded oligonucleotides, within the dispersion can reach the lung where it can be readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.
Pulmonary delivery can be achieved by different approaches, including the use of nebulized, aerosolized, micellular and dry powder-based formulations. Delivery can be achieved with liquid nebulizers, aerosol-based inhalers, and dry powder dispersion devices. Metered-dose devices are preferred. One of the benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self-contained. Dry powder dispersion devices, for example, deliver agents that may be readily formulated as dry powders. A single stranded oligonucleotide composition may be stably stored as lyophilized or spray-dried powders by itself or in combination with suitable powder carriers. The delivery of a composition for inhalation can be mediated by a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.
The term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli. Thus, the powder is said to be “respirable.” Preferably the average particle size is less than about 10 μm in diameter preferably with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 μm and most preferably less than about 5.0 μm. Usually the particle size distribution is between about 0.1 μm and about 5 μm in diameter, particularly about 0.3 μm to about 5 μm.
The term “dry” means that the composition has a moisture content below about 10% by weight (% w) water, usually below about 5% w and preferably less it than about 3% w. A dry composition can be such that the particles are readily dispersible in an inhalation device to form an aerosol.
The types of pharmaceutical excipients that are useful as carrier include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.
Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred. Pulmonary administration of a micellar single stranded oligonucleotide formulation may be achieved through metered dose spray devices with propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants.
Exemplary devices include devices which are introduced into the vasculature, e.g., devices inserted into the lumen of a vascular tissue, or which devices themselves form a part of the vasculature, including stents, catheters, heart valves, and other vascular devices. These devices, e.g., catheters or stents, can be placed in the vasculature of the lung, heart, or leg.
Other devices include non-vascular devices, e.g., devices implanted in the peritoneum, or in organ or glandular tissue, e.g., artificial organs. The device can release a therapeutic substance in addition to a single stranded oligonucleotide, e.g., a device can release insulin.
In one embodiment, unit doses or measured doses of a composition that includes single stranded oligonucleotide are dispensed by an implanted device. The device can include a sensor that monitors a parameter within a subject. For example, the device can include pump, e.g., and, optionally, associated electronics.
Tissue, e.g., cells or organs can be treated with a single stranded oligonucleotide, ex vivo and then administered or implanted in a subject. The tissue can be autologous, allogeneic, or xenogeneic tissue. E.g., tissue can be treated to reduce graft v. host disease. In other embodiments, the tissue is allogeneic and the tissue is treated to treat a disorder characterized by unwanted gene expression in that tissue. E.g., tissue, e.g., hematopoietic cells, e.g., bone marrow hematopoietic cells, can be treated to inhibit unwanted cell proliferation. Introduction of treated tissue, whether autologous or transplant, can be combined with other therapies. In some implementations, the single stranded oligonucleotide treated cells are insulated from other cells, e.g., by a semi-permeable porous barrier that prevents the cells from leaving the implant, but enables molecules from the body to reach the cells and molecules produced by the cells to enter the body. In one embodiment, the porous barrier is formed from alginate.
In one embodiment, a contraceptive device is coated with or contains a single stranded oligonucleotide. Exemplary devices include condoms, diaphragms, IUD (implantable uterine devices, sponges, vaginal sheaths, and birth control devices.
Dosage
In one aspect, the invention features a method of administering a single stranded oligonucleotide (e.g., as a compound or as a component of a composition) to a subject (e.g., a human subject). In one embodiment, the unit dose is between about 10 mg and 25 mg per kg of bodyweight. In one embodiment, the unit dose is between about 1 mg and 100 mg per kg of bodyweight. In one embodiment, the unit dose is between about 0.1 mg and 500 mg per kg of bodyweight. In some embodiments, the unit dose is more than 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 25, 50 or 100 mg per kg of bodyweight.
The defined amount can be an amount effective to treat or prevent a disease or disorder, e.g., a disease or disorder associated with the MECP2. The unit dose, for example, can be administered by injection (e.g., intravenous or intramuscular), an inhaled dose, or a topical application.
In some embodiments, the unit dose is administered daily. In some embodiments, less frequently than once a day, e.g., less than every 2, 4, 8 or 30 days. In another embodiment, the unit dose is not administered with a frequency (e.g., not a regular frequency). For example, the unit dose may be administered a single time. In some embodiments, the unit dose is administered more than once a day, e.g., once an hour, two hours, four hours, eight hours, twelve hours, etc.
In one embodiment, a subject is administered an initial dose and one or more maintenance doses of a single stranded oligonucleotide. The maintenance dose or doses are generally lower than the initial dose, e.g., one-half less of the initial dose. A maintenance regimen can include treating the subject with a dose or doses ranging from 0.0001 to 100 mg/kg of body weight per day, e.g., 100, 10, 1, 0.1, 0.01, 0.001, or 0.0001 mg per kg of bodyweight per day. The maintenance doses may be administered no more than once every 1, 5, 10, or 30 days. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient. In some embodiments the dosage may be delivered no more than once per day, e.g., no more than once per 24, 36, 48, or more hours, e.g., no more than once for every 5 or 8 days. Following treatment, the patient can be monitored for changes in his condition and for alleviation of the symptoms of the disease state. The dosage of the oligonucleotide may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, if the disease state has been ablated, or if undesired side-effects are observed.
The effective dose can be administered in a single dose or in two or more doses, as desired or considered appropriate under the specific circumstances. If desired to facilitate repeated or frequent infusions, implantation of a delivery device, e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable.
In some embodiments, the oligonucleotide pharmaceutical composition includes a plurality of single stranded oligonucleotide species. In another embodiment, the single stranded oligonucleotide species has sequences that are non-overlapping and non-adjacent to another species with respect to a naturally occurring target sequence (e.g., a PRC2-associated region). In another embodiment, the plurality of single stranded oligonucleotide species is specific for different PRC2-associated regions. In another embodiment, the single stranded oligonucleotide is allele specific. In some cases, a patient is treated with a single stranded oligonucleotide in conjunction with other therapeutic modalities.
Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the compound of the invention is administered in maintenance doses, ranging from 0.0001 mg to 100 mg per kg of body weight.
The concentration of the single stranded oligonucleotide composition is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in humans. The concentration or amount of single stranded oligonucleotide administered will depend on the parameters determined for the agent and the method of administration, e.g. nasal, buccal, pulmonary. For example, nasal formulations may tend to require much lower concentrations of some ingredients in order to avoid irritation or burning of the nasal passages. It is sometimes desirable to dilute an oral formulation up to 10-100 times in order to provide a suitable nasal formulation.
Certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a single stranded oligonucleotide can include a single treatment or, preferably, can include a series of treatments. It will also be appreciated that the effective dosage of a single stranded oligonucleotide used for treatment may increase or decrease over the course of a particular treatment. For example, the subject can be monitored after administering a single stranded oligonucleotide composition. Based on information from the monitoring, an additional amount of the single stranded oligonucleotide composition can be administered.
Dosing is dependent on severity and responsiveness of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved. Optimal dosing schedules can be calculated from measurements of MECP2 expression levels in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models. In some embodiments, the animal models include transgenic animals that express a human MECP2. In another embodiment, the composition for testing includes a single stranded oligonucleotide that is complementary, at least in an internal region, to a sequence that is conserved between MECP2 in the animal model and the MECP2 in a human.
In one embodiment, the administration of the single stranded oligonucleotide composition is parenteral, e.g. intravenous (e.g., as a bolus or as a diffusible infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral or ocular. Administration can be provided by the subject or by another person, e.g., a health care provider. The composition can be provided in measured doses or in a dispenser which delivers a metered dose. Selected modes of delivery are discussed in more detail below.
Kits
In certain aspects of the invention, kits are provided, comprising a container housing a composition comprising a single stranded oligonucleotide. In some embodiments, the composition is a pharmaceutical composition comprising a single stranded oligonucleotide and a pharmaceutically acceptable carrier. In some embodiments, the individual components of the pharmaceutical composition may be provided in one container. Alternatively, it may be desirable to provide the components of the pharmaceutical composition separately in two or more containers, e.g., one container for single stranded oligonucleotides, and at least another for a carrier compound. The kit may be packaged in a number of different configurations such as one or more containers in a single box. The different components can be combined, e.g., according to instructions provided with the kit. The components can be combined according to a method described herein, e.g., to prepare and administer a pharmaceutical composition. The kit can also include a delivery device.
The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.
EXAMPLES
The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
Materials and Methods:
Real Time PCR
RNA is harvested from the cells using Promega SV 96 Total RNA Isolation system or Trizol omitting the DNAse step. RNA harvested from cells is normalized so that equal RNA is input to each reverse transcription reaction. Reverse transcriptase reactions are performed using the Superscript II kit and real time PCR performed on cDNA samples using icycler SYBR green chemistry (Biorad). A baseline level of mRNA expression for MECP2 is determined through quantitative PCR as outlined above. Baseline levels are also determined for mRNA of various housekeeping genes which are constitutively expressed. A “control” housekeeping gene with approximately the same level of baseline expression as the target gene is chosen for comparison purposes.
Cell Culture
Human hepatocyte Hep3B, human hepatocyte HepG2 cells, mouse hepatoma Hepa1-6 cells, and human renal proximal tubule epithelial cells (RPTEC) are cultured using conditions known in the art (see, e.g. Current Protocols in Cell Biology).
Oligonucleotide Design
Oligonucleotides were designed within PRC2-interacting regions in order to upregulate MECP2. The sequence and structure of each oligonucleotide is shown in Table 3. The following table provides a description of the nucleotide analogs, modifications and intranucleotide linkages used for certain oligonucleotides tested and described in Table 2.
In Vitro Transfection of Cells with Oligonucleotides
Oligonucleotides are designed within PRC2-interacting regions in order to upregulate MECP2. Cells are seeded into each well of 24-well plates at a density of 25,000 cells per 500 uL and transfections are performed with Lipofectamine and the single stranded oligonucleotides. Control wells contain Lipofectamine alone. At 48 hours post-transfection, approximately 200 uL of cell culture supernatants are stored at −80 C for ELISA. At 48 hours post-transfection, RNA is harvested from the cells and quantitative PCR is carried out as outlined above. The percent induction of target mRNA expression by each oligonucleotide is determined by normalizing mRNA levels in the presence of the oligonucleotide to the mRNA levels in the presence of control (Lipofectamine alone). This is compared side-by-side with the increase in mRNA expression of the “control” housekeeping gene.
In Vitro Delivery of Single Stranded Oligonucleotides
Oligonucleotides are designed as candidates for upregulating MECP2 expression. The single stranded oligonucleotides are designed to be complementary to a PRC2-interacting region within a sequence as set forth in SEQ ID NO: 1 or 2. The oligonucleotides are tested in at least duplicate. Briefly, cells are transfected in vitro with each of the oligonucleotides as described above. MECP2 expression in cells following treatment is evaluated by qRT-PCR. Oligonucleotides that upregulate MECP2 expression are identified.
TABLE
Table 1: Hexamers that are not seed sequences of human miRNAs 
AAAAAA, AAAAAG, AAAACA, AAAAGA, AAAAGC, AAAAGG, AAAAUA, AAACAA, AAACAC, AAACAG, 
AAACAU, AAACCC, AAACCU, AAACGA, AAACGC, AAACGU, AAACUA, AAACUC, AAACUU, AAAGAU, 
AAAGCC, AAAGGA, AAAGGG, AAAGUC, AAAUAC, AAAUAU, AAAUCG, AAAUCU, AAAUGC, AAAUGU, 
AAAUUA, AAAUUG, AACAAC, AACAAG, AACAAU, AACACA, AACACG, AACAGA, AACAGC, AACAGG, 
AACAUC, AACAUG, AACCAA, AACCAC, AACCAG, AACCAU, AACCCC, AACCCG, AACCGA, AACCGC, 
AACCGG, AACCUA, AACCUU, AACGAA, AACGAC, AACGAG, AACGAU, AACGCU, AACGGG, AACGGU, 
AACGUA, AACGUC, AACGUG, AACGUU, AACUAU, AACUCA, AACUCC, AACUCG, AACUGA, AACUGC, 
AACUGU, AACUUA, AACUUC, AACUUG, AACUUU, AAGAAA, AAGAAG, AAGAAU, AAGACG, AAGAGA, 
AAGAGC, AAGAGG, AAGAGU, AAGAUU, AAGCAA, AAGCAC, AAGCAG, AAGCAU, AAGCCA, AAGCCC, 
AAGCCG, AAGCCU, AAGCGA, AAGCGG, AAGCGU, AAGCUA, AAGGAA, AAGGAC, AAGGCU, AAGGGC, 
AAGGGU, AAGGUU, AAGUAA, AAGUAC, AAGUAU, AAGUCC, AAGUCG, AAGUGA, AAGUGG, AAGUUA, 
AAGUUU, AAUAAA, AAUAAC, AAUAAG, AAUAAU, AAUACA, AAUACC, AAUACG, AAUAGA, AAUAGC, 
AAUAGG, AAUAGU, AAUAUC, AAUAUU, AAUCAA, AAUCAU, AAUCCA, AAUCCC, AAUCCG, AAUCGA, 
AAUCGC, AAUCGU, AAUCUA, AAUCUG, AAUCUU, AAUGAA, AAUGAC, AAUGAG, AAUGAU, AAUGCG, 
AAUGCU, AAUGGA, AAUGGU, AAUGUA, AAUGUC, AAUGUG, AAUUAA, AAUUAC, AAUUAG, AAUUCC, 
AAUUCG, AAUUGA, AAUUGG, AAUUGU, AAUUUC, AAUUUG, ACAAAA, ACAAAC, ACAAAG, ACAAAU, 
ACAACC, ACAACG, ACAACU, ACAAGA, ACAAGC, ACAAGU, ACAAUC, ACAAUG, ACAAUU, ACACAG, 
ACACCA, ACACCC, ACACCG, ACACCU, ACACGA, ACACGC, ACACGU, ACACUC, ACACUG, ACACUU, 
ACAGAA, ACAGAC, ACAGCC, ACAGCG, ACAGCU, ACAGGG, ACAGUC, ACAGUG, ACAGUU, ACAUAA, 
ACAUAC, ACAUCC, ACAUCG, ACAUCU, ACAUGA, ACAUGC, ACAUGU, ACAUUG, ACAUUU, ACCAAA, 
ACCAAC, ACCAAG, ACCAAU, ACCACC, ACCACG, ACCAGA, ACCAGU, ACCAUA, ACCAUG, ACCAUU, 
ACCCAA, ACCCAC, ACCCCA, ACCCCG, ACCCGA, ACCCGC, ACCCUA, ACCCUC, ACCCUU, ACCGAA, 
ACCGAC, ACCGAU, ACCGCA, ACCGCC, ACCGCG, ACCGCU, ACCGGA, ACCGGC, ACCGGU, ACCGUA, 
ACCGUC, ACCGUG, ACCGUU, ACCUAA, ACCUAC, ACCUAG, ACCUAU, ACCUCA, ACCUCC, ACCUCG, 
ACCUCU, ACCUGA, ACCUGC, ACCUGU, ACCUUA, ACCUUC, ACCUUU, ACGAAA, ACGAAC, ACGAAG, 
ACGAAU, ACGACA, ACGACC, ACGACG, ACGACU, ACGAGA, ACGAGC, ACGAGG, ACGAGU, ACGAUA, 
ACGAUC, ACGAUG, ACGAUU, ACGCAA, ACGCAG, ACGCAU, ACGCCC, ACGCCG, ACGCCU, ACGCGA, 
ACGCGG, ACGCGU, ACGCUA, ACGCUG, ACGCUU, ACGGAA, ACGGAC, ACGGAG, ACGGAU, ACGGCC, 
ACGGCG, ACGGCU, ACGGGC, ACGGGG, ACGGGU, ACGGUA, ACGGUC, ACGGUG, ACGGUU, ACGUAA, 
ACGUAC, ACGUAU, ACGUCC, ACGUCG, ACGUCU, ACGUGA, ACGUGC, ACGUGG, ACGUGU, ACGUUA, 
ACGUUC, ACGUUG, ACGUUU, ACUAAA, ACUAAG, ACUAAU, ACUACA, ACUACC, ACUACG, ACUACU, 
ACUAGG, ACUAUC, ACUAUG, ACUAUU, ACUCAU, ACUCCC, ACUCCG, ACUCCU, ACUCGA, ACUCGC, 
ACUCGG, ACUCUC, ACUCUU, ACUGAG, ACUGAU, ACUGCC, ACUGCG, ACUGCU, ACUGGG, ACUGGU, 
ACUGUC, ACUUAA, ACUUAC, ACUUAU, ACUUCA, ACUUCC, ACUUCG, ACUUCU, ACUUGA, ACUUGC, 
ACUUGU, ACUUUA, ACUUUC, ACUUUG, AGAAAA, AGAAAC, AGAAAG, AGAACC, AGAACG, AGAACU, 
AGAAGC, AGAAGU, AGAAUA, AGAAUC, AGAAUG, AGAAUU, AGACAA, AGACAC, AGACAU, AGACCA, 
AGACCC, AGACCG, AGACCU, AGACGA, AGACGC, AGACGU, AGACUA, AGACUC, AGACUU, AGAGAC, 
AGAGAG, AGAGAU, AGAGCC, AGAGCG, AGAGCU, AGAGGC, AGAGGG, AGAGGU, AGAGUA, AGAGUU, 
AGAUAC, AGAUAG, AGAUAU, AGAUCC, AGAUCG, AGAUCU, AGAUGA, AGAUGC, AGAUGG, AGAUUA, 
AGAUUC, AGAUUG, AGAUUU, AGCAAC, AGCACA, AGCACG, AGCACU, AGCAGA, AGCAUA, AGCAUC, 
AGCAUG, AGCCAA, AGCCAU, AGCCCA, AGCCGA, AGCCGC, AGCCGG, AGCCGU, AGCCUA, AGCCUC, 
AGCGAA, AGCGAG, AGCGAU, AGCGCA, AGCGCC, AGCGCG, AGCGCU, AGCGGA, AGCGGC, AGCGGU, 
AGCGUA, AGCGUC, AGCGUG, AGCGUU, AGCUAA, AGCUAC, AGCUAG, AGCUAU, AGCUCA, AGCUCC, 
AGCUCG, AGCUCU, AGCUGA, AGCUGG, AGCUGU, AGCUUC, AGCUUU, AGGAAU, AGGACC, AGGACG, 
AGGAGA, AGGAGU, AGGAUA, AGGCAA, AGGCAU, AGGCCG, AGGCGA, AGGCGC, AGGCGG, AGGCUA, 
AGGCUC, AGGCUU, AGGGAC, AGGGAU, AGGGGA, AGGGGU, AGGGUA, AGGGUG, AGGUAA, 
AGGUAC, AGGUCA, AGGUCC, AGGUCU, AGGUGA, AGGUGC, AGGUGG, AGGUGU, AGGUUC, 
AGGUUG, AGUAAA, AGUAAG, AGUAAU, AGUACA, AGUACG, AGUAGC, AGUAGG, AGUAUA, AGUAUC, 
AGUAUG, AGUAUU, AGUCAA, AGUCAC, AGUCAG, AGUCAU, AGUCCA, AGUCCG, AGUCCU, AGUCGA, 
AGUCGC, AGUCGG, AGUCGU, AGUCUA, AGUCUC, AGUCUG, AGUCUU, AGUGAA, AGUGAC, AGUGCG, 
AGUGGG, AGUGUC, AGUUAA, AGUUAC, AGUUAG, AGUUCC, AGUUCG, AGUUGA, AGUUGC, 
AGUUGU, AGUUUA, AGUUUC, AGUUUG, AGUUUU, AUAAAC, AUAAAU, AUAACA, AUAACC, AUAACG, 
AUAACU, AUAAGA, AUAAGC, AUAAGG, AUAAGU, AUAAUC, AUAAUG, AUAAUU, AUACAC, AUACAG, 
AUACAU, AUACCA, AUACCC, AUACCG, AUACGA, AUACGC, AUACGG, AUACGU, AUACUA, AUACUC, 
AUACUG, AUACUU, AUAGAA, AUAGAC, AUAGAU, AUAGCA, AUAGCG, AUAGCU, AUAGGA, AUAGGU, 
AUAGUA, AUAGUC, AUAGUG, AUAGUU, AUAUAC, AUAUAG, AUAUCC, AUAUCG, AUAUCU, AUAUGA, 
AUAUGC, AUAUGG, AUAUGU, AUAUUC, AUAUUG, AUAUUU, AUCAAA, AUCAAC, AUCAAG, AUCAAU, 
AUCACA, AUCACC, AUCACG, AUCAGC, AUCAGG, AUCCAA, AUCCAU, AUCCCC, AUCCCG, AUCCGA, 
AUCCGC, AUCCGG, AUCCUA, AUCCUC, AUCCUG, AUCGAA, AUCGAC, AUCGAG, AUCGAU, AUCGCA, 
AUCGCC, AUCGCG, AUCGCU, AUCGGC, AUCGGG, AUCGGU, AUCGUC, AUCGUG, AUCGUU, AUCUAA, 
AUCUAC, AUCUAG, AUCUAU, AUCUCC, AUCUCG, AUCUGU, AUCUUG, AUCUUU, AUGAAA, AUGAAC, 
AUGAAG, AUGAAU, AUGACC, AUGACU, AUGAGG, AUGAGU, AUGAUA, AUGAUC, AUGAUU, AUGCAA, 
AUGCAG, AUGCCA, AUGCCC, AUGCCG, AUGCGA, AUGCGG, AUGCGU, AUGCUC, AUGCUU, AUGGAC, 
AUGGCC, AUGGGA, AUGGGC, AUGGGU, AUGGUC, AUGGUG, AUGUAC, AUGUAU, AUGUCA, 
AUGUCC, AUGUCG, AUGUGU, AUGUUA, AUGUUC, AUUAAA, AUUAAC, AUUAAG, AUUAAU, AUUACA, 
AUUACC, AUUACG, AUUACU, AUUAGA, AUUAGC, AUUAGG, AUUAGU, AUUAUA, AUUAUC, AUUAUG, 
AUUCAC, AUUCCA, AUUCCG, AUUCCU, AUUCGA, AUUCGC, AUUCGG, AUUCGU, AUUCUA, AUUCUC, 
AUUCUU, AUUGAA, AUUGAC, AUUGAU, AUUGCC, AUUGCG, AUUGCU, AUUGGA, AUUGGC, 
AUUGGG, AUUGGU, AUUGUA, AUUGUC, AUUGUG, AUUGUU, AUUUAA, AUUUAG, AUUUAU, 
AUUUCC, AUUUCG, AUUUCU, AUUUGA, AUUUGC, AUUUGU, AUUUUA, AUUUUC, AUUUUG, 
AUUUUU, CAAAAG, CAAACA, CAAACC, CAAACG, CAAACU, CAAAGA, CAAAGG, CAAAUA, CAAAUU, 
CAACAC, CAACAU, CAACCA, CAACCC, CAACCG, CAACGA, CAACGC, CAACGG, CAACGU, CAACUA, 
CAACUC, CAACUG, CAACUU, CAAGAA, CAAGAC, CAAGAU, CAAGCA, CAAGCC, CAAGCG, CAAGCU, 
CAAGGA, CAAGGG, CAAGUC, CAAGUG, CAAGUU, CAAUAA, CAAUAC, CAAUAG, CAAUCC, CAAUCG, 
CAAUCU, CAAUGA, CAAUGC, CAAUGG, CAAUGU, CAAUUC, CAAUUG, CAAUUU, CACAAU, CACACA, 
CACACG, CACACU, CACAGA, CACAGC, CACAGG, CACAUA, CACAUC, CACAUU, CACCAA, CACCAC, 
CACCAU, CACCCA, CACCCC, CACCCG, CACCGA, CACCGC, CACCGG, CACCGU, CACCUA, CACCUU, 
CACGAA, CACGAC, CACGAG, CACGAU, CACGCA, CACGCC, CACGCU, CACGGA, CACGGC, CACGGG, 
CACGGU, CACGUA, CACGUC, CACGUG, CACGUU, CACUAA, CACUAG, CACUAU, CACUCA, CACUCG, 
CACUGA, CACUGC, CACUGG, CACUUA, CACUUC, CACUUU, CAGAAA, CAGAAG, CAGAAU, CAGACC, 
CAGACG, CAGAGC, CAGAUA, CAGAUC, CAGCCG, CAGCCU, CAGCGA, CAGCGC, CAGCGG, CAGCGU, 
CAGCUC, CAGCUU, CAGGAU, CAGGGG, CAGGGU, CAGGUA, CAGGUC, CAGGUU, CAGUAC, CAGUCG, 
CAGUUG, CAUAAA, CAUAAC, CAUAAG, CAUAAU, CAUACA, CAUACC, CAUACG, CAUACU, CAUAGA, 
CAUAGG, CAUAGU, CAUAUA, CAUAUC, CAUAUG, CAUCAA, CAUCAC, CAUCAG, CAUCAU, CAUCCA, 
CAUCCC, CAUCCG, CAUCGA, CAUCGC, CAUCGG, CAUCGU, CAUCUA, CAUCUC, CAUCUG, CAUCUU, 
CAUGAA, CAUGAC, CAUGAG, CAUGAU, CAUGCA, CAUGCC, CAUGCG, CAUGCU, CAUGGC, CAUGGG, 
CAUGGU, CAUGUA, CAUGUC, CAUGUU, CAUUAA, CAUUAC, CAUUAG, CAUUCA, CAUUCC, CAUUCG, 
CAUUCU, CAUUGA, CAUUGG, CAUUUC, CAUUUG, CAUUUU, CCAAAA, CCAAAC, CCAAAG, CCAAAU, 
CCAACA, CCAACC, CCAACG, CCAACU, CCAAGA, CCAAGC, CCAAGG, CCAAUC, CCAAUG, CCAAUU, 
CCACAA, CCACAC, CCACAG, CCACAU, CCACCA, CCACCC, CCACCG, CCACCU, CCACGA, CCACGC, 
CCACGG, CCACGU, CCACUA, CCACUC, CCACUU, CCAGAA, CCAGAC, CCAGAG, CCAGCC, CCAGGU, 
CCAGUC, CCAGUU, CCAUAA, CCAUAC, CCAUAG, CCAUAU, CCAUCA, CCAUCC, CCAUCU, CCAUGA, 
CCAUGC, CCAUGG, CCAUUC, CCAUUG, CCAUUU, CCCAAC, CCCAAG, CCCAAU, CCCACA, CCCAGA, 
CCCAGC, CCCAGU, CCCAUA, CCCAUC, CCCAUG, CCCAUU, CCCCAA, CCCCAG, CCCCAU, CCCCCC, 
CCCCCG, CCCCCU, CCCCGA, CCCCGC, CCCCGU, CCCCUA, CCCCUC, CCCGAA, CCCGAC, CCCGAU, 
CCCGCA, CCCGCU, CCCGGA, CCCGGC, CCCGUA, CCCGUG, CCCGUU, CCCUAA, CCCUAG, CCCUCA, 
CCCUCU, CCCUGC, CCCUUA, CCCUUC, CCCUUU, CCGAAA, CCGAAC, CCGAAU, CCGACA, CCGACC, 
CCGACG, CCGACU, CCGAGA, CCGAGG, CCGAGU, CCGAUA, CCGAUC, CCGAUG, CCGAUU, CCGCAA, 
CCGCAC, CCGCAG, CCGCAU, CCGCCA, CCGCCC, CCGCCG, CCGCCU, CCGCGA, CCGCGC, CCGCGG, 
CCGCGU, CCGCUA, CCGCUC, CCGCUG, CCGCUU, CCGGAA, CCGGAU, CCGGCA, CCGGCC, CCGGCG, 
CCGGCU, CCGGGA, CCGGGC, CCGGGG, CCGGGU, CCGGUA, CCGGUC, CCGGUG, CCGUAA, CCGUAG, 
CCGUAU, CCGUCA, CCGUCC, CCGUCG, CCGUGA, CCGUGU, CCGUUA, CCGUUC, CCGUUG, CCGUUU, 
CCUAAC, CCUAAG, CCUAAU, CCUACA, CCUACC, CCUACG, CCUACU, CCUAGA, CCUAGC, CCUAGG, 
CCUAGU, CCUAUA, CCUAUC, CCUAUG, CCUAUU, CCUCAA, CCUCAC, CCUCAG, CCUCAU, CCUCCA, 
CCUCCC, CCUCCG, CCUCGA, CCUCGC, CCUCGG, CCUCGU, CCUCUA, CCUCUG, CCUGAC, CCUGAU, 
CCUGCA, CCUGGG, CCUGGU, CCUGUU, CCUUAA, CCUUAC, CCUUAG, CCUUAU, CCUUCG, CCUUGA, 
CCUUGU, CCUUUA, CCUUUC, CCUUUU, CGAAAA, CGAAAC, CGAAAG, CGAAAU, CGAACA, CGAACC, 
CGAACG, CGAACU, CGAAGA, CGAAGC, CGAAGG, CGAAGU, CGAAUA, CGAAUC, CGAAUG, CGAAUU, 
CGACAA, CGACAC, CGACAU, CGACCA, CGACCU, CGACGA, CGACGC, CGACGG, CGACGU, CGACUA, 
CGACUG, CGACUU, CGAGAA, CGAGAC, CGAGAG, CGAGAU, CGAGCA, CGAGCC, CGAGCG, CGAGCU, 
CGAGGC, CGAGGG, CGAGGU, CGAGUA, CGAGUC, CGAGUG, CGAGUU, CGAUAA, CGAUAC, CGAUAG, 
CGAUAU, CGAUCA, CGAUCC, CGAUCG, CGAUCU, CGAUGA, CGAUGC, CGAUGG, CGAUGU, CGAUUA, 
CGAUUC, CGAUUG, CGAUUU, CGCAAA, CGCAAC, CGCAAG, CGCAAU, CGCACA, CGCACC, CGCACG, 
CGCAGA, CGCAGC, CGCAGG, CGCAGU, CGCAUA, CGCAUC, CGCAUG, CGCAUU, CGCCAA, CGCCAC, 
CGCCAG, CGCCAU, CGCCCA, CGCCCC, CGCCCG, CGCCGA, CGCCGC, CGCCGG, CGCCGU, CGCCUA, 
CGCCUG, CGCCUU, CGCGAA, CGCGAC, CGCGAG, CGCGAU, CGCGCA, CGCGCC, CGCGCG, CGCGCU, 
CGCGGA, CGCGGC, CGCGGG, CGCGGU, CGCGUA, CGCGUC, CGCGUG, CGCGUU, CGCUAA, CGCUAC, 
CGCUAG, CGCUAU, CGCUCA, CGCUCC, CGCUCG, CGCUCU, CGCUGA, CGCUGC, CGCUGG, CGCUGU, 
CGCUUA, CGCUUC, CGCUUG, CGGAAA, CGGAAC, CGGAAG, CGGACA, CGGACC, CGGACG, CGGACU, 
CGGAGC, CGGAGG, CGGAGU, CGGAUA, CGGAUU, CGGCAA, CGGCAC, CGGCAG, CGGCCA, CGGCCC, 
CGGCCG, CGGCGC, CGGCGG, CGGCGU, CGGCUA, CGGCUC, CGGCUG, CGGCUU, CGGGAA, CGGGAC, 
CGGGAG, CGGGAU, CGGGCA, CGGGCC, CGGGCG, CGGGCU, CGGGGU, CGGGUA, CGGGUC, CGGGUG, 
CGGUAA, CGGUAC, CGGUAG, CGGUAU, CGGUCA, CGGUCG, CGGUCU, CGGUGA, CGGUGG, CGGUGU, 
CGGUUA, CGGUUC, CGGUUG, CGGUUU, CGUAAA, CGUAAC, CGUAAG, CGUAAU, CGUACA, CGUACG, 
CGUACU, CGUAGA, CGUAGC, CGUAGG, CGUAGU, CGUAUA, CGUAUC, CGUAUG, CGUAUU, CGUCAA, 
CGUCAC, CGUCAG, CGUCAU, CGUCCA, CGUCCC, CGUCCG, CGUCCU, CGUCGA, CGUCGG, CGUCGU, 
CGUCUA, CGUCUC, CGUCUG, CGUCUU, CGUGAA, CGUGAC, CGUGAG, CGUGAU, CGUGCC, CGUGCG, 
CGUGCU, CGUGGA, CGUGGG, CGUGGU, CGUGUA, CGUGUG, CGUUAA, CGUUAC, CGUUAG, 
CGUUAU, CGUUCA, CGUUCC, CGUUCG, CGUUCU, CGUUGA, CGUUGC, CGUUGU, CGUUUA, CGUUUC, 
CGUUUU, CUAAAA, CUAAAC, CUAAAU, CUAACA, CUAACC, CUAACG, CUAACU, CUAAGA, CUAAGC, 
CUAAGU, CUAAUA, CUAAUC, CUAAUG, CUACAC, CUACAU, CUACCA, CUACCC, CUACCG, CUACCU, 
CUACGA, CUACGC, CUACGG, CUACGU, CUACUA, CUACUC, CUACUG, CUAGAA, CUAGAG, CUAGAU, 
CUAGCA, CUAGCC, CUAGCG, CUAGCU, CUAGGA, CUAGGG, CUAGGU, CUAGUG, CUAGUU, CUAUAA, 
CUAUAG, CUAUAU, CUAUCA, CUAUCC, CUAUCG, CUAUCU, CUAUGA, CUAUGC, CUAUGG, CUAUGU, 
CUAUUA, CUAUUG, CUCAAC, CUCAAG, CUCAAU, CUCACC, CUCACG, CUCAGC, CUCAUA, CUCAUC, 
CUCAUG, CUCAUU, CUCCAC, CUCCCC, CUCCCG, CUCCGA, CUCCGC, CUCCGG, CUCCUA, CUCCUC, 
CUCCUU, CUCGAA, CUCGAC, CUCGAG, CUCGAU, CUCGCA, CUCGCC, CUCGCG, CUCGGG, CUCGGU, 
CUCGUA, CUCGUC, CUCGUG, CUCGUU, CUCUAA, CUCUAC, CUCUAU, CUCUCA, CUCUCC, CUCUCU, 
CUCUGC, CUCUGU, CUCUUA, CUCUUG, CUGAAG, CUGACC, CUGACG, CUGAGC, CUGAUA, CUGAUC, 
CUGCCG, CUGCCU, CUGCGA, CUGCUA, CUGCUU, CUGGAG, CUGGAU, CUGGCG, CUGGGU, CUGUAC, 
CUGUCA, CUGUCC, CUGUCG, CUGUGG, CUGUGU, CUGUUA, CUGUUU, CUUAAC, CUUAAG, CUUAAU, 
CUUACC, CUUACG, CUUAGA, CUUAGC, CUUAGG, CUUAGU, CUUAUA, CUUAUC, CUUAUG, CUUAUU, 
CUUCAG, CUUCAU, CUUCCA, CUUCCC, CUUCCG, CUUCCU, CUUCGA, CUUCGC, CUUCGG, CUUCGU, 
CUUCUA, CUUGAC, CUUGAG, CUUGAU, CUUGCA, CUUGCC, CUUGCG, CUUGCU, CUUGGC, CUUGGU, 
CUUGUU, CUUUAC, CUUUAG, CUUUAU, CUUUCA, CUUUCG, CUUUCU, CUUUGA, CUUUGC, CUUUGU, 
CUUUUA, CUUUUC, CUUUUG, CUUUUU, GAAAAA, GAAAAG, GAAAAU, GAAACC, GAAACG, GAAAGA, 
GAAAGC, GAAAGU, GAAAUA, GAAAUC, GAAAUG, GAAAUU, GAACAA, GAACAC, GAACAG, GAACAU, 
GAACCA, GAACCC, GAACCG, GAACCU, GAACGA, GAACGC, GAACGG, GAACGU, GAACUA, GAACUG, 
GAACUU, GAAGAC, GAAGAG, GAAGCA, GAAGCG, GAAGCU, GAAGUC, GAAUAA, GAAUAC, GAAUAG, 
GAAUAU, GAAUCC, GAAUCG, GAAUCU, GAAUGA, GAAUGC, GAAUGU, GAAUUA, GAAUUC, GAAUUU, 
GACAAA, GACAAG, GACAAU, GACACC, GACAGA, GACAGG, GACAUA, GACAUG, GACAUU, GACCAA, 
GACCAC, GACCAG, GACCCA, GACCCC, GACCCG, GACCGC, GACCGG, GACCGU, GACCUA, GACCUC, 
GACCUU, GACGAA, GACGAC, GACGAG, GACGAU, GACGCA, GACGCC, GACGCG, GACGCU, GACGGA, 
GACGGC, GACGGG, GACGGU, GACGUA, GACGUC, GACGUG, GACGUU, GACUAA, GACUAC, GACUAG, 
GACUAU, GACUCA, GACUCC, GACUCG, GACUGG, GACUGU, GACUUA, GACUUG, GACUUU, GAGAAU, 
GAGAGA, GAGAGC, GAGAGG, GAGAUA, GAGAUC, GAGCAA, GAGCAU, GAGCCA, GAGCGA, GAGCGG, 
GAGCGU, GAGGGU, GAGGUC, GAGGUG, GAGUAA, GAGUAG, GAGUCC, GAGUUC, GAGUUU, 
GAUAAA, GAUAAC, GAUAAG, GAUAAU, GAUACA, GAUACC, GAUACG, GAUACU, GAUAGA, GAUAGC, 
GAUAGG, GAUAGU, GAUAUA, GAUCAA, GAUCAC, GAUCAU, GAUCCA, GAUCCC, GAUCCU, GAUCGC, 
GAUCGG, GAUCGU, GAUCUA, GAUCUG, GAUCUU, GAUGAA, GAUGAC, GAUGAG, GAUGCA, GAUGCC, 
GAUGCG, GAUGCU, GAUGGC, GAUGGG, GAUGGU, GAUGUG, GAUGUU, GAUUAA, GAUUAC, 
GAUUAG, GAUUAU, GAUUCA, GAUUCG, GAUUCU, GAUUGA, GAUUGC, GAUUUA, GAUUUC, 
GAUUUG, GAUUUU, GCAAAC, GCAAAG, GCAAAU, GCAACA, GCAACC, GCAAGC, GCAAGU, GCAAUA, 
GCAAUC, GCAAUG, GCAAUU, GCACAA, GCACAC, GCACAG, GCACCC, GCACCG, GCACCU, GCACGA, 
GCACGC, GCACGU, GCACUA, GCACUC, GCACUG, GCACUU, GCAGAU, GCAGCC, GCAGCG, GCAGGC, 
GCAGUA, GCAGUC, GCAGUG, GCAGUU, GCAUAA, GCAUAG, GCAUAU, GCAUCG, GCAUCU, GCAUGA, 
GCAUGC, GCAUGG, GCAUGU, GCAUUA, GCAUUC, GCAUUG, GCAUUU, GCCAAA, GCCAAC, GCCAAU, 
GCCACA, GCCACC, GCCACG, GCCAGA, GCCAGU, GCCAUA, GCCAUC, GCCAUG, GCCAUU, GCCCAA, 
GCCCAC, GCCCAG, GCCCCG, GCCCGA, GCCCGG, GCCCGU, GCCGAA, GCCGAC, GCCGAG, GCCGAU, 
GCCGCA, GCCGCU, GCCGGA, GCCGGC, GCCGGG, GCCGGU, GCCGUA, GCCGUC, GCCGUG, GCCGUU, 
GCCUAA, GCCUAU, GCCUCA, GCCUCC, GCCUCG, GCCUGA, GCCUUA, GCCUUU, GCGAAA, GCGAAC, 
GCGAAG, GCGAAU, GCGACC, GCGACG, GCGACU, GCGAGA, GCGAGC, GCGAGG, GCGAGU, GCGAUA, 
GCGAUC, GCGAUG, GCGAUU, GCGCAA, GCGCAC, GCGCAG, GCGCAU, GCGCCA, GCGCCC, GCGCCU, 
GCGCGA, GCGCGU, GCGCUA, GCGCUC, GCGCUG, GCGCUU, GCGGAA, GCGGAC, GCGGAU, GCGGCA, 
GCGGCC, GCGGCU, GCGGGA, GCGGUA, GCGGUC, GCGGUU, GCGUAA, GCGUAC, GCGUAG, GCGUAU, 
GCGUCA, GCGUCC, GCGUCG, GCGUCU, GCGUGA, GCGUGC, GCGUGG, GCGUGU, GCGUUA, GCGUUC, 
GCGUUG, GCGUUU, GCUAAA, GCUAAC, GCUAAG, GCUAAU, GCUACC, GCUACG, GCUACU, GCUAGA, 
GCUAGG, GCUAGU, GCUAUA, GCUAUC, GCUAUU, GCUCAA, GCUCAC, GCUCAG, GCUCAU, GCUCCA, 
GCUCCC, GCUCCG, GCUCGA, GCUCGC, GCUCGU, GCUCUA, GCUCUC, GCUCUU, GCUGAA, GCUGAC, 
GCUGAU, GCUGCA, GCUGCC, GCUGCG, GCUGCU, GCUGUG, GCUGUU, GCUUAC, GCUUAG, GCUUAU, 
GCUUCA, GCUUCG, GCUUGA, GCUUGG, GCUUGU, GCUUUA, GCUUUG, GGAAAG, GGAACA, GGAACC, 
GGAACG, GGAACU, GGAAGU, GGAAUA, GGAAUC, GGAAUU, GGACAA, GGACAC, GGACAG, GGACAU, 
GGACCG, GGACGA, GGACGC, GGACGU, GGACUA, GGACUC, GGACUU, GGAGAC, GGAGCA, GGAGCG, 
GGAGGG, GGAGUA, GGAUAA, GGAUAC, GGAUCA, GGAUCC, GGAUCG, GGAUCU, GGAUGC, GGAUUA, 
GGAUUG, GGCAAU, GGCACA, GGCACU, GGCAGA, GGCAUA, GGCAUC, GGCCAC, GGCCAG, GGCCCC, 
GGCCGA, GGCCGC, GGCCGU, GGCCUA, GGCCUG, GGCCUU, GGCGAA, GGCGAG, GGCGAU, GGCGCA, 
GGCGCU, GGCGGU, GGCGUA, GGCGUC, GGCGUG, GGCGUU, GGCUAA, GGCUAC, GGCUAG, GGCUAU, 
GGCUCC, GGCUCG, GGCUGA, GGCUUA, GGCUUC, GGCUUG, GGGAAU, GGGACA, GGGAGA, GGGAGU, 
GGGAUA, GGGAUU, GGGCAA, GGGCAC, GGGCAG, GGGCCG, GGGCGG, GGGGCC, GGGGGG, 
GGGGGU, GGGGUA, GGGUAC, GGGUAU, GGGUCA, GGGUCC, GGGUCG, GGGUGA, GGGUGC, 
GGGUUA, GGGUUG, GGUAAA, GGUAAC, GGUAAG, GGUAAU, GGUACA, GGUACC, GGUACG, 
GGUACU, GGUAGC, GGUAGG, GGUAGU, GGUAUA, GGUAUC, GGUAUG, GGUCAA, GGUCAC, 
GGUCAG, GGUCAU, GGUCCA, GGUCCG, GGUCCU, GGUCGA, GGUCGC, GGUCGG, GGUCGU, GGUCUC, 
GGUCUU, GGUGAA, GGUGAC, GGUGAU, GGUGCA, GGUGCC, GGUGGC, GGUGUA, GGUGUC, 
GGUUAA, GGUUAG, GGUUAU, GGUUCA, GGUUCC, GGUUCG, GGUUGC, GGUUUC, GGUUUU, 
GUAAAA, GUAAAG, GUAAAU, GUAACC, GUAACG, GUAACU, GUAAGA, GUAAGC, GUAAGG, GUAAGU, 
GUAAUA, GUAAUC, GUAAUG, GUAAUU, GUACAA, GUACAC, GUACAG, GUACAU, GUACCA, GUACCC, 
GUACCG, GUACCU, GUACGA, GUACGC, GUACGG, GUACGU, GUACUA, GUACUC, GUACUG, GUACUU, 
GUAGAA, GUAGAC, GUAGCA, GUAGCC, GUAGCG, GUAGCU, GUAGGA, GUAGGC, GUAGGG, 
GUAGGU, GUAGUA, GUAGUC, GUAUAA, GUAUAC, GUAUAG, GUAUAU, GUAUCA, GUAUCG, 
GUAUCU, GUAUGA, GUAUGC, GUAUGG, GUAUUA, GUAUUG, GUAUUU, GUCAAA, GUCAAG, 
GUCAAU, GUCACA, GUCACC, GUCACG, GUCAGA, GUCAGC, GUCAGG, GUCAUA, GUCAUC, GUCAUG, 
GUCCAA, GUCCAC, GUCCAU, GUCCCC, GUCCCU, GUCCGA, GUCCGC, GUCCGG, GUCCGU, GUCCUA, 
GUCCUG, GUCCUU, GUCGAA, GUCGAC, GUCGAG, GUCGAU, GUCGCA, GUCGCC, GUCGCG, GUCGCU, 
GUCGGA, GUCGGC, GUCGGG, GUCGGU, GUCGUA, GUCGUC, GUCGUU, GUCUAA, GUCUAG, GUCUCA, 
GUCUCC, GUCUCG, GUCUGA, GUCUGG, GUCUGU, GUCUUC, GUCUUU, GUGAAA, GUGAAC, GUGAAG, 
GUGACC, GUGACG, GUGAGA, GUGAGC, GUGAGU, GUGAUC, GUGAUG, GUGAUU, GUGCAC, 
GUGCAU, GUGCCC, GUGCCG, GUGCGA, GUGCGG, GUGCGU, GUGCUA, GUGCUC, GUGCUG, 
GUGGAG, GUGGCG, GUGGCU, GUGGGU, GUGGUC, GUGGUG, GUGUAA, GUGUAG, GUGUCG, 
GUGUGA, GUGUGC, GUGUGU, GUGUUG, GUGUUU, GUUAAA, GUUAAC, GUUAAG, GUUACA, 
GUUACC, GUUACG, GUUACU, GUUAGA, GUUAGC, GUUAGU, GUUAUA, GUUAUC, GUUAUG, 
GUUAUU, GUUCAA, GUUCAC, GUUCAG, GUUCCA, GUUCCG, GUUCGA, GUUCGC, GUUCGG, GUUCGU, 
GUUCUA, GUUCUG, GUUGAA, GUUGAC, GUUGAG, GUUGAU, GUUGCG, GUUGCU, GUUGGA, 
GUUGGC, GUUGGU, GUUGUC, GUUGUG, GUUGUU, GUUUAA, GUUUAC, GUUUAG, GUUUAU, 
GUUUCA, GUUUCC, GUUUCU, GUUUGA, GUUUGC, GUUUGG, GUUUGU, GUUUUA, GUUUUC, 
GUUUUU, UAAAAA, UAAAAC, UAAAAG, UAAAAU, UAAACA, UAAACC, UAAACG, UAAACU, UAAAGA, 
UAAAGG, UAAAGU, UAAAUA, UAAAUC, UAAAUG, UAAAUU, UAACAA, UAACAC, UAACAG, UAACCA, 
UAACCC, UAACCG, UAACCU, UAACGA, UAACGC, UAACGG, UAACGU, UAACUA, UAACUG, UAACUU, 
UAAGAG, UAAGAU, UAAGCA, UAAGCC, UAAGCG, UAAGCU, UAAGGA, UAAGGC, UAAGGG, UAAGGU, 
UAAGUA, UAAGUC, UAAGUG, UAAGUU, UAAUAA, UAAUCA, UAAUCC, UAAUCG, UAAUCU, UAAUGA, 
UAAUGG, UAAUGU, UAAUUA, UAAUUC, UAAUUG, UACAAC, UACAAG, UACAAU, UACACC, UACACG, 
UACACU, UACAGA, UACAGC, UACAUA, UACAUC, UACAUU, UACCAA, UACCAC, UACCAG, UACCAU, 
UACCCC, UACCCG, UACCCU, UACCGA, UACCGC, UACCGG, UACCGU, UACCUA, UACCUG, UACGAA, 
UACGAC, UACGAG, UACGAU, UACGCA, UACGCC, UACGCG, UACGCU, UACGGC, UACGGG, UACGGU, 
UACGUA, UACGUC, UACGUG, UACGUU, UACUAA, UACUAC, UACUAG, UACUAU, UACUCA, UACUCC, 
UACUCG, UACUCU, UACUGA, UACUGC, UACUGG, UACUUA, UACUUG, UACUUU, UAGAAA, UAGAAG, 
UAGAAU, UAGACA, UAGACG, UAGAGA, UAGAGC, UAGAGU, UAGAUA, UAGAUC, UAGAUG, UAGCAU, 
UAGCCC, UAGCCG, UAGCCU, UAGCGA, UAGCGC, UAGCGU, UAGCUA, UAGCUC, UAGCUG, UAGGAA, 
UAGGAU, UAGGCG, UAGGCU, UAGGGU, UAGGUC, UAGGUG, UAGGUU, UAGUAA, UAGUAC, 
UAGUAG, UAGUAU, UAGUCA, UAGUCG, UAGUGU, UAGUUA, UAGUUC, UAGUUG, UAGUUU, 
UAUAAC, UAUAAG, UAUACU, UAUAGA, UAUAGC, UAUAGG, UAUAGU, UAUAUA, UAUAUC, UAUAUG, 
UAUAUU, UAUCAA, UAUCAC, UAUCAU, UAUCCA, UAUCCC, UAUCCG, UAUCCU, UAUCGA, UAUCGC, 
UAUCGG, UAUCGU, UAUCUA, UAUCUC, UAUCUG, UAUCUU, UAUGAA, UAUGAC, UAUGAG, 
UAUGAU, UAUGCA, UAUGCG, UAUGCU, UAUGGA, UAUGGC, UAUGUC, UAUGUG, UAUGUU, 
UAUUAG, UAUUCA, UAUUCC, UAUUCG, UAUUCU, UAUUGA, UAUUGG, UAUUUA, UAUUUC, 
UAUUUG, UAUUUU, UCAAAA, UCAAAC, UCAAAG, UCAACC, UCAACU, UCAAGA, UCAAGC, UCAAUA, 
UCAAUC, UCAAUG, UCAAUU, UCACCC, UCACCG, UCACCU, UCACGA, UCACGC, UCACGG, UCACGU, 
UCACUA, UCACUC, UCACUU, UCAGAA, UCAGAC, UCAGAG, UCAGCG, UCAGCU, UCAGGA, UCAGGC, 
UCAGGU, UCAGUC, UCAGUU, UCAUAA, UCAUCA, UCAUCC, UCAUCG, UCAUGC, UCAUGG, UCAUGU, 
UCAUUA, UCAUUG, UCCAAA, UCCAAC, UCCAAG, UCCAAU, UCCACA, UCCACC, UCCACG, UCCAGC, 
UCCAGG, UCCAUA, UCCAUC, UCCAUU, UCCCAA, UCCCAG, UCCCAU, UCCCCC, UCCCCG, UCCCCU, 
UCCCGA, UCCCGC, UCCCGG, UCCCGU, UCCCUA, UCCCUC, UCCGAA, UCCGAC, UCCGAG, UCCGAU, 
UCCGCA, UCCGCC, UCCGGA, UCCGGC, UCCGGU, UCCGUA, UCCGUC, UCCGUG, UCCUAA, UCCUCA, 
UCCUCG, UCCUCU, UCCUGC, UCCUGU, UCCUUA, UCCUUC, UCCUUU, UCGAAA, UCGAAC, UCGAAG, 
UCGAAU, UCGACA, UCGACC, UCGACG, UCGACU, UCGAGA, UCGAGC, UCGAGG, UCGAUA, UCGAUC, 
UCGAUG, UCGAUU, UCGCAA, UCGCAC, UCGCAG, UCGCAU, UCGCCA, UCGCCC, UCGCCG, UCGCCU, 
UCGCGA, UCGCGC, UCGCGU, UCGCUA, UCGCUC, UCGGAA, UCGGAC, UCGGAG, UCGGAU, UCGGCA, 
UCGGCU, UCGGGG, UCGGGU, UCGGUC, UCGGUG, UCGGUU, UCGUAA, UCGUAC, UCGUAG, 
UCGUAU, UCGUCA, UCGUCC, UCGUCG, UCGUCU, UCGUGA, UCGUGU, UCGUUA, UCGUUC, UCGUUG, 
UCGUUU, UCUAAC, UCUAAG, UCUAAU, UCUACA, UCUACC, UCUACG, UCUACU, UCUAGC, UCUAGG, 
UCUAGU, UCUAUA, UCUAUC, UCUAUG, UCUAUU, UCUCAG, UCUCAU, UCUCCG, UCUCGC, UCUCGG, 
UCUCGU, UCUCUC, UCUGAA, UCUGAU, UCUGCA, UCUGCG, UCUGCU, UCUGGC, UCUGGU, UCUGUC, 
UCUGUG, UCUGUU, UCUUAA, UCUUAC, UCUUAG, UCUUAU, UCUUCA, UCUUCC, UCUUCG, UCUUCU, 
UCUUGC, UCUUGG, UCUUGU, UCUUUA, UCUUUC, UCUUUG, UCUUUU, UGAAAA, UGAAAC, 
UGAACA, UGAACC, UGAAGG, UGAAUC, UGAAUG, UGACAA, UGACAC, UGACAG, UGACCA, UGACCC, 
UGACCG, UGACGA, UGACGC, UGACGG, UGACGU, UGACUA, UGACUC, UGACUU, UGAGAG, UGAGAU, 
UGAGCA, UGAGCC, UGAGCU, UGAGGC, UGAGGU, UGAGUA, UGAGUU, UGAUAC, UGAUAG, 
UGAUAU, UGAUCA, UGAUCG, UGAUCU, UGAUGA, UGAUGC, UGAUGG, UGAUGU, UGAUUA, 
UGAUUC, UGAUUG, UGAUUU, UGCAAC, UGCAAG, UGCACA, UGCACG, UGCAGG, UGCAGU, UGCAUC, 
UGCCCA, UGCCCC, UGCCCG, UGCCGA, UGCCGC, UGCCGG, UGCCGU, UGCCUA, UGCCUC, UGCCUG, 
UGCCUU, UGCGAA, UGCGAC, UGCGAU, UGCGCC, UGCGCG, UGCGCU, UGCGGC, UGCGGG, UGCGGU, 
UGCGUA, UGCGUC, UGCGUG, UGCGUU, UGCUAC, UGCUAU, UGCUCC, UGCUCG, UGCUGC, UGCUGG, 
UGCUGU, UGCUUA, UGCUUU, UGGAAC, UGGAAG, UGGAGC, UGGAUC, UGGAUU, UGGCAA, 
UGGCAC, UGGCAG, UGGCCG, UGGCCU, UGGCGA, UGGCGC, UGGCGU, UGGCUA, UGGCUC, UGGCUU, 
UGGGAA, UGGGCA, UGGGCC, UGGGGC, UGGGUC, UGGUAA, UGGUAG, UGGUAU, UGGUCC, 
UGGUCG, UGGUCU, UGGUGA, UGGUGC, UGGUGG, UGGUGU, UGGUUA, UGGUUG, UGUAAA, 
UGUAAC, UGUAAG, UGUACC, UGUACG, UGUACU, UGUAGA, UGUAGC, UGUAGU, UGUAUC, 
UGUAUU, UGUCAA, UGUCAC, UGUCAG, UGUCAU, UGUCCA, UGUCCC, UGUCCG, UGUCGA, UGUCGC, 
UGUCGG, UGUCGU, UGUCUA, UGUCUC, UGUGAC, UGUGAG, UGUGAU, UGUGCA, UGUGGU, 
UGUGUA, UGUGUU, UGUUAC, UGUUAG, UGUUAU, UGUUCA, UGUUCC, UGUUCG, UGUUGG, 
UGUUGU, UGUUUA, UGUUUC, UGUUUG, UGUUUU, UUAAAA, UUAAAC, UUAAAG, UUAAAU, 
UUAACC, UUAACG, UUAACU, UUAAGU, UUAAUA, UUAAUC, UUAAUG, UUAAUU, UUACAA, UUACAC, 
UUACAG, UUACAU, UUACCA, UUACCC, UUACCG, UUACCU, UUACGA, UUACGC, UUACGG, UUACGU, 
UUACUA, UUACUC, UUACUG, UUACUU, UUAGAA, UUAGAC, UUAGCC, UUAGCG, UUAGCU, UUAGGC, 
UUAGGU, UUAGUA, UUAGUC, UUAGUU, UUAUAA, UUAUAC, UUAUAG, UUAUAU, UUAUCC, 
UUAUCG, UUAUCU, UUAUGA, UUAUGG, UUAUGU, UUAUUA, UUAUUC, UUAUUG, UUAUUU, 
UUCAAC, UUCAAU, UUCACA, UUCACC, UUCACG, UUCACU, UUCAGC, UUCAGG, UUCAGU, UUCAUA, 
UUCAUC, UUCAUG, UUCAUU, UUCCAA, UUCCCA, UUCCCG, UUCCGA, UUCCGU, UUCCUU, UUCGAA, 
UUCGAC, UUCGAG, UUCGAU, UUCGCA, UUCGCC, UUCGCG, UUCGCU, UUCGGA, UUCGGC, UUCGGG, 
UUCGGU, UUCGUA, UUCGUC, UUCGUG, UUCGUU, UUCUAC, UUCUAG, UUCUCA, UUCUCG, 
UUCUGG, UUCUUA, UUCUUU, UUGAAA, UUGAAC, UUGAAG, UUGAAU, UUGACC, UUGACG, 
UUGACU, UUGAGA, UUGAGC, UUGAGU, UUGAUA, UUGAUC, UUGAUG, UUGAUU, UUGCAA, 
UUGCAC, UUGCAG, UUGCAU, UUGCCC, UUGCCG, UUGCGA, UUGCGC, UUGCGG, UUGCGU, UUGCUA, 
UUGCUC, UUGCUG, UUGCUU, UUGGAA, UUGGAG, UUGGCC, UUGGCG, UUGGCU, UUGGGC, 
UUGGGU, UUGGUA, UUGGUG, UUGUAA, UUGUAC, UUGUCA, UUGUCG, UUGUCU, UUGUGC, 
UUGUGG, UUGUUA, UUGUUG, UUGUUU, UUUAAA, UUUAAC, UUUAAG, UUUAAU, UUUACA, 
UUUACC, UUUACG, UUUACU, UUUAGA, UUUAGC, UUUAGG, UUUAGU, UUUAUA, UUUAUC, 
UUUAUG, UUUAUU, UUUCAU, UUUCCA, UUUCCG, UUUCCU, UUUCGA, UUUCGC, UUUCGG, 
UUUCGU, UUUCUA, UUUCUC, UUUCUG, UUUCUU, UUUGAA, UUUGAC, UUUGAG, UUUGAU, 
UUUGCC, UUUGCU, UUUGGA, UUUGGC, UUUGGG, UUUGGU, UUUGUA, UUUGUC, UUUGUU, 
UUUUAA, UUUUAG, UUUUAU, UUUUCC, UUUUCG, UUUUCU, UUUUGA, UUUUGC, UUUUGG, 
UUUUGU, UUUUUA, UUUUUC, UUUUUU 
TABLE 2
A listing of oligonucleotide modifications
Symbol Feature Description
bio 5′ biotin
dAs DNA w/3′ thiophosphate
dCs DNA w/3′ thiophosphate
dGs DNA w/3′ thiophosphate
dTs DNA w/3′ thiophosphate
dG DNA
enaAs ENA w/3′ thiophosphate
enaCs ENA w/3′ thiophosphate
enaGs ENA w/3′ thiophosphate
enaTs ENA w/3′ thiophosphate
fluAs 2′-fluoro w/3′ thiophosphate
fluCs 2′-fluoro w/3′ thiophosphate
fluGs 2′-fluoro w/3′ thiophosphate
fluUs 2′-fluoro w/3′ thiophosphate
InaAs LNA w/3′ thiophosphate
InaCs LNA w/3′ thiophosphate
InaGs LNA w/3′ thiophosphate
InaTs LNA w/3′ thiophosphate
omeAs 2′-Ome w/3′ thiophosphate
omeCs 2′-Ome w/3′ thiophosphate
omeGs 2′-Ome w/3′ thiophosphate
omeTs 2′-Ome w/3′ thiophosphate
InaAs-Sup LNA w/3′ thiophosphate at 3′ terminus
InaCs-Sup LNA w/3′ thiophosphate at 3′ terminus
InaGs-Sup LNA w/3′ thiophosphate at 3′ terminus
InaTs-Sup LNA w/3′ thiophosphate at 3′ terminus
InaA-Sup LNA w/3′ OH at 3′ terminus
InaC-Sup LNA w/3′ OH at 3′ terminus
InaG-Sup LNA w/3′ OH at 3′ terminus
InaT-Sup LNA w/3′ OH at 3′ terminus
omeA-Sup 2′-Ome w/3′ OH at 3′ terminus
omeC-Sup 2′-Ome w/3′ OH at 3′ terminus
omeG-Sup 2′-Ome w/3′ OH at 3′ terminus
omeU-Sup 2′-Ome w/3′ OH at 3′ terminus
dAs-Sup DNA w/3′ thiophosphate at 3′ terminus
dCs-Sup DNA w/3′ thiophosphate at 3′ terminus
dGs-Sup DNA w/3′ thiophosphate at 3′ terminus
dTs-Sup DNA w/3′ thiophosphate at 3′ terminus
dA-Sup DNA w/3′ OH at 3′ terminus
dC-Sup DNA w/3′ OH at 3′ terminus
dG-Sup DNA w/3′ OH at 3′ terminus
dT-Sup DNA w/3′ OH at 3′ terminus
TABLE 3
Formatted oligonucleotide sequences made for
testing showing nucleotide modifications.
Oligo Base Seq
Name Sequence RaNA Sequence ID
MECP2- CGACGTCGCGC InaCs;omeGs;InaAs;omeCs;InaGs;omeUs;InaCs;omeGs; 1438
01 m01 CCCG InaCs;omeGs;InaCs;omeCs;InaCs;omeCs;InaG-Sup
MECP2- CCGACGTCGCG InaCs;omeCs;InaGs;omeAs;InaCs;omeGs;InaTs;omeCs; 1439
02 m01 CCCC InaGs;omeCs;InaGs;omeCs;InaCs;omeCs;InaC-Sup
MECP2- CCATTTTCCGG InaCs;omeCs;InaAs;omeUs;InaTs;omeUs;InaTs;omeCs; 1521
03 m01 ACGG InaCs;omeGs;InaGs;omeAs;InaCs;omeGs;InaG-Sup
MECP2- GCCATTTTCCG InaGs;omeCs;InaCs;omeAs;InaTs;omeUs;InaTs;omeUs; 1522
04 m01 GACG InaCs;omeCs;InaGs;omeGs;InaAs;omeCs;InaG-Sup
MECP2- GCGGCCATTTT InaGs;omeCs;InaGs;omeGs;InaCs;omeCs;InaAs;omeUs; 1525
05 m01 CCGG InaTs;omeUs;InaTs;omeCs;InaCs;omeGs;InaG-Sup
MECP2- GGCGGCCATTT InaGs;omeGs;InaCs;omeGs;InaGs;omeCs;InaCs;omeAs; 1526
06 m01 TCCG InaTs;omeUs;InaTs;omeUs;InaCs;omeCs;InaG-Sup
MECP2- GCCAGCCGTGT InaGs;omeCs;InaCs;omeAs;InaGs;omeCs;InaCs;omeGs; 1683
07 m01 CGTC InaTs;omeGs;InaTs;omeCs;InaGs;omeUs;InaC-Sup
MECP2- ATCCGCCAGCC InaAs;omeUs;InaCs;omeCs;InaGs;omeCs;InaCs;omeAs; 1687
08 m01 GTGT InaGs;omeCs;InaCs;omeGs;InaTs;omeGs;InaT-Sup
MECP2- GATCGCCGGCG InaGs;omeAs;InaTs;omeCs;InaGs;omeCs;InaCs;omeGs; 2463
09 m01 AAGG InaGs;omeCs;InaGs;omeAs;InaAs;omeGs;InaG-Sup
MECP2- GATCCCGAGCG InaGs;omeAs;InaTs;omeCs;InaCs;omeCs;InaGs;omeAs; 2532
10 m01 CTCC InaGs;omeCs;InaGs;omeCs;InaTs;omeCs;InaC-Sup
MECP2- TGTGGCGACCA InaTs;omeGs;InaTs;omeGs;InaGs;omeCs;InaGs;omeAs; 7070
11 m01 AGTA InaCs;omeCs;InaAs;omeAs;InaGs;omeUs;InaA-Sup
MECP2- AGATCACCAGT InaAs;omeGs;InaAs;omeUs;InaCs;omeAs;InaCs;omeCs; 7117
12 m01 TCCG InaAs;omeGs;InaTs;omeUs;InaCs;omeCs;InaG-Sup
MECP2- TTGTACCTATA InaTs;omeUs;InaGs;omeUs;InaAs;omeCs;InaCs;omeUs; 14460
13 m01 CGCA InaAs;omeUs;InaAs;omeCs;InaGs;omeCs;InaA-Sup
MECP2- TTTGTACCTAT InaTs;omeUs;InaTs;omeGs;InaTs;omeAs;InaCs;omeCs; 14461
14 m01 ACGC InaTs;omeAs;InaTs;omeAs;InaCs;omeGs;InaC-Sup
MECP2- CCCAAACAGCG InaCs;omeCs;InaCs;omeAs;InaAs;omeAs;InaCs;omeAs; 65064
15 m01 GCGC InaGs;omeCs;InaGs;omeGs;InaCs;omeGs;InaC-Sup
MECP2- CCAAACAGCGG InaCs;omeCs;InaAs;omeAs;InaAs;omeCs;InaAs;omeGs; 65065
16 m01 CGCT InaCs;omeGs;InaGs;omeCs;InaGs;omeCs;InaT-Sup
MECP2- CAAACAGCGGC InaCs;omeAs;InaAs;omeAs;InaCs;omeAs;InaGs;omeCs; 65066
17 m01 GCTC InaGs;omeGs;InaCs;omeGs;InaCs;omeUs;InaC-Sup
MECP2- AAACAGCGGCG InaAs;omeAs;InaAs;omeCs;InaAs;omeGs;InaCs;omeGs; 65067
18 m01 CTCC InaGs;omeCs;InaGs;omeCs;InaTs;omeCs;InaC-Sup
MECP2- AACAGCGGCGC InaAs;omeAs;InaCs;omeAs;InaGs;omeCs;InaGs;omeGs; 65068
19 m01 TCCA InaCs;omeGs;InaCs;omeUs;InaCs;omeCs;InaA-Sup
MECP2- TCCATCATCCG InaTs;omeCs;InaCs;omeAs;InaTs;omeCs;InaAs;omeUs; 65079
20 m01 TGAC InaCs;omeCs;InaGs;omeUs;InaGs;omeAs;InaC-Sup
MECP2- GGACCCATGTA InaGs;omeGs;InaAs;omeCs;InaCs;omeCs;InaAs;omeUs; 65097
21 m01 TGAT InaGs;omeUs;InaAs;omeUs;InaGs;omeAs;InaT-Sup
MECP2- CTTTCGCTCTA InaCs;omeUs;InaTs;omeUs;InaCs;omeGs;InaCs;omeUs; 65972
22 m01 AAGT InaCs;omeUs;InaAs;omeAs;InaAs;omeGs;InaT-Sup
MECP2- TCGCTCTAAAG InaTs;omeCs;InaGs;omeCs;InaTs;omeCs;InaTs;omeAs; 65975
23 m01 TGGA InaAs;omeAs;InaGs;omeUs;InaGs;omeGs;InaA-Sup
MECP2- GACTTCACGGT InaGs;omeAs;InaCs;omeUs;InaTs;omeCs;InaAs;omeCs; 66045
24 m01 AACT InaGs;omeGs;InaTs;omeAs;InaAs;omeCs;InaT-Sup
MECP2- CTTCACGGTAA InaCs;omeUs;InaTs;omeCs;InaAs;omeCs;InaGs;omeGs; 66047
25 m01 CTGG InaTs;omeAs;InaAs;omeCs;InaTs;omeGs;InaG-Sup
MECP2- CAAACGCCCCG InaCs;omeAs;InaAs;omeAs;InaCs;omeGs;InaCs;omeCs; 66323
26 m01 GCAG InaCs;omeCs;InaGs;omeGs;InaCs;omeAs;InaG-Sup
MECP2- GAAGCGAAAAG InaGs;omeAs;InaAs;omeGs;InaCs;omeGs;InaAs;omeAs; 66338
27 m01 CTGA InaAs;omeAs;InaGs;omeCs;InaTs;omeGs;InaA-Sup
MECP2- AAGAAAGCCGT InaAs;omeAs;InaGs;omeAs;InaAs;omeAs;InaGs;omeCs; 66432
28 m01 GAAG InaCs;omeGs;InaTs;omeGs;InaAs;omeAs;InaG-Sup
MECP2- CATCAAGAAGC InaCs;omeAs;InaTs;omeCs;InaAs;omeAs;InaGs;omeAs; 66485
29 m01 GCAA InaAs;omeGs;InaCs;omeGs;InaCs;omeAs;InaA-Sup
MECP2- CAATGTCTTTG InaCs;omeAs;InaAs;omeUs;InaGs;omeUs;InaCs;omeUs; 27322
30 m01 CGCT InaTs;omeUs;InaGs;omeCs;InaGs;omeCs;InaT-Sup
MECP2- GGCGTCCGGCT InaGs;omeGs;InaCs;omeGs;InaTs;omeCs;InaCs;omeGs; 27377
31 m01 GTCC InaGs;omeCs;InaTs;omeGs;InaTs;omeCs;InaC-Sup
MECP2- TTTGCAATCCG InaTs;omeUs;InaTs;omeGs;InaCs;omeAs;InaAs;omeUs; 27422
32 m01 CTCC InaCs;omeCs;InaGs;omeCs;InaTs;omeCs;InaC-Sup
MECP2- GCCACGAAACT InaGs;omeCs;InaCs;omeAs;InaCs;omeGs;InaAs;omeAs; 27548
33 m01 CTAA InaAs;omeCs;InaTs;omeCs;InaTs;omeAs;InaA-Sup
MECP2- AGCGCAGGTAT InaAs;omeGs;InaCs;omeGs;InaCs;omeAs;InaGs;omeGs; 28519
34 m01 ATAT InaTs;omeAs;InaTs;omeAs;InaTs;omeAs;InaT-Sup
MECP2- TTCGGAGCTTC InaTs;omeUs;InaCs;omeGs;InaGs;omeAs;InaGs;omeCs; 28565
35 m01 GTGG InaTs;omeUs;InaCs;omeGs;InaTs;omeGs;InaG-Sup
MECP2- GACAAACACGG InaGs;omeAs;InaCs;omeAs;InaAs;omeAs;InaCs;omeAs; 29761
36 m01 TTTT InaCs;omeGs;InaGs;omeUs;InaTs;omeUs;InaT-Sup
MECP2- TTGCTACCACG InaTs;omeUs;InaGs;omeCs;InaTs;omeAs;InaCs;omeCs; 72740
37 m01 GCCT InaAs;omeCs;InaGs;omeGs;InaCs;omeCs;InaT-Sup
MECP2- TGCTACCACGG InaTs;omeGs;InaCs;omeUs;InaAs;omeCs;InaCs;omeAs; 72741
38 m01 CCTC InaCs;omeGs;InaGs;omeCs;InaCs;omeUs;InaC-Sup
MECP2- ATCAATAACAG InaAs;omeUs;InaCs;omeAs;InaAs;omeUs;InaAs;omeAs; 72783
39 m01 CCGC InaCs;omeAs;InaGs;omeCs;InaCs;omeGs;InaC-Sup
MECP2- CAATAACAGCC InaCs;omeAs;InaAs;omeUs;InaAs;omeAs;InaCs;omeAs; 72785
40 m01 GCTC InaGs;omeCs;InaCs;omeGs;InaCs;omeUs;InaC-Sup
MECP2- ACTCAATGTGT InaAs;omeCs;InaTs;omeCs;InaAs;omeAs;InaTs;omeGs; 72848
41 m01 GCCG InaTs;omeGs;InaTs;omeGs;InaCs;omeCs;InaG-Sup
MECP2- CAATGTGTGCC InaCs;omeAs;InaAs;omeUs;InaGs;omeUs;InaGs;omeUs; 72851
42 m01 GAGC InaGs;omeCs;InaCs;omeGs;InaAs;omeGs;InaC-Sup
MECP2- CAAACGCGTCA InaCs;omeAs;InaAs;omeAs;InaCs;omeGs;InaCs;omeGs; 36117
43 m01 CTTA InaTs;omeCs;InaAs;omeCs;InaTs;omeUs;InaA-Sup
MECP2- ATCGAGAATGC InaAs;omeUs;InaCs;omeGs;InaAs;omeGs;InaAs;omeAs; 36165
44 m01 TAAC InaTs;omeGs;InaCs;omeUs;InaAs;omeAs;InaC-Sup
MECP2- CGCACGAGGCC InaCs;omeGs;InaCs;omeAs;InaCs;omeGs;InaAs;omeGs; 76153
45 m01 GGCT InaGs;omeCs;InaCs;omeGs;InaGs;omeCs;InaT-Sup
MECP2- GAGTCAGTGTC InaGs;omeAs;InaGs;omeUs;InaCs;omeAs;InaGs;omeUs; 76180
46 m01 CGCG InaGs;omeUs;InaCs;omeCs;InaGs;omeCs;InaG-Sup
MECP2- GTGTCCGCGGA InaGs;omeUs;InaGs;omeUs;InaCs;omeCs;InaGs;omeCs; 76186
47 m01 CCCG InaGs;omeGs;InaAs;omeCs;InaCs;omeCs;InaG-Sup
MECP2- AGCACTTCTTG InaAs;omeGs;InaCs;omeAs;InaCs;omeUs;InaTs;omeCs; 76316
48 m01 TACG InaTs;omeUs;InaGs;omeUs;InaAs;omeCs;InaG-Sup
MECP2- TTCTTGTACGA InaTs;omeUs;InaCs;omeUs;InaTs;omeGs;InaTs;omeAs; 76321
49 m01 GGTG InaCs;omeGs;InaAs;omeGs;InaGs;omeUs;InaG-Sup
MECP2- TGTGCCGCTTC InaTs;omeGs;InaTs;omeGs;InaCs;omeCs;InaGs;omeCs; 76349
50 m01 TACA InaTs;omeUs;InaCs;omeUs;InaAs;omeCs;InaA-Sup
MECP2- CCGCCGACTGG InaCs;omeCs;InaGs;omeCs;InaCs;omeGs;InaAs;omeCs; 76385
51 m01 TGCC InaTs;omeGs;InaGs;omeUs;InaGs;omeCs;InaC-Sup
MECP2- TGGTGCCAGTT InaTs;omeGs;InaGs;omeUs;InaGs;omeCs;InaCs;omeAs; 76393
52 m01 CGGT InaGs;omeUs;InaTs;omeCs;InaGs;omeGs;InaT-Sup
MECP2- TGATCGTGCGC InaTs;omeGs;InaAs;omeUs;InaCs;omeGs;InaTs;omeGs; 76490
53 m01 GACC InaCs;omeGs;InaCs;omeGs;InaAs;omeCs;InaC-Sup
MECP2- GATCGTGCGCG InaGs;omeAs;InaTs;omeCs;InaGs;omeUs;InaGs;omeCs; 76491
54 m01 ACCA InaGs;omeCs;InaGs;omeAs;InaCs;omeCs;InaA-Sup
MECP2- TCGTGCGCGAC InaTs;omeCs;InaGs;omeUs;InaGs;omeCs;InaGs;omeCs; 76493
55 m01 CAGA InaGs;omeAs;InaCs;omeCs;InaAs;omeGs;InaA-Sup
MECP2- GCGGCTGTGCG InaGs;omeCs;InaGs;omeGs;InaCs;omeUs;InaGs;omeUs; 76515
56 m01 AGCG InaGs;omeCs;InaGs;omeAs;InaGs;omeCs;InaG-Sup
MECP2- GGATCAACCGC InaGs;omeGs;InaAs;omeUs;InaCs;omeAs;InaAs;omeCs; 76565
57 m01 AACG InaCs;omeGs;InaCs;omeAs;InaAs;omeCs;InaG-Sup
MECP2- GATCAACCGCA InaGs;omeAs;InaTs;omeCs;InaAs;omeAs;InaCs;omeCs; 76566
58 m01 ACGC InaGs;omeCs;InaAs;omeAs;InaCs;omeGs;InaC-Sup
MECP2- CGACTGGACAT InaCs;omeGs;InaAs;omeCs;InaTs;omeGs;InaGs;omeAs; 78887
59 m01 CCTT InaCs;omeAs;InaTs;omeCs;InaCs;omeUs;InaT-Sup
MECP2- CCCGAGGAGTA InaCs;omeCs;InaCs;omeGs;InaAs;omeGs;InaGs;omeAs; 79422
60 m01 CATC InaGs;omeUs;InaAs;omeCs;InaAs;omeUs;InaC-Sup
BRIEF DESCRIPTION OF THE SEQUENCE LISTING
SEQ ID Chrom Gene Chr. Start Chr. End Strand
 1 chrX MECP2 153275263 153375188
 2 chrX MECP2 153275263 153375188 +
 3 chrX Mecp2  71260160  71342932
 4 chrX Mecp2  71260160  71342932 +
 5 chrX MECP2 153278064 153278111
 6 chrX MECP2 153278111 153278156
 7 chrX MECP2 153278706 153278747
 8 chrX MECP2 153279512 153279556
 9 chrX MECP2 153279613 153279658
 10 chrX MECP2 153281486 153281531
 11 chrX MECP2 153283707 153283737
 12 chrX MECP2 153284059 153284105
 13 chrX MECP2 153287944 153287992
 14 chrX MECP2 153288681 153288722
 15 chrX MECP2 153290087 153290134
 16 chrX MECP2 153290216 153290263
 17 chrX MECP2 153290364 153290414
 18 chrX MECP2 153291585 153291633
 19 chrX MECP2 153292312 153292362
 20 chrX MECP2 153292731 153292774
 21 chrX MECP2 153293138 153293185
 22 chrX MECP2 153293331 153293377
 23 chrX MECP2 153293427 153293469
 24 chrX MECP2 153293568 153293614
 25 chrX MECP2 153293715 153293764
 26 chrX MECP2 153293792 153293878
 27 chrX MECP2 153293901 153293948
 28 chrX MECP2 153294420 153294467
 29 chrX MECP2 153297927 153297972
 30 chrX MECP2 153315466 153315571
 31 chrX MECP2 153343401 153343447
 32 chrX MECP2 153344298 153344339
 33 chrX MECP2 153348654 153348702
 34 chrX MECP2 153348997 153349021
 35 chrX MECP2 153349179 153349222
 36 chrX MECP2 153349694 153349734
 37 chrX MECP2 153350493 153350518
 38 chrX MECP2 153356667 153356713
 39 chrX MECP2 153356742 153356795
 40 chrX MECP2 153357047 153357106
 41 chrX MECP2 153357161 153357204
 42 chrX MECP2 153361085 153361163
 43 chrX MECP2 153361423 153361467
 44 chrX MECP2 153362464 153362527
 45 chrX MECP2 153276064 153280111
 46 chrX MECP2 153276111 153280156
 47 chrX MECP2 153276706 153280747
 48 chrX MECP2 153277512 153281556
 49 chrX MECP2 153277613 153281658
 50 chrX MECP2 153279486 153283531
 51 chrX MECP2 153281707 153285737
 52 chrX MECP2 153282059 153286105
 53 chrX MECP2 153285944 153289992
 54 chrX MECP2 153286681 153290722
 55 chrX MECP2 153288087 153292134
 56 chrX MECP2 153288216 153292263
 57 chrX MECP2 153288364 153292414
 58 chrX MECP2 153289585 153293633
 59 chrX MECP2 153290312 153294362
 60 chrX MECP2 153290731 153294774
 61 chrX MECP2 153291138 153295185
 62 chrX MECP2 153291331 153295377
 63 chrX MECP2 153291427 153295469
 64 chrX MECP2 153291568 153295614
 65 chrX MECP2 153291715 153295764
 66 chrX MECP2 153291792 153295878
 67 chrX MECP2 153291901 153295948
 68 chrX MECP2 153292420 153296467
 69 chrX MECP2 153295927 153299972
 70 chrX MECP2 153313466 153317571
 71 chrX MECP2 153341401 153345447
 72 chrX MECP2 153342298 153346339
 73 chrX MECP2 153346654 153350702
 74 chrX MECP2 153346997 153351021
 75 chrX MECP2 153347179 153351222
 76 chrX MECP2 153347694 153351734
 77 chrX MECP2 153348493 153352518
 78 chrX MECP2 153354667 153358713
 79 chrX MECP2 153354742 153358795
 80 chrX MECP2 153355047 153359106
 81 chrX MECP2 153355161 153359204
 82 chrX MECP2 153359085 153363163
 83 chrX MECP2 153359423 153363467
 84 chrX MECP2 153360464 153364527
 85 chrX MECP2 153279614 153279660 +
 86 chrX MECP2 153281662 153281720 +
 87 chrX MECP2 153281946 153281988 +
 88 chrX MECP2 153284367 153284448 +
 89 chrX MECP2 153284489 153284534 +
 90 chrX MECP2 153288786 153288832 +
 91 chrX MECP2 153289895 153289940 +
 92 chrX MECP2 153292315 153292365 +
 93 chrX MECP2 153292496 153292548 +
 94 chrX MECP2 153297642 153297688 +
 95 chrX MECP2 153297723 153297765 +
 96 chrX MECP2 153300816 153300879 +
 97 chrX MECP2 153315579 153315621 +
 98 chrX MECP2 153316595 153316640 +
 99 chrX MECP2 153348783 153348830 +
100 chrX MECP2 153349199 153349250 +
101 chrX MECP2 153358221 153358285 +
102 chrX MECP2 153277614 153281660 +
103 chrX MECP2 153279662 153283720 +
104 chrX MECP2 153279946 153283988 +
105 chrX MECP2 153282367 153286448 +
106 chrX MECP2 153282489 153286534 +
107 chrX MECP2 153286786 153290832 +
108 chrX MECP2 153287895 153291940 +
109 chrX MECP2 153290315 153294365 +
110 chrX MECP2 153290496 153294548 +
111 chrX MECP2 153295642 153299688 +
112 chrX MECP2 153295723 153299765 +
113 chrX MECP2 153298816 153302879 +
114 chrX MECP2 153313579 153317621 +
115 chrX MECP2 153314595 153318640 +
116 chrX MECP2 153346783 153350830 +
117 chrX MECP2 153347199 153351250 +
118 chrX MECP2 153356221 153360285 +
Single Strand Oligonucleotides (Antisense Strand of Target Gene)
SeqID range: 119-47653
SeqIDs w/o G Runs:
119-142, 157-202, 217-263, 279-293, 307-350, 364-544, 559-609, 623-677, 691-711, 726-787, 803-839, 854-915, 930-1055, 1070-1081, 1095-1103, 1118-1149, 1163, 1186-1189, 1204-1236, 1259-1301, 1343-1452, 1466-1476, 1490-1610, 1624-1658, 1672-1694, 1730-1740, 1769-1790, 1804-1814, 1843, 1881-1910, 1924-1947, 1978-1980, 2038-2052, 2066-2092, 2108-2114, 2142-2147, 2175-2192, 2207-2261, 2275-2294, 2308-2336, 2350-2379, 2394-2431, 2463-2515, 2529-2631, 2645-2771, 2786-2994, 3009-3291, 3305-3395, 3409-3463, 3477-3515, 3529-3566, 3581-3599, 3613-3686, 3701-3718, 3732-3830, 3844-3861, 3875-3970, 3984-4133, 4157-4235, 4251-4254, 4268-4474, 4488-4575, 4589-4608, 4627-4739, 4745-4756, 4780-4812, 4826-5007, 5034-5123, 5137-5239, 5253-5345, 5353-5371, 5384-5401, 5406-5477, 5503-5517, 5531-5635, 5649-5867, 5881-6171, 6185-6214, 6228-6231, 6245-6265, 6280-6406, 6420-6490, 6505-6661, 6684-6784, 6799-6964, 6979-7024, 7045-7174, 7188-7310, 7337-7388, 7402-7410, 7424-7474, 7489-7729, 7756-7797, 7811-7974, 7988-8049, 8063-8448, 8462-8671, 8686-8728, 8742-8854, 8869-8872, 8893-9071, 9076-9363, 9384-9399, 9423-9613, 9619-9706, 9715-9810, 9818-9931, 9951-9956, 9970-10101, 10116-10148, 10153-10230, 10244-10288, 10292-10379, 10386-10412, 10426-10639, 10680-10979, 11005-11060, 11072-11159, 11173-11198, 11204-11226, 11240-11566, 11580-11763, 11777-12069, 12083-12178, 12183-12197, 12213-12235, 12247-12257, 12268-12315, 12342-12351, 12373-12387, 12402-12409, 12431-12443, 12457-12466, 12485, 12510-12524, 12547, 12561-12802, 12817-12828, 12843-12854, 12868, 12882-12936, 12956-13001, 13015-13044, 13058-13087, 13106-13116, 13139-13141, 13155-13163, 13178-13612, 13634-13823, 13838-13847, 13857-13866, 13877-14524, 14538-14555, 14569-14754, 14768-14791, 14804-14806, 14820-14830, 14842-14851, 14865-14891, 14895-15008, 15022-15295, 15299-15317, 15332-15643, 15656-15658, 15670-15697, 15701-15748, 15765-15872, 15886-15941, 15964-15985, 15992-16007, 16021-16058, 16062-16084, 16098-16202, 16216-16428, 16439-16487, 16500-16758, 16772-16857, 16871-16875, 16891-16933, 16947-16990, 16999-17030, 17057-17072, 17096-17143, 17149-17150, 17165-17200, 17235-17246, 17260-17466, 17480-17545, 17566-17572, 17586-17592, 17638-17675, 17689-18203, 18217-18417, 18431-18540, 18554-18642, 18656-18669, 18683-18724, 18739-18828, 18842-19079, 19110-19222, 19236-19260, 19275-19321, 19335-19336, 19350-19415, 19430-19530, 19555-19666, 19681, 19695-19717, 19731-19841, 19856-19864, 19878-19905, 19945-20156, 20180-20184, 20218-20297, 20349-20360, 20374-20388, 20402-20409, 20423-20435, 20449-20456, 20470-20505, 20519-20524, 20564-20574, 20589-20605, 20620-20641, 20655-20673, 20687-20717, 20745-20752, 20767-20790, 20804-20808, 20832-20834, 20859-20871, 20885-20922, 20936-20972, 20995-21005, 21020-21075, 21089-21097, 21111-21120, 21134-21161, 21175-21210, 21224-21241, 21256-21263, 21277-21283, 21297-21331, 21345-21417, 21431-21526, 21540-21592, 21606-21693, 21707-21746, 21760-21783, 21808-21870, 21884-21896, 21911-21947, 21961-22177, 22191-22199, 22213, 22229-22539, 22553-22572, 22587-22603, 22617-22680, 22719-22733, 22755-22777, 22791-22804, 22818-22848, 22862-22877, 22891-22909, 22923-22938, 22959-22995, 23009-23017, 23034-23037, 23066-23070, 23084-23108, 23130-23171, 23182-23237, 23261-23263, 23274-23279, 23301-23322, 23336-23365, 23379, 23389-23430, 23441-23450, 23464-23561, 23576-23654, 23668-23725, 23739-23770, 23784-23823, 23837-23851, 23865-23908, 23922-24117, 24132-24246, 24261-24314, 24328-24402, 24416-24489, 24512-24778, 24799-24805, 24837-24862, 24884-25011, 25032-25045, 25069-25256, 25271-25316, 25330-25332, 25346-25349, 25363-25395, 25410-25422, 25438-25460, 25474, 25493-25614, 25628-25641, 25655-25722, 25736-25752, 25766-25878, 25892-26037, 26051-26076, 26090-26250, 26264-26309, 26333-26385, 26406-26431, 26450-26465, 26488-26509, 26524-26534, 26548-26667, 26681-26689, 26704-26719, 26746-26842, 26857-26862, 26876-26903, 26918-26919, 26933-26962, 26976-26989, 27004-27020, 27037-27063, 27088, 27114-27116, 27130-27133, 27167-27194, 27208-27226, 27241-27251, 27265-27377, 27391-27490, 27504-27720, 27756-27790, 27804-27812, 27867-27947, 27965-27972, 27998-28071, 28085-28119, 28133-28399, 28413-28459, 28473-28551, 28565-28619, 28634-28665, 28679-28697, 28711-28723, 28737-28748, 28763-28765, 28779-28793, 28824-28897, 28920-28934, 28952-28960, 28974-28997, 29011-29057, 29071-29153, 29174-29185, 29227-29377, 29391-29548, 29575-29623, 29637-29795, 29810-29887, 29929-29939, 29957-29965, 29980-30040, 30056-30211, 30226-30257, 30291-30358, 30386-30390, 30416-30466, 30482-30484, 30509-30550, 30564-30566, 30580-30585, 30600-30662, 30676-30777, 30791-30815, 30835-30881, 30918-31003, 31017-31024, 31038-31049, 31063-31065, 31081-31098, 31113-31192, 31206-31229, 31244-31254, 31268-31390, 31404-31422, 31437-31454, 31468-31487, 31503-31620, 31635-31736, 31750-31754, 31775-31902, 31918-32203, 32235-32249, 32264-32276, 32290-32323, 32337-32384, 32417-32459, 32482-32502, 32522-32568, 32592-32659, 32692-32724, 32738-32829, 32843-33144, 33158-33168, 33182-33188, 33202-33214, 33228-33303, 33331-33339, 33353-33366, 33380-33400, 33414-33490, 33505-33521, 33536-33554, 33581-33745, 33763-33804, 33818-33824, 33846-33867, 33881-33928, 33946-34050, 34064-34065, 34079-34080, 34099-34101, 34119-34176, 34190-34304, 34337-34362, 34383, 34397-34701, 34721-34727, 34741-34742, 34765-34827, 34841-34850, 34872-34878, 34892-34978, 34996-35092, 35107-35130, 35149-35172, 35201-35238, 35252-35271, 35291-35317, 35331-35342, 35356-35359, 35378-35449, 35465-35474, 35500-35532, 35546-35645, 35659-35886, 35917-36221, 36237-36277, 36291-36354, 36369-36447, 36473-36476, 36492-36513, 36535-36563, 36587-36631, 36658-36756, 36770-36787, 36801-36836, 36850-36884, 36900-36955, 36969-37119, 37134-37223, 37238-37280, 37294-37359, 37373-37525, 37539-37566, 37580-37585, 37611, 37651-37671, 37700-37714, 37749, 37774-37797, 37832-37874, 37945-37964, 38004-38016, 38030-38053, 38075-38146, 38178-38238, 38252-38257, 38271-38350, 38365-38374, 38406-38426, 38470, 38510-38519, 38535-38557, 38572, 38586-38594, 38620-38635, 38649-38693, 38713-38727, 38755-38768, 38783-38793, 38816-38858, 38873-38942, 38957-38965, 38991-38994, 39008-39009, 39028-39032, 39047-39048, 39071-39173, 39199-39206, 39220-39229, 39255-39259, 39273-39279, 39300-39326, 39340-39359, 39403-39498, 39512-39536, 39550-39562, 39576-39578, 39593, 39611-39623, 39638-39648, 39662-39718, 39742-39768, 39801-39889, 39914-39917, 39931-39971, 39984-39999, 40006-40065, 40080-40092, 40094-40095, 40113-40124, 40150-40176, 40191-40233, 40249-40295, 40309-40322, 40336-40337, 40351-40361, 40376-40517, 40567-40600, 40614-40631, 40646-40672, 40686-40712, 40727-40761, 40776-40801, 40815-40820, 40836-40958, 40973-40996, 41010-41021, 41035-41049, 41064-41072, 41086-41096, 41110, 41124-41185, 41200-41275, 41290-41300, 41341-41381, 41408-41425, 41450-41466, 41480-41492, 41513-41582, 41597-41637, 41652-41668, 41682-41792, 41807-41826, 41840-41841, 41855-41905, 41920-41924, 41939-42053, 42068-42090, 42105-42108, 42122-42219, 42245-42250, 42283-42334, 42364-42379, 42394-42413, 42433-42434, 42466-42471, 42485-42530, 42548-42598, 42612-42693, 42707-42721, 42736-42741, 42757-42775, 42789-42800, 42822-42824, 42838-42930, 42939-43001, 43015-43127, 43142-43152, 43166-43231, 43245-43290, 43304-43337, 43351-43372, 43404-43470, 43484-43516, 43530-43545, 43560-43599, 43613-43624, 43639-43642, 43657-43667, 43694-43717, 43733-43761, 43789-43815, 43830-43911, 43925-43949, 43963-43977, 43991-44009, 44035-44054, 44078-44128, 44142-44157, 44180-44204, 44218-44230, 44245-44258, 44272-44286, 44310-44336, 44350-44367, 44398-44445, 44472-44493, 44507-44528, 44559-44602, 44631-44633, 44647-44656, 44682-44724, 44743-44832, 44858-44896, 44915-44928, 44942-44946, 44960-44979, 44997, 45010-45037, 45052-45059, 45073-45121, 45184-45202, 45216, 45231-45246, 45261-45266, 45280-45300, 45314-45368, 45374-45420, 45433-45453, 45487-45495, 45509-45535, 45551-45603, 45617-45652, 45668-45740, 45760-45770, 45784-45814, 45828-45906, 45920-45961, 45976-45990, 46004-46016, 46030-46039, 46053-46070, 46084-46126, 46140-46164, 46178-46221, 46235-46311, 46321-46327, 46341-46418, 46432-46504, 46518-46569, 46582-46600, 46614-46617, 46631-46632, 46646-46648, 46663-46785, 46799-46846, 46862-47025, 47049-47197, 47203-47255, 47269-47274, 47288-47314, 47328-47419, 47426-47461, 47463, 47468-47483, 47485-47551, 47554-47559, 47561-47569, 47577-47608, 47612-47623, 47625-47631, 47633-47638, 47643-47653
SeqIDs w/o miR Seeds:
119, 121-123, 125, 130, 132-133, 137-140, 142, 149, 151-152, 161-164, 166-167, 169, 172-176, 178-181, 183, 186-187, 189, 192, 194-195, 198, 202-203, 210-213, 215-218, 220, 222-223, 225-228, 230-231, 233, 235-236, 238-239, 242-243, 247, 251-252, 254-255, 257-259, 261-263, 265, 267, 272-277, 279-282, 285-287, 290-293, 297-300, 305-306, 308, 310, 313, 316, 318, 324-329, 331-332, 335, 337-339, 341-343, 345, 347-349, 353-359, 361-362, 366, 369-371, 378-381, 384-389, 391, 393-394, 401, 404, 406-407, 409, 411-412, 421-422, 424-425, 427-438, 441, 443-446, 449-451, 454-455, 458-459, 461-462, 464, 467-468, 470-471, 473, 476-478, 483-489, 491, 493-498, 502, 504, 506-510, 512-523, 525, 527, 529-530, 532-534, 536, 539-544, 548, 550, 552, 554-558, 562, 565-566, 569-572, 575, 577, 579-588, 590, 594, 598-600, 602-606, 608-609, 612, 614-615, 617-619, 621-624, 630-633, 636, 639-641, 643-647, 649-651, 653, 655, 658, 660-663, 666-667, 669-670, 676-677, 682, 684-688, 690, 699, 701, 703-708, 710-713, 717-720, 724, 726, 730, 732-735, 739-740, 745-746, 748-749, 755-756, 758, 760-762, 764-768, 773, 776-778, 780, 785-787, 796-797, 802, 805-809, 812, 818-824, 826, 831, 834, 836-840, 846, 848, 851, 853-856, 858-859, 862, 864, 868-870, 876, 878-883, 885-886, 889, 893-895, 897-899, 901, 904, 906, 909-910, 913, 916, 918, 924, 927-928, 930-931, 933-939, 943-944, 949, 951-953, 955, 959, 964-967, 969-974, 976-980, 982, 984, 986-987, 989-1000, 1002, 1005-1017, 1020-1023, 1025, 1027-1028, 1030-1031, 1034-1035, 1038-1048, 1050-1055, 1068-1072, 1074-1077, 1080-1082, 1087-1090, 1092, 1094, 1099-1101, 1103, 1105, 1110, 1112-1113, 1115, 1117-1118, 1121, 1125-1131, 1134, 1136, 1138, 1140-1147, 1149, 1151, 1154, 1157-1158, 1162-1163, 1166, 1168-1169, 1171, 1176, 1178-1181, 1183, 1185-1186, 1188-1189, 1195-1196, 1198-1204, 1206-1208, 1210-1212, 1215-1216, 1218-1220, 1223-1224, 1229, 1231, 1233, 1235-1236, 1238, 1243-1245, 1252-1253, 1255-1263, 1265, 1267-1270, 1272-1289, 1293-1301, 1309, 1314-1315, 1317, 1323-1324, 1332-1334, 1336-1341, 1343, 1346-1349, 1351-1352, 1354-1356, 1361-1362, 1365-1369, 1372, 1375, 1379, 1381-1384, 1386, 1389-1390, 1393, 1396, 1398, 1401-1402, 1404-1407, 1409-1410, 1415-1416, 1418-1422, 1424, 1427, 1429-1432, 1434-1435, 1437-1445, 1447-1452, 1455-1465, 1467, 1471, 1473, 1475, 1477, 1481, 1485-1493, 1495, 1499-1501, 1503-1505, 1507, 1510-1512, 1514, 1516, 1518-1523, 1525-1526, 1528, 1531, 1534, 1537, 1539, 1542, 1546-1547, 1549-1550, 1552, 1555, 1558, 1561, 1563, 1565-1569, 1572, 1574-1575, 1577, 1579, 1584-1585, 1591-1602, 1605-1606, 1608-1610, 1612, 1614-1615, 1618-1620, 1622-1623, 1625-1626, 1628-1629, 1631-1632, 1634, 1638-1639, 1641, 1643-1649, 1651, 1653-1655, 1657, 1659, 1661, 1663-1664, 1666-1668, 1670-1677, 1679-1683, 1685-1686, 1688-1692, 1694-1695, 1697, 1699, 1703-1705, 1709-1711, 1717, 1719-1720, 1722, 1725, 1728-1737, 1742, 1744, 1746-1760, 1762, 1764-1767, 1769-1776, 1778, 1781-1783, 1786, 1788-1789, 1796, 1798-1801, 1803, 1806-1809, 1811-1815, 1820-1822, 1828-1829, 1831, 1834-1841, 1843-1844, 1846-1848, 1850-1851, 1854-1855, 1857-1858, 1861-1862, 1865-1866, 1871-1873, 1878-1879, 1881-1887, 1890, 1892-1895, 1898-1901, 1903, 1905, 1907, 1914, 1918-1919, 1921-1922, 1924-1925, 1927, 1929, 1932-1934, 1936, 1939-1946, 1952-1953, 1955-1957, 1959-1960, 1962, 1964-1965, 1967, 1970, 1972-1977, 1979-1980, 1982, 1987, 1991, 1995, 1997-1999, 2007-2008, 2010-2011, 2013-2015, 2017-2023, 2030-2033, 2037, 2040-2042, 2045, 2048-2051, 2055, 2057-2062, 2064-2065, 2067, 2069, 2071-2072, 2074, 2076, 2084, 2087, 2089-2092, 2094, 2096, 2099-2100, 2102, 2104-2109, 2111, 2113, 2121, 2127-2129, 2132, 2139-2140, 2144, 2146, 2148, 2157-2158, 2160-2161, 2166, 2168-2178, 2183-2186, 2191, 2193, 2198-2202, 2204, 2206, 2209, 2211-2213, 2215-2218, 2222-2227, 2229-2230, 2234, 2236-2239, 2241, 2245-2247, 2249-2252, 2254-2255, 2258-2259, 2261, 2267-2269, 2271-2274, 2276-2280, 2283, 2285-2291, 2293-2295, 2297-2300, 2302, 2306-2310, 2312, 2314-2315, 2317-2319, 2322, 2324-2325, 2327-2328, 2332, 2334-2336, 2338-2344, 2346-2349, 2351-2352, 2355-2357, 2359, 2361, 2363-2364, 2366-2375, 2377-2378, 2380-2381, 2389, 2392-2393, 2396-2397, 2399-2400, 2403-2405, 2409-2410, 2413-2416, 2419-2424, 2426, 2429, 2431, 2433-2436, 2439-2440, 2443-2445, 2447-2449, 2452, 2455-2457, 2459-2465, 2473-2475, 2478-2482, 2484, 2487, 2491-2506, 2509-2511, 2513-2515, 2521, 2523-2526, 2528, 2531-2533, 2535-2542, 2545, 2547-2550, 2552-2557, 2559-2565, 2567-2573, 2575, 2580-2581, 2583-2584, 2586-2589, 2592-2593, 2595-2603, 2608-2610, 2613, 2615-2621, 2623-2633, 2635-2638, 2640-2641, 2643-2646, 2650, 2652-2653, 2657, 2661-2663, 2666-2667, 2672, 2674, 2676, 2678-2682, 2684, 2694-2698, 2700-2705, 2707-2715, 2717, 2719-2722, 2724-2726, 2729-2730, 2737, 2740, 2742-2743, 2745-2749, 2751-2760, 2764, 2766-2773, 2775-2778, 2780-2782, 2785-2787, 2789, 2791, 2793-2797, 2800-2803, 2805, 2809-2824, 2826-2833, 2835-2837, 2839-2842, 2844-2846, 2848-2854, 2856-2857, 2861-2865, 2867, 2870-2871, 2873-2876, 2878-2879, 2881-2884, 2886-2889, 2891-2893, 2896-2899, 2901, 2903-2904, 2906, 2909-2911, 2913-2925, 2927, 2929, 2937, 2939-2940, 2942-2945, 2947, 2949, 2952-2954, 2957-2959, 2963, 2965-2970, 2974, 2976, 2979, 2982-2989, 2991-2997, 3001-3002, 3004, 3010-3024, 3031-3039, 3041-3044, 3050, 3054-3055, 3058-3059, 3063-3067, 3069-3072, 3077-3078, 3080, 3084-3091, 3093, 3095-3097, 3100, 3102-3107, 3109-3110, 3112-3113, 3115-3116, 3119, 3121-3125, 3129-3130, 3132-3134, 3136-3138, 3140-3149, 3151, 3153-3161, 3163-3164, 3170-3188, 3193, 3198, 3200, 3202-3204, 3207-3209, 3211, 3214-3215, 3218-3222, 3224-3230, 3234-3235, 3237-3238, 3242-3245, 3247-3250, 3252, 3254-3257, 3260-3267, 3269-3270, 3272-3273, 3276-3278, 3282-3283, 3285-3286, 3289, 3291, 3294, 3297-3299, 3301-3303, 3311-3313, 3316, 3320-3330, 3332-3333, 3335, 3337, 3342-3344, 3350-3351, 3353-3354, 3357-3358, 3360-3366, 3368-3370, 3372-3377, 3381, 3384, 3386-3388, 3390, 3392-3395, 3397, 3400-3403, 3405, 3407-3408, 3410, 3413, 3416-3419, 3423, 3425, 3427-3428, 3430, 3432-3436, 3439, 3441-3442, 3444, 3448, 3453, 3455-3457, 3459-3465, 3467-3468, 3470-3474, 3476, 3478-3480, 3482, 3484-3486, 3489-3496, 3498-3500, 3502-3504, 3506-3510, 3512, 3515-3517, 3519, 3522-3526, 3530, 3534-3542, 3548-3549, 3555-3556, 3558, 3561, 3563-3565, 3568, 3577, 3580-3587, 3589, 3592, 3595-3600, 3604, 3606-3610, 3612, 3614, 3621, 3623-3625, 3627-3634, 3636-3644, 3646, 3649-3650, 3653, 3655, 3660-3667, 3670-3671, 3673-3676, 3679, 3682, 3684-3686, 3688, 3692-3693, 3695-3700, 3702-3707, 3709-3716, 3718, 3724-3727, 3732, 3735, 3738-3739, 3742, 3749-3751, 3754-3755, 3758, 3764, 3766-3770, 3776-3779, 3781, 3783-3786, 3791-3793, 3797-3801, 3805-3806, 3808-3810, 3812-3813, 3817-3820, 3825-3828, 3834-3835, 3837, 3841-3842, 3844, 3848, 3850-3852, 3854-3862, 3865-3867, 3870-3872, 3874-3884, 3886, 3890-3891, 3895-3896, 3898-3899, 3901, 3906-3912, 3915-3916, 3918-3924, 3931, 3934, 3936-3938, 3940, 3943, 3948-3951, 3953-3954, 3956, 3958, 3960-3961, 3964-3965, 3967, 3969-3975, 3977-3981, 3984, 3986-3987, 3989, 3991, 3993, 4001-4008, 4010-4021, 4024-4030, 4034, 4036-4047, 4049-4051, 4054, 4057, 4059, 4065, 4067, 4069-4071, 4073-4075, 4077-4078, 4080-4085, 4088-4092, 4094-4100, 4103, 4105-4106, 4109-4111, 4113, 4115-4117, 4120-4121, 4123, 4125, 4130-4133, 4136, 4138, 4143, 4152, 4155-4158, 4160-4161, 4163, 4165-4166, 4170-4172, 4174-4177, 4179, 4181-4183, 4185, 4188-4193, 4195-4197, 4202-4210, 4212, 4214-4217, 4219-4225, 4227-4234, 4236, 4238-4239, 4242, 4244, 4246-4247, 4249, 4251, 4253, 4258-4259, 4262-4264, 4266-4267, 4269-4276, 4278-4280, 4282-4283, 4285, 4287, 4289-4292, 4294, 4296-4304, 4308-4309, 4311-4312, 4315-4319, 4321-4325, 4328-4329, 4331-4335, 4337, 4339-4341, 4345, 4347, 4351-4353, 4357-4358, 4360-4364, 4367-4371, 4374, 4379-4381, 4383, 4385-4386, 4390, 4392-4393, 4395, 4399, 4401-4406, 4409-4414, 4417-4425, 4429-4431, 4436-4447, 4449-4456, 4459, 4462-4465, 4469-4471, 4473, 4477, 4479-4481, 4483-4484, 4487-4489, 4491, 4493, 4495-4496, 4498-4502, 4505, 4507-4510, 4512-4513, 4515-4516, 4518-4520, 4522, 4525-4527, 4529, 4531-4533, 4535-4536, 4538, 4541-4542, 4545-4546, 4549-4555, 4558, 4562, 4564-4567, 4569-4571, 4575, 4580, 4582, 4584, 4586-4589, 4593-4594, 4597-4598, 4602-4607, 4618, 4621, 4623, 4625-4627, 4629-4631, 4636, 4638, 4640, 4643, 4645-4646, 4649, 4651-4655, 4658, 4664-4683, 4685-4687, 4690-4691, 4693-4694, 4697-4698, 4700-4706, 4708, 4710, 4712-4715, 4719-4720, 4724, 4726-4727, 4734-4737, 4742, 4744, 4746-4748, 4752, 4757-4764, 4766, 4770-4774, 4776-4780, 4782-4783, 4785-4786, 4789-4790, 4792-4794, 4796, 4800-4804, 4806-4808, 4810-4811, 4815, 4817-4819, 4821, 4823-4824, 4826-4829, 4831-4833, 4835-4841, 4843-4844, 4847-4848, 4850, 4852-4853, 4855-4860, 4862-4866, 4869-4870, 4872, 4875-4876, 4880-4881, 4883, 4885, 4890, 4893, 4896-4899, 4901-4903, 4905, 4907, 4909-4912, 4914, 4916-4917, 4919, 4922, 4924-4926, 4931-4932, 4934-4935, 4937-4942, 4945-4948, 4950-4965, 4968-4970, 4973, 4976-4977, 4981-4985, 4987-4992, 4994, 4996-4997, 4999-5000, 5003, 5006-5008, 5016, 5022, 5027-5031, 5033, 5035-5036, 5039, 5042, 5044-5045, 5047-5054, 5057-5062, 5064, 5066, 5069-5070, 5073-5076, 5078, 5080-5081, 5084, 5086, 5092, 5094-5095, 5097, 5100, 5102-5103, 5106, 5110, 5112-5114, 5116-5118, 5120, 5122-5124, 5126-5127, 5129-5133, 5136-5140, 5143-5146, 5152-5154, 5160, 5162, 5164, 5166, 5169-5171, 5173-5176, 5178-5180, 5182-5189, 5191, 5193, 5195-5199, 5201-5202, 5204-5207, 5209-5214, 5216-5218, 5220-5221, 5225-5226, 5230-5232, 5234, 5237-5239, 5243, 5245-5253, 5255-5256, 5258-5260, 5264, 5266, 5268, 5272, 5274-5275, 5277-5279, 5281-5285, 5287-5290, 5292-5297, 5299, 5303-5304, 5306, 5309-5310, 5313, 5315-5318, 5320-5322, 5324-5326, 5328-5332, 5334-5335, 5339, 5345, 5347, 5353, 5357-5358, 5361, 5363-5364, 5368-5369, 5371, 5373-5374, 5376, 5379-5382, 5384-5388, 5393, 5396, 5399, 5404, 5406-5407, 5411, 5413-5418, 5425-5428, 5431, 5433-5446, 5448-5449, 5452-5457, 5459-5460, 5466-5468, 5471, 5474-5475, 5477, 5479, 5482-5483, 5485-5487, 5494, 5496-5498, 5501-5502, 5505-5507, 5513-5514, 5516-5517, 5519, 5521, 5526, 5528-5529, 5531-5533, 5535-5538, 5540-5541, 5543-5550, 5552-5555, 5557-5566, 5569, 5571-5574, 5576-5577, 5579-5580, 5583-5587, 5589, 5592-5593, 5596-5598, 5603-5604, 5606-5609, 5611-5612, 5614, 5616-5623, 5625-5632, 5636-5638, 5642-5643, 5645-5648, 5651-5652, 5656, 5669-5670, 5672, 5676-5677, 5679-5680, 5682, 5685-5688, 5692, 5694-5695, 5699-5704, 5707-5708, 5710-5713, 5715-5719, 5721, 5723-5725, 5727-5728, 5730-5735, 5737, 5739, 5741-5746, 5748-5752, 5754-5755, 5757, 5759-5760, 5762, 5764-5766, 5768-5769, 5773-5778, 5780, 5784, 5789-5792, 5794, 5796-5803, 5805, 5807-5808, 5810-5813, 5816, 5819, 5822-5825, 5827-5828, 5830-5831, 5835-5838, 5841-5842, 5844, 5846-5849, 5851-5854, 5856, 5858-5864, 5866-5867, 5869, 5871, 5874, 5877-5879, 5882, 5885-5888, 5891-5898, 5900-5901, 5903, 5905-5907, 5909-5911, 5913-5914, 5916, 5918-5921, 5923, 5925-5926, 5929, 5932, 5935-5939, 5942-5953, 5955-5957, 5959-5963, 5965-5967, 5972, 5974-5982, 5984-5986, 5989-5995, 5997-6003, 6005, 6007-6008, 6010-6011, 6013-6016, 6018-6023, 6026-6028, 6031-6032, 6034-6037, 6040, 6042-6044, 6046-6049, 6051-6054, 6056, 6058, 6061-6065, 6067-6068, 6070-6074, 6076, 6078-6082, 6085-6098, 6102-6118, 6121, 6124-6127, 6131-6138, 6140, 6142-6145, 6147, 6151, 6154-6155, 6158-6160, 6162-6165, 6167, 6171-6173, 6177, 6180, 6182, 6184, 6186-6194, 6196-6200, 6202-6207, 6209, 6211-6213, 6216, 6223, 6228-6229, 6231, 6236-6239, 6249-6251, 6254-6255, 6259, 6261-6263, 6265, 6271-6272, 6274-6276, 6278-6279, 6281-6282, 6284-6285, 6287, 6290, 6292, 6295-6299, 6301, 6303, 6307-6310, 6312-6313, 6317-6319, 6323-6326, 6329, 6333-6334, 6336, 6340, 6342-6348, 6354-6355, 6359, 6366-6367, 6369-6373, 6375-6377, 6379-6385, 6387-6389, 6391, 6393, 6395-6399, 6401-6404, 6413-6415, 6418, 6420-6427, 6429-6437, 6439-6444, 6446, 6448, 6450-6456, 6458-6459, 6463-6469, 6471-6472, 6474-6476, 6479, 6483-6489, 6491-6492, 6494, 6496-6497, 6499-6500, 6502-6505, 6507, 6510-6512, 6515-6519, 6522, 6524-6525, 6527-6534, 6536-6539, 6541-6546, 6548-6550, 6552, 6554-6557, 6559, 6562, 6564-6565, 6567-6568, 6570-6573, 6575, 6578-6584, 6587, 6590-6594, 6596-6598, 6600, 6602-6603, 6605-6614, 6616, 6618-6620, 6622-6623, 6625-6628, 6630-6632, 6634, 6637-6642, 6644, 6646-6650, 6655-6663, 6666, 6668, 6670-6671, 6677-6678, 6680-6690, 6692, 6695-6696, 6698-6701, 6705-6707, 6709-6711, 6713-6719, 6721-6723, 6725-6726, 6728-6731, 6733-6734, 6737, 6739-6747, 6750-6751, 6754, 6756, 6758, 6760-6761, 6766, 6769-6771, 6773, 6775-6779, 6782-6783, 6786, 6791, 6793, 6795, 6797-6798, 6803-6808, 6810, 6813, 6816, 6819-6822, 6824-6826, 6828-6829, 6833-6838, 6841-6842, 6844-6846, 6848-6850, 6854-6855, 6857-6864, 6867, 6871-6885, 6887-6888, 6893, 6896-6897, 6900-6902, 6905-6907, 6909-6926, 6929, 6931-6943, 6945-6947, 6949-6954, 6956-6961, 6963-6967, 6970, 6972-6974, 6976-6980, 6983-6985, 6988, 6990-6992, 6994-6996, 6998, 7000-7002, 7004-7006, 7008, 7010-7017, 7019-7020, 7022-7023, 7025, 7037, 7039-7042, 7046-7048, 7050, 7053-7054, 7056, 7058-7059, 7061, 7064-7067, 7069-7070, 7072-7079, 7081, 7083-7084, 7087-7088, 7091-7095, 7098-7102, 7105-7107, 7109-7110, 7112-7113, 7116-7117, 7119-7120, 7122, 7124, 7128, 7130-7131, 7133-7135, 7141, 7143, 7145, 7149-7150, 7152-7153, 7155-7164, 7166-7168, 7178-7181, 7183-7187, 7194, 7196, 7198, 7200, 7202-7207, 7209, 7211-7212, 7215-7216, 7219-7222, 7224, 7227-7229, 7232, 7234-7238, 7241-7249, 7251-7254, 7258-7262, 7264, 7267-7268, 7271-7275, 7279, 7281-7282, 7284, 7286-7292, 7294, 7296-7303, 7305-7311, 7315-7318, 7320-7321, 7324, 7326-7328, 7331-7332, 7334, 7336-7338, 7346, 7350-7351, 7354, 7356, 7358-7362, 7364-7366, 7368, 7371-7372, 7375-7378, 7381-7383, 7387, 7392-7404, 7407-7412, 7414, 7417-7420, 7422, 7427-7430, 7432-7435, 7438, 7440-7441, 7444-7446, 7449, 7451-7455, 7457, 7460, 7462-7463, 7465-7467, 7469-7470, 7472, 7475, 7477, 7480-7481, 7483-7487, 7489-7496, 7498, 7503, 7505, 7509-7515, 7521, 7523, 7526, 7528, 7537-7543, 7545-7550, 7552, 7554, 7556, 7559, 7561-7562, 7564-7566, 7568, 7570-7571, 7573-7575, 7577-7578, 7580-7583, 7587-7588, 7590-7591, 7594, 7596, 7599-7601, 7604, 7607-7610, 7612-7617, 7621, 7624, 7627, 7630-7632, 7634, 7636-7637, 7639-7641, 7644-7645, 7647-7651, 7653-7656, 7659, 7662-7664, 7667-7668, 7670-7672, 7674-7679, 7681-7682, 7684, 7686, 7689, 7691, 7695-7701, 7703-7709, 7713, 7716-7724, 7729, 7732-7733, 7738-7741, 7745, 7748-7753, 7755-7758, 7762-7763, 7766-7779, 7781-7783, 7785, 7788, 7790-7794, 7796-7798, 7801, 7803, 7805-7810, 7813-7814, 7819, 7821-7825, 7827-7828, 7830, 7832-7837, 7839-7840, 7842, 7844-7847, 7849, 7851-7855, 7858, 7860, 7862, 7868-7875, 7877-7879, 7881, 7883-7888, 7890-7895, 7898-7899, 7902-7903, 7906-7907, 7909-7911, 7914-7915, 7917-7918, 7921-7922, 7924, 7926, 7928-7930, 7932-7933, 7935, 7937-7939, 7941-7942, 7945-7949, 7951-7952, 7954, 7956, 7958-7963, 7970, 7972-7975, 7979, 7981, 7983, 7985-7986, 7988-7989, 7991, 7996-7997, 7999, 8001, 8003, 8005-8006, 8009-8016, 8018-8021, 8023, 8025-8028, 8030, 8034-8036, 8038-8040, 8042-8043, 8047-8049, 8055, 8057-8060, 8062-8063, 8065-8068, 8071-8072, 8074-8075, 8077, 8079-8083, 8085-8090, 8095, 8099-8103, 8105-8108, 8110, 8112-8115, 8118, 8120-8122, 8125-8127, 8133-8138, 8140-8144, 8146-8148, 8150-8152, 8157-8158, 8160, 8162-8163, 8165-8169, 8172-8175, 8178-8179, 8182-8183, 8185-8187, 8189-8192, 8196, 8198, 8200, 8202-8204, 8207, 8209, 8211, 8214-8218, 8220-8221, 8224-8227, 8233-8235, 8239-8253, 8255-8263, 8266-8269, 8271, 8274, 8276-8278, 8280, 8284, 8287, 8290, 8293-8301, 8303, 8305, 8307-8308, 8312-8313, 8315-8317, 8319-8320, 8322, 8324, 8326-8328, 8330-8331, 8334-8340, 8343-8361, 8364, 8366-8368, 8370-8375, 8377-8380, 8382-8386, 8388-8392, 8395-8400, 8402-8403, 8410-8411, 8413, 8415-8419, 8425-8426, 8428-8430, 8433-8436, 8438-8440, 8442-8443, 8445-8446, 8448-8453, 8455, 8457, 8459-8467, 8469, 8471-8475, 8478-8481, 8483, 8485-8487, 8490, 8492-8496, 8499-8502, 8504-8506, 8508-8517, 8520-8523, 8526-8527, 8529-8530, 8532-8533, 8535-8543, 8548-8554, 8556-8563, 8565-8566, 8569-8574, 8577-8579, 8581-8582, 8584, 8587, 8591, 8593-8596, 8598-8601, 8605, 8607, 8609-8610, 8615, 8617-8618, 8620-8623, 8625, 8627-8629, 8631-8634, 8636, 8638, 8641-8642, 8644-8646, 8648-8650, 8660-8662, 8665-8670, 8672, 8677-8678, 8680-8681, 8683, 8685-8692, 8694-8695, 8697, 8701-8702, 8706, 8708-8714, 8716-8721, 8723-8728, 8734-8743, 8747, 8749-8753, 8755-8758, 8760, 8762-8763, 8765, 8767-8769, 8772-8773, 8776, 8780-8785, 8787-8788, 8792, 8797, 8800-8806, 8809, 8813-8814, 8817, 8820-8822, 8824-8841, 8843-8847, 8849-8851, 8853, 8861-8862, 8864-8866, 8868, 8871, 8877, 8880, 8883, 8885, 8887-8889, 8892, 8896-8897, 8899, 8901-8905, 8907-8908, 8910-8915, 8920-8922, 8924-8925, 8927, 8929-8932, 8934, 8936-8939, 8941, 8943, 8945-8947, 8950, 8952, 8955-8956, 8958-8959, 8961-8963, 8966-8968, 8972, 8974, 8978, 8980-8981, 8983, 8985-8986, 8988, 8990-8991, 8993-8996, 8998-9001, 9003, 9007-9008, 9010, 9017-9018, 9022-9025, 9033-9034, 9036-9039, 9041-9044, 9048-9049, 9052, 9054, 9058-9059, 9061, 9067-9070, 9075-9076, 9079-9086, 9089-9096, 9098, 9100-9102, 9106, 9111-9113, 9120, 9123, 9127, 9129, 9131-9132, 9134-9136, 9138, 9140-9141, 9143, 9145, 9147-9149, 9152, 9154, 9157, 9162, 9164, 9166-9168, 9171, 9173-9175, 9177, 9180, 9183-9185, 9187, 9189, 9191-9196, 9198-9207, 9217-9218, 9220-9226, 9228, 9233-9239, 9241, 9243-9246, 9248, 9252-9261, 9263-9265, 9268-9269, 9271-9273, 9276-9279, 9282-9284, 9287-9288, 9291, 9293-9294, 9298, 9301, 9303-9307, 9309, 9314-9316, 9318, 9320-9323, 9325, 9327-9329, 9331-9332, 9334, 9336-9337, 9340-9342, 9344-9346, 9349, 9351, 9354-9360, 9363, 9365, 9368, 9370-9371, 9373, 9376-9378, 9381, 9384, 9386-9394, 9399, 9402-9403, 9405, 9407-9410, 9415, 9418-9425, 9427, 9431-9436, 9438-9441, 9444-9458, 9462-9468, 9472, 9475-9476, 9478-9485, 9487-9488, 9490, 9492-9494, 9496-9497, 9499-9501, 9503-9504, 9506-9510, 9513-9514, 9516-9517, 9519-9522, 9524, 9528, 9530-9535, 9540-9542, 9544-9546, 9549-9558, 9560, 9562-9565, 9568-9571, 9575, 9577, 9579-9581, 9584-9587, 9590-9592, 9594, 9596-9600, 9603-9604, 9607, 9609, 9611-9613, 9618-9620, 9622-9626, 9628, 9631-9632, 9639, 9643-9650, 9656, 9658, 9662-9667, 9670, 9673-9674, 9676-9680, 9682-9685, 9687-9690, 9694-9704, 9706-9707, 9709-9710, 9712-9713, 9715, 9717-9720, 9722-9724, 9727-9732, 9734, 9737-9740, 9743, 9746-9751, 9753-9754, 9757, 9759-9761, 9763, 9765-9766, 9768, 9770, 9773, 9777-9783, 9785-9797, 9799, 9801-9802, 9809-9810, 9813, 9817-9820, 9822-9829, 9831, 9833, 9835, 9837-9842, 9844, 9846-9849, 9851-9853, 9855-9857, 9863, 9865, 9871, 9875, 9877-9881, 9883-9887, 9890-9892, 9894-9896, 9898, 9900, 9902-9905, 9907, 9910-9911, 9916-9926, 9929, 9931-9932, 9934-9935, 9942-9944, 9947-9950, 9952, 9954, 9956-9957, 9962, 9964-9968, 9971, 9974-9975, 9977-9980, 9982-9983, 9985-9986, 9988-9997, 9999-10011, 10013-10016, 10018-10022, 10027, 10029-10030, 10032-10033, 10035, 10040, 10042, 10045-10049, 10051, 10053-10056, 10059-10060, 10062, 10064-10065, 10067-10068, 10070, 10074-10076, 10078-10083, 10085-10086, 10090-10092, 10094, 10096-10099, 10101-10102, 10107-10108, 10110-10111, 10114-10118, 10120-10121, 10125-10140, 10143-10144, 10147-10148, 10153-10155, 10157, 10159-10160, 10163, 10165, 10168-10173, 10175-10177, 10184, 10194, 10197, 10199-10202, 10208-10212, 10214-10219, 10222-10225, 10227, 10230-10235, 10237, 10239-10240, 10242-10243, 10248, 10250-10251, 10254-10260, 10262, 10264, 10266-10269, 10272-10283, 10285-10290, 10292, 10294-10297, 10301, 10305-10312, 10315, 10319, 10321-10323, 10325-10328, 10331, 10334-10340, 10342-10345, 10347-10348, 10351-10355, 10357-10368, 10370-10371, 10373, 10378-10379, 10382-10383, 10385, 10387-10389, 10391, 10393, 10395-10398, 10400, 10403-10407, 10409-10413, 10416, 10421, 10423, 10425-10427, 10429-10431, 10434, 10437, 10439-10440, 10442-10449, 10452, 10458-10460, 10462-10467, 10470-10472, 10474, 10476-10482, 10484, 10486-10492, 10494, 10496, 10498-10506, 10509, 10512-10517, 10519, 10521, 10523-10524, 10526, 10528, 10530, 10532-10533, 10537, 10547-10553, 10557-10560, 10563-10564, 10566, 10572-10578, 10580, 10585, 10587-10588, 10590, 10594-10595, 10598-10603, 10605-10606, 10608, 10610, 10612-10613, 10616, 10618, 10620-10623, 10626-10627, 10629-10633, 10635, 10637-10638, 10641, 10644-10645, 10647, 10650, 10652, 10654, 10656, 10669-10671, 10673-10674, 10678-10679, 10682-10688, 10690-10692, 10694-10697, 10699-10700, 10702, 10704-10709, 10711-10712, 10715, 10718, 10720-10723, 10725-10727, 10729, 10733, 10735-10736, 10739-10743, 10745-10746, 10749, 10752, 10754-10759, 10761, 10764, 10766-10776, 10778-10779, 10782-10784, 10786-10792, 10794-10804, 10807-10811, 10813-10814, 10816, 10818-10821, 10823-10827, 10829-10834, 10838-10843, 10845-10846, 10849-10859, 10863, 10866-10874, 10876-10881, 10883-10885, 10887-10890, 10892-10897, 10899-10901, 10903-10915, 10918-10925, 10927-10931, 10933, 10938-10941, 10946-10953, 10955, 10957-10963, 10966-10967, 10969-10972, 10974, 10977-10980, 10984, 10990-10993, 10995, 10997-10998, 11000, 11005, 11007, 11011-1_1012, 11014-11015, 11017-11021, 11023-11027, 11029-11030, 11032, 11035, 11039, 11041, 11043, 11045, 11047, 11052, 11054, 11056-11058, 11066, 11069, 11072-11075, 11077-11078, 11081, 11084-11085, 11093-11095, 11097-11099, 11103-11104, 11106, 11112-1_1114, 11119-1_1120, 11122, 11124, 11126, 11128, 11130, 11134-11138, 11140, 11143-11152, 11154, 11156-11159, 11161-11162, 11167-11168, 11170, 11173, 11175-11183, 11185-11189, 11199-11202, 11204-11205, 11207-11208, 11210, 11213, 11215-11218, 11220, 11222-11223, 11226-11227, 11229, 11231-11233, 11235-11243, 11245-11246, 11248, 11250-11251, 11254, 11257-11263, 11266-11269, 11271-11272, 11274-11279, 11281-11282, 11284-11298, 11300-11302, 11308-11309, 11312-11313, 11317-11319, 11322-11323, 11327-11329, 11331-11332, 11334-11345, 11348-11349, 11352-11354, 11357-11359, 11361-11366, 11368, 11372-11375, 11377-11380, 11382-11383, 11386-11392, 11394, 11397, 11399, 11401-11407, 11409-11410, 11412-11418, 11423-11425, 11429-11431, 11435-11437, 11439, 11441-11444, 11447-11453, 11455-11457, 11459, 11462, 11465, 11467-11468, 11470, 11474-11475, 11477-11482, 11485-11489, 11494, 11496-11500, 11502-11507, 11510, 11512, 11514, 11516, 11518, 11521-11523, 11525-11526, 11528-11530, 11532, 11534, 11536-11538, 11540-11541, 11543-11548, 11551-11552, 11554-11559, 11563-11565, 11568, 11571, 11574, 11582-11583, 11587, 11589, 11596-11597, 11599, 11602-11603, 11608, 11611, 11613-11615, 11617, 11619-11621, 11624-11628, 11630, 11632, 11639, 11641, 11644-11647, 11649-11653, 11656, 11660-11661, 11664-11665, 11667-11668, 11670, 11674-11675, 11677-11679, 11681, 11685-11692, 11694, 11697-11700, 11704-11712, 11714-11716, 11718-11724, 11726-11728, 11731, 11734-11736, 11741-11742, 11744, 11746, 11754-11759, 11761-11764, 11766-11767, 11773, 11777, 11779-11782, 11785-11787, 11789-11790, 11792-11793, 11795-11797, 11799, 11806-11810, 11812-11813, 11817-11818, 11821-11824, 11826-11827, 11830-11835, 11837-11840, 11842-11845, 11848-11849, 11852-11856, 11861, 11865-11867, 11870-11872, 11875-11882, 11884, 11886-11888, 11890, 11892, 11894-11900, 11902, 11904-11907, 11909-11910, 11912-11915, 11918, 11922, 11924, 11926-11927, 11929-11931, 11933-11934, 11938-11942, 11944-11947, 11949-11950, 11952-11958, 11960-11963, 11966-11969, 11972-11980, 11982-11984, 11986, 11989-11995, 11997-11998, 12003, 12005-12006, 12008-12010, 12012-12017, 12020-12025, 12027-12030, 12033, 12035-12036, 12040-12043, 12045, 12047, 12049-12052, 12054, 12057-12058, 12060-12062, 12064-12066, 12069-12070, 12073, 12076, 12078, 12081-12082, 12084, 12089, 12091-12092, 12094, 12096-12103, 12105-12107, 12109, 12111, 12113, 12121, 12123-12125, 12127-12129, 12131, 12133-12134, 12136-12139, 12142-12144, 12146-12152, 12154-12156, 12158-12160, 12162-12168, 12170-12171, 12176-12177, 12179-12180, 12182, 12184-12186, 12188, 12190-12194, 12196-12199, 12201, 12204-12205, 12207, 12214-12216, 12218, 12220-12221, 12225, 12227, 12230, 12232-12234, 12241, 12244-12246, 12248, 12250-12251, 12258, 12260-12265, 12269, 12272, 12274, 12276-12278, 12280-12285, 12287, 12291, 12293-12296, 12298, 12300-12303, 12305, 12307-12314, 12318-12320, 12322-12327, 12337-12338, 12341-12342, 12344-12345, 12347, 12350-12351, 12358-12360, 12363-12364, 12366, 12372, 12374-12380, 12382-12383, 12388, 12390, 12392-12397, 12401-12410, 12416, 12419, 12423, 12427-12436, 12438, 12444, 12446-12454, 12458, 12460-12463, 12474-12475, 12477, 12484-12485, 12488, 12490, 12493, 12501, 12505, 12510, 12514, 12516-12518, 12520-12522, 12524-12526, 12528, 12531, 12533-12534, 12540-12542, 12544-12549, 12556-12560, 12562, 12565-12566, 12569-12574, 12576, 12578, 12582-12583, 12586, 12593, 12595-12596, 12600-12601, 12603-12613, 12615, 12618-12624, 12627-12629, 12631-12632, 12636, 12639-12640, 12643, 12647, 12649-12651, 12653, 12657-12661, 12663-12665, 12667-12668, 12670-12672, 12674-12687, 12689-12692, 12694-12695, 12697, 12706-12707, 12709, 12711, 12713-12714, 12716, 12718, 12720-12722, 12725-12727, 12729, 12733-12736, 12738-12745, 12748-12752, 12754, 12757, 12759-12760, 12763-12766, 12769, 12772, 12775-12778, 12780-12784, 12787, 12797, 12799-12802, 12807-12814, 12816-12817, 12824-12827, 12830, 12835-12837, 12841-12842, 12844-12845, 12850, 12852, 12854, 12860-12869, 12871, 12874, 12876-12878, 12886-12887, 12891, 12893-12894, 12896-12898, 12903-12905, 12907, 12915, 12917-12918, 12920-12928, 12930, 12933, 12936, 12944, 12947-12949, 12952, 12960, 12962-12968, 12970, 12972, 12974-12978, 12980-12984, 12986-12990, 12992, 12994, 12996, 12999-13003, 13005, 13007-13008, 13010-13013, 13015-13018, 13021-13022, 13024-13034, 13036-13038, 13041-13042, 13044-13045, 13049-13058, 13060-13067, 13069, 13071, 13073-13078, 13080-13081, 13083-13084, 13087-13088, 13090, 13097-13099, 13101-13104, 13109, 13111-13114, 13117, 13123-13124, 13134-13137, 13139, 13147-13151, 13153-13162, 13164-13165, 13169-13170, 13172-13173, 13176-13177, 13181, 13185, 13187, 13189, 13191-13193, 13195-13200, 13202, 13206-13213, 13215-13216, 13220, 13222-13223, 13225-13227, 13232-13233, 13235, 13239-13245, 13247-13249, 13251-13254, 13257-13258, 13262, 13264-13269, 13271-13275, 13278-13279, 13283, 13286-13287, 13291-13292, 13294-13298, 13300, 13302-13308, 13310, 13312-13314, 13316, 13318, 13321, 13323-13325, 13327-13334, 13338-13339, 13341, 13343-13344, 13347, 13349, 13352-13354, 13356-13358, 13360-13362, 13364-13366, 13368-13372, 13374-13375, 13377, 13379-13380, 13383-13384, 13391, 13393-13395, 13397-13398, 13404, 13406-13411, 13413-13414, 13417-13422, 13426-13428, 13430-13432, 13435-13436, 13438-13441, 13443-13444, 13446, 13452-13453, 13455-13456, 13461-13462, 13464-13470, 13472, 13475, 13477-13481, 13483, 13485, 13487, 13493-13501, 13503, 13506-13507, 13511, 13513, 13515-13518, 13520-13523, 13526, 13529-13531, 13534-13535, 13537-13542, 13544-13545, 13550, 13555, 13558-13560, 13562, 13564, 13566, 13568-13569, 13571-13573, 13578-13582, 13584-13589, 13591, 13593-13594, 13596-13598, 13600, 13602-13605, 13607-13608, 13610-13612, 13617-13619, 13621-13623, 13625-13626, 13629-13630, 13632-13633, 13636, 13641, 13647-13649, 13656-13661, 13664-13670, 13672, 13676, 13678, 13680, 13682-13684, 13687-13692, 13694-13698, 13700-13702, 13704-13705, 13708-13709, 13713-13719, 13722-13724, 13726-13730, 13732-13739, 13741-13742, 13744, 13746-13748, 13750-13753, 13755, 13757-13758, 13760-13765, 13767, 13771, 13775, 13778, 13782-13783, 13785, 13787-13794, 13796, 13799-13801, 13804, 13806-13807, 13809, 13811-13817, 13819-13821, 13823-13824, 13829-13830, 13834, 13838-13843, 13845, 13847-13849, 13851-13857, 13859-13860, 13862-13864, 13866, 13869, 13872, 13874-13878, 13881-13882, 13885-13886, 13890, 13894-13900, 13904, 13909-13911, 13913-13914, 13916-13924, 13926-13931, 13936, 13939-13940, 13942-13957, 13959-13960, 13962-13963, 13969-13971, 13973-13974, 13976-13983, 13985-13987, 13990-13991, 13993, 13996-14010, 14012-14016, 14018-14020, 14023-14030, 14033, 14035-14036, 14038-14041, 14043, 14045-14052, 14055-14057, 14059-14063, 14065-14067, 14069, 14071-14072, 14074-14075, 14078, 14081-14083, 14086, 14088-14094, 14100, 14103, 14105-14107, 14110-14112, 14115-14119, 14121-14127, 14129, 14132-14134, 14136-14140, 14142-14143, 14145-14148, 14151-14157, 14159, 14167-14168, 14170-14173, 14175, 14177-14184, 14190-14192, 14195-14199, 14201-14202, 14204-14205, 14207-14208, 14210, 14212, 14216-14221, 14225, 14227, 14229-14234, 14237-14239, 14242-14243, 14246-14247, 14250-14256, 14258-14263, 14265-14266, 14269-14270, 14272-14274, 14276, 14279-14283, 14286-14289, 14291-14294, 14298-14302, 14304, 14306-14310, 14312, 14314-14315, 14317-14322, 14326, 14328-14330, 14333-14336, 14339-14342, 14345, 14348-14354, 14366-14370, 14372, 14375-14385, 14387-14390, 14392-14398, 14402-14409, 14413-14416, 14418-14421, 14423-14424, 14426-14427, 14429-14433, 14435-14437, 14439-14440, 14443, 14447-14453, 14456-14472, 14476-14479, 14485-14486, 14490-14499, 14503-14505, 14508-14509, 14513, 14515-14517, 14519-14522, 14524, 14532-14533, 14536, 14540, 14544-14545, 14548-14549, 14552-14553, 14555-14556, 14559, 14561-14565, 14567, 14569-14570, 14572-14574, 14576-14588, 14590, 14592-14595, 14600-14607, 14612-14613, 14617-14618, 14620-14628, 14630, 14634-14635, 14637, 14640-14652, 14654-14657, 14660, 14662, 14664, 14667, 14672-14673, 14678-14683, 14685-14686, 14688, 14691-14695, 14697-14701, 14703-14705, 14708-14715, 14717-14720, 14723-14724, 14726, 14729, 14731, 14733, 14735-14739, 14742-14743, 14745-14746, 14748, 14750, 14754-14755, 14758, 14761-14762, 14765-14768, 14771-14783, 14789, 14791-14793, 14795-14799, 14802-14805, 14807, 14809-14815, 14822-14824, 14826, 14829-14830, 14838-14839, 14844-14845, 14847-14850, 14852, 14855-14857, 14861-14872, 14874, 14878-14880, 14882-14883, 14885, 14887-14888, 14890, 14893, 14896, 14899-14900, 14902-14906, 14910, 14913-14917, 14919, 14921-14924, 14926-14928, 14930, 14932-14934, 14936-14939, 14944, 14946-14950, 14952, 14955-14960, 14962, 14966-14968, 14970, 14972, 14974-14975, 14977, 14979-14980, 14985-14986, 14988-14997, 14999-15008, 15011-15014, 15016-15018, 15020-15023, 15025-15029, 15031-15035, 15037, 15039-15041, 15044-15046, 15054-15055, 15059, 15061, 15065, 15067-15074, 15076, 15080-15081, 15085, 15087-15088, 15090-15093, 15095-15099, 15102, 15104-15112, 15114-15116, 15118, 15121-15122, 15126-15127, 15129-15131, 15134, 15136, 15141, 15145-15153, 15157, 15159-15160, 15165-15176, 15181, 15184-15185, 15188-15192, 15195, 15197-15198, 15201, 15204-15205, 15208-15209, 15211-15215, 15217-15230, 15232-15235, 15237-15242, 15244-15245, 15247-15250, 15252, 15257, 15259-15261, 15264-15267, 15271-15272, 15274-15278, 15280, 15283, 15285-15289, 15291, 15294-15295, 15299-15300, 15308-15311, 15314-15316, 15318, 15323-15324, 15326-15328, 15330-15334, 15337-15338, 15341, 15343, 15348-15350, 15353-15354, 15357-15359, 15361-15362, 15366, 15369-15374, 15376-15380, 15383-15384, 15386-15396, 15399, 15401, 15404-15414, 15416-15418, 15420-15423, 15427-15432, 15435-15440, 15443-15451, 15454-15455, 15457, 15461, 15463, 15467-15468, 15470, 15472-15477, 15479-15480, 15482, 15484-15490, 15492, 15494-15497, 15503, 15505-15509, 15511, 15513, 15515-15518, 15521-15522, 15525-15527, 15531, 15533, 15535-15543, 15545-15547, 15549, 15552, 15557, 15559-15560, 15562, 15564, 15566, 15568, 15570-15571, 15573-15584, 15586-15588, 15590-15592, 15594-15596, 15598, 15600, 15603-15604, 15606-15607, 15609, 15611-15612, 15615, 15620-15621, 15625-15626, 15632-15638, 15641, 15643, 15649-15652, 15654-15655, 15657-15658, 15660-15662, 15664, 15666, 15672-15675, 15677-15678, 15681-15682, 15686-15688, 15691-15697, 15700, 15702-15703, 15706, 15708-15713, 15715, 15719, 15721, 15726, 15728-15730, 15732-15733, 15735-15738, 15744-15745, 15747-15749, 15751, 15753-15756, 15761, 15763-15764, 15766, 15768-15769, 15774-15778, 15780-15781, 15785, 15789, 15791-15792, 15794, 15796-15800, 15802, 15808, 15814, 15817-15819, 15821-15822, 15824-15825, 15827, 15831, 15833-15834, 15836-15840, 15842-15843, 15845-15847, 15849, 15852, 15855, 15857, 15860-15862, 15864, 15866-15870, 15876, 15878, 15880, 15884-15886, 15893, 15896, 15898-15901, 15903-15904, 15906-15907, 15911, 15914, 15916-15920, 15922-15924, 15926-15930, 15932-15934, 15936, 15938-15939, 15945, 15947, 15949-15950, 15959-15962, 15968-15969, 15972-15978, 15980-15982, 15984-15985, 15988, 15991-15992, 15994, 15997-15998, 16001, 16003, 16005-16007, 16009-16010, 16013-16014, 16016-16018, 16022-16026, 16028, 16030-16032, 16034-16038, 16040-16043, 16049, 16051, 16053-16057, 16061, 16063, 16065, 16067-16073, 16075, 16078-16080, 16085, 16091-16092, 16096-16100, 16102-16103, 16105, 16107, 16109-16110, 16113-16117, 16119, 16121-16124, 16127-16128, 16130-16135, 16138-16139, 16144, 16149, 16151-16156, 16158, 16160-16162, 16164-16165, 16172-16173, 16175-16182, 16184, 16186-16189, 16191-16193, 16197-16199, 16202, 16208-16211, 16213-16214, 16216-16219, 16221-16230, 16232, 16234-16236, 16238-16240, 16242, 16244-16245, 16247-16248, 16250, 16252, 16255-16256, 16262-16263, 16267, 16271, 16273-16277, 16279, 16281, 16286-16287, 16290, 16295, 16297-16298, 16300-16301, 16310, 16312, 16316, 16321-16322, 16324-16326, 16328-16329, 16333-16336, 16339, 16342, 16347, 16349-16358, 16360, 16362-16363, 16372-16373, 16376-16377, 16379-16381, 16388-16389, 16391-16400, 16402, 16407, 16409-16414, 16416, 16418, 16420-16421, 16423-16424, 16427-16428, 16430-16431, 16434, 16436, 16439, 16441-16443, 16445, 16450, 16453, 16455-16456, 16468, 16473-16479, 16481-16482, 16485, 16487-16489, 16495, 16497, 16499, 16501-16503, 16505-16507, 16510-16513, 16515-16517, 16519-16533, 16535-16536, 16538-16539, 16543-16544, 16546, 16548-16552, 16554, 16556, 16558-16561, 16563-16564, 16566, 16568-16570, 16572-16573, 16575-16578, 16580-16586, 16589-16590, 16592-16594, 16596, 16599-16608, 16610, 16612-16614, 16617-16619, 16623-16624, 16626-16629, 16631, 16633-16634, 16636, 16640-16649, 16651-16655, 16657-16664, 16666-16675, 16679-16680, 16682-16690, 16693, 16696-16697, 16701-16704, 16706, 16708, 16711-16718, 16720-16721, 16725, 16728, 16731-16732, 16734, 16736, 16738-16739, 16742, 16745, 16750-16753, 16755-16756, 16760, 16762-16765, 16767-16768, 16771, 16773-16774, 16776-16778, 16782-16787, 16789-16792, 16795-16796, 16799-16800, 16803-16806, 16810-16815, 16818-16823, 16826, 16828-16829, 16831-16833, 16835-16840, 16842, 16845-16848, 16850-16852, 16854-16858, 16862-16863, 16866-16869, 16873-16875, 16884-16886, 16889-16894, 16897-16901, 16904, 16906-16907, 16909, 16911, 16915-16921, 16923, 16925-16927, 16930, 16937-16938, 16940-16941, 16943-16944, 16946, 16951-16953, 16955-16957, 16959, 16961-16966, 16970, 16972-16973, 16975-16976, 16978, 16981, 16983-16985, 16987-16990, 16992, 16994-16997, 16999-17004, 17006-17007, 17010, 17013-17014, 17016-17024, 17026, 17028-17030, 17033-17034, 17037-17043, 17045, 17050-17056, 17060, 17062-17066, 17069-17071, 17075, 17079-17083, 17087, 17089, 17091-17092, 17094-17101, 17103-17106, 17108-17109, 17111-17113, 17117-17124, 17126, 17133, 17136-17139, 17141-17145, 17147, 17149-17151, 17158, 17163, 17166-17170, 17178-17182, 17184, 17186-17188, 17190, 17192, 17194-17197, 17201, 17205, 17207, 17210, 17217-17220, 17223, 17227, 17230-17231, 17233, 17236-17237, 17240-17241, 17243-17244, 17249, 17252, 17255, 17257-17258, 17260, 17262-17266, 17270-17278, 17280, 17283, 17285, 17292-17293, 17295, 17302, 17305-17307, 17309-17311, 17313, 17318-17321, 17323, 17325, 17327-17328, 17330, 17332-17334, 17338-17339, 17341, 17343-17346, 17349-17353, 17356, 17360, 17363, 17368, 17370, 17372, 17374, 17377-17379, 17381-17396, 17398-17400, 17402-17403, 17406-17407, 17409-17410, 17414-17419, 17421, 17423-17427, 17432-17439, 17443, 17445, 17447-17449, 17451-17454, 17457-17459, 17462-17463, 17465-17467, 17469-17470, 17472-17476, 17478-17479, 17481-17483, 17486, 17488-17489, 17491-17500, 17502-17510, 17512-17515, 17518-17521, 17524, 17526, 17529, 17531-17532, 17534, 17537, 17540-17542, 17545-17547, 17549-17557, 17559, 17561-17565, 17571-17573, 17576-17581, 17584-17586, 17589-17590, 17592-17595, 17600, 17602, 17605, 17611-17613, 17615, 17621-17624, 17629, 17631-17633, 17635-17639, 17641-17648, 17650, 17652-17653, 17656-17657, 17659-17661, 17665-17667, 17669-17674, 17680-17689, 17692, 17695-17696, 17698-17702, 17704-17708, 17715, 17718, 17720, 17723, 17725, 17727, 17730-17735, 17737-17739, 17742-17745, 17747-17749, 17752-17754, 17764-17765, 17768, 17770-17773, 17778-17786, 17788-17793, 17795-17798, 17801, 17803-17807, 17809-17815, 17819-17820, 17822, 17824-17826, 17830-17834, 17838, 17840-17841, 17844-17845, 17847-17850, 17854-17858, 17860-17861, 17863, 17865, 17867-17868, 17870, 17872-17874, 17876-17878, 17880-17881, 17884, 17886, 17888, 17890-17891, 17893-17894, 17896-17900, 17905-17933, 17935, 17937-17940, 17943-17945, 17947-17955, 17958-17961, 17963-17964, 17967, 17980, 17982, 17986, 17988-17994, 17997, 17999-18000, 18002-18005, 18007-18014, 18016-18025, 18029, 18031, 18033-18035, 18038, 18041-18043, 18045-18049, 18051, 18053, 18056-18062, 18064-18065, 18067-18076, 18078, 18081-18082, 18084, 18086-18090, 18092-18098, 18100-18102, 18104-18107, 18109, 18112, 18119-18122, 18125-18126, 18128, 18133, 18137-18140, 18142, 18144-18145, 18147, 18149-18150, 18152, 18155, 18157-18160, 18163-18165, 18170-18175, 18177-18178, 18180-18182, 18184-18185, 18188-18193, 18195-18198, 18200, 18203-18204, 18208-18217, 18219, 18222-18229, 18232-18236, 18238-18241, 18243-18249, 18251-18252, 18256-18258, 18261-18262, 18264-18267, 18270, 18272-18277, 18279, 18282, 18284-18287, 18289-18295, 18298-18301, 18304-18306, 18308-18314, 18316-18317, 18319, 18323-18324, 18328-18333, 18335-18336, 18338, 18342-18345, 18350, 18352, 18359, 18362, 18365-18369, 18374-18387, 18389-18395, 18397-18398, 18401, 18403, 18405-18406, 18414-18415, 18417-18418, 18420-18421, 18423-18425, 18427-18430, 18432-18434, 18438-18439, 18441-18442, 18444-18446, 18450-18452, 18455-18460, 18463-18465, 18467-18471, 18474-18483, 18485-18488, 18490-18493, 18496, 18499, 18501, 18503, 18507, 18509, 18513-18515, 18518-18520, 18523-18525, 18528-18529, 18531, 18533, 18536, 18539-18541, 18549-18551, 18553-18557, 18559-18567, 18570-18573, 18575-18578, 18582-18586, 18588-18599, 18601-18603, 18605, 18609, 18611-18612, 18620, 18622, 18624, 18626, 18628-18629, 18631, 18633, 18635-18642, 18646-18649, 18651, 18654-18657, 18664, 18666-18668, 18671-18672, 18674-18675, 18678, 18681-18686, 18689-18690, 18692-18693, 18695, 18697, 18699-18700, 18702-18704, 18706, 18709, 18711-18712, 18714-18715, 18717, 18720, 18733, 18735-18736, 18739-18742, 18744-18747, 18749-18750, 18754, 18756-18758, 18760, 18762-18766, 18768, 18771-18773, 18775-18778, 18781-18782, 18785-18786, 18788, 18790, 18792-18797, 18799-18802, 18807-18809, 18814, 18816, 18818-18820, 18823, 18825, 18829, 18835, 18839-18840, 18843-18847, 18849-18852, 18857-18861, 18865, 18868-18876, 18878, 18880-18887, 18889-18890, 18892, 18896-18897, 18899-18900, 18903, 18905-18906, 18909-18911, 18913, 18916, 18918-18919, 18921-18922, 18925, 18931, 18934, 18936-18937, 18941-18943, 18948, 18951, 18956, 18958-18960, 18962, 18965-18970, 18972-18975, 18977-18980, 18982-18992, 18995, 18997, 19001, 19008, 19010, 19012-19018, 19020, 19022, 19024-19025, 19028-19033, 19036-19046, 19048-19054, 19057-19058, 19060-19066, 19068-19073, 19075, 19079, 19082-19083, 19089, 19102-19103, 19108, 19111-19115, 19117, 19120-19124, 19126, 19128, 19130-19132, 19137-19139, 19141-19142, 19144-19150, 19152-19156, 19160-19163, 19166-19181, 19183, 19187-19194, 19197, 19199, 19201, 19205, 19208-19209, 19212, 19214, 19216-19218, 19220-19221, 19224, 19228, 19231, 19233-19236, 19240-19241, 19244, 19246-19259, 19266, 19268-19269, 19271, 19274-19275, 19277-19279, 19281, 19286-19288, 19294-19295, 19297-19298, 19301-19305, 19307, 19311, 19313, 19315, 19317-19319, 19321-19323, 19325, 19327-19329, 19331, 19335-19338, 19340-19342, 19345, 19347-19350, 19353-19355, 19357, 19360-19364, 19366, 19368-19369, 19373, 19375, 19377-19378, 19382-19386, 19388-19390, 19395-19401, 19403-19404, 19407-19408, 19410, 19412-19414, 19419, 19421-19423, 19425-19429, 19431-19432, 19434, 19436-19437, 19439, 19441-19442, 19448-19452, 19454, 19456, 19458-19468, 19470, 19472, 19474, 19478, 19481-19483, 19485, 19487-19488, 19492, 19496-19498, 19501, 19504, 19507-19514, 19516-19522, 19524-19526, 19528, 19530-19531, 19535, 19538, 19541, 19543, 19548-19549, 19556-19558, 19560-19563, 19565, 19567-19570, 19573-19574, 19576, 19579-19581, 19583, 19585, 19593-19601, 19603-19616, 19618-19621, 19624-19625, 19627-19628, 19630, 19632-19636, 19639-19644, 19646, 19649, 19653-19657, 19659, 19661-19664, 19666-19668, 19673-19676, 19680-19683, 19687, 19689-19690, 19692-19696, 19698-19699, 19701, 19703, 19706-19707, 19709, 19712-19718, 19725-19726, 19728-19730, 19732-19735, 19738, 19740, 19742-19745, 19748-19749, 19751, 19753-19758, 19760, 19762-19764, 19766, 19768, 19770-19771, 19773-19782, 19784, 19787, 19789-19794, 19797, 19799, 19802-19804, 19806, 19809-19815, 19817-19827, 19829-19833, 19836-19837, 19839-19841, 19846, 19849, 19852, 19857, 19859, 19863, 19866, 19869-19871, 19873, 19881, 19885-19886, 19890-19893, 19895-19896, 19898-19902, 19904, 19915, 19919, 19926, 19928-19930, 19933, 19943-19944, 19947-19949, 19951-19952, 19954-19955, 19960-19961, 19963-19965, 19967-19968, 19970-19975, 19977-19979, 19982-19983, 19986-19987, 19989-19991, 19993, 19995-19997, 20002, 20004, 20006-20009, 20013-20027, 20029-20030, 20032, 20036-20041, 20043-20044, 20047-20051, 20053-20066, 20070-20077, 20079-20080, 20083-20094, 20096-20098, 20100-20101, 20104-20108, 20110-20112, 20115, 20117-20121, 20125-20126, 20128-20130, 20134-20136, 20138, 20140, 20143, 20148-20149, 20152-20153, 20155, 20157, 20161-20162, 20164-20165, 20168, 20175, 20177, 20183-20184, 20186, 20188-20189, 20192-20195, 20200-20202, 20207-20210, 20214, 20218, 20221-20226, 20228-20234, 20237-20240, 20242, 20244, 20246, 20248-20253, 20257, 20259-20260, 20265, 20267-20268, 20270-20274, 20276, 20279-20287, 20289-20292, 20294-20295, 20298-20299, 20301, 20303, 20305, 20309-20311, 20314, 20316, 20318, 20320, 20322, 20324, 20329, 20332-20333, 20338, 20342, 20351-20358, 20360-20361, 20366, 20368-20374, 20376-20381, 20383, 20385-20391, 20393-20394, 20396-20400, 20402, 20404-20407, 20409, 20412, 20416-20417, 20419-20423, 20425, 20430-20438, 20441-20443, 20445, 20448, 20451-20453, 20456, 20458, 20460-20462, 20464, 20466, 20468-20472, 20474, 20477-20479, 20484, 20486, 20488-20491, 20493-20494, 20504, 20506-20508, 20511-20513, 20515-20519, 20521, 20523-20524, 20528-20529, 20532, 20535-20537, 20541, 20543-20545, 20547, 20551-20560, 20564-20565, 20567-20568, 20570, 20572, 20577, 20581-20583, 20585-20586, 20588, 20594-20596, 20599, 20601-20602, 20604-20606, 20608, 20613-20615, 20617-20618, 20625, 20627-20630, 20632-20640, 20642, 20651, 20658-20659, 20661, 20663-20666, 20668, 20670-20671, 20680-20682, 20685, 20687-20688, 20690-20692, 20694, 20699, 20703, 20707-20710, 20712-20717, 20721-20722, 20726-20727, 20730-20731, 20734, 20740-20741, 20745, 20747, 20749, 20751, 20756-20762, 20768, 20772-20783, 20785, 20789-20791, 20794-20797, 20799-20801, 20803-20808, 20814, 20816, 20818, 20827, 20829-20830, 20833, 20835-20836, 20842, 20850, 20852-20854, 20856, 20858, 20860, 20862, 20864, 20868-20872, 20880-20881, 20884-20887, 20891-20893, 20901, 20903, 20905-20906, 20913-20916, 20918, 20920, 20923, 20926-20927, 20931, 20936, 20941-20943, 20945, 20947-20948, 20950-20953, 20956, 20959-20960, 20963-20964, 20968-20974, 20978-20980, 20984-20985, 20987, 20990-20998, 21000-21002, 21011-21012, 21021-21030, 21032-21033, 21035-21036, 21039, 21043-21044, 21047-21049, 21053, 21055-21056, 21058, 21060, 21062-21068, 21070-21071, 21073, 21075, 21077, 21080, 21083-21087, 21093, 21102-21103, 21106-21108, 21110, 21112-21113, 21118-21120, 21123-21127, 21129-21136, 21138, 21141-21149, 21151, 21153, 21156-21158, 21161, 21165-21166, 21168, 21170-21171, 21173, 21175-21182, 21184, 21187, 21191, 21194-21196, 21198, 21200-21204, 21210, 21213, 21216, 21218-21220, 21223-21224, 21226, 21228, 21230, 21234, 21236-21237, 21239-21240, 21242, 21246, 21249, 21252, 21256-21260, 21263, 21268, 21272, 21274, 21277-21278, 21281, 21283-21292, 21294-21300, 21302-21308, 21311, 21314-21317, 21319-21325, 21327, 21330, 21338-21342, 21344-21346, 21352-21353, 21355-21356, 21363-21365, 21369, 21372-21373, 21375, 21378, 21380-21392, 21394-21395, 21397-21400, 21403, 21406, 21409, 21413-21416, 21422-21424, 21427-21428, 21431, 21433, 21442, 21445-21447, 21449, 21451-21452, 21454, 21456, 21459-21460, 21462, 21467, 21469, 21471-21472, 21478-21479, 21484-21486, 21488-21489, 21491-21494, 21496, 21498, 21500, 21502-21504, 21506-21507, 21512, 21514, 21516, 21519, 21527, 21530-21531, 21533, 21535-21536, 21541, 21543-21545, 21547-21553, 21555-21559, 21561, 21565, 21569-21571, 21573-21575, 21577-21578, 21580, 21582, 21584, 21586, 21589-21590, 21592-21593, 21596-21597, 21599-21600, 21603, 21605, 21607, 21611, 21613-21615, 21617, 21619, 21621, 21623-21625, 21627-21634, 21636-21637, 21643-21646, 21648-21649, 21651, 21655-21656, 21658-21660, 21662, 21665-21666, 21668-21670, 21674, 21676-21682, 21684-21685, 21687, 21690-21693, 21698, 21700-21702, 21704, 21706, 21711-21712, 21714-21718, 21721-21722, 21724-21734, 21739-21740, 21742-21744, 21746, 21748, 21751, 21758-21760, 21762-21766, 21770-21773, 21777-21779, 21781, 21783-21788, 21790-21792, 21797-21799, 21801-21805, 21807-21808, 21811-21814, 21818, 21820, 21822, 21826, 21828, 21832, 21834, 21836, 21838-21839, 21842, 21844, 21846-21847, 21849, 21851-21853, 21856-21863, 21869-21871, 21876, 21878, 21880-21882, 21884-21894, 21896-21897, 21899, 21902-21904, 21908-21914, 21916-21920, 21923, 21925, 21927-21933, 21935, 21937-21942, 21944-21951, 21954, 21957, 21960-21961, 21964, 21968-21969, 21972-21973, 21976-21980, 21982, 21985, 21987, 21990, 21998, 22000, 22003-22004, 22006-22008, 22011, 22014, 22019, 22021-22024, 22028, 22031-22032, 22034, 22036-22042, 22047-22048, 22050-22051, 22054, 22057-22059, 22062, 22065, 22069-22071, 22082, 22084-22085, 22089-22091, 22097-22101, 22107-22114, 22116-22117, 22119-22121, 22129, 22137, 22139, 22141, 22143-22145, 22147-22149, 22151-22153, 22155-22156, 22159-22160, 22162-22164, 22167, 22169-22171, 22176-22177, 22179, 22181-22182, 22184-22187, 22189-22192, 22194-22197, 22200-22201, 22203-22210, 22212-22213, 22220-22221, 22223, 22225-22230, 22232-22233, 22237-22239, 22241-22244, 22246, 22249-22264, 22268, 22270-22272, 22274, 22278-22279, 22281-22285, 22287-22289, 22291-22295, 22297-22303, 22305, 22308-22311, 22317-22320, 22322-22323, 22325-22331, 22334, 22337-22338, 22342-22348, 22350-22355, 22357, 22361-22362, 22364-22365, 22369-22370, 22372-22375, 22377-22381, 22385-22388, 22390-22398, 22400-22402, 22404-22409, 22411-22423, 22425-22426, 22428, 22436, 22449, 22452, 22455, 22457-22458, 22463, 22467, 22472, 22478, 22481-22482, 22485, 22488-22492, 22494-22495, 22499-22500, 22502, 22504-22506, 22508, 22510-22513, 22515, 22517-22521, 22523-22524, 22527-22529, 22532, 22535, 22537-22540, 22546-22550, 22552-22555, 22560-22563, 22565-22567, 22569-22572, 22574, 22576-22577, 22579-22580, 22582, 22585, 22588-22593, 22595, 22601, 22607-22609, 22612-22613, 22616, 22618, 22620-22622, 22624, 22626-22630, 22634, 22636-22643, 22645-22646, 22648-22656, 22658-22659, 22661-22662, 22664, 22668, 22672, 22674-22681, 22684-22685, 22687-22691, 22693-22696, 22698-22699, 22701-22705, 22709, 22712, 22717-22719, 22722-22727, 22729, 22732, 22740-22742, 22744, 22751-22753, 22761-22765, 22768-22773, 22780-22781, 22783-22786, 22788-22789, 22794, 22797-22798, 22800, 22803, 22805, 22810-22814, 22816, 22819, 22821-22827, 22829, 22832, 22836-22840, 22842, 22850, 22852, 22856, 22858-22862, 22866, 22872, 22874, 22876-22877, 22879-22881, 22886-22887, 22889, 22892-22896, 22898-22906, 22908, 22910, 22913-22918, 22928, 22930-22933, 22935-22937, 22941, 22944, 22950-22951, 22953-22958, 22963-22965, 22968-22972, 22974-22976, 22979-22984, 22986, 22988-22989, 22991-22999, 23001, 23003, 23006-23011, 23015-23016, 23024-23028, 23030-23032, 23034-23035, 23037-23039, 23042, 23051, 23054, 23057, 23061-23063, 23065-23068, 23073-23074, 23076-23081, 23083-23086, 23088-23099, 23101-23107, 23110, 23113-23117, 23119-23120, 23122, 23128-23130, 23132, 23137, 23140-23141, 23143, 23146, 23150, 23152, 23156, 23163-23164, 23166-23167, 23177, 23180-23184, 23186-23187, 23190-23191, 23193, 23196-23199, 23201-23203, 23206, 23208, 23212-23215, 23217, 23220, 23222, 23225-23226, 23229, 23231-23236, 23239, 23243, 23246-23247, 23249-23251, 23253, 23256, 23258, 23261-23263, 23265, 23272, 23274-23277, 23282-23283, 23285, 23288, 23292-23296, 23299-23301, 23303-23304, 23310-23315, 23318-23325, 23331, 23335-23337, 23339, 23341-23342, 23344-23345, 23349-23354, 23356-23357, 23359-23360, 23362-23363, 23365, 23368-23369, 23371, 23373, 23375-23376, 23378-23380, 23382, 23385, 23389-23391, 23393, 23397-23398, 23400, 23404-23405, 23409, 23411-23416, 23418, 23420-23423, 23427, 23429-23431, 23436-23444, 23446-23447, 23450-23451, 23454-23457, 23461, 23463-23465, 23468-23475, 23477-23482, 23485-23487, 23490-23495, 23499-23500, 23502-23507, 23513, 23515-23520, 23522-23527, 23529-23532, 23534-23538, 23540, 23543-23545, 23548-23549, 23551-23561, 23563, 23565, 23567-23568, 23570-23572, 23575-23578, 23580-23584, 23586, 23592-23595, 23597-23599, 23601, 23603, 23606-23607, 23610-23611, 23615-23616, 23621, 23625-23634, 23638-23639, 23642, 23645, 23652-23654, 23660-23663, 23665-23667, 23670, 23673-23674, 23676-23678, 23681-23684, 23687, 23689, 23693-23695, 23701-23702, 23705-23712, 23716-23717, 23720, 23724-23725, 23735, 23737-23738, 23740-23741, 23745-23746, 23748, 23751-23761, 23764-23765, 23769, 23775, 23777-23779, 23781-23789, 23791-23793, 23795, 23799-23800, 23802-23803, 23805-23810, 23812, 23814, 23817-23820, 23823-23824, 23829-23830, 23834-23838, 23841, 23843-23850, 23852, 23856, 23860, 23862, 23868, 23870, 23872-23874, 23876, 23879, 23881-23883, 23887-23890, 23892, 23895, 23899-23902, 23904-23907, 23910, 23914-23917, 23920, 23923, 23926-23929, 23932-23936, 23938-23939, 23941-23942, 23944-23946, 23948-23949, 23951, 23953-23954, 23956-23962, 23965, 23969-23973, 23976-23983, 23985, 23987, 23992, 23994, 23996-23998, 24001, 24005-24006, 24008-24009, 24013-24018, 24020-24021, 24027-24029, 24034-24035, 24037, 24039, 24041, 24045-24052, 24054-24055, 24057, 24059-24060, 24065, 24067, 24069, 24073, 24077-24083, 24085, 24087-24089, 24093, 24095-24096, 24099, 24104-24107, 24109-24110, 24112, 24114, 24116, 24122-24124, 24127, 24129-24130, 24132-24134, 24136, 24138, 24140, 24144-24145, 24148-24149, 24151, 24153, 24155-24164, 24166, 24168-24169, 24171, 24173-24177, 24179-24180, 24182, 24184, 24188-24190, 24192-24194, 24198, 24200-24204, 24206, 24208, 24211-24215, 24217-24218, 24221, 24224, 24226-24232, 24234, 24237, 24239-24247, 24253-24254, 24256, 24259-24260, 24262-24264, 24266, 24268, 24271-24273, 24278-24279, 24281-24282, 24285-24287, 24289, 24291-24294, 24296-24302, 24304-24308, 24310, 24312-24313, 24322, 24324-24327, 24329-24333, 24335, 24337, 24341-24342, 24347, 24349-24353, 24355, 24357, 24359, 24361-24372, 24375, 24379, 24381-24384, 24387, 24390-24392, 24395-24396, 24399, 24401-24402, 24407-24408, 24411-24413, 24415-24416, 24419-24423, 24426-24427, 24429-24430, 24434, 24437-24439, 24441, 24446-24449, 24452-24457, 24459, 24461-24469, 24471, 24473, 24476-24477, 24479, 24481-24483, 24486-24487, 24490-24491, 24493, 24498-24500, 24502-24504, 24506-24511, 24513, 24519-24522, 24525, 24528, 24530-24532, 24534, 24538-24541, 24544-24545, 24547-24550, 24553-24557, 24561-24563, 24566, 24569, 24571-24572, 24574-24578, 24582, 24584-24585, 24589-24590, 24593-24605, 24607, 24611, 24613, 24615-24624, 24626-24629, 24634, 24637-24638, 24642-24645, 24647-24648, 24651, 24655, 24658-24669, 24673-24678, 24680, 24684, 24688-24689, 24692-24693, 24696-24698, 24700, 24703, 24705-24708, 24711, 24713-24715, 24717-24720, 24722-24723, 24727-24729, 24731, 24733, 24735-24737, 24740-24743, 24746-24752, 24754, 24756-24761, 24764-24768, 24771-24772, 24774-24778, 24782, 24786, 24788-24790, 24792, 24796, 24800, 24802-24803, 24805-24806, 24809, 24811, 24820-24823, 24828, 24830, 24834, 24836, 24838-24845, 24847-24848, 24850-24852, 24854-24855, 24858-24863, 24871, 24873, 24875, 24879-24881, 24883-24885, 24888-24889, 24891, 24894-24902, 24904-24907, 24912-24915, 24917-24919, 24921, 24924-24927, 24929, 24932-24933, 24935, 24937-24938, 24942, 24944, 24948-24949, 24951, 24957-24959, 24961-24962, 24964, 24966-24967, 24969-24970, 24972-24978, 24982, 24985, 24988-24989, 24993-24994, 24998, 25000-25002, 25004, 25007-25008, 25010-25011, 25015, 25017-25018, 25022-25023, 25025-25029, 25031-25042, 25044-25045, 25051, 25053-25054, 25058, 25060-25063, 25065, 25068, 25072, 25077, 25080, 25082-25083, 25085, 25087-25089, 25091-25094, 25098-25102, 25105-25107, 25113, 25115, 25120-25123, 25125, 25127-25128, 25133, 25138-25140, 25142, 25146, 25149, 25151-25152, 25154, 25156-25158, 25164, 25166, 25168-25169, 25171-25175, 25181, 25183-25190, 25194-25195, 25197-25202, 25209, 25214-25215, 25217-25219, 25221-25222, 25227-25230, 25232, 25234-25237, 25240, 25247, 25249-25250, 25252, 25255-25256, 25260, 25264-25278, 25280, 25282-25294, 25296, 25300-25302, 25305, 25308-25309, 25312-25316, 25319-25321, 25323, 25325, 25329-25330, 25332-25333, 25338-25339, 25345, 25348, 25352, 25354, 25356-25358, 25360-25361, 25366-25370, 25372, 25375, 25378, 25380, 25384-25385, 25387, 25389-25390, 25394, 25397, 25400-25410, 25412, 25414, 25416-25418, 25420, 25429-25437, 25439, 25441-25442, 25445, 25450-25456, 25459-25460, 25462-25465, 25468-25469, 25472-25476, 25482-25483, 25488-25490, 25494-25495, 25498, 25501-25504, 25506, 25508, 25510, 25512-25515, 25517-25522, 25525-25531, 25534, 25537-25541, 25543-25544, 25547, 25549, 25552-25555, 25557-25564, 25566-25568, 25570-25572, 25574-25576, 25579, 25581-25586, 25588, 25596, 25599, 25605, 25607-25608, 25611, 25614-25615, 25617, 25620-25622, 25625-25626, 25629, 25631-25640, 25642-25644, 25650, 25653-25654, 25656-25661, 25664-25672, 25674-25675, 25677, 25683-25686, 25688, 25691, 25693-25697, 25701, 25704-25707, 25709-25710, 25712, 25714-25719, 25721-25722, 25730-25731, 25734-25739, 25742-25744, 25747-25748, 25750, 25753, 25757, 25760, 25762, 25765, 25768, 25772, 25774, 25776-25779, 25782, 25784, 25786, 25788-25789, 25791-25794, 25796-25797, 25799-25800, 25803-25805, 25807, 25810, 25812-25814, 25817, 25819-25821, 25823-25824, 25826-25831, 25833-25835, 25837, 25839-25841, 25843-25845, 25847, 25852-25856, 25858, 25861-25863, 25866, 25870-25874, 25878-25879, 25883-25884, 25886-25892, 25894-25896, 25900-25904, 25907-25910, 25912, 25915, 25923-25925, 25927-25932, 25936-25939, 25942-25943, 25945, 25947, 25949-25951, 25953, 25956-25958, 25961-25963, 25966, 25968-25969, 25971, 25975-25976, 25979, 25982-25983, 25985, 25987, 25991, 25994-26000, 26003, 26006-26011, 26013-26015, 26017, 26020, 26025-26027, 26029, 26031-26032, 26037-26038, 26046-26049, 26051, 26054, 26059-26061, 26066, 26069, 26072-26076, 26078, 26080, 26083-26087, 26090, 26092, 26095-26097, 26100, 26102-26108, 26111-26112, 26117-26118, 26121, 26129, 26131-26132, 26134-26135, 26137-26142, 26146, 26149-26151, 26153-26154, 26157-26158, 26161-26162, 26164-26166, 26168-26170, 26172, 26175, 26183, 26185, 26192-26196, 26198-26199, 26203-26206, 26208-26223, 26228, 26230-26232, 26234, 26236-26238, 26240-26242, 26245-26248, 26251, 26256-26259, 26261-26267, 26270, 26272-26273, 26276-26277, 26279, 26281, 26284-26285, 26287-26290, 26292-26293, 26298, 26301-26311, 26316, 26318, 26329-26330, 26333-26334, 26337-26342, 26344-26348, 26350, 26352-26356, 26358-26364, 26366-26373, 26375-26376, 26378-26382, 26384-26385, 26388, 26391, 26393-26394, 26396, 26398-26400, 26402, 26406-26408, 26410, 26412-26419, 26421-26423, 26426, 26428-26429, 26431-26432, 26437, 26439-26445, 26447, 26452-26454, 26458-26459, 26461-26463, 26466, 26469-26470, 26472-26473, 26476, 26479, 26481-26482, 26485-26486, 26491, 26493-26494, 26498-26499, 26503-26504, 26506-26510, 26515, 26518, 26521-26530, 26532-26535, 26537-26538, 26542-26543, 26545-26546, 26549-26552, 26555-26557, 26559, 26561-26562, 26564-26565, 26567-26568, 26571-26574, 26577, 26580, 26584-26586, 26588-26589, 26594-26596, 26598, 26603, 26605-26606, 26608, 26610-26614, 26617-26624, 26626-26630, 26634, 26636-26638, 26642, 26644-26649, 26651-26652, 26656, 26659-26662, 26664, 26671, 26676-26680, 26682-26687, 26689-26690, 26694-26697, 26699, 26701, 26703, 26705-26708, 26710-26715, 26719-26721, 26723, 26727-26730, 26735, 26738, 26740-26747, 26750-26752, 26755-26757, 26759-26761, 26763-26765, 26767-26769, 26772, 26774-26778, 26780-26781, 26783, 26786-26787, 26789-26792, 26794-26798, 26801-26805, 26808-26812, 26814, 26816-26818, 26820-26821, 26823-26825, 26827-26829, 26831-26832, 26835-26841, 26843-26844, 26848-26851, 26856-26861, 26863, 26865-26866, 26868-26869, 26871-26872, 26874-26876, 26878, 26881-26887, 26889-26891, 26893-26897, 26899, 26901, 26903-26904, 26908, 26915-26917, 26922-26925, 26927-26928, 26931, 26933, 26935-26940, 26943-26946, 26948-26955, 26958, 26960-26962, 26969-26971, 26974-26976, 26978-26980, 26983, 26985-26986, 26989, 27000-27002, 27004-27005, 27007-27008, 27010-27014, 27022, 27024, 27029, 27033-27034, 27036-27037, 27039-27040, 27042-27043, 27045-27052, 27054-27055, 27064, 27069, 27072-27073, 27075, 27078-27079, 27082, 27096-27097, 27106, 27110, 27112, 27114, 27119, 27121-27122, 27124-27125, 27128-27129, 27131-27132, 27134-27135, 27140, 27149, 27160-27163, 27165-27166, 27169-27170, 27172-27177, 27180, 27182-27183, 27186-27187, 27191, 27193-27195, 27197, 27201-27203, 27205-27206, 27208-27209, 27216-27220, 27222-27226, 27235, 27237-27238, 27241-27245, 27247, 27252, 27254, 27256-27261, 27263, 27265-27266, 27268-27269, 27273, 27276-27280, 27282, 27284-27286, 27288-27295, 27297-27300, 27302-27305, 27307, 27310-27315, 27317-27319, 27322-27326, 27328-27330, 27338, 27342, 27345-27353, 27355, 27357-27358, 27360-27361, 27364-27369, 27372-27378, 27381-27389, 27391-27393, 27396-27398, 27400-27402, 27405-27411, 27413-27415, 27417-27420, 27422, 27424-27429, 27433-27437, 27439-27448, 27451-27452, 27456, 27458-27460, 27464, 27466-27470, 27473-27474, 27479, 27481-27488, 27490, 27493, 27495, 27497-27498, 27500, 27502-27503, 27506-27517, 27519-27525, 27527, 27531-27540, 27543, 27545-27549, 27551, 27554, 27559, 27563-27566, 27568-27570, 27572-27579, 27581-27586, 27588-27590, 27592-27594, 27596-27598, 27600, 27606, 27609-27610, 27613-27614, 27616-27620, 27623-27624, 27626, 27632-27633, 27635, 27638-27640, 27643, 27650-27659, 27661, 27668-27669, 27671-27673, 27676-27678, 27684, 27686-27690, 27695, 27698-27699, 27701, 27703, 27705-27707, 27711, 27714, 27718-27719, 27724, 27726, 27728-27729, 27731, 27733-27735, 27738, 27741, 27747, 27750, 27752-27759, 27762, 27764-27765, 27767-27773, 27777-27781, 27783, 27785, 27789, 27792-27793, 27795, 27799-27803, 27805, 27807-27808, 27810-27814, 27817-27818, 27820-27822, 27825, 27834, 27844, 27852, 27855, 27860, 27862-27868, 27870-27871, 27876-27877, 27879, 27883-27886, 27888, 27891-27892, 27894, 27896-27904, 27907, 27910, 27914, 27916-27922, 27924-27925, 27928-27929, 27936-27937, 27942-27948, 27954-27961, 27963-27969, 27971-27973, 27975, 27981, 27989, 27991-27992, 27994-27995, 27997, 27999-28000, 28003, 28006-28011, 28013, 28017-28018, 28020, 28022, 28024, 28026-28028, 28032-28033, 28036, 28040, 28043-28044, 28046, 28048, 28050-28051, 28053-28057, 28059-28060, 28062, 28065-28072, 28074, 28076, 28079, 28081, 28086, 28088-28092, 28094, 28096-28098, 28101-28104, 28107-28108, 28110, 28113, 28115-28116, 28118-28119, 28128, 28130-28131, 28133-28134, 28136-28139, 28143-28144, 28146-28147, 28149-28151, 28154-28159, 28163-28164, 28166-28167, 28169-28177, 28179, 28182-28185, 28188-28195, 28197, 28201, 28203-28204, 28207, 28210, 28214-28215, 28217, 28222-28225, 28227-28229, 28231-28234, 28237, 28240, 28243-28250, 28253, 28255-28256, 28258-28262, 28264-28267, 28277, 28281-28282, 28284-28285, 28287-28291, 28293-28295, 28299-28301, 28303-28304, 28306-28309, 28311, 28313-28316, 28318, 28322, 28324-28328, 28330, 28339-28340, 28342, 28344-28345, 28347-28349, 28351-28352, 28354, 28356-28357, 28360-28364, 28366, 28368-28370, 28372, 28374-28376, 28378-28379, 28384-28388, 28390-28391, 28393, 28395-28400, 28402, 28404-28405, 28408-28410, 28412-28423, 28426, 28428-28430, 28432-28435, 28437-28438, 28440-28442, 28446-28449, 28451-28459, 28462, 28466-28472, 28474, 28476-28478, 28480-28483, 28485, 28487, 28489, 28491, 28494, 28496, 28498-28500, 28502, 28505, 28509-28510, 28512-28514, 28516, 28518-28520, 28522-28529, 28531-28533, 28535-28536, 28538-28539, 28542, 28545-28547, 28549, 28551-28552, 28554, 28556, 28558-28561, 28564-28567, 28569-28572, 28574, 28576-28577, 28579-28581, 28586, 28589, 28591, 28594-28602, 28604-28605, 28608-28610, 28612-28613, 28616-28617, 28621, 28623, 28629, 28631, 28633, 28635, 28639-28641, 28643-28646, 28648, 28650-28651, 28655, 28658-28660, 28662-28663, 28665-28666, 28690-28692, 28694, 28696-28697, 28700, 28706-28707, 28714-28715, 28717-28723, 28725-28727, 28730, 28732, 28737-28742, 28745-28746, 28748, 28755-28756, 28758-28759, 28762, 28765, 28769-28774, 28785, 28788-28790, 28801-28806, 28808, 28810, 28817-28819, 28821, 28826-28829, 28831, 28834, 28837, 28839-28844, 28846-28847, 28849, 28853, 28856-28857, 28859, 28861, 28863, 28865-28868, 28870-28871, 28874-28877, 28880-28881, 28883, 28886, 28888, 28890, 28892-28898, 28904-28906, 28913-28921, 28923-28930, 28933-28934, 28937, 28941-28942, 28944-28946, 28948-28955, 28957-28964, 28967-28968, 28970-28973, 28979-28981, 28983-28984, 28986, 28989, 28991, 28993-28994, 28996-28997, 29000, 29002, 29004, 29006-29010, 29012-29016, 29018, 29021, 29025-29027, 29036-29039, 29042, 29044, 29047, 29049-29056, 29058, 29061, 29063, 29065, 29072, 29075, 29081-29084, 29089-29093, 29102, 29104, 29111, 29114-29119, 29121, 29124-29125, 29128, 29132-29141, 29143-29146, 29149, 29151, 29153, 29155, 29159, 29161, 29163-29165, 29167-29168, 29170-29171, 29174, 29176-29182, 29185, 29195, 29203, 29211-29213, 29218-29223, 29225, 29229-29231, 29234-29236, 29239, 29241, 29243-29244, 29248, 29250-29251, 29254-29260, 29262, 29269, 29271, 29274-29276, 29280-29282, 29285-29288, 29290-29291, 29293, 29297-29298, 29301-29303, 29306-29308, 29310, 29312-29314, 29316-29320, 29322, 29325-29330, 29332, 29334-29336, 29338-29341, 29345-29348, 29350, 29353-29356, 29358-29364, 29368-29371, 29373-29374, 29377-29378, 29381-29383, 29385-29391, 29394, 29397-29399, 29404-29405, 29407, 29409-29412, 29414-29417, 29421-29423, 29425, 29429-29431, 29433-29434, 29438-29440, 29442-29443, 29445, 29447-29457, 29459, 29462, 29465-29466, 29468, 29470-29474, 29476-29478, 29480-29483, 29486-29487, 29490, 29492-29493, 29495-29496, 29498, 29500-29502, 29504-29506, 29508-29512, 29514, 29516-29519, 29521-29524, 29527, 29529, 29534-29539, 29544-29548, 29552, 29554, 29559-29563, 29565-29566, 29571-29573, 29579, 29581-29583, 29587, 29589, 29591-29592, 29594-29595, 29597, 29599-29600, 29603, 29605-29606, 29610-29613, 29617-29621, 29623-29626, 29631, 29635-29647, 29649-29652, 29654-29655, 29657-29659, 29661-29662, 29664-29665, 29667-29668, 29670-29672, 29674-29676, 29678, 29681, 29683, 29685, 29689, 29691-29692, 29695, 29698, 29702, 29704-29706, 29708-29711, 29715, 29719-29723, 29725-29733, 29735, 29737-29743, 29745-29756, 29758-29763, 29765-29767, 29769-29770, 29773-29775, 29777-29780, 29782-29785, 29787-29789, 29791-29795, 29797, 29800-29803, 29805-29809, 29812-29813, 29816, 29820-29829, 29831-29833, 29835, 29838-29840, 29842, 29844, 29847, 29849-29850, 29852, 29855-29860, 29863-29865, 29867, 29869-29874, 29879, 29881-29882, 29884-29887, 29889, 29891-29893, 29895-29896, 29899-29900, 29902-29904, 29907, 29909, 29911, 29914, 29916, 29918, 29925, 29933, 29937-29941, 29943, 29949, 29951, 29953-29955, 29957-29961, 29964-29965, 29974, 29976, 29979, 29981, 29983-29984, 29986-29987, 29992, 29995, 29997-29998, 30000, 30003-30004, 30009, 30011-30012, 30014-30017, 30023, 30027, 30029-30030, 30048-30051, 30053, 30056-30061, 30063, 30072-30075, 30078-30079, 30082, 30084-30087, 30090, 30092-30093, 30095-30098, 30100-30101, 30103-30104, 30106-30109, 30111, 30115, 30117, 30119, 30123-30124, 30126, 30128-30134, 30136, 30138-30141, 30144-30148, 30150, 30153, 30155-30159, 30163-30177, 30179, 30181-30183, 30185, 30187-30189, 30192, 30194-30200, 30206-30207, 30210-30211, 30216-30221, 30223, 30225-30229, 30231-30232, 30235-30236, 30238, 30242-30246, 30248-30250, 30252, 30255-30258, 30263, 30265, 30267, 30269, 30273-30276, 30278-30279, 30281-30289, 30291-30294, 30302-30303, 30305-30306, 30308, 30310, 30312-30322, 30324, 30326-30329, 30331-30333, 30335, 30337-30344, 30346, 30348, 30350, 30352-30358, 30361, 30365, 30370, 30379-30381, 30385-30389, 30392-30393, 30399-30400, 30402-30403, 30414-30418, 30424-30425, 30428, 30431, 30436, 30439, 30441-30443, 30448, 30450-30452, 30454, 30457, 30460-30462, 30464, 30466, 30473, 30475-30476, 30482-30484, 30489-30493, 30495-30496, 30498, 30500, 30503-30504, 30506-30511, 30513-30514, 30518-30519, 30521, 30527, 30533-30534, 30537, 30539, 30541-30544, 30546-30550, 30562, 30564, 30567, 30574, 30577-30579, 30581, 30583, 30590, 30596-30601, 30603-30604, 30607, 30609-30610, 30612, 30615, 30618-30619, 30621, 30623, 30629-30631, 30633, 30636, 30640-30642, 30644-30646, 30648, 30650, 30653, 30655-30657, 30659-30660, 30662, 30664, 30667, 30672, 30674-30677, 30680-30684, 30687-30689, 30691-30694, 30697-30699, 30701-30705, 30709-30711, 30713-30719, 30721-30724, 30727, 30730-30731, 30733, 30737, 30739-30740, 30743-30744, 30747-30749, 30751-30752, 30758-30766, 30768, 30771-30772, 30776-30779, 30781-30785, 30788-30792, 30794-30802, 30806, 30811, 30813, 30817, 30824-30826, 30828-30831, 30835-30839, 30842-30843, 30845-30847, 30854, 30856, 30858-30862, 30864-30865, 30869-30880, 30892, 30894, 30897-30898, 30900, 30902-30904, 30906, 30913, 30919, 30921-30927, 30929-30930, 30932-30933, 30936, 30941-30949, 30951-30955, 30957, 30959-30962, 30965-30967, 30972-30976, 30979-30983, 30985, 30993-30995, 30998, 31001-31002, 31010-31012, 31015-31016, 31018, 31021-31025, 31027-31028, 31030, 31032-31038, 31042, 31046-31048, 31050, 31053, 31055-31062, 31065, 31072, 31074-31075, 31078, 31080-31084, 31086-31091, 31093-31095, 31097-31101, 31105, 31107-31108, 31113, 31115-31118, 31122-31126, 31129, 31131-31132, 31136-31149, 31151-31152, 31154-31158, 31161, 31164-31165, 31167-31168, 31171-31173, 31175-31180, 31182-31184, 31186-31187, 31193, 31195, 31197-31199, 31201-31204, 31206, 31210, 31212-31214, 31216, 31218, 31220-31221, 31226-31227, 31229, 31235, 31237-31241, 31243-31244, 31248-31250, 31255, 31257, 31260, 31263-31269, 31273, 31275-31278, 31282-31290, 31293-31297, 31299-31302, 31304-31305, 31311-31312, 31314, 31316, 31318, 31320-31328, 31331-31338, 31340-31341, 31343, 31345-31346, 31348-31352, 31355-31356, 31358, 31360, 31366-31372, 31374-31379, 31381-31385, 31387-31391, 31400, 31402-31403, 31406-31409, 31411, 31414-31418, 31420-31423, 31426-31427, 31429-31432, 31434, 31437-31440, 31445-31450, 31452-31455, 31458, 31462, 31464-31467, 31469-31472, 31477-31479, 31481-31482, 31485-31486, 31488-31489, 31493-31494, 31496-31500, 31502-31505, 31510-31512, 31520-31522, 31527, 31530-31531, 31534-31536, 31538-31541, 31544-31545, 31547-31549, 31556-31559, 31561-31563, 31566-31569, 31572, 31574-31575, 31578-31579, 31581-31582, 31584, 31586-31587, 31589-31591, 31593-31595, 31597-31599, 31601-31603, 31606-31610, 31613-31614, 31616, 31618-31622, 31626, 31628-31635, 31638-31639, 31641-31642, 31644-31646, 31648, 31650, 31652, 31657, 31659-31662, 31664, 31666-31669, 31671-31672, 31674, 31677-31680, 31682, 31684, 31689-31691, 31693-31694, 31696-31698, 31700-31701, 31708, 31710-31713, 31715-31716, 31721, 31723-31727, 31730, 31733-31735, 31739-31740, 31742-31743, 31747-31748, 31750, 31753, 31766-31767, 31769, 31771-31772, 31774, 31777-31783, 31787-31788, 31791, 31795-31798, 31800-31802, 31805, 31809-31810, 31812-31813, 31815, 31819, 31823-31828, 31831-31832, 31835, 31837-31839, 31841-31844, 31847, 31849-31857, 31861-31866, 31869-31872, 31874, 31878-31895, 31897, 31899, 31913, 31915-31918, 31921, 31925, 31928-31934, 31937-31938, 31940-31945, 31950-31952, 31954, 31957-31959, 31962-31963, 31965-31970, 31973, 31975-31980, 31982-31989, 31992, 31994-31995, 32000-32002, 32005, 32008-32018, 32021, 32024, 32026, 32028, 32030-32036, 32041-32045, 32047, 32051-32052, 32058, 32060-32070, 32072, 32081, 32083, 32085-32088, 32095, 32097-32098, 32100, 32107, 32111, 32115, 32120-32121, 32123-32129, 32131-32132, 32134-32135, 32138-32139, 32141-32143, 32145-32147, 32149-32152, 32154, 32158-32160, 32162, 32164, 32166, 32168-32172, 32174, 32176-32182, 32184-32185, 32187-32189, 32191-32192, 32195-32199, 32201, 32204, 32209-32210, 32212-32213, 32216-32218, 32224, 32226, 32229-32230, 32235-32236, 32238-32244, 32247, 32249, 32256-32262, 32264-32265, 32267, 32269, 32272-32276, 32280, 32286-32289, 32292, 32295, 32300-32301, 32303, 32306, 32308-32310, 32312, 32314, 32318, 32325-32326, 32328, 32331, 32339, 32341-32344, 32346-32349, 32352-32354, 32356-32357, 32360-32361, 32364-32365, 32368-32369, 32372, 32375-32378, 32393, 32395, 32398, 32403, 32408-32410, 32412, 32416-32418, 32423-32425, 32428, 32430, 32432, 32436-32437, 32441-32443, 32445-32446, 32449, 32452, 32454-32456, 32458-32459, 32461, 32463, 32467, 32471-32472, 32474-32476, 32478-32479, 32483-32489, 32491-32494, 32499, 32501, 32508, 32512, 32514, 32516, 32519-32521, 32524-32526, 32530-32531, 32535, 32537, 32543, 32545, 32547, 32549, 32553, 32555-32562, 32564-32565, 32567-32568, 32570, 32575-32576, 32580, 32585-32589, 32592-32593, 32597-32601, 32603-32604, 32607, 32612-32613, 32617-32618, 32622-32623, 32628, 32630, 32632, 32634-32635, 32638-32646, 32648, 32650, 32652-32655, 32662, 32664, 32669-32671, 32676-32677, 32679, 32683, 32685-32687, 32689-32691, 32694, 32697, 32699-32700, 32702, 32706-32713, 32724-32726, 32728, 32730, 32732-32733, 32736, 32741-32744, 32746-32750, 32752, 32754, 32756-32758, 32761-32765, 32768, 32770, 32773-32775, 32778, 32783, 32785-32786, 32789-32795, 32797-32798, 32802, 32804-32808, 32810, 32815, 32817-32820, 32822, 32825-32832, 32834-32836, 32838, 32840-32846, 32849-32852, 32854-32856, 32859, 32863-32871, 32877, 32881, 32883, 32885, 32887-32889, 32891-32892, 32894, 32897, 32900-32905, 32907-32914, 32920-32922, 32924-32925, 32927, 32929-32930, 32934, 32936, 32940, 32942-32949, 32951-32952, 32954-32956, 32959, 32961-32962, 32964, 32966, 32968-32971, 32973-32976, 32978-32979, 32981-32984, 32986-32987, 32991-32993, 32996, 32998, 33000-33002, 33004, 33008, 33013-33045, 33048, 33052, 33056-33060, 33062-33063, 33066-33069, 33073, 33075, 33078-33085, 33089-33090, 33096-33100, 33102, 33104, 33106, 33110-33113, 33117-33120, 33125-33126, 33129-33130, 33132-33133, 33136-33137, 33141-33144, 33146, 33148, 33152, 33161, 33163-33165, 33167, 33170-33171, 33173, 33175-33178, 33181, 33183-33184, 33187-33188, 33196-33198, 33200-33201, 33203-33204, 33207-33208, 33211-33213, 33215, 33219, 33221-33224, 33229-33231, 33233-33234, 33236, 33238-33249, 33252, 33258-33260, 33262, 33269, 33271, 33273-33275, 33277-33279, 33284-33285, 33291-33297, 33300-33302, 33305, 33310-33311, 33315, 33320, 33322-33328, 33330-33331, 33333, 33337, 33339, 33343-33344, 33347-33349, 33351-33352, 33354-33355, 33358, 33364, 33373, 33376-33378, 33380, 33383-33384, 33386-33389, 33391-33392, 33394-33396, 33403, 33405, 33410, 33412-33416, 33420, 33425, 33428-33430, 33432-33435, 33438-33441, 33447, 33451, 33454-33461, 33463, 33466-33468, 33472-33473, 33475, 33477-33486, 33490, 33492, 33497, 33499-33503, 33506, 33508-33510, 33521, 33525, 33527, 33529, 33533-33536, 33538-33539, 33541-33543, 33547, 33549-33557, 33559, 33561-33562, 33567, 33572, 33575-33579, 33581-33584, 33586, 33588, 33590, 33592, 33594, 33596-33598, 33600, 33602-33604, 33608-33612, 33614-33615, 33617, 33619-33622, 33624-33625, 33628-33629, 33631-33635, 33637-33642, 33644-33646, 33649-33650, 33652-33656, 33658, 33660-33667, 33669, 33672, 33674, 33676-33679, 33681-33684, 33686-33689, 33691, 33694-33702, 33708-33709, 33711-33713, 33715, 33717-33718, 33720-33721, 33723, 33725-33731, 33733, 33738-33741, 33743, 33745, 33750, 33759, 33761-33763, 33765-33768, 33771-33772, 33774-33775, 33779-33780, 33782, 33784, 33786-33797, 33801-33805, 33808-33809, 33814, 33817-33821, 33823-33825, 33827-33832, 33836, 33838, 33840-33842, 33845-33846, 33848, 33853-33855, 33857, 33859, 33863, 33865-33867, 33874, 33877-33878, 33880-33881, 33885, 33888, 33890-33895, 33897-33899, 33902-33903, 33905-33907, 33909-33911, 33914-33918, 33921, 33923-33924, 33926, 33928-33929, 33931, 33936, 33943, 33945-33946, 33949, 33951, 33954-33957, 33959, 33961-33964, 33966, 33969, 33971, 33974-33978, 33980, 33982-33986, 33988-33994, 33996-33997, 33999, 34001-34005, 34008-34012, 34014-34015, 34018-34022, 34024-34028, 34030-34034, 34036, 34038-34043, 34045-34051, 34055-34057, 34059-34062, 34064, 34067-34069, 34071-34077, 34079-34080, 34088-34089, 34091-34094, 34096-34102, 34108-34109, 34111-34113, 34116-34117, 34119, 34121-34125, 34127-34130, 34134-34136, 34140, 34143, 34145, 34147-34150, 34152-34155, 34157, 34159, 34162, 34166-34168, 34170, 34181, 34185-34187, 34189, 34191-34193, 34198, 34200-34202, 34205, 34207-34208, 34211-34213, 34215, 34219-34220, 34222-34233, 34235-34241, 34246, 34249-34258, 34260, 34262, 34264, 34266-34267, 34270, 34272-34273, 34275, 34277-34278, 34280, 34282-34283, 34285, 34287, 34290-34292, 34294-34296, 34298-34302, 34305, 34308-34309, 34312-34317, 34320-34322, 34326, 34328, 34330-34334, 34338, 34340, 34342, 34344-34352, 34355-34360, 34362, 34366, 34372, 34377, 34380, 34382-34383, 34385, 34387-34392, 34394-34396, 34399-34407, 34410-34417, 34419, 34421, 34423-34425, 34428-34430, 34434, 34436, 34438, 34442, 34444-34447, 34450-34457, 34459-34461, 34463, 34465-34466, 34469-34471, 34476-34477, 34479, 34482-34483, 34485-34486, 34488, 34490, 34492-34493, 34495, 34497-34504, 34507-34509, 34513, 34515-34516, 34520-34523, 34525-34528, 34530-34535, 34543, 34545-34547, 34549-34550, 34552-34554, 34556-34562, 34565, 34568-34571, 34573, 34575-34579, 34581-34587, 34590-34593, 34595-34599, 34601-34605, 34611-34619, 34621, 34624-34625, 34627, 34631-34634, 34636-34646, 34648-34656, 34658, 34660, 34662-34666, 34668, 34670-34671, 34673, 34675, 34677, 34679-34681, 34683-34686, 34688-34695, 34697-34699, 34701-34703, 34705-34706, 34710, 34714-34718, 34721-34722, 34725-34728, 34731-34732, 34734-34738, 34741-34743, 34750-34752, 34756, 34760, 34762-34764, 34767-34769, 34771-34776, 34778-34779, 34781, 34783, 34785, 34787-34789, 34791, 34794, 34796-34797, 34799, 34802-34803, 34805, 34808-34809, 34811, 34813, 34816, 34819, 34822, 34824-34827, 34829, 34832-34833, 34837-34839, 34841-34845, 34849-34850, 34854, 34856, 34862-34865, 34867-34873, 34876-34878, 34881, 34883, 34885-34886, 34888-34890, 34892-34895, 34897-34899, 34901-34908, 34910-34911, 34915-34916, 34918-34926, 34933-34938, 34940, 34942, 34944-34946, 34948-34949, 34951-34956, 34958-34960, 34962-34963, 34965, 34968-34972, 34976-34978, 34986, 34988, 34990, 34992, 34995-35000, 35002-35006, 35009, 35012-35017, 35021, 35025-35026, 35028-35031, 35034-35036, 35041-35043, 35045, 35048-35050, 35055, 35057-35058, 35061-35062, 35067-35070, 35072-35074, 35076-35078, 35080-35082, 35085, 35089-35090, 35092-35094, 35097-35099, 35101-35103, 35106-35107, 35111-35113, 35115, 35119, 35122, 35124-35128, 35130, 35140, 35146, 35152-35154, 35156, 35159, 35162-35164, 35168-35169, 35171-35173, 35180-35182, 35185, 35190, 35196-35197, 35199-35203, 35206, 35208-35210, 35213, 35215-35216, 35219-35222, 35228-35229, 35231, 35233, 35235, 35237, 35239-35246, 35248-35249, 35251-35254, 35256-35264, 35268-35272, 35275, 35280-35281, 35288-35296, 35298, 35302, 35304, 35306, 35308-35310, 35313, 35316-35318, 35320-35321, 35323-35329, 35331-35334, 35338, 35340-35341, 35347-35348, 35350-35351, 35353, 35355-35358, 35365, 35369, 35374, 35376-35377, 35381, 35383-35386, 35388-35389, 35392-35393, 35395, 35398, 35400, 35402, 35404-35407, 35409-35411, 35414-35415, 35417-35418, 35421-35422, 35424-35425, 35430-35431, 35433-35437, 35439-35440, 35442, 35445-35447, 35450, 35456, 35459, 35462-35465, 35467, 35469-35471, 35473-35474, 35478-35484, 35493, 35499, 35501-35504, 35506-35510, 35512, 35514-35518, 35521-35524, 35526-35527, 35530-35531, 35533, 35535-35540, 35542, 35546, 35549-35551, 35555, 35557-35558, 35564, 35566-35568, 35570, 35572, 35575, 35577-35578, 35581-35583, 35586, 35588, 35590, 35592, 35597-35598, 35600-35601, 35609, 35614-35616, 35618, 35621, 35624-35627, 35633-35635, 35637, 35639-35640, 35642-35644, 35650, 35652-35657, 35659, 35662-35663, 35667, 35669, 35674, 35677-35679, 35681, 35683, 35685, 35687-35692, 35694, 35698-35705, 35707-35713, 35715-35724, 35726, 35729-35734, 35736, 35738, 35740-35742, 35744, 35747, 35751-35752, 35754, 35756-35765, 35768-35769, 35773, 35776-35780, 35782, 35785, 35787-35788, 35790, 35792, 35800, 35803-35817, 35819, 35821-35833, 35835-35836, 35838-35839, 35842, 35844, 35848-35851, 35854, 35856, 35859, 35862, 35864-35868, 35871, 35873-35882, 35884-35886, 35890, 35898, 35901, 35903, 35905-35906, 35908, 35910-35911, 35914-35916, 35918-35921, 35925, 35927-35929, 35931, 35933-35935, 35937, 35939-35944, 35947-35949, 35952-35962, 35965-35966, 35970, 35973-35975, 35979-35981, 35983-35989, 35991, 35997-36008, 36011-36018, 36020-36029, 36031, 36033-36038, 36040-36041, 36044, 36046, 36048-36049, 36051, 36053, 36056, 36058, 36060-36062, 36065-36068, 36070-36074, 36077, 36079, 36081-36088, 36090, 36092, 36097-36098, 36100, 36104-36107, 36109-36110, 36112-36115, 36117-36119, 36122-36123, 36126-36128, 36131-36136, 36138, 36140, 36143-36147, 36149-36151, 36154-36157, 36160-36172, 36174-36176, 36179, 36181, 36183-36186, 36188, 36191-36193, 36195-36204, 36206-36209, 36211-36213, 36217, 36220, 36222, 36228, 36230, 36232, 36234-36236, 36239-36242, 36244, 36246-36249, 36254-36255, 36257-36258, 36263-36271, 36273, 36276, 36278-36280, 36283, 36285, 36288, 36290-36294, 36302, 36304-36305, 36308, 36310, 36314-36322, 36327, 36329-36330, 36338-36342, 36346, 36349, 36351-36352, 36355, 36357, 36363, 36365-36367, 36371, 36373-36375, 36378-36380, 36383, 36386, 36392, 36399-36400, 36402-36406, 36408-36410, 36412-36414, 36416, 36424-36430, 36432-36433, 36436, 36439-36441, 36443-36444, 36446, 36456-36457, 36459, 36462-36471, 36473, 36475-36478, 36480, 36483-36489, 36492-36494, 36496, 36499-36500, 36502, 36505, 36507-36512, 36514, 36517, 36523, 36526, 36531-36535, 36537, 36545-36546, 36548, 36552-36558, 36563-36565, 36567, 36570-36573, 36575, 36578, 36581, 36585, 36587, 36591-36599, 36603-36605, 36608, 36612, 36621, 36623-36626, 36628-36629, 36631, 36633-36636, 36639, 36641, 36643, 36645, 36649, 36651-36652, 36657, 36659, 36663-36665, 36667-36671, 36677, 36679, 36683, 36686, 36688, 36692-36698, 36703, 36706, 36708, 36710-36716, 36719-36722, 36724-36728, 36732, 36734, 36736, 36740, 36742-36743, 36746-36752, 36754, 36756-36765, 36768, 36773, 36778-36780, 36782, 36784-36788, 36796-36798, 36801, 36803-36807, 36809-36811, 36813, 36818-36821, 36823-36825, 36827-36831, 36833, 36841-36853, 36855-36857, 36863-36864, 36867, 36870, 36872-36873, 36875, 36877-36879, 36881, 36884-36886, 36890-36896, 36898-36900, 36903-36905, 36907-36908, 36910-36911, 36916-36917, 36919, 36922, 36924-36927, 36930, 36932-36939, 36943, 36945-36952, 36954-36958, 36960-36962, 36964, 36967-36968, 36970-36972, 36975-36990, 36992-36994, 36999-37003, 37005, 37007, 37009, 37013, 37018-37023, 37025, 37028, 37032, 37034, 37038, 37042-37044, 37046, 37050, 37054, 37056-37060, 37065-37069, 37073, 37075-37081, 37083, 37086-37088, 37090-37091, 37095, 37097-37098, 37100-37101, 37103, 37107-37111, 37113-37114, 37120, 37123, 37126-37130, 37132, 37134, 37136-37137, 37139-37140, 37142, 37144, 37147-37148, 37152, 37155, 37157, 37162, 37166, 37168, 37170-37171, 37178, 37185-37192, 37194-37196, 37198-37200, 37203-37204, 37206, 37208, 37212-37214, 37216-37217, 37219-37221, 37223, 37229-37230, 37232, 37238, 37240-37242, 37245, 37248, 37250-37257, 37261, 37263, 37265-37273, 37275-37281, 37283, 37290-37294, 37296-37298, 37301-37306, 37310, 37313, 37315, 37318-37323, 37328-37329, 37333, 37335-37337, 37340-37347, 37353, 37356, 37358-37359, 37361-37364, 37367, 37369, 37371, 37373, 37375, 37379-37381, 37383, 37385-37386, 37388-37397, 37403-37414, 37417, 37419-37424, 37426-37430, 37432, 37434-37435, 37440, 37443-37445, 37447-37450, 37452-37453, 37455-37456, 37458-37466, 37469-37470, 37475, 37477, 37479-37481, 37483-37484, 37486, 37489-37496, 37500-37501, 37504, 37509, 37511, 37520-37525, 37533, 37535, 37537-37538, 37540-37541, 37544, 37546-37547, 37551, 37554-37560, 37562, 37566, 37568, 37575, 37578-37583, 37586, 37588-37590, 37592-37593, 37595-37596, 37598-37599, 37602, 37604-37606, 37609, 37611, 37614-37615, 37617, 37622, 37625, 37633, 37636-37638, 37644-37654, 37656-37657, 37659-37664, 37668, 37678, 37680, 37682-37687, 37689-37690, 37692-37695, 37699-37702, 37706-37711, 37714-37715, 37720-37723, 37726-37728, 37730, 37735, 37739-37741, 37744, 37746-37749, 37755-37756, 37758, 37760-37764, 37766-37768, 37770-37771, 37773-37777, 37779, 37783-37792, 37794-37795, 37800-37801, 37803-37806, 37809-37810, 37817, 37819, 37824-37835, 37837-37839, 37842-37844, 37846-37851, 37853, 37855-37858, 37861-37862, 37865-37866, 37868-37872, 37874-37879, 37881-37883, 37885, 37890, 37892, 37894, 37901, 37903-37904, 37906-37907, 37912-37913, 37918, 37920-37923, 37925, 37929-37931, 37933-37938, 37940-37941, 37943-37945, 37949-37951, 37953-37955, 37957-37958, 37960, 37962-37964, 37967-37968, 37971-37975, 37977, 37979, 37981, 37987-37989, 37996-37997, 38001-38011, 38013, 38015-38016, 38018, 38024-38028, 38031-38040, 38042-38046, 38048-38054, 38059, 38061-38062, 38064, 38067, 38069-38073, 38077, 38081-38082, 38084-38086, 38088-38093, 38095-38096, 38101, 38103-38105, 38107-38108, 38110-38111, 38113-38116, 38121-38122, 38132-38133, 38135, 38137-38140, 38143-38147, 38155, 38159, 38161, 38163-38164, 38166, 38170, 38172-38182, 38184-38185, 38187-38189, 38191-38192, 38194-38208, 38210-38211, 38213-38215, 38217-38220, 38222, 38224-38226, 38229-38233, 38236-38239, 38244, 38246, 38248-38249, 38251-38258, 38261-38262, 38264-38268, 38270-38271, 38273-38280, 38282, 38288-38291, 38293, 38298, 38305-38307, 38309-38312, 38314, 38316-38317, 38319, 38322-38324, 38326, 38331, 38334-38338, 38340, 38343, 38345, 38347-38352, 38356, 38358-38363, 38365-38366, 38369-38372, 38377, 38380, 38382-38384, 38395-38396, 38398, 38402, 38404, 38406-38407, 38411-38412, 38414, 38416, 38420-38422, 38424, 38426-38427, 38435-38440, 38442-38443, 38445, 38450-38451, 38454-38455, 38465-38467, 38475-38478, 38484, 38486-38487, 38489-38490, 38492, 38497-38499, 38502, 38505-38506, 38511-38512, 38517, 38519-38520, 38525, 38528-38531, 38534, 38536, 38543, 38548, 38550, 38557, 38559, 38565-38569, 38571, 38575-38576, 38578-38586, 38588, 38591-38599, 38601-38602, 38604, 38606, 38612, 38616-38617, 38619-38620, 38622-38624, 38628-38632, 38634, 38639, 38648, 38651, 38654, 38657, 38661-38664, 38668, 38670-38672, 38675, 38677-38682, 38685-38686, 38699, 38702-38703, 38706, 38714, 38717, 38719, 38721-38723, 38727, 38733-38734, 38740-38741, 38746-38750, 38755, 38757, 38759, 38762-38763, 38767, 38776, 38779-38780, 38782-38784, 38788-38795, 38797-38798, 38811-38812, 38814-38818, 38820-38822, 38824, 38826, 38830, 38832-38836, 38839-38840, 38842, 38844-38847, 38849-38850, 38852-38854, 38856-38857, 38864-38865, 38868-38869, 38871-38873, 38875, 38877, 38879-38880, 38882-38883, 38886-38887, 38889-38893, 38896-38898, 38900-38901, 38905, 38907-38908, 38910, 38913, 38915-38918, 38920-38923, 38929, 38932-38933, 38937, 38942, 38944, 38949, 38951-38952, 38954-38955, 38961-38965, 38968, 38971-38972, 38978, 38985-38987, 38989-38993, 38995-38997, 38999, 39005-39006, 39009-39010, 39012, 39015, 39019, 39021-39023, 39033, 39035, 39038, 39041, 39047-39048, 39051-39052, 39055-39059, 39061, 39063-39065, 39068, 39070-39074, 39076, 39078, 39080-39082, 39084-39092, 39094, 39096-39097, 39099-39100, 39102, 39104-39107, 39109-39115, 39117-39126, 39128, 39131, 39134-39140, 39142, 39145, 39147, 39149, 39153-39154, 39156-39157, 39159-39160, 39162, 39164, 39167-39168, 39170, 39172-39173, 39175-39177, 39183, 39185, 39187, 39189, 39191, 39193, 39196-39200, 39202, 39204-39208, 39210, 39214-39215, 39217, 39219, 39223, 39227, 39230, 39236, 39238-39240, 39250-39251, 39254, 39258-39260, 39265-39272, 39274-39276, 39278, 39282, 39286, 39288, 39291-39299, 39301-39303, 39307-39308, 39310-39317, 39323, 39325-39327, 39329, 39331-39333, 39335, 39339-39346, 39349, 39351, 39353, 39355-39359, 39362-39364, 39366-39367, 39386, 39388-39389, 39391-39393, 39396, 39401, 39404, 39406-39417, 39421, 39423-39424, 39426-39427, 39430, 39432, 39434, 39436, 39438, 39440, 39442, 39446-39453, 39455-39459, 39461, 39464, 39466, 39472, 39474-39475, 39477, 39479, 39481-39490, 39494, 39496, 39501, 39503-39504, 39509, 39512-39514, 39516-39519, 39521, 39523-39526, 39528-39533, 39536, 39541-39548, 39550, 39552-39553, 39563, 39565-39566, 39568-39578, 39581, 39593, 39596, 39601-39603, 39606-39608, 39611-39615, 39617, 39619-39622, 39627, 39629-39640, 39642-39650, 39652-39655, 39658-39665, 39668, 39675-39676, 39680-39681, 39683-39684, 39687-39692, 39694-39696, 39699, 39706-39709, 39711-39713, 39721-39722, 39725-39727, 39734, 39736, 39739, 39741-39742, 39744, 39747, 39752, 39756-39758, 39760, 39762-39763, 39765, 39767, 39769, 39771-39780, 39783, 39787-39792, 39794-39795, 39800, 39802-39804, 39806-39807, 39809, 39813, 39816-39823, 39825, 39827-39829, 39833-39834, 39837-39839, 39842-39843, 39847-39849, 39853-39854, 39856-39857, 39859, 39863, 39866, 39870-39871, 39875, 39878, 39884, 39888, 39896, 39898-39900, 39902-39906, 39908-39909, 39912, 39916-39917, 39922, 39924-39926, 39929-39935, 39938-39942, 39944-39945, 39947-39949, 39951-39952, 39954, 39957-39962, 39964, 39968, 39970, 39973-39974, 39977-39979, 39982, 39984-39987, 39995-39997, 39999, 40002, 40004-40007, 40009-40011, 40017-40020, 40024, 40027, 40029, 40031, 40033, 40038, 40042-40045, 40052-40053, 40055-40056, 40058-40063, 40065-40067, 40074-40076, 40078, 40080-40082, 40085, 40087, 40090, 40094-40095, 40097, 40099-40106, 40108-40109, 40111-40117, 40119, 40121-40122, 40124-40125, 40127, 40131, 40134-40135, 40137, 40139, 40141-40143, 40145-40146, 40149-40156, 40161, 40163, 40165, 40169-40170, 40172, 40174-40175, 40177, 40181, 40183-40185, 40187-40189, 40191-40192, 40194-40199, 40202-40205, 40208, 40213-40215, 40217-40219, 40223, 40225-40229, 40231, 40236, 40240, 40243, 40253-40256, 40259-40260, 40262-40264, 40266, 40268, 40270-40278, 40280-40282, 40284, 40288, 40290, 40292-40296, 40298, 40300-40303, 40305, 40307, 40310-40311, 40313-40314, 40316, 40319-40322, 40329, 40331-40338, 40343, 40347-40360, 40362-40363, 40372-40373, 40375-40376, 40378-40380, 40382-40384, 40387-40388, 40391-40394, 40396-40398, 40402, 40404, 40409-40411, 40418, 40421, 40423-40424, 40427-40428, 40430, 40432-40433, 40438, 40441-40442, 40444-40445, 40447-40449, 40453-40457, 40462-40463, 40468-40473, 40475-40480, 40482, 40485, 40487-40491, 40493, 40495-40497, 40499, 40501-40507, 40512-40516, 40521-40526, 40531-40533, 40535, 40537, 40543, 40546-40547, 40550, 40553, 40556, 40559, 40561-40564, 40566, 40570, 40573, 40576, 40578-40581, 40584-40585, 40592-40594, 40597-40599, 40603-40604, 40606-40609, 40615, 40618-40621, 40624, 40626, 40628, 40630, 40641-40643, 40648, 40652-40653, 40656-40658, 40660, 40662, 40664, 40666-40668, 40671, 40673, 40676-40677, 40679, 40681, 40685, 40687-40689, 40691-40692, 40695, 40700, 40703-40706, 40710-40711, 40713, 40715, 40718-40722, 40724-40733, 40736-40737, 40739-40741, 40744-40746, 40752, 40755-40757, 40759, 40761, 40765-40774, 40778, 40780, 40782-40783, 40785, 40787-40790, 40793-40794, 40799-40800, 40806-40807, 40811-40814, 40818-40819, 40823, 40830-40831, 40837-40840, 40843, 40849-40853, 40856-40858, 40861-40871, 40874, 40876, 40878, 40880, 40883, 40887, 40891-40896, 40902-40905, 40907, 40909-40916, 40919, 40921-40924, 40926, 40928-40931, 40933-40934, 40936, 40938, 40942-40947, 40950, 40954, 40958, 40960, 40966-40971, 40973-40977, 40980-40981, 40984-40988, 40991-40992, 40994-40995, 40997, 41000, 41002, 41004, 41006-41007, 41010-41011, 41015-41016, 41022, 41024-41025, 41027-41029, 41031-41036, 41039, 41041-41043, 41045, 41059, 41064-41065, 41067-41073, 41075-41076, 41078-41079, 41082-41084, 41087, 41089, 41091-41100, 41103, 41106-41107, 41109, 41113, 41115-41123, 41125-41127, 41130, 41133-41135, 41139-41140, 41144-41149, 41152-41155, 41157-41158, 41162-41164, 41168, 41170-41175, 41178, 41180-41181, 41186-41187, 41189, 41191, 41194, 41199-41201, 41204-41206, 41209, 41214-41216, 41218, 41222, 41226, 41228-41230, 41232, 41239, 41242-41243, 41246, 41248, 41252-41254, 41263, 41265-41267, 41269-41271, 41273-41274, 41276, 41285-41288, 41291, 41295-41296, 41307, 41311-41312, 41314-41315, 41320, 41329-41331, 41335-41337, 41340, 41342, 41344-41345, 41347-41350, 41352, 41354-41359, 41361, 41363, 41365, 41367, 41369-41370, 41372-41373, 41376, 41378-41380, 41383-41384, 41386, 41388, 41390, 41392, 41398, 41400-41404, 41408, 41410-41411, 41414, 41418-41421, 41428-41430, 41432-41433, 41435-41437, 41440-41441, 41443-41444, 41448-41449, 41455, 41457, 41459, 41464-41466, 41473, 41475, 41478-41479, 41485, 41487-41490, 41492, 41494, 41497-41499, 41504-41507, 41510, 41513-41515, 41517-41518, 41520-41521, 41525-41526, 41529, 41531, 41533, 41535-41536, 41540-41541, 41545-41546, 41548, 41550-41556, 41558-41560, 41562, 41566-41568, 41570, 41572-41576, 41578, 41582, 41588, 41590-41594, 41596, 41606-41608, 41611, 41613-41615, 41624, 41629, 41637, 41643-41644, 41647-41648, 41650-41655, 41658-41660, 41662-41664, 41666-41674, 41676-41677, 41679-41680, 41682, 41685, 41689, 41692, 41697, 41700-41702, 41707, 41710-41712, 41714, 41716-41717, 41719, 41724-41731, 41734-41738, 41740-41741, 41746-41747, 41749-41750, 41754-41755, 41758, 41760, 41763-41765, 41771, 41775-41780, 41787-41788, 41790, 41792, 41799, 41801, 41803-41804, 41806-41808, 41811, 41814, 41816-41817, 41819, 41821, 41824-41827, 41835, 41840-41842, 41844-41845, 41847, 41849, 41854, 41858-41861, 41865-41866, 41868-41869, 41872-41879, 41881-41894, 41898, 41903, 41906, 41908, 41910-41913, 41916-41917, 41924, 41927, 41931, 41936-41937, 41940, 41943-41944, 41946, 41948-41949, 41954, 41957-41958, 41960, 41962-41963, 41967, 41971, 41974-41975, 41980, 41982-41986, 41989-41992, 41994, 41999, 42004, 42007, 42010-42016, 42018, 42020, 42022-42023, 42027, 42034-42035, 42038, 42042-42045, 42049, 42051-42054, 42063-42067, 42071, 42079-42086, 42094-42100, 42105-42107, 42111-42112, 42114-42116, 42118, 42120, 42122-42126, 42128, 42130, 42133, 42136, 42138, 42140, 42142-42143, 42145, 42149-42152, 42154, 42156-42157, 42159-42160, 42164-42166, 42169, 42172, 42174-42178, 42180, 42182-42187, 42191-42195, 42198-42200, 42202-42204, 42208-42212, 42214, 42216-42217, 42219-42220, 42226-42230, 42235, 42240-42244, 42246-42250, 42255, 42261-42262, 42264, 42273-42274, 42276-42278, 42281, 42287, 42290-42291, 42293, 42298-42300, 42304-42306, 42309, 42311, 42318-42321, 42324, 42326-42335, 42340-42341, 42343, 42345, 42353-42354, 42358, 42361-42362, 42364-42367, 42370, 42372-42377, 42379-42380, 42382, 42385-42387, 42389, 42392-42394, 42399, 42402, 42404-42410, 42414, 42418-42419, 42422, 42424-42429, 42431-42433, 42435-42436, 42438, 42444-42445, 42455, 42459, 42462-42464, 42466-42470, 42472, 42483, 42485-42486, 42488, 42491, 42494-42495, 42497-42502, 42504-42505, 42508-42513, 42516-42523, 42526-42529, 42531-42532, 42538, 42542-42546, 42554, 42556-42558, 42561, 42565, 42568, 42570, 42573, 42577-42580, 42585, 42587-42590, 42593-42594, 42601-42602, 42605, 42608-42609, 42611, 42613-42615, 42618-42624, 42626, 42628-42634, 42636-42643, 42645-42646, 42648-42651, 42653-42656, 42659-42662, 42664-42666, 42669-42671, 42674-42676, 42679-42680, 42682, 42686-42689, 42691, 42694, 42698-42700, 42703, 42705-42707, 42710, 42719-42721, 42728, 42731, 42734-42736, 42740-42741, 42743, 42749, 42751, 42754-42755, 42757, 42759-42760, 42762, 42765-42766, 42768-42769, 42771, 42775, 42784-42785, 42787-42791, 42793-42794, 42799-42803, 42805-42807, 42817, 42819-42820, 42824-42825, 42830, 42833-42837, 42839-42842, 42844-42848, 42850-42852, 42854-42855, 42857, 42859-42863, 42865-42866, 42869, 42873-42876, 42878, 42882, 42886, 42888-42892, 42895-42897, 42904-42907, 42909-42910, 42912-42920, 42922-42923, 42925, 42929, 42931, 42936, 42939-42942, 42947-42948, 42952, 42954-42961, 42965, 42967-42968, 42971-42975, 42984, 42986-42987, 42989, 42991, 42994-42996, 42999-43002, 43004, 43006-43007, 43014-43019, 43021-43022, 43024-43028, 43030-43037, 43039-43048, 43055, 43057, 43060-43062, 43064, 43068-43070, 43073, 43076-43077, 43082, 43084-43086, 43088-43089, 43091, 43093, 43095-43097, 43101, 43104-43106, 43114-43122, 43125-43128, 43133-43134, 43136-43137, 43139-43145, 43147, 43149-43151, 43153, 43156, 43158-43160, 43162-43165, 43167-43168, 43170-43171, 43173, 43175-43179, 43181-43182, 43184, 43186-43187, 43189, 43195-43196, 43198, 43200-43202, 43205-43206, 43208, 43210-43214, 43216-43218, 43222-43224, 43226, 43228-43233, 43237-43238, 43240-43247, 43250-43251, 43253-43254, 43257-43258, 43260-43262, 43264-43267, 43269-43272, 43277, 43280-43281, 43283, 43286, 43292, 43294, 43299, 43301, 43305-43307, 43310, 43312, 43314-43317, 43320, 43323, 43325-43328, 43332-43333, 43335, 43341-43344, 43346, 43348-43349, 43352, 43354-43356, 43358, 43361, 43368, 43370-43371, 43373-43374, 43380, 43382-43383, 43385, 43393, 43396, 43398, 43401-43402, 43404-43405, 43411, 43417, 43422, 43426, 43429, 43439, 43442, 43445-43449, 43452-43458, 43460, 43467-43468, 43470-43474, 43477-43481, 43484, 43487-43488, 43491, 43494-43495, 43497-43498, 43500-43505, 43508, 43510-43512, 43514-43515, 43519, 43521-43524, 43530, 43536, 43540, 43542, 43544, 43546-43547, 43551-43552, 43554, 43558, 43560, 43565-43569, 43571-43573, 43575, 43579-43580, 43584, 43588-43591, 43593-43594, 43597-43599, 43601, 43603-43610, 43612-43616, 43618, 43620, 43622-43625, 43630, 43632, 43634, 43637, 43639-43641, 43643, 43645, 43647, 43649-43650, 43652, 43659, 43662-43668, 43673, 43676-43680, 43682, 43687, 43690-43693, 43695-43696, 43700-43702, 43704, 43706-43708, 43714-43716, 43723, 43728-43732, 43734, 43737, 43744-43748, 43750-43751, 43755-43763, 43765, 43767, 43771-43777, 43781, 43783-43785, 43789, 43793-43794, 43797-43804, 43807-43810, 43813, 43818, 43820-43821, 43823, 43826-43827, 43831-43837, 43839-43840, 43846-43849, 43853, 43856-43862, 43864-43868, 43870-43871, 43874-43875, 43878, 43882-43883, 43886, 43888-43891, 43894, 43896-43898, 43900, 43902-43903, 43909, 43913, 43916-43917, 43919-43924, 43926, 43928-43932, 43934-43937, 43939, 43941, 43944, 43946, 43948-43950, 43952, 43955, 43960-43961, 43963-43967, 43970, 43973-43974, 43976, 43984, 43986, 43989, 43992-44001, 44004, 44006-44007, 44009, 44014-44016, 44018, 44021, 44023-44024, 44026, 44028-44037, 44039, 44046, 44048, 44050-44051, 44053-44054, 44056-44058, 44061-44063, 44065, 44067, 44069-44070, 44072-44073, 44078, 44080-44081, 44083-44084, 44086-44092, 44096-44099, 44105-44106, 44110, 44113-44115, 44118-44122, 44124-44125, 44127-44128, 44130-44132, 44134-44136, 44138-44144, 44147, 44150, 44152, 44156-44158, 44171, 44174, 44180, 44182, 44184-44185, 44187-44188, 44190, 44194-44195, 44199, 44203, 44210, 44219, 44223, 44226-44227, 44230, 44235, 44240-44244, 44246-44247, 44249, 44253-44254, 44257-44261, 44266-44268, 44271, 44275, 44281-44282, 44284, 44289, 44294, 44299-44304, 44306-44307, 44309, 44311-44314, 44316, 44318-44319, 44321, 44323-44324, 44326-44327, 44329-44331, 44334, 44342-44344, 44346, 44357-44358, 44362, 44364, 44366, 44372, 44374, 44377-44380, 44382-44383, 44385, 44387, 44395-44396, 44399-44403, 44405, 44413-44416, 44419-44422, 44424, 44428-44435, 44437-44438, 44440-44442, 44444, 44446, 44452-44454, 44456-44458, 44460, 44464-44465, 44467-44471, 44473, 44475, 44477-44479, 44482-44483, 44485, 44487-44488, 44492-44494, 44496, 44502, 44504-44506, 44508, 44510, 44513, 44516-44517, 44519-44520, 44522, 44525-44526, 44528, 44533-44534, 44536, 44538-44540, 44553, 44556, 44559-44561, 44569, 44574-44575, 44577-44578, 44580-44581, 44583-44584, 44586-44587, 44590, 44593-44595, 44597, 44599, 44601-44604, 44606, 44609, 44611, 44615, 44617, 44624-44625, 44629, 44636, 44641-44645, 44647-44648, 44650, 44652, 44655, 44661, 44676, 44678-44680, 44684-44688, 44690, 44692-44693, 44695, 44701, 44704, 44707-44713, 44715, 44717-44721, 44723-44724, 44733-44741, 44745, 44747-44748, 44750-44752, 44756-44757, 44760, 44762-44763, 44765, 44771-44774, 44776, 44779, 44782-44783, 44785-44790, 44794-44796, 44798-44802, 44804-44806, 44808-44810, 44812-44818, 44821, 44823-44825, 44827-44828, 44832, 44840-44841, 44843-44845, 44848-44850, 44854, 44857, 44861-44863, 44866-44873, 44878-44881, 44883, 44885, 44887-44890, 44892, 44894-44896, 44898, 44900, 44904, 44906-44909, 44912, 44914-44915, 44922, 44925-44926, 44929, 44933, 44935-44941, 44943-44945, 44947, 44952, 44954-44955, 44960, 44963, 44972-44974, 44978, 44984, 44991, 44996-44997, 44999, 45005-45006, 45008, 45010, 45012-45017, 45020-45021, 45023, 45026, 45028-45029, 45031-45032, 45035, 45037-45038, 45043, 45045, 45047, 45051, 45054, 45056, 45058-45062, 45064-45075, 45078-45080, 45084, 45086, 45088-45092, 45096-45097, 45102, 45104-45105, 45107-45112, 45114-45115, 45117, 45119-45120, 45122, 45128-45130, 45132-45133, 45139, 45141, 45147, 45149, 45151-45153, 45155, 45158, 45161, 45165, 45168, 45175, 45177-45178, 45183-45187, 45189-45190, 45192, 45194, 45199-45200, 45202-45203, 45205, 45207-45208, 45210, 45212, 45216, 45222, 45227-45230, 45232, 45238-45240, 45242, 45245, 45247, 45253, 45256, 45258-45259, 45262, 45273-45274, 45276-45278, 45280, 45284, 45294-45298, 45301, 45304, 45308, 45311-45317, 45319-45320, 45322-45323, 45325-45326, 45329-45331, 45333, 45335, 45338-45339, 45344-45346, 45348-45349, 45351-45359, 45361, 45363-45364, 45366, 45368, 45370, 45372-45379, 45385-45389, 45391-45399, 45403, 45409, 45412-45413, 45415-45420, 45424-45426, 45430-45431, 45433-45438, 45440, 45442, 45444-45451, 45453-45454, 45457, 45461, 45463, 45465, 45467, 45469-45473, 45482-45487, 45490-45495, 45502, 45507-45508, 45510, 45516, 45518-45521, 45524-45527, 45529-45534, 45545, 45549-45552, 45554-45556, 45558-45559, 45563-45564, 45567, 45570-45572, 45574, 45576-45581, 45586, 45588-45589, 45591-45593, 45595, 45599, 45601, 45604, 45606, 45608-45610, 45612-45616, 45618-45620, 45624, 45627, 45630-45632, 45634, 45636, 45638-45643, 45645, 45647-45648, 45652-45653, 45659, 45661, 45663-45665, 45667-45668, 45670-45677, 45681-45683, 45685, 45690-45693, 45697-45700, 45703, 45706, 45708-45709, 45716, 45722-45729, 45735-45736, 45741, 45744-45746, 45749, 45751-45752, 45754-45757, 45759-45760, 45764-45765, 45767, 45769-45771, 45779-45780, 45784, 45786, 45788, 45791-45796, 45798-45802, 45806, 45808, 45811, 45814-45815, 45818, 45827, 45832, 45834-45835, 45838-45839, 45842-45844, 45847-45848, 45852-45853, 45856-45858, 45865, 45868-45870, 45872-45875, 45877-45879, 45881-45887, 45889-45893, 45900, 45903, 45905-45906, 45909-45919, 45921, 45923, 45925-45926, 45930, 45934-45936, 45938-45939, 45942-45943, 45945-45947, 45949-45951, 45953, 45955-45957, 45961, 45965-45966, 45969-45971, 45973, 45975-45976, 45979-45980, 45983-45986, 45990, 45997, 46000, 46002-46003, 46006-46007, 46009, 46012-46013, 46015-46016, 46018-46022, 46024-46025, 46027-46033, 46037, 46040, 46042-46043, 46047-46049, 46051-46053, 46055, 46058-46063, 46068-46069, 46075, 46078-46079, 46081, 46084-46098, 46100-46108, 46110-46113, 46115, 46119-46122, 46126-46127, 46131-46136, 46138-46139, 46142-46143, 46153, 46157-46158, 46160-46165, 46168-46170, 46173, 46176-46177, 46179-46180, 46182-46183, 46188-46196, 46198-46201, 46205, 46207-46210, 46212-46214, 46218-46219, 46221, 46227, 46233-46234, 46236-46240, 46242-46244, 46247, 46249, 46252-46253, 46255-46256, 46258-46267, 46269-46279, 46283, 46285-46288, 46291, 46293-46294, 46296, 46298-46299, 46301-46302, 46308, 46310, 46312-46314, 46316-46319, 46321-46328, 46331, 46334-46335, 46337-46338, 46340-46342, 46344, 46346-46350, 46352-46354, 46356-46358, 46362-46367, 46374-46375, 46377-46379, 46383, 46385-46388, 46390-46393, 46395, 46398, 46403, 46405-46414, 46416-46418, 46420, 46422, 46424, 46428-46429, 46431, 46433-46434, 46436, 46441-46442, 46444, 46446, 46448, 46450, 46452-46453, 46455-46456, 46459-46460, 46462, 46464-46465, 46467-46472, 46475, 46478-46480, 46482-46483, 46485-46488, 46491, 46493-46494, 46496-46497, 46501-46504, 46507, 46511-46513, 46515-46516, 46518-46525, 46528-46529, 46532-46533, 46540-46541, 46543, 46545, 46547-46550, 46552, 46555, 46557, 46560-46561, 46563, 46566, 46569-46570, 46583-46586, 46590-46593, 46595, 46601, 46604, 46608-46609, 46612-46616, 46618, 46621, 46623, 46625-46629, 46631-46633, 46636, 46638, 46641, 46646, 46649, 46653, 46655, 46657, 46660-46661, 46664-46666, 46668-46672, 46674-46679, 46690, 46692, 46696-46697, 46700, 46702-46703, 46710-46713, 46716-46717, 46719-46721, 46723, 46726-46728, 46730, 46732-46733, 46738-46742, 46744-46745, 46747-46752, 46754-46755, 46757-46762, 46764, 46768, 46771-46774, 46776, 46779-46781, 46783, 46785-46786, 46795-46796, 46800, 46806, 46809, 46820, 46823-46825, 46827-46833, 46835-46836, 46838-46839, 46841, 46843, 46845-46846, 46852-46855, 46857-46859, 46861-46864, 46866-46869, 46871-46872, 46874-46875, 46882, 46884, 46886-46887, 46889, 46891-46893, 46895-46905, 46907-46910, 46912-46913, 46915-46916, 46918, 46921-46922, 46927, 46929-46933, 46936, 46939-46940, 46942, 46944-46947, 46950-46951, 46954-46956, 46959-46960, 46963-46965, 46967-46968, 46970-46973, 46978, 46983-46984, 46986-46990, 46992-46993, 47000, 47002-47005, 47008-47009, 47011-47012, 47014-47017, 47019, 47021, 47029, 47031-47032, 47036, 47038, 47040, 47043, 47045-47046, 47048, 47051, 47055-47057, 47059-47062, 47065, 47068-47070, 47072-47073, 47075-47086, 47088, 47090-47093, 47095-47099, 47102-47104, 47108, 47110-47112, 47114, 47117, 47119, 47123, 47128-47131, 47133, 47136-47139, 47141, 47144-47148, 47150-47151, 47153, 47155, 47158, 47162-47164, 47168, 47170-47172, 47174, 47176-47181, 47184, 47188, 47190-47191, 47193-47197, 47199-47201, 47204, 47206-47211, 47213, 47217, 47221-47227, 47231-47232, 47234, 47237, 47239-47240, 47243-47249, 47255-47259, 47265-47271, 47274, 47281-47285, 47287-47292, 47295, 47298, 47300, 47302, 47306-47307, 47311, 47317-47318, 47320-47322, 47326-47330, 47333-47335, 47340, 47342, 47344-47345, 47347-47350, 47353-47358, 47360-47361, 47366-47369, 47371, 47373, 47375-47377, 47379, 47381-47385, 47387-47389, 47393-47398, 47400-47401, 47404-47413, 47418, 47420-47421, 47425-47426, 47428, 47431-47441, 47444, 47446-47447, 47451-47457, 47459, 47461, 47463-47466, 47468-47471, 47473-47482, 47485-47493, 47500, 47508-47509, 47513, 47515, 47517-47518, 47520-47524, 47528, 47532, 47536, 47538-47540, 47542-47551, 47553, 47557, 47560-47562, 47564-47565, 47567, 47570, 47573-47583, 47588-47590, 47592-47596, 47599, 47604-47605, 47607, 47609-47611, 47613-47616, 47618, 47620-47621, 47623-47625, 47627-47628, 47630-47631, 47633-47635, 47639, 47642, 47646, 47648, 47650-47651, 47653
Single Strand Oligonucleotides (Sense Strand of Target Gene)
SeqID range: 47462-83660
SeqIDs w/o G Runs:
47463, 47468-47483, 47485-47551, 47554-47559, 47561-47569, 47577-47608, 47612-47623, 47625-47631, 47633-47638, 47643-47674, 47688-47851, 47866-47986, 48000-48094, 48108-48129, 48143-48269, 48321-48337, 48353-48404, 48418-48478, 48492-48556, 48571-48682, 48696-48755, 48768-48818, 48831-48973, 48987-49046, 49060-49081, 49095-49191, 49205-49278, 49292-49314, 49329-49522, 49536-49641, 49655-49675, 49689-49930, 49944-49988, 50002-50012, 50028-50153, 50176-50367, 50381-50395, 50415-50545, 50560-50602, 50616-50664, 50680-50746, 50760-50783, 50799-51199, 51225-51348, 51374-51408, 51422-51470, 51495-51511, 51534-51721, 51743-51840, 51859-52001, 52016-52040, 52060-52100, 52115-52133, 52147-52382, 52406-52416, 52431-52473, 52487-52509, 52524-52745, 52759-52766, 52780-52823, 52837-52862, 52889-52956, 52971-53167, 53180-53285, 53294-53359, 53373-53428, 53451-53505, 53530-53571, 53585-53604, 53618-53784, 53811-53935, 53949-54341, 54363-54490, 54504-54683, 54697-54730, 54744-54788, 54794-55004, 55018-55204, 55218-55435, 55456-55626, 55640-55644, 55658-55702, 55710-55744, 55758-55909, 55923-55926, 55929-55967, 55980-55991, 55996-56006, 56027-56082, 56096-56108, 56123-56183, 56196-56198, 56214-56228, 56236-56309, 56323-56326, 56340-56392, 56406-56411, 56425-56570, 56584-56627, 56641-56666, 56680-56772, 56786-56823, 56837-57013, 57028-57164, 57178-57215, 57229-57350, 57366-57375, 57390-57466, 57480-57622, 57636-57726, 57740-57847, 57861-58139, 58153-58223, 58239-58267, 58281-58522, 58536-58690, 58704-58874, 58894-58907, 58921-58981, 58995-59009, 59023-59119, 59133-59208, 59222-59264, 59278-59297, 59312-59359, 59373-59460, 59474-59782, 59802-59988, 60002-60175, 60189-60193, 60207-60360, 60374-60437, 60445-60506, 60521-60525, 60530-60552, 60556-60563, 60577-60617, 60627-60844, 60854-60889, 60894-61004, 61019-61074, 61088-61149, 61158-61183, 61197-61221, 61235-61261, 61268-61445, 61459-61480, 61494-61511, 61525-61559, 61573-61746, 61760-61784, 61809-61858, 61870-61884, 61892-61962, 61970-62018, 62029-62113, 62127-62223, 62237-62409, 62423-62449, 62471-62621, 62635-62700, 62722-62823, 62859-62874, 62888-62901, 62915-62965, 62987-63173, 63198-63219, 63233-63278, 63292-63311, 63338, 63353-63569, 63597-63630, 63661-63663, 63681-63708, 63722-63836, 63858-63880, 63894-63931, 63946-63959, 63973-63984, 63999-64067, 64081-64097, 64111-64222, 64237-64280, 64294-64519, 64534-64563, 64577-64598, 64612-64668, 64682-64701, 64716-64737, 64752-64754, 64770-64836, 64850-64867, 64881-64930, 64944-65009, 65023-65082, 65097-65162, 65176-65216, 65244-65272, 65299-65357, 65371-65413, 65428-65455, 65480-65567, 65581-65638, 65652-65686, 65700-65753, 65771-65805, 65820-65950, 65964-66047, 66067-66129, 66157-66181, 66195-66198, 66212-66218, 66232-66257, 66293-66369, 66397-66492, 66506-66563, 66577-66593, 66607-66622, 66637-66926, 66945-67095, 67114-67181, 67199-67203, 67217-67374, 67388-67543, 67557-67613, 67628-67675, 67689-67717, 67744-67814, 67830-67868, 67883, 67908-67921, 67935-68334, 68348-68522, 68557-68693, 68707-68770, 68784-68843, 68866, 68880-68903, 68917-68979, 68994-68997, 69011-69110, 69125-69143, 69158-69168, 69182-69219, 69234-69269, 69285-69330, 69345-69466, 69480-69484, 69498-69590, 69605-69701, 69715-69722, 69736-69763, 69783-69839, 69853-69869, 69883-69945, 69968-69979, 69993-70085, 70115-70138, 70152-70232, 70246-70268, 70282-70290, 70308-70315, 70329-70345, 70359-70456, 70470-70478, 70493-70655, 70670-70707, 70721-70828, 70842-70855, 70870-70983, 70997, 71011-71024, 71038-71094, 71109-71334, 71348-71555, 71569-71653, 71667-71747, 71761-71820, 71834-71837, 71852-71880, 71894-71925, 71939-71965, 71981-71983, 71997-72034, 72048-72064, 72079-72280, 72294-72366, 72380-72395, 72439-72459, 72473-72488, 72509-72546, 72560-72645, 72660-72670, 72685-72866, 72880-72949, 72964, 72978-73070, 73084-73203, 73222-73229, 73244-73466, 73493-73508, 73537-73545, 73559-73560, 73574-73617, 73631-73646, 73660-73694, 73708-73739, 73753-73760, 73776-73885, 73899-73961, 73975-73988, 74002-74092, 74106-74128, 74142-74143, 74174-74227, 74241-74574, 74588-74677, 74691-74744, 74758-74869, 74883-74956, 74975-75006, 75021-75101, 75115-75165, 75179-75213, 75227-75280, 75294-75310, 75324-75355, 75388-75412, 75438-75452, 75473-75525, 75540-75543, 75570-75597, 75624-75632, 75646-75683, 75703-75723, 75737-75792, 75833-75859, 75884-75924, 75938-75956, 75970-75989, 76013-76030, 76051-76053, 76068-76104, 76124-76134, 76148-76159, 76174-76263, 76293-76330, 76344-76395, 76445-76521, 76535-76621, 76635-76647, 76669-76670, 76705, 76719-76740, 76754-76879, 76893-77017, 77031-77116, 77130-77185, 77208-77210, 77225-77229, 77262-77314, 77328-77361, 77376-77396, 77438-77491, 77505-77585, 77599-77610, 77631-77703, 77719-77790, 77806-77813, 77828-77851, 77865-77875, 77889-77897, 77911-78128, 78156-78163, 78177-78235, 78250-78282, 78296-78459, 78473-78487, 78510-78525, 78543-78562, 78585-78605, 78639-78718, 78734-78787, 78801-78891, 78916-78967, 78982-78986, 79022-79030, 79045-79048, 79062-79080, 79111-79142, 79156-79164, 79190-79211, 79225-79234, 79248-79303, 79317-79340, 79354-79389, 79404-79429, 79443-79466, 79481-79530, 79546-79551, 79572-79595, 79609-79665, 79679-79838, 79852-79893, 79916-79946, 79971-80016, 80030-80077, 80091-80099, 80143-80220, 80234-80260, 80274-80321, 80336-80343, 80357-80396, 80410-80476, 80491-80497, 80512-80540, 80554-80617, 80633-80702, 80717-80755, 80777-80901, 80917, 80932-80934, 80949-80953, 80968, 80983-81032, 81047-81070, 81092-81104, 81118-81161, 81175-81182, 81193-81198, 81200-81232, 81255-81258, 81272-81377, 81389-81626, 81640-81679, 81693-81699, 81725-81743, 81757-81789, 81809-81912, 81927-81935, 81957-82023, 82037-82122, 82144-82217, 82248-82256, 82270-82278, 82293-82323, 82351-82418, 82442-82509, 82524-82687, 82701-82706, 82722-82732, 82748-82777, 82799, 82813-82816, 82830-82865, 82879-82981, 83006-83018, 83032-83063, 83085, 83105-83113, 83127-83239, 83254-83308, 83323-83370, 83399-83504, 83518-83606, 83620-83653
SeqIDs w/o miR Seeds:
47463-47466, 47468-47471, 47473-47482, 47485-47493, 47500, 47508-47509, 47513, 47515, 47517-47518, 47520-47524, 47528, 47532, 47536, 47538-47540, 47542-47551, 47553, 47557, 47560-47562, 47564-47565, 47567, 47570, 47573-47583, 47588-47590, 47592-47596, 47599, 47604-47605, 47607, 47609-47611, 47613-47616, 47618, 47620-47621, 47623-47625, 47627-47628, 47630-47631, 47633-47635, 47639, 47642, 47646, 47648, 47650-47651, 47653, 47657, 47660-47662, 47664-47665, 47667-47668, 47670-47678, 47680, 47682, 47687, 47690-47691, 47695-47696, 47698-47700, 47702, 47704-47706, 47710, 47714-47716, 47718, 47722-47730, 47733, 47735, 47737, 47739, 47741, 47747, 47749, 47751-47769, 47774, 47776-47777, 47781, 47783-47785, 47788, 47790-47791, 47793-47794, 47797-47801, 47803, 47807, 47809, 47811-47812, 47815, 47817, 47822-47823, 47826-47830, 47832-47837, 47839, 47841-47844, 47848-47850, 47853, 47856-47860, 47863, 47865-47866, 47869-47873, 47875-47876, 47878, 47882, 47886-47888, 47892, 47894-47895, 47897, 47904, 47909-47911, 47913, 47915, 47917-47922, 47926, 47931-47933, 47935-47936, 47938, 47940-47942, 47946, 47951-47952, 47955, 47957-47959, 47961, 47963-47967, 47969, 47974-47975, 47977-47992, 47994, 47996, 48001, 48003, 48005, 48007, 48009-48016, 48018-48020, 48026-48027, 48029, 48031, 48036-48039, 48041, 48043-48045, 48047, 48049-48050, 48052, 48057-48059, 48061, 48063-48066, 48068, 48070-48071, 48073-48076, 48078-48080, 48088-48095, 48097, 48100-48101, 48104-48105, 48107-48108, 48111-48114, 48117, 48120-48123, 48125-48126, 48128-48130, 48133, 48135-48136, 48138-48139, 48142, 48144-48146, 48149-48151, 48154-48156, 48158, 48160, 48162, 48166-48167, 48169, 48171-48174, 48176, 48178, 48180, 48182, 48184-48188, 48195, 48199-48204, 48207-48211, 48213-48217, 48219, 48221-48226, 48231-48235, 48237, 48239-48241, 48243-48244, 48246-48248, 48251-48253, 48255-48262, 48264-48265, 48268, 48270, 48273-48274, 48276, 48281-48287, 48291, 48297-48299, 48301, 48303-48304, 48308, 48313, 48320, 48322-48323, 48327-48328, 48333-48334, 48338-48340, 48342-48346, 48353-48356, 48359-48366, 48368, 48370-48373, 48376-48377, 48379, 48384, 48386-48393, 48396, 48399-48402, 48405-48407, 48409-48410, 48412, 48414-48415, 48417-48418, 48423-48428, 48431-48435, 48437, 48439-48444, 48447-48450, 48454, 48457-48459, 48461, 48463-48465, 48467-48469, 48473-48476, 48478, 48482-48483, 48485-48486, 48492-48496, 48499, 48501, 48503, 48505, 48507-48508, 48512-48513, 48515-48516, 48519, 48521-48525, 48527-48534, 48537-48538, 48541, 48543, 48545, 48547-48549, 48552-48558, 48560-48561, 48563-48565, 48567, 48571-48575, 48577, 48579, 48581, 48583, 48586-48599, 48602-48603, 48605-48610, 48612-48613, 48616-48619, 48621-48624, 48628-48639, 48641-48643, 48648, 48650, 48652-48658, 48660-48662, 48664, 48667, 48669-48672, 48675-48683, 48685-48690, 48692-48693, 48696-48700, 48702, 48708, 48710-48712, 48714, 48720, 48722, 48726-48732, 48736-48737, 48739-48740, 48742-48764, 48767-48768, 48770, 48772, 48774-48779, 48781-48786, 48788-48789, 48792-48798, 48800, 48802-48811, 48813-48816, 48818, 48820, 48829-48832, 48834-48841, 48843-48846, 48848, 48850, 48852, 48854, 48856-48862, 48864-48865, 48868-48871, 48873-48875, 48877-48882, 48884-48885, 48887-48889, 48891, 48893-48897, 48899, 48903-48904, 48908, 48914-48919, 48921, 48928, 48930-48931, 48933, 48935-48938, 48940-48942, 48944, 48946-48948, 48951-48953, 48958-48959, 48966, 48969-48970, 48972, 48974-48975, 48977-48979, 48981, 48987, 48989, 48991-48992, 48997-49004, 49006-49008, 49011-49016, 49018, 49020-49025, 49027-49035, 49038-49041, 49043-49050, 49052, 49054, 49058, 49060, 49064, 49067-49068, 49070-49071, 49073-49081, 49083, 49085-49088, 49090, 49094-49095, 49097-49101, 49105-49106, 49109, 49112-49113, 49115-49116, 49118-49121, 49124-49125, 49128-49130, 49133-49136, 49138, 49140, 49142, 49144-49148, 49151, 49153, 49159-49160, 49162-49164, 49166-49167, 49170-49173, 49176-49177, 49179, 49181, 49183-49185, 49187, 49190, 49193, 49197, 49199, 49201, 49205-49209, 49211, 49213-49222, 49225, 49229-49231, 49233, 49236-49239, 49241, 49245-49247, 49252-49253, 49255, 49257-49266, 49269-49271, 49274, 49279, 49281-49286, 49288, 49291, 49295-49301, 49304-49305, 49307-49314, 49316, 49319, 49321-49322, 49329, 49331-49336, 49338, 49340-49342, 49344-49346, 49349, 49351, 49353-49354, 49356-49360, 49362-49366, 49368-49370, 49372-49374, 49377-49380, 49383-49386, 49389-49395, 49397-49403, 49405-49406, 49408-49409, 49411-49413, 49415-49419, 49421, 49424, 49426-49431, 49433-49434, 49436-49443, 49445-49450, 49452-49461, 49463-49466, 49469-49472, 49476-49478, 49480-49481, 49484-49485, 49488-49489, 49491-49494, 49501, 49503-49504, 49506-49510, 49512-49513, 49515, 49517-49518, 49524-49525, 49527, 49529, 49531-49533, 49535-49536, 49539-49541, 49545-49546, 49549, 49552-49553, 49559-49561, 49563, 49565, 49567-49573, 49575-49577, 49579-49580, 49582-49585, 49587-49588, 49592-49597, 49599-49602, 49604-49610, 49615, 49617-49619, 49622-49623, 49625-49629, 49631, 49633-49634, 49637-49638, 49640, 49642-49646, 49648, 49653, 49658-49660, 49662, 49664-49669, 49674-49675, 49679-49681, 49683, 49686, 49689, 49691, 49693-49700, 49703-49707, 49709-49710, 49713, 49716-49723, 49725-49726, 49728-49729, 49736-49741, 49743-49744, 49746, 49748-49750, 49752, 49754, 49756-49757, 49760, 49762-49763, 49765-49768, 49771-49773, 49775-49780, 49782-49787, 49789-49794, 49796-49798, 49800, 49802-49808, 49811, 49813-49819, 49821, 49823-49824, 49826-49827, 49830-49833, 49836, 49838-49841, 49843, 49845-49849, 49851-49858, 49860-49866, 49868-49878, 49881-49882, 49885, 49887-49888, 49890-49895, 49898, 49901-49902, 49904-49905, 49907, 49910, 49912-49915, 49917, 49919-49931, 49933-49936, 49938, 49941, 49944, 49946, 49948-49949, 49951, 49953, 49955-49961, 49963-49973, 49975, 49978, 49981-49984, 49986, 49988-49989, 49991, 49993, 49999, 50002-50004, 50008, 50015-50020, 50029, 50031-50035, 50037-50040, 50042-50058, 50060-50062, 50064, 50066-50071, 50073-50074, 50079-50080, 50082, 50085, 50087-50094, 50096, 50099-50100, 50103, 50105-50108, 50110-50120, 50123-50124, 50131-50132, 50135, 50138-50140, 50142-50143, 50145, 50147, 50151, 50154-50155, 50157-50161, 50167-50169, 50178-50184, 50186-50189, 50191-50209, 50211, 50213, 50217-50219, 50222-50243, 50246-50247, 50249, 50254-50256, 50258-50259, 50261-50270, 50274, 50278-50279, 50282, 50285, 50287-50290, 50292-50293, 50296-50298, 50300, 50303-50309, 50315-50317, 50319, 50325-50327, 50331-50332, 50334-50338, 50342, 50344-50347, 50352-50353, 50364-50365, 50370, 50372-50374, 50376-50377, 50379, 50381-50383, 50385, 50387-50402, 50409, 50414-50417, 50420-50422, 50424-50425, 50427-50432, 50434, 50436-50440, 50442, 50444, 50446-50451, 50454-50457, 50459, 50461, 50463-50464, 50467-50471, 50473, 50475-50476, 50478, 50481-50483, 50485-50487, 50489-50490, 50492-50496, 50500-50503, 50505-50509, 50511-50512, 50514-50515, 50520-50524, 50526-50533, 50536-50537, 50539-50547, 50549, 50553-50554, 50557, 50559-50561, 50565-50568, 50572, 50574, 50577, 50580-50581, 50585-50586, 50593-50595, 50600-50602, 50607-50608, 50610, 50612-50613, 50615-50616, 50618, 50620-50621, 50623, 50625, 50627, 50629, 50632, 50635-50637, 50639, 50642, 50644-50646, 50648, 50656, 50659, 50662-50664, 50666, 50669, 50671-50672, 50674, 50677, 50680-50682, 50684-50693, 50700-50701, 50704-50706, 50708-50709, 50711, 50713-50716, 50718-50721, 50723, 50725, 50727-50728, 50730, 50733, 50736, 50738-50741, 50743-50746, 50748, 50754, 50759, 50764, 50773-50775, 50778-50786, 50789, 50796, 50798, 50800-50802, 50804, 50807-50813, 50815, 50818, 50820-50821, 50824, 50826, 50828-50829, 50832-50833, 50836, 50839, 50841-50842, 50844-50847, 50849, 50851, 50853, 50855, 50857, 50860, 50862, 50864, 50871-50878, 50880-50885, 50889-50891, 50893, 50896, 50898-50902, 50904-50907, 50909-50910, 50912-50913, 50915-50917, 50919, 50921-50922, 50924-50927, 50930-50932, 50934-50953, 50955-50958, 50960-50963, 50965-50970, 50974, 50976, 50978, 50980-50991, 50993, 50995-50996, 50999-51000, 51005, 51007, 51011, 51013-51016, 51019-51020, 51023, 51025-51027, 51030-51031, 51033-51035, 51037-51046, 51048, 51050-51051, 51053-51063, 51066-51072, 51078-51079, 51081-51086, 51089-51093, 51095-51099, 51101-51102, 51104, 51106-51108, 51110-51114, 51116, 51120, 51122-51131, 51133-51141, 51143-51144, 51147, 51153-51155, 51159-51161, 51163-51164, 51169, 51171, 51173, 51175-51176, 51178, 51181-51184, 51186-51192, 51194, 51196, 51198, 51200, 51204-51207, 51210-51216, 51218, 51223, 51227, 51230-51232, 51234-51236, 51240, 51242-51247, 51251, 51259, 51262-51265, 51268, 51271-51274, 51276-51277, 51279-51280, 51282-51283, 51285-51293, 51295-51296, 51299, 51301-51302, 51304-51309, 51314, 51318-51319, 51321-51323, 51326, 51328-51329, 51333-51338, 51341-51342, 51346-51347, 51349-51352, 51354-51356, 51363, 51365, 51374-51375, 51378-51379, 51381-51382, 51386-51387, 51389-51398, 51400-51409, 51411, 51413, 51416, 51420, 51423, 51427-51428, 51430, 51432, 51437-51439, 51441, 51444-51451, 51453-51454, 51456-51459, 51467-51472, 51475, 51478, 51480-51481, 51486, 51488, 51491, 51494-51496, 51498, 51500, 51508-51510, 51512, 51515, 51518, 51520-51522, 51528-51530, 51533-51535, 51537-51541, 51543-51551, 51555-51556, 51558-51559, 51562-51568, 51570, 51577, 51581, 51583, 51585-51586, 51588, 51590-51593, 51595-51598, 51601, 51603, 51605-51606, 51610-51612, 51616-51617, 51619-51620, 51624, 51628-51630, 51633, 51635-51637, 51639, 51641, 51644, 51646-51649, 51651-51657, 51659-51662, 51665-51669, 51672-51673, 51676-51678, 51680, 51684-51689, 51691, 51694, 51697, 51700-51701, 51703-51706, 51708-51709, 51711, 51713, 51715-51716, 51719, 51721-51725, 51730-51732, 51734, 51736, 51742-51745, 51747-51751, 51753-51754, 51757-51761, 51763, 51766-51770, 51772-51776, 51778-51796, 51798-51800, 51803, 51806-51807, 51809-51816, 51818-51819, 51821, 51823, 51825-51827, 51830, 51832-51834, 51836-51837, 51840-51847, 51849-51850, 51852, 51855, 51859-51862, 51864-51865, 51867-51874, 51879-51882, 51884-51887, 51889-51899, 51901-51907, 51910-51912, 51914-51929, 51932-51935, 51937-51938, 51941, 51943, 51945-51946, 51950, 51954-51959, 51961-51962, 51965, 51967, 51973-51974, 51976, 51979, 51981-51984, 51988, 51991, 51993-51994, 51998-51999, 52002, 52004, 52007-52009, 52011, 52015-52016, 52018-52019, 52021-52023, 52025, 52029, 52031-52032, 52034, 52036, 52038-52039, 52041-52042, 52045-52046, 52051-52052, 52055, 52057, 52060, 52063-52064, 52066-52070, 52076-52080, 52083-52097, 52099-52102, 52104-52106, 52109-52111, 52114-52115, 52117, 52121-52123, 52126-52128, 52134, 52137-52139, 52143, 52146-52154, 52156-52157, 52159, 52161, 52166-52170, 52172-52173, 52175-52182, 52184-52188, 52191, 52195-52200, 52202-52207, 52209-52216, 52218, 52221, 52226-52227, 52229, 52232-52234, 52238-52247, 52251, 52253-52257, 52259-52264, 52266-52267, 52269, 52272, 52276-52277, 52279, 52282-52285, 52287, 52289-52291, 52293-52294, 52296, 52299, 52301-52304, 52306-52308, 52310-52312, 52316-52317, 52319-52324, 52328, 52330-52331, 52334-52336, 52339-52341, 52343, 52348-52350, 52352-52353, 52357-52360, 52362-52364, 52366-52372, 52375-52377, 52379-52380, 52382, 52384, 52388-52391, 52396, 52399, 52407-52408, 52410-52414, 52416-52423, 52425, 52427, 52430-52434, 52437-52438, 52443-52447, 52451-52454, 52456, 52458, 52461-52463, 52465, 52467-52468, 52470, 52472-52482, 52489-52496, 52498-52500, 52502-52503, 52505-52506, 52508, 52511-52512, 52514-52520, 52522, 52524-52525, 52528-52530, 52532, 52535-52538, 52541-52542, 52544, 52549-52550, 52555-52557, 52559-52560, 52562-52564, 52566, 52570, 52573-52574, 52577-52582, 52584-52585, 52588, 52590, 52592-52593, 52595-52596, 52598, 52600-52601, 52604-52606, 52611-52613, 52615-52625, 52628, 52630, 52632, 52635, 52639-52640, 52644, 52646-52648, 52650-52653, 52656-52657, 52659-52660, 52662-52666, 52668, 52670, 52672-52676, 52678-52679, 52681-52683, 52685, 52687-52689, 52691-52694, 52697, 52699, 52701-52703, 52708, 52711-52712, 52714, 52716, 52722-52727, 52729-52735, 52739, 52741-52743, 52745-52746, 52748, 52750-52753, 52755, 52760-52764, 52767, 52770, 52772, 52776, 52779, 52781-52791, 52793-52794, 52796-52802, 52805, 52807-52809, 52814, 52817, 52820-52821, 52824, 52828-52830, 52832, 52838, 52840-52842, 52844, 52850, 52854, 52856-52859, 52861-52866, 52868, 52870-52871, 52878-52883, 52890, 52893, 52895, 52897-52903, 52910-52915, 52918, 52920, 52923-52925, 52930-52931, 52935, 52938-52948, 52950-52951, 52953-52955, 52958-52959, 52961, 52965, 52969, 52971-52972, 52974-52975, 52979-52980, 52983-52989, 52993-52994, 52996, 53000-53001, 53003-53006, 53009, 53011, 53017-53018, 53021, 53023, 53025-53027, 53030-53032, 53034, 53039-53041, 53044, 53046, 53049-53051, 53056, 53058, 53060, 53062-53067, 53069, 53072-53079, 53081, 53088-53090, 53094, 53097, 53102, 53104-53123, 53125-53127, 53129-53137, 53140, 53145-53146, 53152-53154, 53156, 53159, 53162-53165, 53170-53173, 53175, 53177, 53180-53182, 53184-53185, 53187, 53189, 53193-53200, 53202-53206, 53210-53212, 53214-53222, 53225-53226, 53228, 53230-53231, 53234-53236, 53238-53239, 53241, 53243-53247, 53249-53251, 53254, 53257-53260, 53262-53265, 53267, 53269-53271, 53275-53277, 53282-53283, 53285-53287, 53292-53294, 53296, 53300, 53302-53305, 53312-53320, 53324-53325, 53328-53329, 53332-53335, 53337, 53339, 53343-53345, 53347-53349, 53351-53352, 53354-53357, 53359, 53361-53363, 53372, 53374-53377, 53383-53387, 53389, 53391, 53393, 53396, 53399, 53401-53407, 53409, 53411, 53413-53418, 53420-53423, 53426, 53428, 53431-53432, 53436-53437, 53441, 53450-53451, 53455, 53458, 53460, 53464-53468, 53472-53475, 53477, 53481-53482, 53485-53486, 53491, 53494-53497, 53500-53502, 53504, 53508, 53511, 53517, 53520-53527, 53529-53531, 53534-53535, 53537, 53540, 53542, 53550-53551, 53553, 53557-53558, 53560-53565, 53569-53574, 53578-53579, 53585, 53587-53588, 53594-53597, 53603, 53605, 53614, 53616, 53619-53621, 53623-53626, 53629-53630, 53632, 53635-53647, 53649-53654, 53656-53673, 53675-53680, 53683-53690, 53692-53697, 53700-53701, 53706, 53708-53712, 53714-53715, 53717-53718, 53720-53722, 53724, 53729, 53731-53733, 53736, 53738-53739, 53741-53745, 53747, 53751, 53753-53754, 53756, 53763, 53767, 53771-53774, 53776, 53779-53780, 53782-53784, 53786-53790, 53800, 53805, 53812-53815, 53817-53820, 53822, 53824-53826, 53828-53830, 53832-53833, 53836, 53839-53840, 53842, 53844-53850, 53852-53853, 53855-53857, 53859-53861, 53863-53864, 53868-53872, 53875-53876, 53878, 53880, 53882-53885, 53889-53891, 53893-53895, 53897, 53900, 53903-53906, 53908, 53913-53914, 53916-53920, 53922, 53924-53929, 53934-53945, 53947-53950, 53952, 53955-53957, 53959-53960, 53962-53963, 53965, 53967, 53970-53971, 53973-53975, 53979-53980, 53982, 53984-53988, 53990-53991, 53993, 53995-53997, 54002, 54004-54005, 54007-54011, 54013-54014, 54016, 54020, 54022-54023, 54026-54027, 54030-54031, 54033-54034, 54036-54037, 54040-54041, 54043-54046, 54052-54053, 54055-54056, 54058, 54060, 54062, 54064-54067, 54074, 54076, 54079, 54082-54084, 54088-54090, 54095-54096, 54098-54099, 54102, 54105-54109, 54111-54119, 54121-54126, 54129, 54131-54132, 54134-54137, 54140-54141, 54144, 54148-54149, 54151, 54154-54155, 54160-54162, 54164, 54168-54169, 54171, 54173, 54175-54176, 54180-54182, 54188-54189, 54191-54193, 54195-54200, 54204-54208, 54210, 54212, 54214-54218, 54220-54222, 54224-54225, 54228-54230, 54232, 54234, 54236-54242, 54244-54249, 54252, 54254, 54256, 54259-54260, 54262-54265, 54267, 54273, 54275-54278, 54280-54281, 54283, 54285, 54287, 54289-54293, 54295-54296, 54298-54299, 54301, 54303, 54305, 54309-54313, 54315, 54317-54321, 54323-54325, 54327-54331, 54333, 54337-54338, 54341, 54343-54349, 54353, 54359, 54361-54362, 54364, 54366, 54368, 54371, 54373-54374, 54376, 54379, 54381, 54384-54386, 54388, 54392-54395, 54397-54402, 54405-54409, 54411-54415, 54417-54420, 54422-54423, 54427, 54431, 54433-54442, 54446, 54448-54449, 54451-54455, 54458, 54461, 54463-54464, 54466, 54468-54472, 54474-54475, 54477-54485, 54489-54493, 54495-54496, 54498, 54504, 54506-54510, 54512, 54514-54523, 54526-54530, 54532, 54534-54536, 54538, 54540, 54544-54548, 54554-54556, 54558-54559, 54561, 54563-54566, 54572, 54575-54576, 54581, 54585-54587, 54589-54592, 54595-54596, 54598-54601, 54603-54607, 54609-54611, 54613-54615, 54617-54622, 54624, 54626-54630, 54633-54637, 54642-54643, 54645-54649, 54651-54652, 54654, 54656-54662, 54664-54673, 54676-54678, 54681, 54683-54688, 54690, 54692-54694, 54698-54701, 54703-54712, 54714-54715, 54718-54719, 54721-54728, 54732-54736, 54738, 54741, 54745, 54747-54748, 54750-54751, 54753-54755, 54758-54760, 54762-54763, 54765-54766, 54770-54772, 54774-54785, 54787, 54796-54798, 54800, 54806, 54808-54809, 54811-54812, 54814, 54816, 54818, 54821, 54823-54824, 54828-54829, 54831, 54834-54836, 54838-54841, 54845, 54849, 54853-54856, 54858-54862, 54864-54865, 54868-54872, 54874-54875, 54877-54878, 54881, 54883-54885, 54887, 54889, 54891, 54893, 54897, 54899-54902, 54905-54912, 54914-54915, 54917, 54920-54921, 54925-54929, 54931-54932, 54936-54940, 54942, 54944, 54946-54948, 54950, 54953-54960, 54962-54969, 54972, 54974, 54976-54993, 54995-55001, 55003-55005, 55007-55008, 55010-55011, 55014, 55017, 55019, 55022-55025, 55027-55030, 55032-55034, 55037, 55039, 55045-55048, 55050-55053, 55057-55060, 55062-55064, 55067-55069, 55072, 55074-55075, 55077-55080, 55083-55084, 55086-55090, 55092-55094, 55096-55098, 55100-55102, 55105, 55107, 55111-55112, 55114, 55116-55121, 55123-55124, 55128, 55130-55134, 55136, 55138, 55140, 55142-55149, 55151-55152, 55156-55162, 55164, 55168-55174, 55176-55178, 55180-55182, 55186-55195, 55197-55202, 55204-55206, 55210-55211, 55213-55215, 55218-55223, 55225, 55228-55231, 55233-55236, 55238-55243, 55247, 55249-55253, 55256-55257, 55259-55266, 55269-55272, 55274-55276, 55280, 55283, 55286-55288, 55291, 55293-55296, 55299, 55301, 55303-55306, 55308-55312, 55316-55320, 55322-55327, 55329-55337, 55339, 55341, 55343-55348, 55350-55351, 55354-55367, 55369, 55371, 55373-55374, 55376, 55378, 55381-55388, 55390-55398, 55400-55402, 55404-55406, 55409, 55411-55412, 55415-55418, 55421, 55425, 55427-55429, 55431-55433, 55435-55436, 55438, 55447, 55450, 55458-55466, 55468-55469, 55473, 55476, 55478, 55480, 55482-55487, 55491-55492, 55494, 55497, 55499, 55502-55503, 55506-55507, 55510, 55513-55515, 55517, 55519-55520, 55522-55524, 55526, 55528, 55530-55533, 55537, 55541-55543, 55545-55546, 55548, 55551-55558, 55560-55566, 55570-55571, 55573-55575, 55578, 55580-55582, 55584-55587, 55590-55598, 55603-55605, 55610-55611, 55613-55617, 55619, 55621, 55623-55624, 55626-55628, 55631, 55633-55637, 55640-55641, 55643-55644, 55646, 55653-55655, 55658, 55660-55661, 55664-55667, 55669, 55671-55676, 55679-55685, 55687, 55691, 55693, 55696, 55699, 55702-55708, 55710-55719, 55721, 55727-55729, 55731-55732, 55737-55738, 55740-55741, 55745, 55747-55748, 55750-55751, 55753, 55757-55759, 55761, 55763, 55765-55769, 55773-55775, 55777-55778, 55780-55784, 55786-55795, 55798-55801, 55803, 55806-55809, 55811-55815, 55817, 55819-55828, 55830-55833, 55835-55840, 55843-55844, 55846-55848, 55852-55859, 55861-55868, 55870-55871, 55873, 55875-55877, 55879-55881, 55883, 55887, 55892-55893, 55895, 55898-55903, 55905, 55909-55915, 55922, 55924, 55926, 55934, 55939-55944, 55952, 55954-55956, 55958-55961, 55963-55964, 55967, 55970-55975, 55979-55986, 55988-55991, 55998, 56000-56002, 56007-56009, 56015, 56018, 56022-56026, 56028-56029, 56031-56036, 56038, 56040, 56042-56044, 56047, 56050-56053, 56055-56056, 56058-56059, 56061-56066, 56068, 56071, 56073-56078, 56080, 56084, 56089, 56091-56092, 56096-56097, 56104-56111, 56113, 56116, 56120, 56123-56124, 56126, 56128, 56130, 56132, 56136, 56138-56139, 56144-56148, 56150-56155, 56158, 56160-56164, 56167, 56170, 56176, 56178-56179, 56186-56187, 56189, 56192, 56195-56196, 56198-56199, 56201-56203, 56212, 56215-56218, 56220-56221, 56223-56227, 56232, 56234-56235, 56237, 56239, 56241, 56244, 56247-56250, 56253-56259, 56262, 56264-56268, 56270-56272, 56274-56275, 56277-56280, 56282-56284, 56286, 56288-56290, 56292-56296, 56298, 56306-56311, 56313-56314, 56321-56324, 56326-56327, 56329, 56332, 56334-56338, 56340-56341, 56343-56348, 56350, 56352-56356, 56358-56359, 56363-56366, 56372, 56380-56381, 56384, 56386-56393, 56395-56401, 56403, 56405-56406, 56413, 56415-56416, 56425-56426, 56428-56430, 56432, 56435-56438, 56440-56445, 56447-56449, 56451, 56457, 56459-56461, 56465-56469, 56471-56476, 56478, 56481-56482, 56484-56487, 56490-56495, 56500-56501, 56504-56513, 56515-56516, 56521, 56526-56528, 56530-56532, 56534, 56536-56544, 56548-56550, 56553-56555, 56557-56561, 56564-56568, 56570, 56572, 56574, 56576, 56578-56579, 56582, 56585-56588, 56590, 56592, 56594, 56597-56601, 56603-56606, 56608-56609, 56611-56613, 56616-56619, 56621, 56623-56627, 56629, 56631-56633, 56635, 56642, 56645, 56647, 56650, 56652-56654, 56657-56660, 56662, 56664-56671, 56673-56675, 56679, 56681-56688, 56691, 56693, 56696, 56698-56699, 56701-56704, 56707, 56710, 56712-56715, 56717-56718, 56720, 56722, 56727-56729, 56731-56732, 56734-56735, 56737-56741, 56743-56744, 56746-56755, 56757-56761, 56766-56768, 56773-56780, 56793, 56795-56799, 56805-56806, 56808, 56811, 56813-56814, 56820-56826, 56836, 56841-56847, 56849, 56851, 56853-56857, 56859-56861, 56864, 56866-56868, 56870-56871, 56874-56879, 56881, 56883-56890, 56892-56894, 56896, 56899, 56901, 56903-56904, 56906-56907, 56910-56914, 56917, 56920-56923, 56925-56926, 56929-56930, 56932-56933, 56935-56937, 56939-56940, 56942-56943, 56945-56946, 56951-56952, 56955-56959, 56961, 56963-56964, 56966, 56970, 56972-56973, 56975-56979, 56981-56982, 56984-56985, 56987-56992, 56994, 56997, 56999, 57001, 57004-57009, 57011-57013, 57015-57020, 57022, 57029-57032, 57034-57037, 57039-57040, 57043-57044, 57046-57049, 57051-57053, 57055-57056, 57058-57060, 57062-57069, 57071-57074, 57076-57078, 57080-57081, 57085-57086, 57090, 57093, 57095-57099, 57101-57108, 57110, 57112-57119, 57121-57122, 57124-57125, 57131, 57133-57137, 57140-57141, 57143-57145, 57147-57149, 57151-57158, 57160-57161, 57164-57168, 57172, 57177, 57180-57184, 57186-57187, 57190-57192, 57196-57197, 57200, 57202-57203, 57205-57206, 57210-57213, 57219, 57221, 57225, 57227, 57229-57236, 57238, 57240-57242, 57244-57246, 57248, 57251-57253, 57255-57256, 57258, 57260, 57263-57264, 57266-57267, 57269, 57271, 57273-57275, 57277, 57281-57282, 57284-57285, 57292-57296, 57298-57299, 57301-57305, 57309, 57312-57313, 57316-57324, 57326-57327, 57329-57334, 57338, 57340, 57342, 57344-57349, 57351-57353, 57358, 57366-57370, 57372-57376, 57378-57381, 57383, 57389-57392, 57394-57396, 57398-57406, 57409-57411, 57413-57414, 57418, 57423-57424, 57426-57433, 57435-57438, 57444, 57447-57449, 57454, 57456, 57458-57461, 57463, 57465, 57467-57469, 57471, 57474-57475, 57480, 57484-57489, 57495-57496, 57498-57499, 57503-57504, 57507-57509, 57514, 57518-57519, 57521, 57524-57527, 57529-57534, 57536, 57538, 57540, 57542-57545, 57550-57554, 57556-57559, 57562-57568, 57571-57578, 57580-57587, 57589, 57594-57595, 57597-57599, 57601, 57605, 57608, 57613, 57616, 57618-57619, 57621-57631, 57636, 57638-57641, 57643-57644, 57648-57649, 57651-57655, 57657, 57659-57661, 57663-57666, 57668-57671, 57673-57676, 57679-57683, 57685-57686, 57689-57694, 57697, 57699-57706, 57708, 57710, 57712, 57715-57720, 57722-57723, 57725, 57727-57731, 57739-57741, 57743-57747, 57749-57761, 57763, 57766-57769, 57771, 57773, 57775-57778, 57780-57781, 57783-57785, 57787-57790, 57792, 57795-57796, 57798-57802, 57805-57806, 57808, 57811, 57813, 57815-57817, 57819-57822, 57824-57826, 57828, 57833, 57835, 57840-57846, 57849, 57854-57855, 57860, 57862-57863, 57865-57866, 57870-57872, 57875, 57877, 57884-57885, 57887, 57891, 57894, 57898, 57901-57904, 57906-57909, 57911-57919, 57921-57922, 57926, 57929-57931, 57935, 57937, 57939, 57945-57946, 57948, 57951, 57953-57954, 57958, 57960, 57962-57968, 57970, 57972-57974, 57976-57978, 57980, 57982, 57987-57989, 57991-57994, 57996-58004, 58006, 58009-58011, 58013-58014, 58016-58017, 58019, 58025, 58029-58031, 58033-58035, 58037, 58039, 58043, 58046-58047, 58050, 58052, 58054, 58056-58057, 58060, 58062-58066, 58069, 58071, 58073, 58075, 58080-58084, 58086-58088, 58092-58093, 58096, 58098-58099, 58101-58102, 58106, 58108-58120, 58122-58124, 58126-58132, 58134-58135, 58137, 58140, 58142, 58145, 58149, 58151-58152, 58154, 58159, 58161-58162, 58165, 58167-58171, 58178-58179, 58182, 58188-58190, 58192-58193, 58195, 58197-58200, 58204-58205, 58207, 58209-58210, 58216-58218, 58220, 58223, 58225-58226, 58229-58231, 58239, 58242, 58244, 58246-58250, 58254, 58259-58266, 58270, 58272, 58274-58275, 58280, 58282-58283, 58285, 58288-58289, 58291, 58293-58295, 58297, 58299, 58301, 58303, 58305-58309, 58317-58319, 58321, 58324-58325, 58327, 58331, 58333-58334, 58340-58342, 58344, 58346-58352, 58355, 58357-58358, 58360, 58365, 58367, 58376-58377, 58379-58380, 58382, 58388, 58392, 58399-58402, 58404, 58406-58415, 58418-58419, 58422, 58427, 58430-58431, 58433, 58439-58440, 58442, 58444-58448, 58450-58453, 58455, 58457, 58459-58462, 58464-58467, 58469, 58471-58476, 58478-58480, 58484-58486, 58488, 58490, 58493-58498, 58500, 58503-58505, 58508, 58510, 58512-58514, 58519-58527, 58535-58536, 58539-58542, 58544-58548, 58550, 58553-58554, 58556-58557, 58561, 58563-58564, 58568-58569, 58571-58574, 58577-58596, 58599-58601, 58604, 58606-58613, 58615-58616, 58619, 58621-58627, 58629, 58632, 58634, 58637-58640, 58643, 58649, 58651, 58654-58659, 58662-58668, 58670-58674, 58676-58677, 58679-58685, 58689-58690, 58692, 58694-58700, 58705, 58708-58710, 58713, 58719-58720, 58722, 58724, 58727-58728, 58731-58733, 58736-58739, 58742-58746, 58748, 58750-58753, 58755-58757, 58759-58761, 58763-58764, 58767-58769, 58771, 58773-58776, 58778-58779, 58781, 58783, 58785-58788, 58793, 58797-58798, 58800, 58802-58804, 58807-58809, 58814-58815, 58817-58818, 58820, 58825, 58829, 58831-58832, 58835-58836, 58838, 58840, 58842-58846, 58849-58850, 58852-58853, 58857-58859, 58863, 58865-58866, 58869-58872, 58875-58877, 58879-58881, 58884, 58888-58889, 58892, 58894-58896, 58898-58899, 58902, 58904-58910, 58912-58917, 58923, 58926-58927, 58929-58933, 58935, 58937, 58939, 58941-58944, 58947, 58951, 58953, 58955, 58957, 58960-58969, 58971, 58973-58974, 58976, 58978, 58981-58989, 58998-58999, 59001, 59003, 59005-59006, 59008-59013, 59016, 59018-59019, 59025-59030, 59033, 59036-59038, 59041-59051, 59053-59054, 59056, 59058-59063, 59067, 59069, 59071-59072, 59074-59075, 59077-59081, 59083-59086, 59088, 59090-59092, 59094, 59096, 59098-59102, 59106, 59109-59110, 59113, 59115, 59117-59118, 59121, 59127, 59135, 59137, 59139, 59141-59142, 59144-59147, 59149, 59152-59153, 59157-59159, 59164, 59169-59171, 59173-59177, 59179, 59182, 59185-59186, 59188-59193, 59195, 59197-59203, 59206-59207, 59209-59219, 59221-59222, 59224, 59227, 59230-59233, 59238, 59241-59242, 59246-59247, 59249-59251, 59253-59254, 59259-59260, 59263-59264, 59277, 59285, 59287-59288, 59290-59292, 59295-59296, 59304-59306, 59312, 59318-59319, 59321-59325, 59327, 59329, 59331, 59335-59337, 59339, 59344, 59350-59351, 59355-59357, 59359-59362, 59365-59366, 59369, 59371-59377, 59385-59386, 59391-59395, 59399, 59402-59405, 59407-59408, 59410, 59416-59419, 59422-59424, 59426, 59428, 59432-59433, 59435-59438, 59443-59444, 59449, 59451-59452, 59454, 59458, 59460-59462, 59464-59466, 59468-59469, 59471-59472, 59474-59475, 59478-59480, 59482-59485, 59487, 59490-59492, 59494-59497, 59500-59512, 59515, 59518-59520, 59522-59528, 59532-59535, 59538, 59540, 59542-59556, 59558-59565, 59570-59573, 59577-59579, 59581, 59583-59584, 59586-59587, 59589, 59591-59592, 59594-59595, 59597-59598, 59600-59602, 59604-59607, 59609-59611, 59613, 59615, 59617-59618, 59620-59622, 59624, 59626-59630, 59632, 59634, 59636-59639, 59641, 59643-59644, 59646, 59648, 59651, 59654-59657, 59661, 59663-59667, 59670, 59673-59675, 59677-59684, 59687-59690, 59692-59697, 59699, 59701-59702, 59704-59705, 59707-59708, 59711-59715, 59717-59720, 59725-59726, 59729-59730, 59733-59737, 59740-59742, 59745-59746, 59748-59749, 59751-59754, 59758, 59760-59766, 59769-59770, 59772-59775, 59778-59780, 59783-59785, 59787-59788, 59792, 59797-59798, 59800, 59802-59812, 59814, 59816, 59818, 59821-59824, 59827-59831, 59834-59838, 59843, 59845, 59847-59848, 59850-59854, 59856, 59858-59859, 59866, 59872-59873, 59875, 59877-59881, 59887, 59891-59895, 59900, 59904-59906, 59908-59914, 59917-59918, 59922-59926, 59929-59933, 59937-59938, 59941, 59945, 59947-59948, 59951-59953, 59957-59958, 59961, 59963-59965, 59968-59972, 59974, 59976-59977, 59979, 59981, 59983-59985, 59987-59990, 59993, 59995-59996, 59999, 60002, 60004, 60006-60009, 60013, 60016-60018, 60021-60022, 60024, 60026, 60029, 60031-60032, 60034, 60037, 60040-60041, 60043-60044, 60047, 60049-60050, 60052-60055, 60058-60059, 60061-60063, 60065, 60067, 60069-60071, 60073, 60075-60076, 60078-60079, 60081, 60087-60089, 60092, 60096-60098, 60100, 60102-60104, 60106-60115, 60118, 60120, 60123-60124, 60126-60127, 60129-60131, 60133-60137, 60140-60144, 60146-60151, 60153, 60157, 60162, 60166, 60168-60169, 60173-60174, 60176-60177, 60179, 60181-60190, 60197-60201, 60206, 60213-60217, 60219, 60222-60224, 60227, 60229-60230, 60233-60238, 60243-60244, 60246, 60248, 60252, 60254-60261, 60263, 60265-60267, 60269-60270, 60276-60288, 60291, 60296, 60301, 60305-60306, 60310, 60314-60318, 60320, 60322, 60328, 60331, 60335, 60337, 60339-60345, 60347-60352, 60354-60367, 60370, 60375-60377, 60379-60383, 60385-60387, 60389-60391, 60395, 60397-60401, 60412, 60414, 60416-60417, 60420-60422, 60424, 60426-60430, 60432, 60435-60439, 60442, 60445-60449, 60451, 60453, 60455-60456, 60460-60463, 60468-60470, 60474, 60476-60478, 60482-60485, 60487, 60489, 60493-60497, 60499-60503, 60505-60506, 60508, 60510-60511, 60514-60515, 60520-60521, 60524, 60529-60533, 60535-60536, 60540-60544, 60548-60549, 60552-60554, 60556-60558, 60560-60561, 60563, 60566, 60569, 60572, 60579, 60582, 60589-60593, 60595-60602, 60604-60613, 60615, 60617-60621, 60623, 60625-60626, 60628-60629, 60633, 60636, 60638-60645, 60651, 60653, 60655-60656, 60658-60659, 60661-60664, 60666-60668, 60670, 60672-60680, 60683-60684, 60686-60693, 60695, 60699, 60701, 60703, 60705-60706, 60709-60710, 60712-60713, 60715, 60717, 60719, 60721-60722, 60724-60731, 60733-60735, 60738-60739, 60741, 60743-60746, 60750-60751, 60755-60756, 60758-60763, 60765, 60773-60777, 60779, 60781-60782, 60786-60796, 60799, 60801, 60803, 60805, 60807-60809, 60811-60819, 60821, 60826-60828, 60831-60832, 60835-60836, 60840-60844, 60846, 60848-60850, 60853, 60855-60857, 60861-60864, 60868-60876, 60878-60879, 60881, 60883-60886, 60888, 60892-60894, 60896-60898, 60902-60906, 60908-60910, 60912, 60914, 60916-60917, 60921-60924, 60926-60927, 60930-60934, 60936-60938, 60940-60941, 60943-60944, 60946-60950, 60952-60953, 60955-60957, 60959-60967, 60972, 60976, 60978-60979, 60981-60982, 60984, 60986-60987, 60991-60995, 60998-61002, 61004-61008, 61010-61012, 61015, 61018-61019, 61022-61024, 61026-61043, 61047-61049, 61051-61055, 61057-61058, 61060, 61062-61066, 61068-61075, 61077, 61080-61082, 61084, 61088, 61090-61095, 61097, 61099-61104, 61112, 61114-61116, 61118-61126, 61129, 61131-61139, 61142-61143, 61145-61149, 61154, 61157-61159, 61161, 61163-61166, 61168, 61173-61176, 61178, 61182, 61186, 61188-61191, 61196-61198, 61200, 61203-61211, 61213-61214, 61216-61218, 61220-61222, 61224, 61226-61228, 61231, 61234-61238, 61240, 61244-61249, 61251, 61253-61254, 61256-61259, 61262-61263, 61265, 61270, 61272-61276, 61280, 61284-61285, 61287-61292, 61294, 61296-61298, 61300, 61302-61309, 61312, 61314-61315, 61323, 61326-61329, 61331-61332, 61334-61337, 61341, 61343, 61345, 61348-61349, 61351-61353, 61355, 61358, 61360-61361, 61364, 61366, 61369-61371, 61373-61375, 61377-61378, 61382-61384, 61386-61390, 61392-61393, 61395, 61399-61400, 61402, 61404-61405, 61408-61409, 61411, 61413, 61415-61420, 61424, 61426, 61430, 61432, 61436-61443, 61445, 61450, 61458-61460, 61462, 61469, 61472-61474, 61476-61477, 61479, 61485-61490, 61496, 61500-61506, 61509-61512, 61514, 61516-61518, 61521-61522, 61526-61528, 61530-61532, 61534-61535, 61537-61540, 61542-61549, 61551-61552, 61555, 61557, 61559-61561, 61563-61564, 61573-61580, 61582, 61584-61592, 61594, 61599, 61605-61607, 61609-61622, 61624-61627, 61631, 61633, 61637, 61640, 61642, 61648-61649, 61653-61659, 61663, 61666-61669, 61671, 61673-61682, 61685-61688, 61690-61694, 61696-61717, 61719-61747, 61749-61751, 61754-61756, 61759, 61761-61763, 61765, 61770-61775, 61777-61780, 61785-61789, 61791, 61793, 61797-61798, 61800, 61803, 61805, 61811-61815, 61817-61819, 61823-61824, 61827-61829, 61836, 61840-61847, 61850, 61853, 61855, 61857-61866, 61869-61874, 61876, 61879-61888, 61890, 61892, 61898, 61903-61906, 61909, 61912, 61914, 61917-61921, 61924-61927, 61929-61932, 61934-61936, 61940-61941, 61945, 61947-61954, 61956-61967, 61969-61971, 61974-61977, 61979-61980, 61985, 61989-61990, 61993-61999, 62003-62006, 62008, 62010-62015, 62017-62018, 62022-62023, 62028-62029, 62031-62034, 62036-62038, 62041, 62043-62045, 62053-62054, 62056, 62058-62060, 62062-62073, 62075, 62077-62081, 62084, 62086-62091, 62093, 62095-62101, 62103-62111, 62113, 62115-62123, 62126-62127, 62132-62134, 62136, 62139-62140, 62142-62146, 62149-62152, 62154-62160, 62162-62166, 62168, 62170, 62172-62178, 62180-62181, 62186-62187, 62189, 62191, 62193, 62201-62209, 62211-62215, 62218-62220, 62222-62230, 62236, 62238-62242, 62244-62251, 62255, 62257, 62259, 62263-62264, 62266-62271, 62273-62275, 62277-62279, 62281, 62284-62289, 62291-62293, 62295-62298, 62300-62302, 62306-62307, 62309-62310, 62312-62313, 62315-62317, 62319-62324, 62327, 62329-62331, 62333, 62335, 62338, 62342-62345, 62351, 62353-62356, 62359, 62361-62365, 62369-62371, 62373-62374, 62376-62385, 62388, 62390, 62393, 62395-62397, 62399, 62401-62402, 62405, 62407-62408, 62415, 62423-62424, 62426-62437, 62439, 62443, 62447, 62451, 62453-62454, 62456-62457, 62460, 62462-62465, 62467-62468, 62471-62474, 62478, 62480, 62483-62484, 62489-62492, 62494, 62496-62498, 62501, 62504-62505, 62508-62509, 62511-62512, 62514, 62516, 62518-62519, 62522-62526, 62529-62534, 62536-62540, 62542, 62546-62547, 62549, 62553-62555, 62557-62561, 62563-62567, 62570, 62574, 62576-62584, 62586-62593, 62595, 62598-62607, 62609-62610, 62612-62621, 62623, 62627-62628, 62630, 62632, 62635-62636, 62638, 62640, 62643, 62645, 62647-62649, 62651-62654, 62656-62657, 62659, 62661, 62663-62667, 62670-62672, 62674-62677, 62679-62680, 62684-62689, 62696, 62698-62699, 62702-62708, 62710, 62714-62717, 62724, 62730-62734, 62736, 62745-62747, 62749, 62752-62753, 62755, 62757-62762, 62765-62770, 62773-62779, 62784-62785, 62787-62788, 62790-62792, 62795, 62797, 62800, 62803, 62806-62813, 62815, 62817, 62819, 62821, 62823, 62826-62831, 62839, 62848-62850, 62852-62853, 62855, 62857-62864, 62867-62868, 62870, 62872-62875, 62880, 62882, 62885-62886, 62888, 62890, 62894-62896, 62898-62902, 62904, 62907, 62909, 62911, 62917-62921, 62924-62925, 62927-62931, 62933-62936, 62938, 62941-62942, 62945-62946, 62949, 62951, 62953-62962, 62965, 62967, 62970, 62975-62976, 62979, 62981, 62984-62991, 62994, 62996-62997, 63002-63006, 63008-63013, 63016-63017, 63019, 63021-63026, 63028-63029, 63031, 63035-63039, 63043-63047, 63049-63051, 63053-63058, 63063-63064, 63066, 63073, 63075-63082, 63084-63087, 63089-63091, 63093, 63095, 63098, 63101-63108, 63110, 63112-63115, 63119, 63122, 63124, 63126-63129, 63131, 63133, 63136-63140, 63143, 63145-63149, 63151-63152, 63154, 63156, 63158-63159, 63161, 63163-63165, 63169-63172, 63174, 63176-63177, 63180-63181, 63185-63187, 63190-63192, 63195, 63198, 63200-63201, 63204-63208, 63213-63216, 63221, 63225-63227, 63229, 63231, 63236-63237, 63239-63240, 63242-63243, 63245, 63248, 63251-63254, 63258-63259, 63263-63267, 63269, 63273, 63275, 63277, 63280-63283, 63293, 63295-63299, 63301, 63303, 63311-63313, 63316-63317, 63319, 63327, 63329, 63333-63334, 63336, 63338, 63341-63346, 63351-63355, 63357-63358, 63360, 63363-63365, 63367, 63370-63372, 63375-63376, 63378, 63380-63381, 63383-63384, 63386, 63388, 63390-63397, 63400-63402, 63404-63406, 63408, 63410-63413, 63415-63416, 63420-63421, 63423-63424, 63428-63429, 63431, 63434-63443, 63446-63447, 63450-63451, 63458, 63461-63462, 63465-63471, 63473-63474, 63476, 63479-63487, 63489, 63491-63493, 63495, 63498-63503, 63505-63507, 63510-63512, 63514-63515, 63517, 63520-63522, 63525, 63528, 63532, 63538-63544, 63547, 63549-63550, 63553-63555, 63557, 63559-63561, 63563, 63565, 63569-63575, 63577-63578, 63580, 63583-63584, 63586, 63589-63590, 63594, 63597, 63600, 63602-63607, 63611-63612, 63614-63615, 63617-63618, 63620, 63622-63625, 63627-63628, 63631-63634, 63636, 63639-63640, 63642-63647, 63649, 63652-63654, 63660, 63666-63667, 63669-63674, 63679-63681, 63683-63689, 63691, 63693-63696, 63699-63704, 63706-63709, 63711-63716, 63719, 63721-63726, 63729-63731, 63734, 63736-63738, 63742-63743, 63745-63749, 63752, 63754, 63758, 63760-63762, 63765, 63769, 63771, 63776, 63779-63781, 63783-63784, 63790-63791, 63793-63798, 63801, 63803-63808, 63810, 63813, 63816-63817, 63819-63820, 63822-63823, 63825, 63827-63829, 63831-63832, 63834-63837, 63840-63842, 63844, 63855, 63858-63865, 63869-63873, 63876-63880, 63882-63884, 63887-63888, 63890-63891, 63894-63895, 63898, 63900-63906, 63908, 63918-63919, 63921-63927, 63930-63935, 63938-63941, 63947-63950, 63953-63955, 63957, 63960-63964, 63967-63971, 63973, 63975, 63977, 63981-63987, 63995, 64000, 64002-64003, 64005, 64008, 64010, 64017, 64019, 64021-64029, 64032-64033, 64035, 64037-64038, 64040, 64042-64048, 64052-64054, 64057-64061, 64065-64068, 64070, 64072-64075, 64080-64083, 64085-64086, 64088-64089, 64092, 64094, 64096-64099, 64101-64103, 64111, 64113, 64115, 64117, 64120-64121, 64123-64126, 64129, 64133, 64136-64138, 64140-64145, 64147-64150, 64152, 64154, 64157-64159, 64162, 64164-64171, 64173-64176, 64178-64181, 64186-64187, 64189-64190, 64193-64198, 64202, 64205-64209, 64211, 64217-64219, 64222-64223, 64225, 64227-64231, 64235, 64237-64241, 64243-64249, 64252-64255, 64260, 64262, 64264-64273, 64278-64281, 64284-64288, 64290, 64293, 64295-64297, 64299-64302, 64304-64305, 64307-64310, 64312-64314, 64318, 64321, 64328-64329, 64331-64332, 64337-64339, 64341-64342, 64344, 64346, 64348, 64350, 64352, 64355, 64358, 64361-64362, 64364, 64366, 64369-64371, 64374, 64376, 64379-64380, 64382-64384, 64386-64387, 64389-64390, 64392, 64394-64396, 64399-64400, 64404-64406, 64409-64411, 64414-64418, 64423-64425, 64427, 64431, 64434-64436, 64438, 64441-64442, 64444, 64446-64448, 64450-64453, 64455-64459, 64462-64463, 64465, 64471-64478, 64483-64484, 64486-64488, 64491-64492, 64494-64497, 64499-64502, 64505, 64507, 64510, 64512, 64516-64519, 64521-64525, 64527, 64535-64539, 64543, 64548-64551, 64555-64558, 64561-64562, 64565, 64570, 64572-64573, 64579, 64581-64583, 64587-64588, 64590, 64594, 64596-64597, 64599, 64602-64604, 64606, 64608, 64611, 64614-64616, 64618, 64624-64628, 64631-64632, 64634-64639, 64645-64653, 64655-64656, 64658-64659, 64661-64662, 64664, 64667, 64669, 64671-64675, 64677-64680, 64683-64684, 64686, 64688-64690, 64693, 64695-64696, 64698, 64701-64702, 64704-64705, 64708, 64717, 64719, 64722-64725, 64727-64728, 64737-64738, 64740-64744, 64749, 64751, 64754-64755, 64757, 64760-64762, 64766, 64768-64774, 64778-64779, 64781-64782, 64786, 64788, 64790-64791, 64794, 64796, 64802, 64807-64809, 64814-64815, 64817, 64819-64823, 64825-64836, 64838, 64840-64844, 64851-64853, 64857-64860, 64862, 64865, 64869, 64871-64873, 64875, 64881-64883, 64885-64886, 64888-64890, 64892-64893, 64895-64898, 64900-64908, 64911-64913, 64916-64919, 64922-64923, 64925-64927, 64929, 64931-64932, 64935-64936, 64938-64939, 64942, 64944-64947, 64949, 64951, 64954-64955, 64960, 64962-64965, 64969-64970, 64972-64973, 64975, 64978, 64983-64984, 64988-64990, 64993, 64997, 64999, 65001, 65004-65005, 65008, 65010, 65013, 65015-65016, 65019, 65021-65024, 65026-65029, 65031-65033, 65035-65037, 65039, 65042-65045, 65048, 65050, 65055-65060, 65062, 65064-65070, 65072-65076, 65078-65080, 65082-65083, 65085-65090, 65092, 65097, 65099, 65101-65102, 65104-65105, 65107-65112, 65115, 65118, 65120, 65122, 65124, 65127, 65133, 65136-65137, 65140, 65144, 65146-65147, 65149-65152, 65155-65157, 65159, 65161-65165, 65167, 65170, 65173, 65175, 65177-65180, 65182-65185, 65187-65195, 65198-65206, 65208-65209, 65211-65214, 65217-65218, 65221-65222, 65225, 65234, 65241-65244, 65246, 65249-65250, 65252-65253, 65255-65256, 65259, 65267, 65269-65271, 65274, 65277-65279, 65282-65283, 65289-65292, 65298-65299, 65301-65312, 65314-65316, 65321, 65323, 65325, 65327, 65331, 65333, 65335, 65337-65343, 65346-65347, 65350-65351, 65353-65354, 65356-65357, 65366, 65368, 65370, 65375, 65377, 65382-65383, 65386, 65391-65398, 65400, 65402-65404, 65406, 65408-65410, 65412, 65414-65420, 65431-65435, 65437, 65440, 65443-65445, 65451-65456, 65460, 65462-65464, 65466, 65469-65470, 65472, 65474, 65476, 65478-65480, 65483-65489, 65491-65492, 65494-65495, 65498, 65501-65509, 65511-65512, 65514, 65516, 65518, 65520-65521, 65523, 65525-65526, 65530, 65532-65533, 65540, 65543-65546, 65548, 65554-65557, 65559, 65562-65567, 65570-65571, 65577-65579, 65581-65583, 65585-65587, 65590-65598, 65600-65602, 65605-65606, 65608, 65610, 65614, 65617-65618, 65622-65624, 65627-65629, 65632-65634, 65637-65638, 65640, 65643-65645, 65649, 65652, 65654, 65656-65657, 65659-65665, 65667-65668, 65671, 65675, 65682-65686, 65690, 65692-65693, 65696, 65700-65702, 65704, 65706-65707, 65709, 65711-65712, 65714-65715, 65720-65723, 65728-65730, 65732, 65734, 65736, 65738, 65740-65743, 65745, 65748-65750, 65752-65753, 65756-65757, 65760, 65767, 65769-65776, 65778, 65781, 65783-65787, 65790, 65794-65795, 65797, 65799-65802, 65804-65805, 65807-65809, 65811-65812, 65815, 65820, 65831-65832, 65834, 65836, 65838-65848, 65850-65853, 65855-65860, 65862-65870, 65872-65875, 65877-65879, 65881-65882, 65884, 65891-65892, 65899-65900, 65902-65904, 65906-65907, 65911-65912, 65914, 65916-65918, 65920-65922, 65924, 65926, 65928, 65934-65937, 65939-65943, 65945-65946, 65949-65950, 65952, 65955, 65957, 65964-65967, 65969-65975, 65977, 65980, 65982, 65984, 65988-65998, 66000-66006, 66010-66013, 66016, 66019-66021, 66030-66043, 66045, 66047-66054, 66056, 66059, 66061-66062, 66070, 66072-66076, 66078-66081, 66084, 66086-66088, 66090-66096, 66098-66099, 66101-66103, 66105, 66107, 66109, 66112, 66114, 66118-66119, 66121, 66125-66126, 66130-66131, 66134, 66136, 66138-66139, 66143-66146, 66148, 66150-66152, 66156-66160, 66163-66168, 66170-66174, 66177, 66179-66184, 66186-66188, 66190-66192, 66195-66196, 66201-66208, 66210-66212, 66215, 66219-66220, 66223-66225, 66229, 66232, 66234, 66236, 66238, 66240-66244, 66246-66247, 66249-66252, 66257-66264, 66267, 66271, 66275, 66277, 66284, 66290, 66292-66295, 66297-66300, 66302-66304, 66307-66320, 66322-66323, 66325-66327, 66329-66331, 66337-66343, 66346, 66349, 66351-66354, 66357-66359, 66361, 66365-66367, 66369-66376, 66378-66379, 66381-66392, 66395, 66400-66403, 66405, 66407-66415, 66417-66421, 66425-66426, 66428-66429, 66431-66440, 66444, 66447-66450, 66452-66461, 66463, 66468, 66471-66473, 66475-66479, 66481-66490, 66492-66494, 66496, 66498-66499, 66502-66504, 66506, 66508-66512, 66515-66524, 66526-66527, 66529, 66531, 66533-66536, 66539, 66543, 66546, 66549-66550, 66552-66555, 66557, 66559-66562, 66564, 66568-66571, 66573-66574, 66576, 66578-66579, 66584, 66586, 66588, 66590, 66593-66597, 66605, 66607-66608, 66610-66611, 66613, 66616, 66618, 66620, 66624, 66628-66631, 66637-66638, 66645-66647, 66650, 66652-66654, 66656-66657, 66659, 66661-66665, 66674-66680, 66682-66684, 66686-66689, 66691-66692, 66695, 66698, 66700, 66702, 66704-66705, 66709, 66711-66713, 66715, 66720-66721, 66723-66724, 66728-66729, 66732, 66735, 66740, 66742-66746, 66748, 66750-66751, 66754, 66756-66759, 66761-66765, 66768, 66770-66771, 66774, 66777, 66781-66782, 66786-66787, 66791, 66796-66801, 66807-66811, 66813, 66816-66817, 66819, 66822, 66828-66834, 66841, 66843, 66846, 66848, 66851-66853, 66855-66859, 66861, 66863, 66865-66868, 66872, 66877-66879, 66882-66883, 66885, 66891-66895, 66899-66904, 66906-66916, 66918-66920, 66923-66925, 66927-66929, 66931-66932, 66934-66935, 66937, 66940, 66943, 66945-66946, 66948-66952, 66955-66957, 66959-66965, 66967, 66969, 66972-66974, 66977, 66982-66986, 66989-66990, 66999, 67003, 67005-67008, 67010-67020, 67023-67026, 67028, 67030-67035, 67037-67043, 67045-67054, 67056, 67058, 67061, 67063, 67066-67068, 67070-67072, 67074-67076, 67078, 67085-67086, 67088-67091, 67095, 67099-67103, 67105, 67108-67109, 67118-67120, 67124, 67126-67136, 67140, 67142, 67144-67145, 67147-67162, 67164, 67167, 67169-67171, 67173, 67175-67178, 67180-67181, 67184-67189, 67191-67192, 67197-67199, 67202, 67204-67206, 67208, 67210-67212, 67217-67218, 67220-67221, 67226, 67228, 67231, 67233-67234, 67236, 67239, 67242-67243, 67245, 67248-67250, 67253-67255, 67258, 67264-67265, 67267, 67272-67274, 67276-67277, 67280-67287, 67289-67291, 67293, 67295-67301, 67304, 67307, 67309-67311, 67313, 67317, 67319, 67326, 67328-67329, 67336, 67339-67340, 67343, 67345, 67347-67348, 67350, 67356, 67360-67362, 67364-67367, 67380, 67384, 67389, 67396-67401, 67406-67407, 67412-67413, 67416, 67418-67419, 67421, 67425-67427, 67437-67438, 67440-67442, 67444-67445, 67447, 67449-67450, 67453-67455, 67458-67460, 67463-67464, 67468, 67470-67472, 67474-67478, 67480, 67483-67484, 67487, 67489-67491, 67493, 67496, 67502-67509, 67512-67514, 67517-67518, 67520-67521, 67523-67527, 67531-67532, 67535, 67537, 67542, 67544, 67551, 67557-67561, 67563-67566, 67568-67570, 67575-67576, 67578-67581, 67584, 67588, 67591, 67593, 67596-67597, 67602-67603, 67605-67609, 67611, 67617-67619, 67621-67623, 67627-67628, 67631-67633, 67636-67642, 67644-67646, 67648-67650, 67652-67653, 67656-67661, 67664, 67668-67675, 67689, 67691-67692, 67694-67702, 67704, 67708, 67710-67711, 67713-67716, 67718-67720, 67723, 67725, 67731-67732, 67734, 67736-67737, 67740-67742, 67744, 67746-67748, 67752, 67754, 67756-67758, 67761-67765, 67767-67770, 67773, 67775, 67777-67778, 67780, 67784, 67789-67790, 67794-67797, 67800, 67802-67805, 67807-67817, 67822-67824, 67827, 67829-67831, 67834, 67836-67837, 67839-67840, 67842-67844, 67847, 67850, 67853-67854, 67857-67858, 67860-67864, 67866-67875, 67877, 67882-67884, 67887, 67889, 67891-67893, 67896, 67898-67902, 67904, 67907-67917, 67920, 67922-67923, 67925-67927, 67934-67935, 67937-67948, 67950-67953, 67955-67958, 67960-67973, 67975, 67978-67981, 67983-67987, 67991-68000, 68002-68006, 68008-68016, 68019, 68024, 68027-68029, 68031-68034, 68036-68049, 68053, 68055, 68057, 68059-68061, 68063-68065, 68069-68070, 68073, 68076, 68085, 68087, 68089-68090, 68092-68093, 68096, 68099-68101, 68103, 68105-68110, 68113, 68115-68118, 68120-68121, 68125-68127, 68130, 68132-68133, 68136-68139, 68141-68146, 68151, 68153-68158, 68161, 68164, 68166-68168, 68171-68172, 68175-68176, 68178, 68180-68181, 68186-68187, 68189-68192, 68194-68197, 68199-68202, 68204-68206, 68209-68210, 68214, 68217-68219, 68221-68222, 68224, 68227-68230, 68233-68234, 68236-68239, 68241-68246, 68249, 68252-68253, 68255-68259, 68263-68264, 68266-68267, 68270-68279, 68281, 68283, 68285-68289, 68295-68296, 68300, 68303-68306, 68311-68312, 68314-68319, 68323, 68325, 68331, 68333-68338, 68340, 68346, 68348-68359, 68361-68365, 68367, 68369, 68372-68375, 68377-68379, 68381, 68384-68395, 68397-68400, 68403-68413, 68415, 68417, 68420-68423, 68425, 68427-68433, 68435-68444, 68446-68449, 68453-68458, 68462-68463, 68465, 68469-68470, 68472, 68475, 68477, 68479-68480, 68482, 68487, 68491, 68493-68497, 68499-68500, 68502-68503, 68505-68507, 68509-68512, 68517, 68519, 68521-68522, 68525, 68540, 68542-68546, 68548-68555, 68557, 68559-68560, 68563, 68566, 68568, 68571, 68573-68574, 68577, 68579-68582, 68584-68587, 68590-68592, 68595, 68598, 68601-68605, 68609, 68611-68615, 68617-68618, 68623-68625, 68627-68634, 68636, 68638-68643, 68645-68651, 68653-68655, 68658, 68660-68665, 68667-68669, 68671-68673, 68676-68677, 68685, 68687-68694, 68697, 68699-68700, 68703, 68706-68711, 68713-68715, 68717-68721, 68723-68727, 68730-68731, 68734-68736, 68739-68741, 68744, 68748, 68750, 68752, 68754, 68756, 68759, 68761, 68764-68765, 68768, 68770-68771, 68773-68776, 68783-68786, 68788, 68790, 68792-68794, 68796, 68798-68802, 68805, 68808-68811, 68816, 68818, 68824, 68826-68827, 68831-68835, 68837-68839, 68841, 68843, 68847, 68849, 68851, 68855-68860, 68866-68868, 68871, 68873, 68877, 68879-68883, 68887-68888, 68892-68897, 68899-68905, 68907-68908, 68910-68912, 68914, 68916, 68920, 68922-68923, 68927-68929, 68931-68933, 68935-68936, 68938-68939, 68943-68945, 68947-68953, 68957, 68962, 68964, 68967, 68969-68974, 68977, 68979, 68982, 68985, 68988, 68991, 68993-68994, 68997, 68999-69000, 69002-69005, 69007, 69010-69013, 69015-69016, 69018-69019, 69021-69022, 69025-69026, 69028-69031, 69033-69034, 69036, 69038, 69040, 69043, 69045-69050, 69053-69054, 69056-69057, 69060-69061, 69063-69068, 69070, 69072-69080, 69082, 69086, 69090-69091, 69095-69096, 69098-69100, 69102-69107, 69113, 69115, 69120, 69122, 69126-69127, 69131-69138, 69140-69141, 69143, 69146, 69148-69149, 69156-69161, 69163, 69165-69166, 69172, 69174-69175, 69177, 69181-69184, 69186-69188, 69190, 69193, 69197, 69200-69202, 69210-69212, 69215-69218, 69221-69223, 69225, 69227-69228, 69234-69236, 69238-69244, 69247-69249, 69251-69254, 69256, 69258-69262, 69264-69266, 69270-69273, 69277-69278, 69282, 69288-69289, 69291, 69294, 69297-69299, 69303-69306, 69309, 69311-69312, 69314-69317, 69320, 69323-69325, 69328, 69332, 69334, 69337-69339, 69345-69349, 69351-69353, 69355, 69358-69363, 69365-69366, 69368, 69370-69371, 69373-69374, 69378, 69380, 69382-69383, 69385-69386, 69389-69403, 69405, 69407-69408, 69410, 69414, 69416-69417, 69419, 69421, 69427-69435, 69437-69441, 69443, 69445-69447, 69450-69452, 69454, 69456-69460, 69464, 69466, 69471, 69474, 69479-69480, 69482-69484, 69490, 69493, 69496-69505, 69508, 69510, 69512-69514, 69520-69521, 69523, 69525, 69528-69532, 69534, 69537-69538, 69540-69541, 69547-69550, 69552, 69554-69560, 69563, 69567, 69570-69573, 69575, 69578, 69580, 69582-69586, 69588-69592, 69595, 69597-69601, 69603-69607, 69609-69614, 69617-69624, 69626-69634, 69641-69644, 69647, 69649-69652, 69654, 69656, 69658-69659, 69661-69662, 69665-69672, 69674, 69679, 69683, 69686, 69689-69690, 69692-69694, 69696-69699, 69702-69705, 69708-69710, 69712-69714, 69719-69723, 69725, 69728, 69730, 69732, 69735, 69738, 69740, 69743-69744, 69746, 69751-69752, 69754-69757, 69759-69762, 69764, 69767, 69769, 69775-69778, 69785, 69789, 69791-69799, 69801, 69803, 69809, 69812-69814, 69816-69817, 69819, 69821-69823, 69825-69828, 69830, 69832, 69834, 69837-69839, 69841-69845, 69847-69850, 69852-69860, 69862, 69866-69867, 69869-69870, 69875, 69879, 69883, 69887, 69889, 69891, 69893-69904, 69906-69911, 69916, 69919, 69921-69925, 69929-69930, 69932-69941, 69943-69949, 69954, 69960, 69963, 69965-69974, 69976, 69978, 69980-69981, 69983, 69986, 69988-69990, 69995-69996, 70001, 70003-70004, 70008-70014, 70017, 70019-70020, 70024-70025, 70027, 70029, 70032-70033, 70035, 70039-70041, 70044-70048, 70051-70056, 70058-70062, 70064-70069, 70072, 70075, 70077-70079, 70082, 70084-70086, 70088, 70090-70091, 70098-70099, 70102-70103, 70107, 70110-70111, 70118-70119, 70122-70128, 70132-70133, 70135, 70138, 70142-70145, 70147-70149, 70151-70154, 70156-70165, 70169, 70172, 70174, 70176-70178, 70180, 70182, 70185, 70187, 70190, 70192-70196, 70200, 70203-70204, 70207, 70209-70210, 70213, 70215-70220, 70222, 70225, 70227, 70231, 70233, 70236, 70238-70240, 70244, 70247-70249, 70251-70257, 70259-70263, 70267-70271, 70277-70279, 70282, 70284, 70288, 70291, 70294-70295, 70297-70298, 70307, 70310, 70314, 70317-70318, 70320, 70322-70323, 70325-70326, 70328-70331, 70334-70337, 70339, 70342-70343, 70345, 70352-70354, 70356-70357, 70359-70362, 70364-70368, 70370-70371, 70374-70382, 70385-70388, 70392-70395, 70397-70398, 70400, 70402, 70404-70419, 70422-70426, 70428, 70430, 70432-70438, 70440-70446, 70449-70461, 70463, 70466, 70470, 70472-70473, 70475-70476, 70478-70479, 70483-70484, 70487, 70489, 70493-70494, 70497-70498, 70500-70501, 70503-70504, 70506, 70508, 70510, 70512, 70516, 70518, 70521-70523, 70525-70528, 70531, 70536-70539, 70541-70542, 70544-70545, 70547-70548, 70550, 70552-70553, 70555-70557, 70559-70560, 70562-70571, 70573-70574, 70576-70582, 70584, 70586-70590, 70592-70593, 70595, 70597, 70599-70601, 70605, 70608, 70610-70614, 70616-70617, 70619-70620, 70622-70623, 70625, 70628-70629, 70632-70636, 70639, 70641-70642, 70646, 70648, 70650-70652, 70654-70655, 70657, 70661, 70664, 70666, 70669-70671, 70674, 70679-70685, 70687, 70693-70694, 70696, 70698-70699, 70703, 70705-70706, 70708, 70712-70716, 70719, 70724-70727, 70733, 70735-70743, 70746, 70749-70750, 70762-70763, 70768-70770, 70772, 70775-70776, 70778-70779, 70782, 70784, 70786, 70788-70790, 70792-70793, 70795, 70797-70798, 70801, 70807, 70809-70810, 70812-70820, 70823-70825, 70830-70831, 70833-70834, 70841-70842, 70844-70846, 70852-70855, 70859, 70861, 70870-70871, 70875-70876, 70879-70882, 70884, 70886, 70888, 70893, 70896-70899, 70901-70902, 70904, 70906, 70909, 70911, 70913-70914, 70922-70923, 70925, 70928, 70932, 70936-70942, 70944-70946, 70950, 70952, 70954, 70956, 70965-70968, 70974, 70976, 70979, 70982-70983, 70987, 70989-70990, 71001, 71003, 71006, 71012-71013, 71015-71017, 71020-71021, 71023-71032, 71034-71035, 71037-71044, 71046-71051, 71055, 71058, 71060-71065, 71070, 71076, 71079, 71081-71082, 71084, 71086-71088, 71090, 71094-71095, 71098, 71100-71101, 71103, 71108-71110, 71112-71113, 71116-71117, 71122-71126, 71129, 71131, 71133-71134, 71137-71140, 71143-71144, 71146, 71148-71149, 71151-71152, 71154-71156, 71158-71164, 71169, 71176-71178, 71181-71182, 71184-71187, 71189-71194, 71200, 71202-71203, 71207-71211, 71214, 71217-71218, 71221-71225, 71227, 71230-71231, 71233, 71235-71240, 71244-71246, 71250, 71253-71254, 71257, 71260, 71262, 71266-71267, 71272-71273, 71276, 71278-71281, 71285, 71287-71289, 71291-71293, 71300-71301, 71303, 71305-71306, 71309, 71315-71318, 71322, 71325-71332, 71334-71341, 71349-71353, 71355-71358, 71360-71366, 71368-71371, 71373-71382, 71384-71387, 71389-71399, 71402-71404, 71406-71408, 71411-71412, 71415, 71418, 71421, 71423-71427, 71429, 71431-71434, 71436, 71438, 71440, 71442-71445, 71449-71451, 71454-71458, 71461-71462, 71464-71469, 71471-71475, 71477, 71479, 71481-71488, 71490, 71492, 71495, 71497-71500, 71503, 71505-71507, 71509-71511, 71513, 71515-71516, 71519-71521, 71524-71526, 71528-71531, 71533-71534, 71537-71541, 71543-71544, 71546-71551, 71553-71558, 71561-71562, 71564, 71569-71570, 71572, 71574-71577, 71579-71582, 71584-71590, 71593-71598, 71600-71603, 71609, 71613, 71615-71617, 71620, 71623-71632, 71634-71637, 71639-71647, 71649-71651, 71653, 71656-71658, 71662-71663, 71669, 71671, 71678, 71680-71682, 71689-71691, 71693, 71701-71702, 71705-71706, 71708, 71710, 71712, 71714, 71716-71723, 71726-71728, 71730, 71733, 71737, 71739, 71741-71744, 71747-71749, 71751-71752, 71754-71755, 71757, 71759-71760, 71766, 71768-71771, 71775-71777, 71780, 71784-71785, 71787-71796, 71798-71809, 71812, 71814-71818, 71821, 71823-71824, 71826-71827, 71835, 71837, 71840-71842, 71845-71846, 71851, 71853-71856, 71858-71862, 71864-71866, 71869-71870, 71872, 71874-71880, 71884, 71887-71888, 71890-71892, 71894-71895, 71897, 71899, 71904, 71908-71909, 71911-71918, 71922-71923, 71926, 71930, 71933-71935, 71937-71942, 71945-71952, 71955, 71957-71958, 71961, 71964-71970, 71982-71986, 71990, 71992, 71994, 71999, 72003-72004, 72008-72010, 72012-72015, 72017, 72020-72022, 72025, 72031-72032, 72035, 72037-72038, 72041, 72045, 72048-72054, 72056, 72058, 72062-72065, 72067, 72069-72073, 72075, 72077, 72079-72081, 72083, 72085, 72088-72090, 72094-72095, 72097, 72099-72100, 72104-72105, 72107-72112, 72114-72117, 72119, 72123-72124, 72126-72128, 72130, 72132-72140, 72143, 72145-72150, 72152-72155, 72157-72158, 72160-72166, 72168-72169, 72171, 72173-72175, 72178, 72180-72183, 72185-72192, 72195, 72197, 72199, 72203-72205, 72207-72211, 72214-72232, 72234, 72236-72239, 72241-72242, 72246, 72249-72251, 72253-72256, 72261-72265, 72268-72269, 72272-72273, 72275, 72277, 72279-72280, 72282-72283, 72285, 72294-72297, 72300, 72302, 72304, 72306, 72309, 72312, 72314-72315, 72317, 72319-72320, 72325, 72330, 72333-72334, 72337-72344, 72346-72348, 72350-72353, 72355-72358, 72364-72366, 72368, 72373, 72375-72377, 72379-72382, 72384-72388, 72392-72397, 72400, 72402, 72415-72417, 72419, 72426-72432, 72434, 72436, 72438, 72441-72452, 72454-72456, 72461-72462, 72468-72473, 72475, 72477-72479, 72481, 72483, 72486, 72489-72490, 72492-72494, 72500, 72502, 72508, 72515-72516, 72523-72527, 72529-72534, 72536-72537, 72539-72551, 72554, 72556, 72559, 72563, 72565-72580, 72582-72586, 72595-72598, 72600-72609, 72611-72612, 72614-72620, 72622-72623, 72626-72629, 72631-72633, 72635-72637, 72640, 72643-72646, 72651-72653, 72657, 72660, 72662-72663, 72668-72670, 72674-72678, 72686, 72690, 72692, 72695, 72703-72704, 72706-72708, 72710-72711, 72715-72718, 72720, 72723, 72728, 72730-72731, 72733, 72738-72739, 72741-72747, 72750, 72752-72754, 72756-72757, 72759, 72761-72769, 72772-72774, 72776, 72778-72779, 72781-72795, 72798, 72802, 72807-72814, 72816, 72819-72829, 72831-72832, 72840, 72842-72846, 72848-72852, 72854, 72856-72858, 72860, 72866-72868, 72870-72872, 72874, 72879-72885, 72887-72889, 72894, 72896, 72900-72906, 72908-72921, 72923, 72925, 72927, 72929, 72931-72933, 72936-72940, 72943-72949, 72951, 72953-72957, 72963-72967, 72969-72974, 72978-72979, 72983-72984, 72987-72995, 72998-73002, 73005, 73007-73018, 73020, 73024-73025, 73027-73031, 73033-73034, 73036, 73038-73043, 73045-73048, 73050, 73052, 73054, 73056-73059, 73061-73064, 73067-73068, 73070, 73073, 73075-73078, 73080, 73082-73084, 73087-73091, 73093-73096, 73098-73105, 73110, 73113-73120, 73122-73123, 73125, 73127, 73129-73130, 73133-73134, 73136-73144, 73146-73150, 73152-73157, 73159-73160, 73163, 73165, 73167-73177, 73180-73181, 73183-73184, 73186-73194, 73196-73198, 73200-73202, 73204, 73206-73211, 73215, 73222-73225, 73229, 73231, 73233-73234, 73236-73238, 73240, 73242, 73244-73245, 73247-73248, 73250-73252, 73255-73259, 73262, 73265-73267, 73269, 73276-73279, 73281, 73283-73286, 73288, 73291, 73296-73297, 73300-73301, 73305, 73307, 73312, 73316-73319, 73325-73337, 73339-73343, 73349-73351, 73353-73355, 73357, 73359, 73362, 73370, 73372-73373, 73375, 73377-73378, 73380-73381, 73384-73387, 73392, 73394-73395, 73397-73400, 73402-73404, 73407, 73409-73410, 73412-73417, 73419-73420, 73422-73423, 73425, 73427-73432, 73434-73438, 73440, 73442, 73444-73446, 73448-73449, 73451, 73455, 73458-73465, 73467-73470, 73472-73473, 73477, 73481, 73487, 73489, 73493-73494, 73496, 73498, 73500-73501, 73506, 73508-73510, 73512-73514, 73516, 73521, 73523-73524, 73537, 73539-73545, 73558-73559, 73561, 73563, 73566-73568, 73571-73575, 73577-73581, 73583-73587, 73590-73591, 73593-73595, 73597-73599, 73602-73604, 73606-73607, 73613-73614, 73618, 73620, 73622, 73624-73625, 73628, 73631-73633, 73635-73638, 73641-73642, 73645, 73647, 73649-73653, 73655, 73657, 73660-73663, 73666-73669, 73673, 73675-73683, 73685-73687, 73691-73696, 73698, 73700, 73702, 73708-73709, 73711, 73713, 73717, 73721-73722, 73725-73726, 73728, 73734, 73736, 73738-73740, 73742, 73744-73746, 73751-73755, 73757, 73760-73762, 73764-73765, 73769, 73775, 73777-73778, 73780, 73782-73783, 73785-73788, 73792-73804, 73812-73813, 73815, 73817, 73819, 73821-73822, 73825, 73828-73829, 73832, 73834-73840, 73843-73844, 73846-73849, 73851-73856, 73858-73870, 73872-73877, 73879-73883, 73885, 73887-73888, 73891, 73893-73895, 73898-73899, 73901, 73903, 73905-73906, 73908, 73910-73911, 73913, 73915, 73919, 73921, 73923, 73926-73928, 73932-73934, 73936, 73945, 73947, 73950, 73953, 73956-73958, 73961, 73964, 73966-73974, 73979-73981, 73987-73989, 73991-73992, 73998-73999, 74001, 74007, 74009-74010, 74017, 74019-74021, 74023, 74025-74033, 74042, 74044-74047, 74049, 74051-74057, 74059, 74061-74063, 74065, 74070, 74072, 74075, 74080-74083, 74087-74089, 74095, 74099, 74107, 74110-74112, 74115-74116, 74123-74124, 74126, 74130, 74133, 74135, 74140, 74142-74143, 74145-74147, 74149, 74156-74160, 74162, 74164-74165, 74167, 74169-74173, 74176-74178, 74180-74183, 74185, 74192, 74195, 74197-74201, 74207-74209, 74211-74212, 74214-74219, 74221-74223, 74225-74226, 74228, 74231-74233, 74235-74236, 74239-74242, 74244-74255, 74257-74259, 74261-74263, 74265-74273, 74275-74276, 74278, 74282, 74285-74293, 74295-74296, 74298-74299, 74301, 74303, 74306-74307, 74309-74315, 74317-74318, 74321-74323, 74326, 74329-74330, 74333-74335, 74338-74339, 74345, 74347-74354, 74356-74362, 74364-74365, 74367-74369, 74372-74375, 74377-74379, 74381, 74383-74384, 74387, 74389-74395, 74397-74398, 74401, 74404, 74406-74407, 74409, 74413-74414, 74416-74423, 74427, 74429-74433, 74436, 74439-74440, 74442-74443, 74445-74449, 74454, 74457-74459, 74465-74470, 74472-74475, 74477, 74479, 74483, 74485-74490, 74492-74496, 74498-74499, 74503-74507, 74509, 74512-74516, 74518, 74520, 74526-74532, 74534-74537, 74541-74542, 74545, 74547-74552, 74554-74561, 74564-74566, 74568-74575, 74578-74580, 74582-74585, 74590-74595, 74597-74608, 74610-74623, 74625-74626, 74628, 74632, 74634, 74636, 74638-74639, 74642-74643, 74645-74646, 74648, 74651-74653, 74655-74659, 74661-74671, 74673, 74675, 74677-74685, 74688, 74690, 74692, 74694, 74698, 74700-74702, 74706-74711, 74713, 74715-74718, 74720-74726, 74729-74730, 74732-74733, 74736, 74738, 74740-74741, 74743-74744, 74746, 74750, 74752, 74759-74762, 74764-74767, 74771-74776, 74778-74781, 74783, 74787-74789, 74793-74794, 74796, 74800-74804, 74806-74808, 74810-74814, 74816, 74818-74821, 74823-74825, 74827, 74832-74834, 74840, 74842-74843, 74845, 74847-74849, 74851-74853, 74856-74858, 74861, 74866-74874, 74877-74878, 74884-74886, 74888, 74890, 74892-74896, 74898, 74901, 74903-74905, 74907, 74911, 74913-74919, 74923-74929, 74931, 74935, 74937-74938, 74941, 74945-74950, 74952-74953, 74957-74965, 74967, 74971, 74974, 74981-74982, 74985, 74987-74989, 74991, 74997-75001, 75006-75008, 75010-75015, 75022, 75026, 75029, 75031-75034, 75037, 75039-75041, 75043, 75045-75046, 75050-75052, 75054, 75057-75058, 75060, 75063-75064, 75067, 75069, 75073-75077, 75079, 75081, 75087, 75091-75092, 75097-75098, 75104-75106, 75108, 75111, 75113, 75115-75118, 75122, 75124-75127, 75131-75132, 75135-75136, 75138-75149, 75151, 75154, 75159, 75161-75168, 75170-75171, 75173-75175, 75178-75179, 75181, 75185-75190, 75192-75193, 75195, 75197-75198, 75203-75204, 75206-75208, 75210-75211, 75216-75217, 75219-75223, 75227-75228, 75230-75231, 75233, 75236, 75241-75249, 75252-75253, 75255-75259, 75261, 75265-75267, 75270-75274, 75276-75280, 75283, 75285-75290, 75293-75298, 75300-75302, 75305, 75307, 75310-75312, 75314-75316, 75322, 75328-75330, 75332, 75335-75336, 75338-75347, 75350-75351, 75353-75354, 75356-75357, 75360-75361, 75363-75365, 75367, 75369, 75373-75375, 75380, 75384-75390, 75392-75402, 75405, 75408-75414, 75416-75417, 75421, 75426-75427, 75429, 75437-75439, 75442-75445, 75447, 75449-75453, 75455-75458, 75460-75461, 75464, 75467, 75469, 75472-75478, 75480, 75482, 75486, 75489, 75491-75492, 75497, 75499, 75503, 75505, 75507-75509, 75511-75516, 75518, 75520, 75522-75529, 75531, 75533, 75539-75542, 75545-75548, 75550, 75555, 75561-75562, 75564, 75566, 75569-75570, 75572-75573, 75575, 75578, 75580-75582, 75584-75589, 75591-75601, 75606, 75608, 75610-75612, 75614-75620, 75623, 75625, 75632, 75634, 75636-75640, 75643, 75648, 75653, 75658, 75660, 75662-75664, 75667-75668, 75670, 75672-75673, 75675-75676, 75678, 75680, 75683, 75686-75687, 75690-75691, 75708, 75710, 75712-75713, 75715-75719, 75721-75725, 75727-75728, 75730, 75734, 75737-75741, 75743-75744, 75746, 75748-75749, 75751-75752, 75755-75756, 75759-75764, 75766, 75768, 75775, 75779, 75781-75782, 75785, 75788, 75790-75798, 75802, 75808, 75810-75814, 75818, 75821, 75824, 75832, 75836, 75838-75839, 75841-75843, 75847-75848, 75851, 75853-75857, 75861, 75864, 75869, 75872-75873, 75875-75877, 75882-75883, 75885-75887, 75894, 75896-75899, 75906-75908, 75910-75911, 75913-75914, 75916, 75919-75920, 75922-75924, 75926, 75929, 75932, 75934-75935, 75938-75940, 75942, 75945, 75950-75956, 75958-75961, 75963-75967, 75971, 75973-75981, 75984, 75987, 75989, 75992-75993, 75995-75997, 75999, 76002-76004, 76007, 76009-76010, 76014-76027, 76029-76035, 76037-76041, 76044, 76047-76048, 76053-76055, 76057-76059, 76062, 76068-76069, 76071-76080, 76082, 76084-76085, 76087, 76089-76092, 76094-76095, 76097, 76100-76102, 76104, 76106-76107, 76112, 76115, 76118, 76120-76122, 76124-76128, 76131, 76133, 76136-76139, 76141-76144, 76147-76148, 76150-76156, 76158, 76160-76167, 76170, 76173, 76175, 76177, 76180, 76184, 76186-76187, 76189-76192, 76194, 76196-76198, 76200-76201, 76204, 76212, 76214-76215, 76218-76219, 76221-76223, 76230-76232, 76235-76236, 76238-76240, 76243-76244, 76247-76249, 76252-76255, 76258, 76260-76261, 76263, 76265-76270, 76272-76273, 76277-76278, 76280-76282, 76285, 76287, 76296-76299, 76303, 76305-76307, 76309-76312, 76315-76318, 76321, 76323-76328, 76330-76333, 76335, 76340-76345, 76349-76353, 76355-76357, 76360, 76363, 76365-76366, 76368, 76370-76372, 76377-76378, 76384-76390, 76392-76393, 76396-76397, 76399-76403, 76405, 76408-76409, 76413, 76416, 76419-76423, 76428, 76430-76431, 76435, 76438, 76440, 76442, 76444, 76449-76450, 76453-76458, 76460-76466, 76468-76470, 76472-76481, 76483, 76487-76491, 76493, 76495-76504, 76508, 76511, 76513-76515, 76517, 76520, 76522-76523, 76525-76529, 76531-76532, 76535-76539, 76541-76544, 76547-76552, 76554, 76563-76572, 76574, 76576-76581, 76585-76593, 76596-76597, 76599-76600, 76602-76607, 76609-76610, 76612-76613, 76619, 76621-76622, 76624, 76626, 76628, 76630-76634, 76637, 76639-76641, 76643-76645, 76650-76651, 76654, 76656-76658, 76660-76663, 76665-76667, 76669-76671, 76674-76677, 76685, 76687-76689, 76692, 76694, 76698-76700, 76704-76707, 76711-76712, 76715-76716, 76719-76722, 76724-76725, 76727-76730, 76732-76734, 76736-76737, 76740-76745, 76747, 76752, 76754, 76756, 76758-76760, 76762-76768, 76770-76775, 76777, 76784, 76787-76788, 76790-76792, 76794-76795, 76799-76800, 76806, 76808, 76811-76812, 76815-76817, 76819-76823, 76825-76829, 76832, 76835-76836, 76841, 76843-76844, 76846, 76849, 76853-76854, 76856-76859, 76861-76869, 76871, 76873, 76875, 76877, 76879, 76881-76888, 76893, 76896, 76898-76900, 76902-76905, 76907-76909, 76914-76915, 76917-76918, 76920, 76922-76924, 76926-76927, 76929-76930, 76932-76947, 76951-76952, 76954, 76957, 76960-76961, 76963, 76966-76967, 76970, 76972, 76976-76977, 76980, 76984-76985, 76987-76988, 76991-76997, 76999, 77001, 77003-77005, 77007, 77010-77012, 77014-77019, 77021-77023, 77025, 77030-77031, 77033-77034, 77036, 77041, 77043, 77045, 77048-77052, 77055, 77057, 77060, 77065, 77068, 77070-77082, 77086, 77091, 77095-77102, 77106-77110, 77112-77114, 77116, 77119, 77121, 77123, 77131-77137, 77139-77140, 77142, 77150-77153, 77156, 77158, 77160, 77162-77165, 77168-77173, 77176, 77180-77182, 77184-77185, 77188, 77190-77191, 77193, 77195-77200, 77202, 77213-77218, 77223, 77225-77226, 77231-77232, 77239-77240, 77242, 77244, 77251-77253, 77256-77257, 77259, 77262-77263, 77266, 77268-77270, 77272, 77274, 77277, 77279-77280, 77283-77285, 77287-77290, 77298-77300, 77302-77304, 77306, 77311, 77313-77315, 77319-77320, 77332-77333, 77336-77337, 77339-77340, 77342-77343, 77345-77348, 77352, 77354-77358, 77360-77362, 77364-77366, 77368-77369, 77371, 77374, 77376-77380, 77382-77385, 77387-77388, 77390-77391, 77397-77401, 77403-77406, 77410-77412, 77414-77416, 77418, 77420-77421, 77423, 77425-77428, 77430-77432, 77434, 77436-77437, 77439-77444, 77448-77450, 77452-77455, 77458-77459, 77461-77462, 77465, 77467-77469, 77472-77474, 77481, 77483, 77486-77492, 77498, 77502, 77516-77518, 77521, 77523-77525, 77527-77529, 77532, 77534-77536, 77542-77543, 77545-77546, 77550-77552, 77554-77555, 77557, 77559, 77563-77565, 77568-77573, 77575-77576, 77581, 77583, 77585, 77587-77595, 77597, 77599, 77605, 77610-77612, 77617-77618, 77624-77628, 77630-77634, 77636-77640, 77642-77643, 77647-77648, 77650, 77654, 77656-77658, 77660-77667, 77669-77677, 77679-77680, 77683-77686, 77689, 77692, 77695, 77697, 77699, 77703-77708, 77719, 77724-77729, 77735, 77746, 77749-77750, 77752-77754, 77757, 77759, 77761, 77764, 77766, 77769-77770, 77772, 77774-77775, 77781, 77783-77784, 77786-77787, 77789, 77792, 77795-77797, 77799, 77806, 77808-77809, 77811, 77814-77816, 77819-77820, 77822, 77827-77829, 77831-77838, 77840-77841, 77843-77844, 77847, 77853-77855, 77861-77863, 77865, 77867, 77870, 77873, 77877, 77879, 77883, 77885, 77888-77890, 77892, 77895, 77898, 77900-77902, 77911, 77913-77914, 77916-77917, 77919-77920, 77922-77924, 77926-77929, 77931, 77935-77936, 77940-77944, 77946-77949, 77954-77956, 77958, 77960, 77962-77969, 77971-77973, 77975, 77977-77978, 77982-77988, 77991-77994, 77999, 78003, 78005-78006, 78008-78010, 78012-78018, 78021, 78023-78024, 78026-78031, 78033, 78035, 78038-78042, 78044-78047, 78052, 78056-78059, 78061-78062, 78064, 78067-78068, 78072-78073, 78075-78078, 78080, 78082, 78089-78092, 78094-78097, 78099-78101, 78105, 78107-78108, 78110, 78113-78115, 78117, 78120, 78122-78124, 78132-78133, 78136-78138, 78143, 78146, 78148, 78150-78151, 78157, 78159, 78161, 78165, 78167-78169, 78172-78178, 78186, 78189, 78194, 78196, 78199-78202, 78206-78209, 78211-78212, 78219-78220, 78222-78224, 78228-78229, 78232, 78234-78235, 78238, 78240-78243, 78248-78256, 78258-78259, 78261, 78263, 78265, 78267-78272, 78275, 78277, 78279, 78281-78285, 78287-78290, 78292, 78295-78298, 78300, 78302-78305, 78309-78317, 78319-78321, 78323, 78325, 78327, 78329-78332, 78334-78336, 78339-78340, 78342-78345, 78348, 78350-78351, 78354-78360, 78362, 78365-78367, 78369-78370, 78373, 78375-78378, 78380, 78382, 78384-78385, 78388, 78390, 78395-78397, 78404-78406, 78408-78412, 78415-78418, 78420-78422, 78424-78425, 78427-78428, 78430, 78433-78434, 78442, 78444-78445, 78447, 78449, 78451-78455, 78457-78464, 78466, 78468-78469, 78472-78477, 78482-78484, 78486, 78488, 78490, 78493-78494, 78496, 78499, 78503, 78509-78512, 78516, 78521-78526, 78528-78529, 78531, 78538, 78542, 78544, 78548, 78550-78551, 78553, 78557-78558, 78561-78562, 78564-78565, 78567-78568, 78570-78571, 78575, 78577-78579, 78581-78582, 78587-78588, 78591, 78597-78598, 78600, 78602-78611, 78616-78622, 78624, 78627, 78629, 78640-78641, 78643, 78645-78648, 78651-78652, 78654-78656, 78658-78662, 78664-78666, 78669-78670, 78672-78674, 78676-78678, 78680-78682, 78684, 78687-78688, 78695-78701, 78705-78711, 78713-78721, 78724-78725, 78736-78737, 78739, 78742, 78744-78747, 78751-78752, 78755, 78757, 78760, 78762-78763, 78765, 78770, 78772, 78774-78777, 78779-78780, 78782, 78785-78786, 78792, 78794, 78800-78802, 78804-78805, 78807-78808, 78810-78811, 78813-78815, 78820-78821, 78824-78827, 78831-78835, 78837, 78839-78840, 78843-78852, 78858, 78862-78863, 78865, 78867, 78869-78871, 78877, 78879-78883, 78885-78887, 78891, 78893, 78896, 78899, 78901, 78903-78907, 78910, 78912-78917, 78920-78921, 78923-78929, 78931-78933, 78936, 78938, 78942-78947, 78949-78952, 78954, 78960, 78963-78965, 78967-78968, 78970, 78976, 78979, 78984-78986, 78989-78996, 79005, 79007, 79014, 79019, 79021-79023, 79025-79029, 79032-79037, 79044, 79046-79047, 79049, 79051-79055, 79062-79065, 79067, 79069-79071, 79073-79074, 79076-79083, 79086, 79091, 79093-79097, 79101-79102, 79106-79107, 79113-79116, 79118-79119, 79121, 79123, 79126, 79129, 79132, 79140, 79142-79144, 79146-79148, 79163-79165, 79168-79169, 79171-79172, 79175-79176, 79183-79184, 79186-79187, 79192, 79194-79199, 79201-79203, 79206-79207, 79209-79222, 79227-79229, 79231, 79236-79238, 79240-79242, 79244-79245, 79247-79251, 79253, 79257, 79260-79261, 79264-79265, 79267, 79269-79270, 79272, 79274-79284, 79287, 79292, 79294-79296, 79299-79300, 79302-79309, 79311, 79315, 79318-79320, 79322-79325, 79331, 79335-79337, 79339-79342, 79344-79353, 79356, 79360-79362, 79365-79366, 79373-79378, 79382-79383, 79385-79386, 79388-79390, 79394, 79396-79398, 79402, 79404, 79410-79411, 79413-79416, 79419-79420, 79422, 79425-79426, 79428-79430, 79432-79436, 79438, 79440, 79444, 79451-79452, 79456, 79459-79466, 79468-79473, 79475, 79481-79482, 79484-79486, 79490, 79493-79494, 79496-79499, 79502, 79505, 79509, 79516, 79519, 79521, 79523-79525, 79530, 79533, 79536, 79538, 79546, 79554, 79556-79558, 79560, 79562, 79564, 79567, 79569, 79572-79574, 79580-79581, 79583-79586, 79595, 79599-79601, 79603, 79605, 79607, 79609-79611, 79613, 79615, 79617-79621, 79628, 79631-79633, 79635, 79638-79639, 79642-79648, 79650, 79652-79658, 79660, 79662-79665, 79667-79668, 79673-79674, 79679-79685, 79687, 79689-79691, 79694, 79696-79700, 79704-79708, 79710-79712, 79714, 79716, 79719, 79721-79723, 79725-79726, 79728-79731, 79733, 79735, 79737, 79739-79742, 79746-79751, 79754-79759, 79761, 79763-79764, 79766, 79773-79774, 79777, 79782, 79786, 79789-79790, 79793-79796, 79798-79799, 79802-79803, 79806-79807, 79809-79810, 79812-79814, 79817-79819, 79821, 79825, 79827-79830, 79832-79833, 79836-79837, 79843-79845, 79847, 79852, 79855, 79857-79860, 79862, 79864-79865, 79867, 79873, 79875-79876, 79879-79882, 79884, 79886, 79888-79889, 79895-79896, 79898, 79906, 79911, 79913-79915, 79918-79921, 79924, 79926, 79929, 79931, 79938, 79941-79944, 79948-79949, 79953, 79959-79963, 79965, 79971-79972, 79976-79977, 79979-79980, 79984-79985, 79987, 79989-79990, 79993-79994, 79997-79998, 80000, 80004, 80006, 80008, 80010-80011, 80013-80015, 80017, 80020-80021, 80029-80030, 80032-80047, 80051-80055, 80059-80061, 80063, 80065, 80069-80071, 80073-80075, 80080, 80083-80085, 80087, 80090, 80092, 80094, 80096-80102, 80105, 80121, 80128, 80130-80132, 80136, 80141-80145, 80149-80154, 80157, 80159, 80164-80165, 80167, 80170, 80175, 80179, 80181, 80183, 80188, 80192-80193, 80195, 80198, 80201, 80206-80209, 80211, 80214-80216, 80218, 80222-80223, 80225, 80233, 80235-80236, 80240, 80244, 80249, 80251-80252, 80254-80264, 80274-80275, 80277, 80279-80280, 80283-80293, 80295, 80297-80298, 80300, 80302-80303, 80306, 80308, 80311-80314, 80316-80318, 80320, 80324, 80326-80329, 80333, 80335, 80339, 80342-80343, 80345-80347, 80349, 80353, 80356-80361, 80364-80367, 80369-80370, 80372, 80374, 80378-80379, 80382, 80388-80389, 80391-80392, 80394, 80397-80400, 80404, 80409, 80411-80415, 80417-80424, 80428-80431, 80433, 80435, 80437, 80439-80444, 80447, 80450, 80454, 80457-80459, 80461-80462, 80464, 80466, 80468-80470, 80476-80477, 80479-80485, 80489-80491, 80493, 80496, 80498, 80500, 80502-80505, 80511-80513, 80515-80520, 80523, 80525, 80529-80533, 80538-80539, 80548-80551, 80553-80557, 80563-80564, 80566-80569, 80574, 80576, 80578-80579, 80581-80591, 80593-80594, 80596, 80599-80600, 80604-80605, 80608-80610, 80612-80614, 80620-80621, 80623, 80629, 80631-80633, 80639, 80641-80642, 80647, 80649-80654, 80658, 80661-80662, 80665, 80667-80669, 80674, 80676, 80678-80679, 80683-80684, 80688, 80691, 80693-80694, 80696-80701, 80704, 80708-80710, 80715-80717, 80723-80725, 80728, 80730-80734, 80736, 80738, 80740-80743, 80745, 80747-80750, 80752-80753, 80755, 80757-80759, 80761, 80768-80772, 80776-80779, 80782, 80785-80787, 80791, 80793, 80795, 80797-80799, 80801-80806, 80808, 80811-80819, 80821-80822, 80825-80826, 80828-80832, 80834-80840, 80842-80843, 80846, 80848, 80852, 80859, 80861, 80863-80864, 80867-80868, 80870-80871, 80875, 80877-80878, 80881, 80885-80888, 80890-80894, 80896-80903, 80905-80906, 80921, 80923-80924, 80926, 80936-80940, 80946-80949, 80951, 80954-80957, 80959-80961, 80966, 80968, 80970, 80972, 80974-80976, 80982-80983, 80987-80989, 80992-80993, 80995-80996, 80999, 81004, 81006-81007, 81009, 81011-81013, 81016-81017, 81019, 81021-81022, 81025, 81027-81033, 81035-81037, 81040-81041, 81047-81048, 81050-81051, 81055, 81061-81062, 81064-81068, 81070-81074, 81078, 81080-81082, 81085, 81088, 81092, 81094-81098, 81100, 81103, 81106, 81108, 81110-81113, 81118-81120, 81126, 81129, 81134-81136, 81140-81143, 81145-81154, 81161-81170, 81172, 81174-81176, 81180-81181, 81183-81184, 81191, 81195-81196, 81200, 81204, 81208, 81210-81211, 81214, 81216-81219, 81223-81224, 81228-81230, 81232-81233, 81237, 81239, 81241, 81243, 81245-81249, 81257-81263, 81273, 81275, 81279, 81282-81294, 81296-81303, 81305, 81307, 81312-81314, 81316-81322, 81325-81328, 81330, 81333-81337, 81341-81343, 81345-81346, 81348-81350, 81353-81355, 81357, 81359, 81361-81362, 81367, 81369, 81372, 81374, 81376, 81381, 81383, 81385-81386, 81389, 81391, 81393-81396, 81398, 81400, 81402, 81405, 81410, 81412, 81420-81421, 81424, 81427-81430, 81432-81438, 81442-81451, 81453-81455, 81458, 81461-81468, 81470, 81473, 81475-81476, 81478-81480, 81483, 81497, 81502, 81508-81510, 81513, 81515-81517, 81519-81524, 81527, 81531-81537, 81540-81546, 81549, 81552, 81554, 81559-81560, 81567, 81578, 81583-81584, 81586-81589, 81592-81594, 81596-81597, 81599-81600, 81604-81608, 81611-81614, 81617-81618, 81620-81621, 81625, 81628, 81630-81631, 81640, 81642-81643, 81645-81646, 81648-81655, 81657-81662, 81664-81670, 81672, 81679-81681, 81687, 81689-81690, 81694, 81697-81698, 81700, 81702, 81704-81705, 81707, 81712, 81718, 81724, 81728, 81731-81732, 81736-81737, 81739-81741, 81744, 81747-81754, 81757-81761, 81768, 81770, 81772-81777, 81780-81781, 81783-81784, 81791, 81794, 81796-81798, 81803-81805, 81808, 81811-81812, 81814-81822, 81825-81830, 81832, 81836, 81839-81840, 81843, 81846, 81849-81857, 81859-81860, 81864, 81866, 81868, 81870-81874, 81876-81877, 81881, 81885-81886, 81888-81891, 81893-81897, 81899-81901, 81904-81905, 81908, 81911, 81915, 81917-81921, 81927-81931, 81933-81935, 81937, 81940-81942, 81947, 81949-81950, 81953-81954, 81957, 81959-81961, 81963-81966, 81968, 81971, 81974-81976, 81978-81983, 81985, 81987, 81989, 81992, 81994, 81996, 81998-82000, 82005, 82007-82008, 82010-82011, 82014, 82016-82019, 82021, 82023-82024, 82026, 82028, 82031, 82037, 82039-82040, 82044, 82046-82048, 82051-82053, 82056-82063, 82065-82070, 82072, 82074-82076, 82078, 82080-82082, 82085, 82087, 82090, 82094-82096, 82098, 82100-82101, 82103, 82105-82111, 82114, 82118-82119, 82122-82126, 82128-82129, 82136-82137, 82147-82148, 82150-82151, 82153, 82155-82158, 82160-82165, 82168-82172, 82176-82181, 82183, 82185-82186, 82189-82191, 82193-82195, 82197, 82199-82201, 82203-82206, 82209-82211, 82214-82215, 82217, 82223-82228, 82230-82232, 82235, 82240, 82242, 82247, 82250-82254, 82256-82258, 82262, 82266-82267, 82269, 82271-82273, 82276-82279, 82281-82282, 82294-82301, 82303-82304, 82306, 82309-82310, 82314, 82320-82321, 82325-82329, 82331-82334, 82336-82344, 82351, 82354-82356, 82360, 82366, 82369, 82371-82373, 82376-82379, 82382, 82384-82386, 82390-82391, 82393-82399, 82401, 82403-82405, 82408-82409, 82412, 82415, 82422-82425, 82430, 82432-82436, 82438-82439, 82442-82447, 82450-82451, 82453-82454, 82459, 82461, 82463-82467, 82469, 82471, 82473-82477, 82480, 82483, 82485-82487, 82489-82492, 82495, 82500-82502, 82505-82506, 82509, 82511-82514, 82516, 82518, 82524, 82526-82527, 82530-82531, 82533, 82535, 82543, 82545-82554, 82558, 82560, 82564-82566, 82574, 82583, 82588-82590, 82593, 82595-82599, 82601, 82604-82605, 82607-82608, 82614-82621, 82623, 82625, 82627-82628, 82630, 82635, 82637, 82640-82641, 82645, 82648-82650, 82656-82658, 82660-82664, 82667-82669, 82672, 82676-82677, 82683, 82685, 82689-82690, 82692-82694, 82702, 82704-82706, 82709, 82712-82713, 82716, 82720-82721, 82724, 82726, 82730, 82732-82738, 82740, 82746, 82753, 82756, 82758-82763, 82766-82773, 82775, 82782-82785, 82790, 82792, 82794-82795, 82798, 82800-82801, 82805, 82807-82808, 82810, 82813-82815, 82823, 82825-82826, 82830-82831, 82833-82834, 82841-82844, 82846, 82850-82856, 82860-82861, 82864, 82866-82867, 82870-82872, 82879-82880, 82882, 82884-82891, 82897-82898, 82900-82903, 82906-82908, 82912, 82915-82916, 82919-82920, 82922-82923, 82925, 82930-82934, 82937, 82939-82941, 82943, 82945, 82947-82948, 82953-82954, 82956-82957, 82961, 82966-82969, 82973-82980, 82984, 82987, 82992, 82994-82996, 82998, 83001, 83007-83008, 83011-83012, 83014-83017, 83019, 83022-83024, 83026, 83033, 83043, 83045, 83054-83056, 83059-83060, 83063-83064, 83067, 83070, 83081-83083, 83085, 83087, 83089, 83092, 83094, 83096, 83105, 83107-83109, 83112, 83114-83116, 83118-83120, 83122, 83125, 83131-83134, 83136-83141, 83147, 83155, 83157, 83160-83161, 83163-83164, 83166, 83168, 83170-83179, 83181-83182, 83184-83190, 83192-83194, 83196, 83198-83202, 83205, 83208-83211, 83213-83215, 83219-83223, 83226-83229, 83231, 83239-83243, 83248, 83251, 83259, 83261-83262, 83265, 83271, 83273, 83275-83279, 83283-83285, 83287, 83289, 83291, 83293, 83295, 83297-83301, 83303-83305, 83312, 83315, 83321, 83323, 83327, 83329, 83331-83332, 83334, 83336-83337, 83340-83341, 83346, 83348-83349, 83351, 83354, 83359, 83362-83365, 83367-83370, 83372, 83374-83376, 83383-83385, 83391-83396, 83399, 83402, 83405, 83408, 83412-83414, 83416-83420, 83424-83425, 83427-83435, 83437, 83440-83441, 83443-83444, 83446-83448, 83451-83453, 83458, 83460, 83468, 83470, 83472-83474, 83476, 83478, 83480-83482, 83484, 83488, 83490, 83494-83495, 83498, 83500, 83502-83508, 83510, 83512-83517, 83523, 83527, 83530-83531, 83535, 83537, 83539-83540, 83544, 83546-83548, 83552, 83555-83556, 83562-83564, 83566-83568, 83570-83572, 83574, 83576-83582, 83584-83587, 83591-83593, 83596-83601, 83603, 83605-83606, 83608-83612, 83614, 83619, 83621, 83623-83624, 83626-83629, 83631-83634, 83638-83640, 83644-83646, 83648-83651, 83658-83659
The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

Claims (21)

What is claimed is:
1. A method of increasing expression of a MECP2 gene in a cell, the method comprising delivering a single stranded oligonucleotide into the cell, wherein the single stranded oligonucleotide
(a) has a sequence 5′-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 3-23 nucleotides in length,
(b) is complementary with at least 10 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, wherein the PRC2-associated region is a region of the MECP2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an anti-body that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the MECP2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody, and
(c) has at least one nucleotide that is a nucleotide analogue.
2. A method increasing levels of a MECP2 gene in a subject, the method comprising administering a single stranded oligonucleotide to the subject, wherein the single stranded oligonucleotide
(a) has a sequence 5′-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 3-23 nucleotides in length,
(b) is complementary with at least 10 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, wherein the PRC2-associated region is a region of the MECP2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an anti-body that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the MECP2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody, and
(c) has at least one nucleotide that is a nucleotide analogue.
3. The method of claim 2, wherein the is subject has Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, or PPM-X syndrome.
4. The method of claim 2, wherein the oligonucleotide does not comprise three or more consecutive guanosine nucleotides.
5. The method of claim 2, wherein the oligonucleotide is 8 to 30 nucleotides in length.
6. The method of claim 2, wherein the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
7. The method of claim 2, wherein at least one nucleotide of the oligonucleotide comprises a 2′ O-methyl.
8. The method of claim 2, wherein the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide.
9. The method of claim 8, wherein the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide.
10. The method of claim 2, wherein the oligonucleotide further comprises phosphorothioate internucleotide linkages between at least two nucleotides.
11. The method of claim 10, wherein the oligonucleotide further comprises phosphorothioate internucleotide linkages between all nucleotides.
12. The method of claim 2, wherein the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group.
13. The method of claim 1, wherein the oligonucleotide does not comprise three or more consecutive guanosine nucleotides.
14. The method of claim 1, wherein the oligonucleotide is 8 to 30 nucleotides in length.
15. The method of claim 1, wherein the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
16. The method of claim 1, wherein at least one nucleotide of the oligonucleotide comprises a 2′ O-methyl.
17. The method of claim 1, wherein the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide.
18. The method of claim 17, wherein the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide.
19. The method of claim 1, wherein the oligonucleotide further comprises phosphorothioate internucleotide linkages between at least two nucleotides.
20. The method of claim 1, wherein the oligonucleotide further comprises phosphorothioate internucleotide linkages between all nucleotides.
21. The method of claim 1, wherein the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group.
US16/876,271 2012-05-16 2020-05-18 Compositions and methods for modulating MECP2 expression Active 2034-09-14 US11788089B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/876,271 US11788089B2 (en) 2012-05-16 2020-05-18 Compositions and methods for modulating MECP2 expression

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648051P 2012-05-16 2012-05-16
PCT/US2013/041394 WO2013173608A1 (en) 2012-05-16 2013-05-16 Compositions and methods for modulating mecp2 expression
US201414401237A 2014-11-14 2014-11-14
US15/787,876 US10655128B2 (en) 2012-05-16 2017-10-19 Compositions and methods for modulating MECP2 expression
US16/876,271 US11788089B2 (en) 2012-05-16 2020-05-18 Compositions and methods for modulating MECP2 expression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/787,876 Continuation US10655128B2 (en) 2012-05-16 2017-10-19 Compositions and methods for modulating MECP2 expression

Publications (2)

Publication Number Publication Date
US20210102203A1 US20210102203A1 (en) 2021-04-08
US11788089B2 true US11788089B2 (en) 2023-10-17

Family

ID=49584296

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/401,237 Abandoned US20150152410A1 (en) 2012-05-16 2013-05-16 Compositions and methods for modulating mecp2 expression
US15/787,876 Active US10655128B2 (en) 2012-05-16 2017-10-19 Compositions and methods for modulating MECP2 expression
US16/876,271 Active 2034-09-14 US11788089B2 (en) 2012-05-16 2020-05-18 Compositions and methods for modulating MECP2 expression

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US14/401,237 Abandoned US20150152410A1 (en) 2012-05-16 2013-05-16 Compositions and methods for modulating mecp2 expression
US15/787,876 Active US10655128B2 (en) 2012-05-16 2017-10-19 Compositions and methods for modulating MECP2 expression

Country Status (8)

Country Link
US (3) US20150152410A1 (en)
EP (1) EP2850190B1 (en)
JP (1) JP2015518712A (en)
CN (1) CN104583402A (en)
AU (1) AU2013262709A1 (en)
CA (1) CA2873779A1 (en)
EA (1) EA201492116A1 (en)
WO (1) WO2013173608A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
DK2638163T3 (en) 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
DK2756080T3 (en) 2011-09-14 2019-05-20 Translate Bio Ma Inc MULTIMERIC OILONCLEOTID CONNECTIONS
JP2015523853A (en) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating ATP2A2 expression
BR112014028634A2 (en) 2012-05-16 2017-06-27 Rana Therapeutics Inc compositions and methods for modulating utrn expression
JP2015518710A (en) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Compositions and methods for regulating hemoglobin gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CA2873779A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
KR20150030205A (en) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Compositions and methods for modulating smn gene family expression
WO2014025887A1 (en) 2012-08-07 2014-02-13 The General Hospital Corporation Selective reactivation of genes on the inactive x chromosome
JP2015529469A (en) 2012-09-14 2015-10-08 ラナ セラピューティクス インコーポレイテッド Multimeric oligonucleotide compounds
EP2906258A4 (en) 2012-10-15 2016-08-10 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc Methods for monitoring c9orf72 expression
JP2016531570A (en) 2013-08-16 2016-10-13 ラナ セラピューティクス インコーポレイテッド Oligonucleotides targeting the euchromatin region
EP3055414A4 (en) 2013-10-11 2017-07-19 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US20150376612A1 (en) 2014-06-10 2015-12-31 The General Hospital Corporation CCCTC-Binding Factor (CTCF) RNA Interactome
CA2958524A1 (en) * 2014-08-20 2016-02-25 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
EP3265564B1 (en) * 2015-03-03 2022-01-26 Ionis Pharmaceuticals, Inc. Methods for modulating mecp2 expression
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
JP6866379B2 (en) 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション Neurodevelopmental disorder therapy
CN109563516B (en) * 2016-07-28 2023-10-27 雷杰纳荣制药公司 GPR156 variants and uses thereof
CA3042401A1 (en) 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
EP3604531A4 (en) * 2017-03-31 2020-12-23 Aichi Medical University Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate
EP3679139B1 (en) 2017-09-08 2022-11-02 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP3773618A1 (en) * 2018-04-06 2021-02-17 Camp4 Therapeutics Corporation Treating diseases via targeted modulation of gene signaling networks
MX2020013667A (en) 2018-06-14 2021-03-02 Ovid Therapeutics Inc Use of mir-92a or mir-145 in the treatment of angelman syndrome.
CA3110289A1 (en) * 2018-08-30 2020-03-05 The University Of North Carolina At Chapel Hill Feedback enabled synthetic genes, target seed match cassettes, and their uses
WO2020081764A1 (en) * 2018-10-18 2020-04-23 Synerk Inc. Compositions and methods for inhibiting tigit gene expression
WO2020097414A1 (en) 2018-11-08 2020-05-14 Greenlight Biosciences, Inc. Control of insect infestation
CN114585633A (en) 2019-08-19 2022-06-03 米纳治疗有限公司 Oligonucleotide conjugate compositions and methods of use
WO2021178557A1 (en) * 2020-03-03 2021-09-10 Arizona Board Of Regents On Behalf Of Arizona State University Rational design of upstream enhancement rna for circuit dynamics regulation and viral diagnostics optimization
EP4347837A2 (en) * 2021-06-04 2024-04-10 Takeda Pharmaceuticals U.S.A., Inc. Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity

Citations (305)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725677A (en) 1983-08-18 1988-02-16 Biosyntech Gmbh Process for the preparation of oligonucleotides
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
WO1992000386A1 (en) 1990-06-27 1992-01-09 The Trustees Of Columbia University In The City Of New York Methods for detecting spinal muscular atrophy type i and types ii/iii and marker therefor
JPH04320700A (en) 1991-04-17 1992-11-11 Nippon Shoji Kk Method for testing apolipoprotein e genotype and primer and probe suitable for its testing
WO1993013121A1 (en) 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
WO1994002499A1 (en) 1992-07-27 1994-02-03 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
WO1994017093A1 (en) 1993-01-25 1994-08-04 Hybridon, Inc. Oligonucleotide alkylphosphonates and alkylphosphonothioates
WO1995033852A1 (en) 1994-06-03 1995-12-14 Institut National De La Sante Et De La Recherche Medicale Method and probes for detecting markers bound to the locus of child spinal muscular atrophies
US5576208A (en) 1991-06-14 1996-11-19 Isis Pharmaceuticals Inc. Antisense oligonucleotide inhibition of the RAS gene
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
JPH1133863A (en) 1997-07-23 1999-02-09 Howa Mach Ltd Tool replacing device and extruding device for replacing tool
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US5914396A (en) 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5919619A (en) 1981-10-23 1999-07-06 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5965722A (en) 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5976879A (en) 1993-05-11 1999-11-02 The University Of North Carolina At Chapel Hill Antisense oligonucleotides which combat aberrant splicing and methods of using the same
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO2000020645A1 (en) 1998-10-05 2000-04-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION
EP0999270A1 (en) 1998-10-09 2000-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of regulating SMN gene expression
US6063400A (en) 1997-07-02 2000-05-16 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
US6080577A (en) 1994-10-19 2000-06-27 Institut National De La Sante Et De La Recherche Medicale Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
US6107094A (en) 1996-06-06 2000-08-22 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US6143881A (en) 1992-07-23 2000-11-07 University Of Massachusetts Worcester Hybrid oligonucleotide phosphorothioates
WO2001007662A1 (en) 1999-07-22 2001-02-01 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2 gene
US6187545B1 (en) 2000-01-19 2001-02-13 Isis Pharmaceuticals Inc. Antisense modulation of pepck-cytosolic expression
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
WO2001036627A2 (en) 1999-11-16 2001-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
US6284458B1 (en) 1992-09-10 2001-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
WO2001066129A1 (en) 2000-03-10 2001-09-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Substances for the treatment of spinal muscular atrophy
WO2001072765A1 (en) 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
WO2001090341A1 (en) 2000-05-24 2001-11-29 Isis Pharmaceuticals, Inc. Antisense modulation of pten expression
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
WO2002022635A1 (en) 2000-09-11 2002-03-21 Isis Pharmaceuticals, Inc. Antisense modulation of clusterin expression
WO2002038738A2 (en) 2000-11-09 2002-05-16 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6451991B1 (en) 1996-02-14 2002-09-17 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
WO2002103015A2 (en) 2001-06-14 2002-12-27 Active Pass Pharmaceuticals, Inc. Abca10 transporter
US6503754B1 (en) 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
US6531584B1 (en) 1990-01-11 2003-03-11 Isis Pharmaceuticals, Inc. 2'modified oligonucleotides
JP3420984B2 (en) 1999-02-12 2003-06-30 三共株式会社 New nucleoside and oligonucleotide analogs
US6602857B1 (en) 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US20030198983A1 (en) 2002-02-01 2003-10-23 Affymetrix, Inc. Methods of genetic analysis of human genes
US20030208061A1 (en) 2001-03-30 2003-11-06 Muthiah Manoharan Labeled oligonucleotides, methods for making same, and compounds useful therefor
US20030219770A1 (en) 2001-11-08 2003-11-27 Eshleman James R. Methods and systems of nucleic acid sequencing
US20030228690A1 (en) 2002-06-10 2003-12-11 Isis Pharmaceuticals Inc. Antisense modulation of IL-1 receptor-associated kinase-1 expression
US20030235822A1 (en) 1998-04-03 2003-12-25 Epoch Biosciences, Inc. Systems and methods for predicting oligonucleotide melting temperature (TmS)
US20040002153A1 (en) 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
WO2004011613A2 (en) 2002-07-29 2004-02-05 Epigenesis Pharmaceuticals, Inc. Composition & methods for treatment and screening
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
US20040096848A1 (en) 2002-04-05 2004-05-20 Thrue Charlotte Albaek Oligomeric compounds for the modulation HIF-1alpha expression
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
WO2004092356A2 (en) 2003-04-14 2004-10-28 Aventis Pharma S.A. Method for obtaining mastocyte lines from porcine tissue and method for production of heparin type molecules
WO2004099382A2 (en) 2003-04-30 2004-11-18 Genpathway, Inc. Methods for global profiling gene regulatory element activity
US20040241651A1 (en) 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US20040248840A1 (en) 2003-02-10 2004-12-09 Santaris Pharma A/S Oligomeric compounds for the modulation of ras expression
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO2004113867A2 (en) 2003-06-16 2004-12-29 University Of Massachusetts Exon analysis
US20050003369A1 (en) 2002-10-10 2005-01-06 Affymetrix, Inc. Method for depleting specific nucleic acids from a mixture
US20050026160A1 (en) 2002-11-05 2005-02-03 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005042018A2 (en) 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050100923A1 (en) 1998-09-17 2005-05-12 Trustees Of The University Of Pennsylvania Compositions, methods, and kits useful for the diagnosis and treatment of spinal muscular atrophy
US20050108783A1 (en) 2003-09-23 2005-05-19 Chihiro Koike Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region
WO2005044981A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US20050164209A1 (en) 2004-01-23 2005-07-28 Bennett C. F. Hepatocyte free uptake assays
US20050176025A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
WO2005089169A2 (en) 2004-03-12 2005-09-29 Exelixis, Inc. Mptens as modifiers of the pten pathway and methods of use
WO2005094370A2 (en) 2004-03-29 2005-10-13 The General Hospital Corporation Oligonucleotide complex compositions and methods of use as gene alteration tools
US20050226848A1 (en) 2003-05-29 2005-10-13 Tomoko Kuwabara Transcriptional regulation of gene expression by small double-stranded modulatory RNA
US20050233455A1 (en) 2001-10-29 2005-10-20 Damha Masad J Acyclic linker-containing oligonucleotides and uses thereof
US20050246794A1 (en) 2002-11-14 2005-11-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20050272080A1 (en) 2004-05-03 2005-12-08 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
US20060003322A1 (en) 2002-11-14 2006-01-05 Isaac Bentwich Bioinformatically detectable group of novel regulatory genes and uses thereof
US20060046260A1 (en) 2004-09-01 2006-03-02 Viral Therapeutics, Inc Amplified Bioassay
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US7041816B2 (en) 1999-02-04 2006-05-09 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060128646A1 (en) 2002-11-18 2006-06-15 Santaris Pharma A/S Antisense design
US20060135458A1 (en) 2002-09-13 2006-06-22 Andrew Vaillant Antiviral oligonucleotides
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US20060270624A1 (en) 1991-12-24 2006-11-30 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
WO2006130201A1 (en) 2005-03-14 2006-12-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
WO2007002390A2 (en) 2005-06-23 2007-01-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing
WO2007004977A1 (en) 2005-07-01 2007-01-11 Index Pharmaceuticals Ab Immunostimulatory method
EP1752536A1 (en) 2004-05-11 2007-02-14 RNAi Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US20070042380A1 (en) 2003-08-13 2007-02-22 Rosetta Genomics Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US20070111963A1 (en) 2005-11-17 2007-05-17 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal DNA
US20070123484A1 (en) 2004-06-03 2007-05-31 Balkrishen Bhat Double strand compositions comprising differentially modified strands for use in gene modulation
US7226785B2 (en) 2000-03-27 2007-06-05 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
WO2007076328A2 (en) 2005-12-19 2007-07-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis c virus
US20070191294A1 (en) 2003-03-21 2007-08-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
US20070219244A1 (en) 2005-11-11 2007-09-20 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
WO2007112753A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2007115578A1 (en) 2006-04-07 2007-10-18 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Synthetic mecp2 sequence for protein substitution therapy
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
US20070269815A1 (en) 2005-11-21 2007-11-22 Rivory Laurent P Multitargeting interfering RNAs having two active strands and methods for their design and use
US20070292408A1 (en) 2004-12-03 2007-12-20 University Of Massachusetts Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
WO2008024499A2 (en) 2006-08-25 2008-02-28 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
JP2008044958A (en) 2000-11-20 2008-02-28 Board Of Trustees Of The Univ Of Illinois Membrane scaffold protein
WO2008025069A1 (en) 2006-08-28 2008-03-06 The Walter And Eliza Hall Institute Of Medical Research Methods of modulating cellular activity and compositions therefor
WO2008029619A1 (en) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Ena antisense oligonucleotide having sequence-specific action
WO2008061537A2 (en) 2006-11-23 2008-05-29 Querdenker Aps Oligonucleotides for modulating target rna activity
US20080139472A1 (en) 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
US20080176793A1 (en) 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
US20080194463A1 (en) 2005-07-13 2008-08-14 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2008103763A2 (en) 2007-02-20 2008-08-28 Sequenom, Inc. Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
EP1967525A2 (en) 2001-05-08 2008-09-10 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
US20080242629A1 (en) 2001-08-01 2008-10-02 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
US20080249039A1 (en) 2004-01-30 2008-10-09 Santaris Pharma A/S Modified Short Interfering Rna (Modified Sirna)
WO2008132234A2 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
US7449297B2 (en) 2005-04-14 2008-11-11 Euclid Diagnostics Llc Methods of copying the methylation pattern of DNA during isothermal amplification and microarrays
WO2008141282A2 (en) 2007-05-11 2008-11-20 The Regents Of The University Of Michigan Materials and methods for foxp3 tumor suppression
WO2008138904A2 (en) 2007-05-11 2008-11-20 Santaris Pharma A/S Rna antagonist compounds for the modulation of her3
US20080293655A1 (en) 2006-02-08 2008-11-27 Huseyin Aygun Novel tandem siRNAS
US20080311039A1 (en) 2004-09-09 2008-12-18 The Regents Of The University Of California Therapeutic and Prognostic Factor Yy1 in Human Cancer
US20080318895A1 (en) 2004-05-17 2008-12-25 Yale University Intranasal delivery of nucleic acid molecules
US20090082297A1 (en) 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
WO2009046397A2 (en) 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agrna and gapmers targeting antisense transcripts
WO2009043353A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009044383A1 (en) 2007-10-05 2009-04-09 Consiglio Nazionale Delle Ricerche Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof
US20090099109A1 (en) 2007-02-26 2009-04-16 Shames David S Interfering rnas against the promoter region of p53
US20090099066A1 (en) 2007-06-29 2009-04-16 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
WO2009061851A2 (en) 2007-11-09 2009-05-14 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
US20090123467A1 (en) 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
WO2009064920A2 (en) 2007-11-13 2009-05-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
US20090156538A1 (en) 2002-12-12 2009-06-18 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
US20090155910A1 (en) 2007-12-18 2009-06-18 E.I.Du Pont De Nemours And Company Down-regulation of gene expression using artificial micrornas
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
US20090221685A1 (en) 2006-01-27 2009-09-03 Isis Pharmaceuticals, Inc Oligomeric compounds and compositions for the use in modulation of micrornas
US20090258925A1 (en) 2005-12-28 2009-10-15 Claes Wahlestedt Natural antisense and non-coding rna transcripts as drug targets
WO2009124341A1 (en) 2008-04-07 2009-10-15 The University Of Queensland Rna molecules and uses thereof
WO2009127680A1 (en) 2008-04-16 2009-10-22 Santaris Pharma A/S Pharmaceutical composition comprising anti pcsk9 oligomers
WO2009134710A2 (en) 2008-04-28 2009-11-05 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microrna
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US20090324549A1 (en) 2007-01-29 2009-12-31 Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta" Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases
WO2010000665A1 (en) 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
US20100004314A1 (en) 2008-03-07 2010-01-07 Senesco Technologies, Inc. Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide
WO2010007522A1 (en) 2008-07-15 2010-01-21 Santaris Pharma A/S Rna antagonists targeting gli2
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
JP2010507579A (en) 2006-10-18 2010-03-11 アイシス ファーマシューティカルズ, インコーポレーテッド Antisense compound
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
WO2010040112A2 (en) 2008-10-03 2010-04-08 Curna, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
US20100111982A1 (en) 2006-06-27 2010-05-06 Shanghai Institutes For Biological Sciences Rheumatoid arthritis t cell vaccine
US20100112042A1 (en) 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
JP2010516256A (en) 2007-01-19 2010-05-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ADRB2 cancer marker
US20100124547A1 (en) 2008-11-17 2010-05-20 Birgit Bramlage Compositions and methods for inhibiting expression of factor vii genes
WO2010065787A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US20100143359A1 (en) 2006-11-27 2010-06-10 Ludwig Institute For Cancer Research Ltd. Expression of foxp3 by cancer cells
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
US20100210707A1 (en) 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
WO2010093860A2 (en) 2009-02-13 2010-08-19 The General Hospital Corporation Isolation of factors that associate directly or indirectly with chromatin
WO2010093904A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010102058A2 (en) 2009-03-04 2010-09-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
US20100247543A1 (en) 2007-08-24 2010-09-30 Oryzon Genomics, S.A. Treatment and prevention of neurodegenerative diseases
US20100256223A1 (en) 2007-06-14 2010-10-07 Querdenker Aps Oligonucleotides for modulating target rna activity
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US20100280100A1 (en) 2009-05-01 2010-11-04 Curna, Inc. Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
US20100286234A1 (en) 2006-04-03 2010-11-11 Joacim Elmen Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
US20100286141A1 (en) 2000-05-30 2010-11-11 Durden Donald L Compositions and Methods for Identifying Agents Which Modulate PTEN Function and PI-3 Kinase Pathways
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US20100317606A1 (en) 2005-04-27 2010-12-16 Pacific Arrow Limited Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
WO2010148065A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
WO2010151674A2 (en) 2009-06-26 2010-12-29 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
WO2011005786A2 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011009624A1 (en) 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011010706A1 (en) 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21 cis-element binding substance
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
US7888012B2 (en) 2005-02-09 2011-02-15 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
US20110039910A1 (en) 2003-06-02 2011-02-17 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2011019815A2 (en) 2009-08-11 2011-02-17 Curna, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011025862A2 (en) 2009-08-28 2011-03-03 Curna, Inc. Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
WO2011032109A1 (en) 2009-09-11 2011-03-17 Sma Foundation Biomarkers for spinal muscular atrophy
WO2011038205A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
WO2011038210A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US20110077286A1 (en) 2008-06-05 2011-03-31 Damha Masad J Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
KR20110050134A (en) 2009-11-06 2011-05-13 성균관대학교산학협력단 Novel peptides upregulating bdnf expression and pharmaceutical composition for protection and therapy against alzheimer's disease and parkinson's disease comprising the same
US7960541B2 (en) 2004-06-28 2011-06-14 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US20110150868A1 (en) 2003-11-05 2011-06-23 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011079263A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011082409A2 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2011084455A2 (en) 2009-12-16 2011-07-14 Opko Curna, Llc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
US20110191912A1 (en) 2000-04-26 2011-08-04 Nickolai Alexandrov Promoter, promoter control elements, and combinations, and uses thereof
WO2011097641A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
WO2011097582A2 (en) 2010-02-08 2011-08-11 Opko Curna Llc Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
US20110237606A1 (en) 2008-09-26 2011-09-29 Agency Of Science, Technology And Research 3-Deazaneplanocin Derivatives
US20110237649A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
US20110237651A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2011123745A2 (en) 2010-04-02 2011-10-06 Opko Curna Llc Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
US20110251261A1 (en) 2010-04-13 2011-10-13 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
WO2011146675A2 (en) 2010-05-19 2011-11-24 Opko Curna Llc Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
WO2011146674A2 (en) 2010-05-19 2011-11-24 Opko Curna Llc Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
US8067569B2 (en) 2000-05-04 2011-11-29 Avi Biopharma, Inc. Splice-region antisense composition and method
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
WO2011159836A2 (en) 2010-06-15 2011-12-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
US20110319283A1 (en) 2008-11-24 2011-12-29 Trillion Genomics Limited Oligonucleotides capable of discriminating between nucleic acid sequences that comprise a conserved sequence
WO2011163499A2 (en) 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
US20110319476A1 (en) 2009-02-12 2011-12-29 Opko Curna, Llc Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2011161460A2 (en) 2010-06-23 2011-12-29 Mina Therapeutics Limited Rna molecules and uses thereof
US20120004278A1 (en) 2010-06-18 2012-01-05 The Board Of Trustees Of The Leland Stanford Junior University Linc rnas in cancer diagnosis and treatment
US20120010156A1 (en) 2009-03-17 2012-01-12 OPKP CuRNA, LLC Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2012009347A2 (en) 2010-07-12 2012-01-19 Opko Curna Llc Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
WO2012009402A2 (en) 2010-07-14 2012-01-19 Opko Curna Llc Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2012012467A2 (en) 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
WO2012024478A2 (en) 2010-08-19 2012-02-23 Opko Curna Llc Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
WO2012027033A1 (en) 2010-07-19 2012-03-01 Isis Pharmaceuticals, Inc. Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
WO2012036433A2 (en) 2010-09-13 2012-03-22 서울대학교 산학협력단 Treatment of neurodegenerative diseases by targeting mirna
US20120071418A1 (en) 2010-09-10 2012-03-22 Epizyme, Inc. Inhibitors of Human EZH2 and Methods of Use Thereof
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US8153365B2 (en) 1997-09-12 2012-04-10 Exiqon A/S Oligonucleotide analogues
WO2012047956A2 (en) 2010-10-06 2012-04-12 Opko Curna Llc Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012058268A2 (en) 2010-10-27 2012-05-03 Opko Curna Llc Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2012064806A2 (en) 2010-11-11 2012-05-18 The University Of North Carolina At Chapel Hill Methods and compositions for unsilencing imprinted genes
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
US20120157333A1 (en) 2002-10-21 2012-06-21 Exiqon A/S Oligonucleotides useful for detecting and analyzing nucleic acids of interest
WO2012087983A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012109476A2 (en) 2011-02-09 2012-08-16 The University Of Rochester Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US20120264812A1 (en) 2009-12-29 2012-10-18 Curna, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2012144220A1 (en) 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
US20120277290A1 (en) 2010-01-11 2012-11-01 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
US20120289581A1 (en) 2011-05-13 2012-11-15 Chang Howard Y Diagnostic, prognostic and therapeutic uses of long non-coding rnas for cancer and regenerative medicine
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
US20120295953A1 (en) 2009-12-29 2012-11-22 Joseph Colalrd Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
US20120295959A1 (en) 2010-01-25 2012-11-22 Curna, Inc. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
US20120309814A1 (en) 2010-02-22 2012-12-06 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2012170771A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2013006619A1 (en) 2011-07-05 2013-01-10 The General Hospital Corporation Rna-yy1 interactions
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
US20130035373A1 (en) 2010-04-09 2013-02-07 Curna, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2013036403A1 (en) 2011-09-06 2013-03-14 Curna, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
US20130065947A1 (en) 2010-05-14 2013-03-14 Cu RNA ,Inc. Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2013040429A1 (en) 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
US20130072546A1 (en) 2010-05-26 2013-03-21 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
US20130079505A1 (en) 2010-03-24 2013-03-28 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
US8415313B2 (en) 2004-01-23 2013-04-09 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
EP2591797A1 (en) 2010-07-09 2013-05-15 Institut Pasteur Of Shanghai, Cas Regulatory factor of foxp3 and regulatory t cells and use thereof
WO2013124807A2 (en) 2012-02-24 2013-08-29 Biogenera Societa' A Responsabilita' Limitata Oligonucleotides for modulating gene expression and uses thereof
WO2013138374A2 (en) 2012-03-15 2013-09-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013173652A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173638A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
WO2013173635A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173637A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173601A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating bdnf expression
WO2013173647A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating apoa1 and abca1 expression
WO2013173608A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
WO2013173599A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
WO2013173605A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating pten expression
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2014076195A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Oligonucleotide conjugates
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
WO2014172698A1 (en) 2013-04-19 2014-10-23 Isis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
US20140356459A1 (en) 2011-12-15 2014-12-04 Oncostamen S.R.L. Micrornas and uses thereof
WO2014197826A1 (en) 2013-06-07 2014-12-11 Rana Therapeutics, Inc. Compositions and methods for modulating foxp3 expression
WO2014203518A1 (en) 2013-06-16 2014-12-24 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
WO2014205551A1 (en) 2013-06-28 2014-12-31 London Health Sciences Centre Research Inc. Inhibition of microrna for treatment of sepsis
WO2015035476A1 (en) 2013-09-16 2015-03-19 University Of Western Sydney Modulation of gene expression
US20150225717A1 (en) 2012-08-07 2015-08-13 The General Hospital Corporation Selective Reactivation of Genes on the Inactive X Chromosome
WO2016077837A1 (en) 2014-11-14 2016-05-19 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
US20160201064A1 (en) 2013-08-16 2016-07-14 Rana Therapeutics, Inc. Compositions and methods for modulating expression of frataxin
US20160201063A1 (en) 2013-08-16 2016-07-14 Rana Therapeutics, Inc. Epigenetic regulators of frataxin
US20160222391A1 (en) 2013-10-04 2016-08-04 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US20170037396A1 (en) 2010-11-12 2017-02-09 The General Hospital Corporation Polycomb-Associated Non-Coding RNAs
US20180298384A1 (en) 2012-05-16 2018-10-18 Translate Bio Ma, Inc. Compositions and methods for modulating smn gene family expression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics

Patent Citations (432)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919619A (en) 1981-10-23 1999-07-06 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US4725677A (en) 1983-08-18 1988-02-16 Biosyntech Gmbh Process for the preparation of oligonucleotides
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US6197944B1 (en) 1987-11-30 2001-03-06 Integrated Dna Technologies, Inc. DNA molecules stabilized by modifications of the 3′-terminal phosphodiester linkage
US5491133A (en) 1987-11-30 1996-02-13 University Of Iowa Research Foundation Methods for blocking the expression of specifically targeted genes
US6919439B2 (en) 1990-01-11 2005-07-19 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5914396A (en) 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US6531584B1 (en) 1990-01-11 2003-03-11 Isis Pharmaceuticals, Inc. 2'modified oligonucleotides
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO1992000386A1 (en) 1990-06-27 1992-01-09 The Trustees Of Columbia University In The City Of New York Methods for detecting spinal muscular atrophy type i and types ii/iii and marker therefor
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
JPH04320700A (en) 1991-04-17 1992-11-11 Nippon Shoji Kk Method for testing apolipoprotein e genotype and primer and probe suitable for its testing
US5965722A (en) 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5576208A (en) 1991-06-14 1996-11-19 Isis Pharmaceuticals Inc. Antisense oligonucleotide inhibition of the RAS gene
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US20040038274A1 (en) 1991-12-24 2004-02-26 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
EP1044987A2 (en) 1991-12-24 2000-10-18 Isis Pharmaceuticals, Inc. Gapped 2'-modified oligonucleotides
US20020160379A1 (en) 1991-12-24 2002-10-31 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
WO1993013121A1 (en) 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
EP1695979A2 (en) 1991-12-24 2006-08-30 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US6326199B1 (en) 1991-12-24 2001-12-04 Isis Pharmaceuticals, Inc. Gapped 2′ modified oligonucleotides
US6146829A (en) 1991-12-24 2000-11-14 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US20070032446A1 (en) 1991-12-24 2007-02-08 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US20060270624A1 (en) 1991-12-24 2006-11-30 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US7045609B2 (en) 1992-07-23 2006-05-16 University Of Massachusetts Worcester Hybrid oligonucleotide phosphorothioates
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US6143881A (en) 1992-07-23 2000-11-07 University Of Massachusetts Worcester Hybrid oligonucleotide phosphorothioates
WO1994002499A1 (en) 1992-07-27 1994-02-03 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US6284458B1 (en) 1992-09-10 2001-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO1994017093A1 (en) 1993-01-25 1994-08-04 Hybridon, Inc. Oligonucleotide alkylphosphonates and alkylphosphonothioates
US5976879A (en) 1993-05-11 1999-11-02 The University Of North Carolina At Chapel Hill Antisense oligonucleotides which combat aberrant splicing and methods of using the same
WO1995033852A1 (en) 1994-06-03 1995-12-14 Institut National De La Sante Et De La Recherche Medicale Method and probes for detecting markers bound to the locus of child spinal muscular atrophies
US6040142A (en) 1994-06-03 2000-03-21 Institut National De La Santa Et De La Recherche Medicale Method and probes for detecting markers linked to the infantile spinal muscular atrophy locus
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US7033752B1 (en) 1994-10-19 2006-04-25 Institut National De La Sante Et De La Recherche Medicale Spinal muscular atrophy diagnostic methods
US20070166737A1 (en) 1994-10-19 2007-07-19 Judith Melki Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
US6080577A (en) 1994-10-19 2000-06-27 Institut National De La Sante Et De La Recherche Medicale Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
US20060089490A1 (en) 1994-10-19 2006-04-27 Judith Melki Survival motor neuron (SMN) gene: a Gene for spinal muscular atrophy
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US6359124B1 (en) 1995-04-03 2002-03-19 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6451991B1 (en) 1996-02-14 2002-09-17 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6046307A (en) 1996-04-09 2000-04-04 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6294650B1 (en) 1996-04-09 2001-09-25 The Board Of Regents, University Of Texas System Inhibition of mammalian telomerase by peptide nucleic acids
US6107094A (en) 1996-06-06 2000-08-22 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US6063400A (en) 1997-07-02 2000-05-16 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
JPH1133863A (en) 1997-07-23 1999-02-09 Howa Mach Ltd Tool replacing device and extruding device for replacing tool
US8153365B2 (en) 1997-09-12 2012-04-10 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030235822A1 (en) 1998-04-03 2003-12-25 Epoch Biosciences, Inc. Systems and methods for predicting oligonucleotide melting temperature (TmS)
US20050100923A1 (en) 1998-09-17 2005-05-12 Trustees Of The University Of Pennsylvania Compositions, methods, and kits useful for the diagnosis and treatment of spinal muscular atrophy
WO2000020645A1 (en) 1998-10-05 2000-04-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
EP0999270A1 (en) 1998-10-09 2000-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of regulating SMN gene expression
US7041816B2 (en) 1999-02-04 2006-05-09 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
JP3420984B2 (en) 1999-02-12 2003-06-30 三共株式会社 New nucleoside and oligonucleotide analogs
US20040002153A1 (en) 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
WO2001007662A1 (en) 1999-07-22 2001-02-01 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2 gene
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
WO2001036627A2 (en) 1999-11-16 2001-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
US6602857B1 (en) 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6187545B1 (en) 2000-01-19 2001-02-13 Isis Pharmaceuticals Inc. Antisense modulation of pepck-cytosolic expression
WO2001066129A1 (en) 2000-03-10 2001-09-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Substances for the treatment of spinal muscular atrophy
US7226785B2 (en) 2000-03-27 2007-06-05 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
WO2001072765A1 (en) 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
US20040241651A1 (en) 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US20110191912A1 (en) 2000-04-26 2011-08-04 Nickolai Alexandrov Promoter, promoter control elements, and combinations, and uses thereof
US8067569B2 (en) 2000-05-04 2011-11-29 Avi Biopharma, Inc. Splice-region antisense composition and method
WO2001090341A1 (en) 2000-05-24 2001-11-29 Isis Pharmaceuticals, Inc. Antisense modulation of pten expression
US20100286141A1 (en) 2000-05-30 2010-11-11 Durden Donald L Compositions and Methods for Identifying Agents Which Modulate PTEN Function and PI-3 Kinase Pathways
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
US6503754B1 (en) 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
WO2002022635A1 (en) 2000-09-11 2002-03-21 Isis Pharmaceuticals, Inc. Antisense modulation of clusterin expression
WO2002038738A2 (en) 2000-11-09 2002-05-16 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
US20050054836A1 (en) 2000-11-09 2005-03-10 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
US20110159587A1 (en) 2000-11-09 2011-06-30 Krainer Adrian R Chimeric Molecules to Modulate Gene Expression
JP2008044958A (en) 2000-11-20 2008-02-28 Board Of Trustees Of The Univ Of Illinois Membrane scaffold protein
US20030208061A1 (en) 2001-03-30 2003-11-06 Muthiah Manoharan Labeled oligonucleotides, methods for making same, and compounds useful therefor
EP1967525A2 (en) 2001-05-08 2008-09-10 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
US20050176025A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
WO2002103015A2 (en) 2001-06-14 2002-12-27 Active Pass Pharmaceuticals, Inc. Abca10 transporter
US20080242629A1 (en) 2001-08-01 2008-10-02 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
US20050233455A1 (en) 2001-10-29 2005-10-20 Damha Masad J Acyclic linker-containing oligonucleotides and uses thereof
US20030219770A1 (en) 2001-11-08 2003-11-27 Eshleman James R. Methods and systems of nucleic acid sequencing
US20030198983A1 (en) 2002-02-01 2003-10-23 Affymetrix, Inc. Methods of genetic analysis of human genes
US20040096848A1 (en) 2002-04-05 2004-05-20 Thrue Charlotte Albaek Oligomeric compounds for the modulation HIF-1alpha expression
US20030228690A1 (en) 2002-06-10 2003-12-11 Isis Pharmaceuticals Inc. Antisense modulation of IL-1 receptor-associated kinase-1 expression
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
WO2004011613A2 (en) 2002-07-29 2004-02-05 Epigenesis Pharmaceuticals, Inc. Composition & methods for treatment and screening
US20060135458A1 (en) 2002-09-13 2006-06-22 Andrew Vaillant Antiviral oligonucleotides
US20050003369A1 (en) 2002-10-10 2005-01-06 Affymetrix, Inc. Method for depleting specific nucleic acids from a mixture
US20120157333A1 (en) 2002-10-21 2012-06-21 Exiqon A/S Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US20050026160A1 (en) 2002-11-05 2005-02-03 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US20060003322A1 (en) 2002-11-14 2006-01-05 Isaac Bentwich Bioinformatically detectable group of novel regulatory genes and uses thereof
US20050246794A1 (en) 2002-11-14 2005-11-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US20060128646A1 (en) 2002-11-18 2006-06-15 Santaris Pharma A/S Antisense design
US7687617B2 (en) 2002-11-18 2010-03-30 Santaris Pharma A/S Oligonucleotides with alternating segments of locked and non-locked nucleotides
US20090156538A1 (en) 2002-12-12 2009-06-18 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
US20040248840A1 (en) 2003-02-10 2004-12-09 Santaris Pharma A/S Oligomeric compounds for the modulation of ras expression
US20070191294A1 (en) 2003-03-21 2007-08-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
WO2004092356A2 (en) 2003-04-14 2004-10-28 Aventis Pharma S.A. Method for obtaining mastocyte lines from porcine tissue and method for production of heparin type molecules
JP2006522597A (en) 2003-04-14 2006-10-05 アヴェンティス ファーマ エス.エー. Method for obtaining mast cell line from porcine tissue and method for producing heparin type molecules
WO2004099382A2 (en) 2003-04-30 2004-11-18 Genpathway, Inc. Methods for global profiling gene regulatory element activity
US20050226848A1 (en) 2003-05-29 2005-10-13 Tomoko Kuwabara Transcriptional regulation of gene expression by small double-stranded modulatory RNA
US8092992B2 (en) 2003-05-29 2012-01-10 Salk Institute For Biological Studies Transcriptional regulation of gene expression by small double-stranded modulatory RNA
US20110039910A1 (en) 2003-06-02 2011-02-17 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2004113867A2 (en) 2003-06-16 2004-12-29 University Of Massachusetts Exon analysis
US20110224277A1 (en) 2003-07-31 2011-09-15 Regulus Therapeutics, Llc. Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20050261218A1 (en) 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20070042380A1 (en) 2003-08-13 2007-02-22 Rosetta Genomics Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US20050108783A1 (en) 2003-09-23 2005-05-19 Chihiro Koike Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region
WO2005044981A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2005042018A2 (en) 2003-10-30 2005-05-12 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20110150868A1 (en) 2003-11-05 2011-06-23 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
US20050203042A1 (en) 2003-12-23 2005-09-15 Santaris Pharma A/S Oligomeric compounds for the modulation of Bcl-2
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US8415313B2 (en) 2004-01-23 2013-04-09 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US20050164209A1 (en) 2004-01-23 2005-07-28 Bennett C. F. Hepatocyte free uptake assays
US20080249039A1 (en) 2004-01-30 2008-10-09 Santaris Pharma A/S Modified Short Interfering Rna (Modified Sirna)
WO2005089169A2 (en) 2004-03-12 2005-09-29 Exelixis, Inc. Mptens as modifiers of the pten pathway and methods of use
WO2005094370A2 (en) 2004-03-29 2005-10-13 The General Hospital Corporation Oligonucleotide complex compositions and methods of use as gene alteration tools
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
US20050272080A1 (en) 2004-05-03 2005-12-08 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
EP1752536A1 (en) 2004-05-11 2007-02-14 RNAi Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
US20080318895A1 (en) 2004-05-17 2008-12-25 Yale University Intranasal delivery of nucleic acid molecules
US20070123484A1 (en) 2004-06-03 2007-05-31 Balkrishen Bhat Double strand compositions comprising differentially modified strands for use in gene modulation
US7960541B2 (en) 2004-06-28 2011-06-14 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8232384B2 (en) 2004-06-28 2012-07-31 University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US20060046260A1 (en) 2004-09-01 2006-03-02 Viral Therapeutics, Inc Amplified Bioassay
US20080311039A1 (en) 2004-09-09 2008-12-18 The Regents Of The University Of California Therapeutic and Prognostic Factor Yy1 in Human Cancer
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US8110560B2 (en) 2004-12-03 2012-02-07 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US20070292408A1 (en) 2004-12-03 2007-12-20 University Of Massachusetts Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
US20100087511A1 (en) 2004-12-03 2010-04-08 University Of Massachusetts Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
US7888012B2 (en) 2005-02-09 2011-02-15 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
WO2006130201A1 (en) 2005-03-14 2006-12-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
US7449297B2 (en) 2005-04-14 2008-11-11 Euclid Diagnostics Llc Methods of copying the methylation pattern of DNA during isothermal amplification and microarrays
US20100210707A1 (en) 2005-04-15 2010-08-19 Longcheng Li Small Activating RNA Molecules and Methods of Use
US20100317606A1 (en) 2005-04-27 2010-12-16 Pacific Arrow Limited Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
US20100216238A1 (en) 2005-06-23 2010-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing
US8361977B2 (en) 2005-06-23 2013-01-29 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of SMN2 splicing
WO2007002390A2 (en) 2005-06-23 2007-01-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing
WO2007004977A1 (en) 2005-07-01 2007-01-11 Index Pharmaceuticals Ab Immunostimulatory method
US20080194463A1 (en) 2005-07-13 2008-08-14 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US20070219244A1 (en) 2005-11-11 2007-09-20 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
US20070111963A1 (en) 2005-11-17 2007-05-17 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal DNA
EP2431467A2 (en) 2005-11-17 2012-03-21 Board Of Regents, The University Of Texas Modulation of gene expression by oligomers targeted to chromosomal DNA
EP1957648A2 (en) 2005-11-17 2008-08-20 Board of Regents, The University of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
US20110207217A1 (en) 2005-11-17 2011-08-25 Board Of Regents, The University Of Texas System Modulation of Gene Expression by Oligomers Targeted to Chromosomal DNA
WO2007086990A2 (en) 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
US7709456B2 (en) 2005-11-17 2010-05-04 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal DNA
US20070269815A1 (en) 2005-11-21 2007-11-22 Rivory Laurent P Multitargeting interfering RNAs having two active strands and methods for their design and use
WO2007076328A2 (en) 2005-12-19 2007-07-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis c virus
US20090258925A1 (en) 2005-12-28 2009-10-15 Claes Wahlestedt Natural antisense and non-coding rna transcripts as drug targets
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
US20130053428A1 (en) 2005-12-28 2013-02-28 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
US20090221685A1 (en) 2006-01-27 2009-09-03 Isis Pharmaceuticals, Inc Oligomeric compounds and compositions for the use in modulation of micrornas
US20080293655A1 (en) 2006-02-08 2008-11-27 Huseyin Aygun Novel tandem siRNAS
WO2007112753A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20120083596A1 (en) 2006-04-03 2012-04-05 Santaris Pharma A/S Pharmaceutical Composition
WO2007112754A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
US20100286234A1 (en) 2006-04-03 2010-11-11 Joacim Elmen Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides
WO2007115578A1 (en) 2006-04-07 2007-10-18 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Synthetic mecp2 sequence for protein substitution therapy
EP2023940A2 (en) 2006-05-05 2009-02-18 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
US20080015162A1 (en) 2006-05-05 2008-01-17 Sanjay Bhanot Compounds and methods for modulating gene expression
JP2009536037A (en) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for modulating gene expression
EP2021472A2 (en) 2006-05-05 2009-02-11 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
US20100111982A1 (en) 2006-06-27 2010-05-06 Shanghai Institutes For Biological Sciences Rheumatoid arthritis t cell vaccine
WO2008024499A2 (en) 2006-08-25 2008-02-28 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
WO2008025069A1 (en) 2006-08-28 2008-03-06 The Walter And Eliza Hall Institute Of Medical Research Methods of modulating cellular activity and compositions therefor
WO2008029619A1 (en) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Ena antisense oligonucleotide having sequence-specific action
US20080176793A1 (en) 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
US20080139472A1 (en) 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
US20100197762A1 (en) 2006-10-18 2010-08-05 Swayze Eric E Antisense compounds
JP2010507579A (en) 2006-10-18 2010-03-11 アイシス ファーマシューティカルズ, インコーポレーテッド Antisense compound
US20100021914A1 (en) 2006-11-23 2010-01-28 Querdenker Aps Oligonucleotides for modulating target rna activity
WO2008061537A2 (en) 2006-11-23 2008-05-29 Querdenker Aps Oligonucleotides for modulating target rna activity
US20100143359A1 (en) 2006-11-27 2010-06-10 Ludwig Institute For Cancer Research Ltd. Expression of foxp3 by cancer cells
JP2010516256A (en) 2007-01-19 2010-05-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ADRB2 cancer marker
US20090324549A1 (en) 2007-01-29 2009-12-31 Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta" Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases
WO2008103761A2 (en) 2007-02-20 2008-08-28 Sequenom, Inc. Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
WO2008103763A2 (en) 2007-02-20 2008-08-28 Sequenom, Inc. Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
US7858592B2 (en) 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
US20090099109A1 (en) 2007-02-26 2009-04-16 Shames David S Interfering rnas against the promoter region of p53
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
US20100210712A1 (en) 2007-03-22 2010-08-19 Santaris Pharma A/S Short RNA Antagonist Compounds for the Modulation of Target mRNA
WO2008132234A2 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
WO2008138904A2 (en) 2007-05-11 2008-11-20 Santaris Pharma A/S Rna antagonist compounds for the modulation of her3
WO2008141282A2 (en) 2007-05-11 2008-11-20 The Regents Of The University Of Michigan Materials and methods for foxp3 tumor suppression
US20090325868A1 (en) 2007-05-11 2009-12-31 The Regents Of The University Of Michigan Materials And Methods For FOXP3 Tumor Suppression
US20100256223A1 (en) 2007-06-14 2010-10-07 Querdenker Aps Oligonucleotides for modulating target rna activity
US20090082297A1 (en) 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
US20090099066A1 (en) 2007-06-29 2009-04-16 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20090123467A1 (en) 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
US20100247543A1 (en) 2007-08-24 2010-09-30 Oryzon Genomics, S.A. Treatment and prevention of neurodegenerative diseases
US20120288869A1 (en) 2007-10-04 2012-11-15 Schwartz Jacob C Modulating Gene Expression With agRNA and Gapmers Targeting Antisense Transcripts
WO2009046397A2 (en) 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agrna and gapmers targeting antisense transcripts
WO2009043353A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
US20090143326A1 (en) 2007-10-04 2009-06-04 Santaris Pharma A/S MICROMIRs
US20090092988A1 (en) 2007-10-04 2009-04-09 Schwartz Jacob C Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts
US8288356B2 (en) 2007-10-04 2012-10-16 Santaris Pharma A/S MicroRNAs
US20100298410A1 (en) 2007-10-04 2010-11-25 Santaris Pharma A/S MICROMIRs
WO2009044383A1 (en) 2007-10-05 2009-04-09 Consiglio Nazionale Delle Ricerche Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof
WO2009061851A2 (en) 2007-11-09 2009-05-14 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
WO2009064920A2 (en) 2007-11-13 2009-05-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
US20090155910A1 (en) 2007-12-18 2009-06-18 E.I.Du Pont De Nemours And Company Down-regulation of gene expression using artificial micrornas
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
US20100004314A1 (en) 2008-03-07 2010-01-07 Senesco Technologies, Inc. Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US20110263687A1 (en) 2008-04-07 2011-10-27 Riken Rna molecules and uses thereof
WO2009124341A1 (en) 2008-04-07 2009-10-15 The University Of Queensland Rna molecules and uses thereof
WO2009127680A1 (en) 2008-04-16 2009-10-22 Santaris Pharma A/S Pharmaceutical composition comprising anti pcsk9 oligomers
WO2009134710A2 (en) 2008-04-28 2009-11-05 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microrna
US20110086833A1 (en) 2008-05-27 2011-04-14 Paushkin Sergey V Methods for treating spinal muscular atrophy
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
US20090326051A1 (en) 2008-06-04 2009-12-31 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
US20110077286A1 (en) 2008-06-05 2011-03-31 Damha Masad J Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof
WO2010000665A1 (en) 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
US20110172292A1 (en) 2008-06-30 2011-07-14 Hansen Jens Bo Rode Antidote oligomers
WO2010007522A1 (en) 2008-07-15 2010-01-21 Santaris Pharma A/S Rna antagonists targeting gli2
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
US20110237606A1 (en) 2008-09-26 2011-09-29 Agency Of Science, Technology And Research 3-Deazaneplanocin Derivatives
WO2010040112A2 (en) 2008-10-03 2010-04-08 Curna, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
US20100105760A1 (en) 2008-10-03 2010-04-29 Curna, Inc. Treatment of Apolipoprotein-A1 Related Diseases by Inhibition of Natural Antisense Transcript to Apolipoprotein-A1
US8153606B2 (en) 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
US20100112042A1 (en) 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
US20100124547A1 (en) 2008-11-17 2010-05-20 Birgit Bramlage Compositions and methods for inhibiting expression of factor vii genes
US20110319283A1 (en) 2008-11-24 2011-12-29 Trillion Genomics Limited Oligonucleotides capable of discriminating between nucleic acid sequences that comprise a conserved sequence
WO2010065787A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US20110237649A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
US20110237651A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
US20110237650A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
US20110319476A1 (en) 2009-02-12 2011-12-29 Opko Curna, Llc Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
US20130137751A1 (en) 2009-02-12 2013-05-30 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
US20110319475A1 (en) 2009-02-12 2011-12-29 Opko Curna, Llc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010093904A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010093860A2 (en) 2009-02-13 2010-08-19 The General Hospital Corporation Isolation of factors that associate directly or indirectly with chromatin
US20110319317A1 (en) 2009-03-04 2011-12-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
WO2010102058A2 (en) 2009-03-04 2010-09-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
US20120004184A1 (en) 2009-03-16 2012-01-05 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
US20120010156A1 (en) 2009-03-17 2012-01-12 OPKP CuRNA, LLC Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8318690B2 (en) 2009-05-01 2012-11-27 Curna, Inc. Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
US20100280100A1 (en) 2009-05-01 2010-11-04 Curna, Inc. Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
US20120046344A1 (en) 2009-05-06 2012-02-23 Joseph Collard Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
US20120046236A1 (en) 2009-05-06 2012-02-23 Opko Curna Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
US20120046345A1 (en) 2009-05-08 2012-02-23 Opko Curna, Llc Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US20120064048A1 (en) 2009-05-18 2012-03-15 Opko Curna, Llc Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
US20120095079A1 (en) 2009-05-22 2012-04-19 Opko Curna, Llc Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US20120088817A1 (en) 2009-05-28 2012-04-12 Opko Curna, Llc Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2010148065A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US20120095081A1 (en) 2009-06-16 2012-04-19 Joseph Collard Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US20120094934A1 (en) 2009-06-24 2012-04-19 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
US20120142758A1 (en) 2009-06-26 2012-06-07 OPKO CuRNA,, LLC Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2010151674A2 (en) 2009-06-26 2010-12-29 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2011005786A2 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011009624A1 (en) 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011010706A1 (en) 2009-07-23 2011-01-27 武田薬品工業株式会社 Fgf21 cis-element binding substance
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US20120149759A1 (en) 2009-08-05 2012-06-14 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011019815A2 (en) 2009-08-11 2011-02-17 Curna, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US20120129917A1 (en) 2009-08-11 2012-05-24 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
US20120135941A1 (en) 2009-08-21 2012-05-31 Joseph Collard Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20120142610A1 (en) 2009-08-25 2012-06-07 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
WO2011025862A2 (en) 2009-08-28 2011-03-03 Curna, Inc. Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
WO2011032109A1 (en) 2009-09-11 2011-03-17 Sma Foundation Biomarkers for spinal muscular atrophy
WO2011038205A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2011038210A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
US20120322851A1 (en) 2009-10-20 2012-12-20 Gregroy Hardee Oral delivery of therapeutically effective lna oligonucleotides
KR20110050134A (en) 2009-11-06 2011-05-13 성균관대학교산학협력단 Novel peptides upregulating bdnf expression and pharmaceutical composition for protection and therapy against alzheimer's disease and parkinson's disease comprising the same
US20130116300A1 (en) 2009-12-16 2013-05-09 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2011084455A2 (en) 2009-12-16 2011-07-14 Opko Curna, Llc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
US20120329727A1 (en) 2009-12-23 2012-12-27 Curna, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
US20130184325A9 (en) 2009-12-23 2013-07-18 CuRNA ,Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011079263A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
US20120329855A1 (en) 2009-12-23 2012-12-27 CuRNA ,Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
US20120295953A1 (en) 2009-12-29 2012-11-22 Joseph Colalrd Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
US20120264812A1 (en) 2009-12-29 2012-10-18 Curna, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
US20120295954A1 (en) 2010-01-04 2012-11-22 Joseph Collard Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011082409A2 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
US20120322853A1 (en) 2010-01-06 2012-12-20 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US20120277290A1 (en) 2010-01-11 2012-11-01 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
US20120295959A1 (en) 2010-01-25 2012-11-22 Curna, Inc. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
WO2011097582A2 (en) 2010-02-08 2011-08-11 Opko Curna Llc Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
WO2011097641A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
US20120309814A1 (en) 2010-02-22 2012-12-06 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
US20130079505A1 (en) 2010-03-24 2013-03-28 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
WO2011123745A2 (en) 2010-04-02 2011-10-06 Opko Curna Llc Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
US20130035372A1 (en) 2010-04-02 2013-02-07 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
US20130035373A1 (en) 2010-04-09 2013-02-07 Curna, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US20110251261A1 (en) 2010-04-13 2011-10-13 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US20130072421A1 (en) 2010-05-03 2013-03-21 Curna, Inc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US20130065947A1 (en) 2010-05-14 2013-03-14 Cu RNA ,Inc. Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2011146674A2 (en) 2010-05-19 2011-11-24 Opko Curna Llc Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
WO2011146675A2 (en) 2010-05-19 2011-11-24 Opko Curna Llc Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
US20130085112A1 (en) 2010-05-26 2013-04-04 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
US20130072546A1 (en) 2010-05-26 2013-03-21 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
WO2011159836A2 (en) 2010-06-15 2011-12-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating interaction between proteins and target nucleic acids
US20130289092A1 (en) 2010-06-15 2013-10-31 Cold Spring Harbor Laboratory Compounds and methods for modulating interaction between proteins and target nucleic acids
US20120004278A1 (en) 2010-06-18 2012-01-05 The Board Of Trustees Of The Leland Stanford Junior University Linc rnas in cancer diagnosis and treatment
US20130164846A1 (en) 2010-06-23 2013-06-27 Mina Therapeutics Limited Rna molecules and uses thereof
WO2011163499A2 (en) 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2011161460A2 (en) 2010-06-23 2011-12-29 Mina Therapeutics Limited Rna molecules and uses thereof
US20130096183A1 (en) 2010-06-23 2013-04-18 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP2591797A1 (en) 2010-07-09 2013-05-15 Institut Pasteur Of Shanghai, Cas Regulatory factor of foxp3 and regulatory t cells and use thereof
WO2012009347A2 (en) 2010-07-12 2012-01-19 Opko Curna Llc Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
WO2012009402A2 (en) 2010-07-14 2012-01-19 Opko Curna Llc Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US20130143946A1 (en) 2010-07-14 2013-06-06 Curna Inc. Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2012012467A2 (en) 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
CA2805791A1 (en) 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
WO2012027033A1 (en) 2010-07-19 2012-03-01 Isis Pharmaceuticals, Inc. Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
WO2012024478A2 (en) 2010-08-19 2012-02-23 Opko Curna Llc Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
US20120071418A1 (en) 2010-09-10 2012-03-22 Epizyme, Inc. Inhibitors of Human EZH2 and Methods of Use Thereof
WO2012036433A2 (en) 2010-09-13 2012-03-22 서울대학교 산학협력단 Treatment of neurodegenerative diseases by targeting mirna
US20130245095A1 (en) 2010-10-06 2013-09-19 Joseph Collard Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012047956A2 (en) 2010-10-06 2012-04-12 Opko Curna Llc Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US20130253036A1 (en) 2010-10-22 2013-09-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012058268A2 (en) 2010-10-27 2012-05-03 Opko Curna Llc Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
US20130210893A1 (en) 2010-10-27 2013-08-15 Curna, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2012064806A2 (en) 2010-11-11 2012-05-18 The University Of North Carolina At Chapel Hill Methods and compositions for unsilencing imprinted genes
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs
US20140142160A1 (en) 2010-11-12 2014-05-22 The General Hospital Corporation Polycomb-associated Non-Coding RNAs
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US20170037396A1 (en) 2010-11-12 2017-02-09 The General Hospital Corporation Polycomb-Associated Non-Coding RNAs
US20130245099A1 (en) 2010-11-18 2013-09-19 Curna, Inc. Antagonat compositions and methods of use
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
US20130261065A1 (en) 2010-11-23 2013-10-03 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012087983A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012109476A2 (en) 2011-02-09 2012-08-16 The University Of Rochester Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
WO2012144220A1 (en) 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
US20120289581A1 (en) 2011-05-13 2012-11-15 Chang Howard Y Diagnostic, prognostic and therapeutic uses of long non-coding rnas for cancer and regenerative medicine
US20140187606A1 (en) 2011-06-09 2014-07-03 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2012170771A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
WO2013006619A1 (en) 2011-07-05 2013-01-10 The General Hospital Corporation Rna-yy1 interactions
WO2013036403A1 (en) 2011-09-06 2013-03-14 Curna, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
WO2013040429A1 (en) 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
US20140356459A1 (en) 2011-12-15 2014-12-04 Oncostamen S.R.L. Micrornas and uses thereof
WO2013124807A2 (en) 2012-02-24 2013-08-29 Biogenera Societa' A Responsabilita' Limitata Oligonucleotides for modulating gene expression and uses thereof
WO2013138374A2 (en) 2012-03-15 2013-09-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013173601A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating bdnf expression
WO2013173638A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
WO2013173605A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating pten expression
WO2013173635A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173599A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
US20150252364A1 (en) 2012-05-16 2015-09-10 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
WO2013173608A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
WO2013173647A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating apoa1 and abca1 expression
US20150218560A1 (en) 2012-05-16 2015-08-06 Rana Therapeutics, Inc. Compositions for modulating gene expression
WO2013173637A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
US20180298384A1 (en) 2012-05-16 2018-10-18 Translate Bio Ma, Inc. Compositions and methods for modulating smn gene family expression
WO2013173652A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
US20150099791A1 (en) 2012-05-16 2015-04-09 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
US20150133529A1 (en) 2012-05-16 2015-05-14 Rana Therapeutics, Inc. Compositions and methods for modulating bdnf expression
US20150133528A1 (en) 2012-05-16 2015-05-14 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
US20150133362A1 (en) 2012-05-16 2015-05-14 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
US20150141320A1 (en) 2012-05-16 2015-05-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
US20150159161A1 (en) 2012-05-16 2015-06-11 Rana Therapeutics, Inc. Compositions and methods for modulating pten expression
US20150159160A1 (en) 2012-05-16 2015-06-11 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
JP2015518714A (en) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Compositions and methods for regulating gene expression
US20150191722A1 (en) 2012-05-16 2015-07-09 Rana Therapeutics, Inc. Compositions and methods for modulating apoa1 and abca1 expression
US20150225717A1 (en) 2012-08-07 2015-08-13 The General Hospital Corporation Selective Reactivation of Genes on the Inactive X Chromosome
US9567581B2 (en) 2012-08-07 2017-02-14 The General Hospital Corporation Selective reactivation of genes on the inactive X chromosome
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2014076195A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Oligonucleotide conjugates
WO2014172698A1 (en) 2013-04-19 2014-10-23 Isis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
WO2014197826A1 (en) 2013-06-07 2014-12-11 Rana Therapeutics, Inc. Compositions and methods for modulating foxp3 expression
US20160122760A1 (en) 2013-06-07 2016-05-05 Rana Therapeutics, Inc. Compositions and methods for modulating foxp3 expression
WO2014203518A1 (en) 2013-06-16 2014-12-24 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
WO2014205551A1 (en) 2013-06-28 2014-12-31 London Health Sciences Centre Research Inc. Inhibition of microrna for treatment of sepsis
US20160201064A1 (en) 2013-08-16 2016-07-14 Rana Therapeutics, Inc. Compositions and methods for modulating expression of frataxin
US20160201063A1 (en) 2013-08-16 2016-07-14 Rana Therapeutics, Inc. Epigenetic regulators of frataxin
WO2015035476A1 (en) 2013-09-16 2015-03-19 University Of Western Sydney Modulation of gene expression
US20160222391A1 (en) 2013-10-04 2016-08-04 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2016077837A1 (en) 2014-11-14 2016-05-19 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins

Non-Patent Citations (314)

* Cited by examiner, † Cited by third party
Title
[No Author Listed] Catalogue of Parent of Origin Effects, Imprinted Genes and Related Effects, Parental Origins of de novo Mutations, downloaded at http://igc.otago.ac.nz/home.html on May 22, 2015, 2 pages.
[No Author Listed] Designing Antisense Oligonucleotides. Integrated DNA Technologies. 2011. 1-16.
[No Author Listed] Locked Nucleic Acid. Exiqon. 2009. Retrieved from http://www.exiqon.com/Is/documents/scientific/lna_folder.pdf on Jun. 6, 2016.
[No Author Listed] ncRNA. 2011;29(11):1716-1721.
[No Author Listed] UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly. Retrieved from http://genome.ucsc.edu/cgi-bin/hgTracks?db=hgl9&position=chr5%3A70211956-70271955&hgsid=452570083sxavccFldzrwhzM3tcNOyMcxbye7 on Nov. 9, 2015.
[No Author Listed], Geneimprint. 2012. http://www.geneimprint.com/site/about-this-site [last accessed May 22, 2015]. 1 page.
[No Author Listed], Imprinted gene. Mosby's Dictionary of Medicine, Nursing and Health Professions. 8th ed. 2009;949.
[No Author Listed], New England BioLabs 1998/99 Catalog. 121, 284.
Aartsma-Rus et al., Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet. Jan. 2004;74(1):83-92.
Ahn et al., Retinoic acid accelerates downregulation of the Xist repressor, Oct4, and increases the likelihood of Xist activation when Tsix is deficient. BMC Develop Biol. 201 O; 10:90. 14 pages.
Alvarez-Salas, Nucleic acids as therapeutic agents. Curr Top Med Chem. 2008;8(15): 1379-404.
Anderson et al., Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. Jan. 2010;10(1):24-35. doi: 10.1038/nri2685.
Arvey et al., Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 inregulatoiy T cells. Nat Immunol. Jun. 2014;15(6):580-587, doi: 10.1038/ni.2868. Epub Apr. 13, 2014.
Astuti et al., Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer. Apr. 25, 2005;92(8): 1574-80.
Axelson, The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett. Feb. 20, 2004;204(2): 171-8.
Bauer et al., The quest for mammalian Polycomb response elements: are we there yet? Chromosoma. Jun. 2016;125(3):471-96. doi:10.1007/s00412-015-0539-4.
Behlke et al., Designing antisense oligonucleotides. Integrated DNA Technologies. 2005. 1-17.
Beletskii et al., PNA interference mapping demonstrates functional domains in the noncoding RNA Xist. Proc Natl Acad Sci US A Jul. 31, 2001;98(16):9215-20.
Beltran et al., The interaction of PRC2 with RN A or chromatin is mutually antagonistic. Genome Res. Jul. 2016;26(7):896-907. doi: 10.1101/gr.197632.115. Epub May 9, 2016.
Bernardi et al., Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. Dec. 2007;8(12):1006-16. Review.
Bernstein et al., Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol. Apr. 2006;26(7):2560-9.
Bernstein et al., RNA meets chromatin. Genes Dev. Jul. 15, 2005;19(14):1635-55. Review.
Blauw et al., SMN1 gene duplications are associated with sporadic ALS. Neurology. Mar. 13, 2012;78(11):776-80. doi: 10.1212/WNL.0b013e318249f697. Epub Feb. 8, 2012.
Boyer et al., Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. May 18, 2006;441(7091):349-53. Epub Apr. 19, 2006.
Braasch et al., Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA Chem Biol. Jan. 2001;S(1):1-7.
Bracken et al., "Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions," Genes & Development, 2006, 20:1123-1136.
Brockdorff et al., The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell. Oct. 30, 1992;71(3):515-26.
Broderick et al., Micro RNA therapeutics. Gene Ther. Dec. 2011; 18(12): 1104-10. doi: 10.1038/gt.2011.50. Epub Apr. 28, 2011.
Brown et al., A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. Jan. 3, 1991;349:38-44.
Brown et al., The Human XIST Gene: Analysis of a 17 kb Inactive X-Specific RNA That Contains Conserved Repeats and Is Highly Localized within the Nucleus. Cell. Oct. 30, 1992;71:527-42.
Buck et al., Design strategies and performance of custom DNA sequencing primers. Biotechniques. Sep. 1999;27(3):528-36.
Burghes et al., Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev. Aug. 1, 2010;24(15):1574-9. doi:10.1101/gad.1961710.
Burglen et al., Structure and organization of the human survival motor neuron (SMN) gene. Genomics. Mar. 15, 1996;32(3):479-82.
Cantafora et al., Evaluation of RNA messengers involved in lipid trafficking of human intestinal cells by reverse-transcription polymerase chain reaction with competimer technology and microchip electrophoresis. Electrophoresis. Nov. 2003;24(21):3748-54.
Carninci et al., The transcriptional landscape of the mammalian genome. Science. Sep. 2, 2005;309(5740): 1559-63.
Chahrour et al., MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. May 30, 2008;320(5880):1224-9.
Chen et al., Decoding the function of nuclear long non-coding RN As. Curr Opin Cell Biol. Jun. 2010;22(3):357-64. doi: 10.1016/j.ceb.2010.03.003. Epub Mar. 29, 2010. Review.
Chow et al., Inducible XIST-dependent X-chromosome inactivation in human somatic cells is reversible. Proc Natl Acad Sci USA. Jun. 12, 2007;104(24):10104-9. Epub May 30, 2007.
Clark et al., The Reality of Pervasive Transcription. PLOS Bio. Jul. 2011;9(7):e1000625. 6 pages.
Clemson et al., XIST RNA paints the inactive X chromosome at interphase: evidence for a novel RNA involved in nuclear/chromosome structure. J Cell Biol. Feb. 1996;132(3):259-75.
Cloonan et al., Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods. Jul. 2008;5(7):613-9.
Cohen et al., X-chromosome inactivation and the search for chromosome-wide silencers. Curr Opin Genet Dev. 2002;12:219-24.
Coombes et al., Epigenetic properties and identification of an imprint mark in the Nesp-Gnasxl domain of the mouse Gnas imprinted locus. Mol Cell Biol. Aug. 2003;23(16):5475-88.
Corcia et al., Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. Eur J Hum Genet. May 2012;20(5):588-91. doi: 10.1038/ejhg.2011.255. Epub Jan. 25, 2012.
Corcia et al., The importance of the SMN genes in the genetics of sporadic ALS. Amyotroph Lateral Scler. Oct.-Dec. 2009;10(5-6):436-40. doi: 10.3109/17482960902759162.
Core et al., Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science. Dec. 19, 2008;322(5909): 1845-8. doi: 10.1126/science.1162228. Epub Dec. 4, 2008.
Costa, Non-coding RNAs: new players in eukaryotic biology. Gene. Sep. 12, 2005;357(2):83-94. Review.
Crea et al., Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. Apr. 18, 2011;10:40. doi: 10.1186/1476-4598-10-40.
Crooke et al., Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J. Dec. 1, 1995;312 ( Pt 2):599-608.
Cuddapa h et al., A novel human polycomb binding site acts as a functional polycomb response element in Drosophila. PLoS One. 2012;7(5):e36365. doi: 10.1371/journal.pone.0036365. Epub May 3, 2012.
Cushman et al., Synthesis of the covalent hydrate of the incorrectly assumed structure of aurintricarboxylic acid (ATA). Tetrahedron. 1990;46(5):1491-1498.
Daughters et al., RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet. Aug. 2009;5(8):e1000600. doi: 10.1371/journal.pgen.1000600. Epub Aug. 14, 2009.
Davidovich et al., The recruitment of chromatin modifiers by long noncoding RN As: lessons from PRC2. RNA Dec. 2015;21(12):2007-22. doi: 10.1261/rna.053918.115.
Davidovich et al., Toward a consensus on the binding specificity and promiscuity of PRC2 for RNA. Mol Cell. Feb. 5, 2015;57(3):552-8. doi: 10.1016/j.molcel.2014.12.017. Epub Jan. 15, 2015.
Davidson et al., Singles engage the RNA interference pathway. Cell. Aug. 31, 2012;150(5):873-5. doi: 10.1016/j.cell.2012.08.008.
Denisenko et al., Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol. Oct. 1998;18(10):5634-42.
Dheda et al., Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques. Jul. 2004;37(1):112-4, 116, 118-9.
Di Certo et al., The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. Hum Mol Genet. Mar. 1, 2010;19(5):752-60. doi: 10.1093/hmg/ddp539. Epub Dec. 4, 2009.
Dias et al., Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. Mar. 2002;1(5):347-55.
Dinger et al., NRED: a database of long noncoding RNA expression. Nucleic Acids Res. Jan. 2009;37(Database issue):D122-6. doi: 10.1093/nar/gkn617. Epub Oct. 1, 2008.
Dominski et al., Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing. Mol Cell Biol. Nov. 1994; 14(11): 7445-7454.
Dominski et al., Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA Sep. 15, 1993;90(18):8673-7.
Du et al., Progress toward therapy with antisense-mediated splicing modulation. Curr Opin Mol Ther. Apr. 2009;11(2):116-23.
Duthie et al., Xist RNA exhibits a banded localization on the inactive X chromosome and is excluded from autosomal material in cis. Hum Mol Genet. Feb. 1999;8(2):195-204.
Ebralidze et al., PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev. Aug. 1, 2008;22(15):2085-92. doi: 10.1101/ gad.1654808. Supplemental Data.
Eddy, Non-coding RNA genes and the modern RNA world. Nat Rev Genet. Dec. 2001;2(12):919-29.
Edwards et al., Mechanisms regulating imprinted genes in clusters. Curr Opin Cell Biol. Jun. 2007;19(3):281-9. Review.
Edwards et al., The evolution of the DLK1-DIO3 imprinted domain in mammals. PLoS Biol. Jun. 3, 2008;6(6):e135. doi: 10.1371/journal.pbio.0060135.
Efthymiou, T. et al., Chemical architecture and applications of nucleic acid derivatives containing 1, 2, 3-triazole functionalities synthesized via click chemistry, Molecules, 2012, vol. 17, No. 11, pp. 12665-12703.
ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. Apr. 2011;9(4):e1001046. doi: 10.1371/journal.pbio.1001046. Epub Apr. 19, 2011.
Engstrom et al., Complex Loci in human and mouse genomes. PLoS Genet. Apr. 2006;2(4):e47. Epub Apr. 28, 2006.
Extended European Search Report in European Appln. No. 13791546.8, dated Jan. 11, 2016, 10 pages.
Faghihi et al., Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of [beta]-secretase. Nat Med. Jul. 2008;14(7):723-30. doi:10.1038/nml 784. Epub Feb. 23, 2010, 19 pages.
Feldkotter et al., Quantitative analyses of SMN1 and SMN2 based on real-time light Cycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. Feb. 2002;70(2):358-68. Epub Dec. 21, 2001.
Fish et al., Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. J Biol Chem. May 25, 2007;282(21):15652-66. Epub Apr. 2, 2007.
Francis et al., Reconstitution of a functional core polycomb repressive complex. Mol Cell. Sep. 2001;8(3):545-56.
Frieden et al., Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. Nov. 1, 2003;31(21):6365-72.
Froberg et al., Guided by RN As: X-inactivation as a model for IncRNA function. J Mol Biol. Oct. 9, 2013;425(19):3698-706. doi: 10.1016/j.jmb.2013.06.031. Epub Jun. 28, 2013. Review. 15 pages.
Fu et al., Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood. Feb. 5, 2009;113(6):1340-9.
Gadalla et al., "MeCP2 and Rett syndrome: reversibility and potential avenues for therapy," Biochem. J., 2011, 439(1):1-14.
Gajera et al., Molecular and biochemical characterization of Trichoderma isolates inhibiting a phytopathogenic fungi Aspergillus niger Van Tieghem. Phys Mol Plant Path. 2010;74:274-282.
Ganguli et al., Antagomirbase—a putative antagomir database. Bioinformation. 2011;7(1):41-3.
Genbank Submission; Accession No. AM750048. Gupta et al. Jul. 12, 2007.
Genbank Submission; NCBI, Accession No. AM773775. Radha et al., Jul. 13, 2007.
Genbank Submission; NCBI, Accession No. AM911724.1; Talwar et al. Nov. 26, 2007.
Genbank Submission; NCBI, Accession No. NG 008691.1 Mar. 2011. 11 pages.
Genbank Submission; NCBI, Accession No. NG 009361.1; Salomons et al.; Jun. 27, 2016.
Genbank Submission; NCBI, Accession No. NM 007294.3; Orban et al.; May 25, 2016.
Genbank Submission; NCBI, Accession No. NM 022876.2. Apr. 2010. 5 pages.
Genbank Submission; NCBI, Accession No. NM 199461.3; Miles et al.; Jun. 4, 2016.
Genbank Submission; NIH/NCBI, Accession No. AA106140. Marra et al., Feb. 4, 1997. 1 page.
Genbank Submission; NIH/NCBI, Accession No. ABZ86223. Nyce et al. Oct. 17, 2003.
Genbank Submission; NIH/NCBI, Accession No. AL137002. Holt, Dec. 13, 2012. 29 pages.
Genbank Submission; NIH/NCBI, Accession No. BX383579. Li et al., Dec. 23, 2010. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NM_001079668. Young et al., Jan. 18, 2014. 4 pages.
Genbank Submission; NIH/NCBI, Accession No. NM_003317. Young et al., Jan. 18, 2014. 4 pages.
Genbank Submission; NIH/NCBI, Accession No. NM_022876.2. Singh et al. Mar. 13, 2011. 11 pages.
Genbank Submission; NIH/NCBI, Accession No. NM_028475. Diez-Roux et al., Feb. 3, 2014. 6 pages.
Gerbino et al., Mislocalised FUS mutants stall spliceosomal snRNPs in the cytoplasm. Neurobiol Dis. Jul. 2013;55:120-8. doi:10.1016/j.nbd.2013.03.003. Epub Mar. 21, 2013.
Golding et al., Depletion of Kcnq1ot1 non-coding RNA does not affect imprinting maintenance in stem cells. Development. 2011;138:3667-8. doi: 10.1242/dev.057778.
Gontan et al., Long Noncoding RNAs and X Chromosome Inactivation. Prog Mol Subcell Biol. 2011;51:43-64. doi: 10.1007/978-3-642-16502-3_3.
Gooding, M. et al., Oligonucleotide conjugates—Candidates for gene silencing therapeutics. European Journal of Pharmaceutics and Biopharmaceutics, 2016, vol. 107, pp. 321-340, [Epub.] Aug. 10, 2016.
Guo et al., High resolution genome wide binding event finding and motif discovery reveals transcription factor spatial binding constraints. PLoS Comput Biol. 2012;8(8):e1002638. doi: 10.1371/journal.pcbi.1002638. Epub Aug. 9, 2012.
Gupta et al., Long non-coding RNA Hot Air reprograms chromatin state to promote cancer metastasis. Nature. Apr. 15, 2010;464(7291):1071-6. doi: 10.1038/nature08975. E-pub version.
Guttman et al., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. Mar. 12, 2009;458(7235):223-7. doi: 10.1038/nature07672. Epub Sep. 30, 2009. 13 pages.
Guttman et al., Modular regulatory principles of large non-coding RN As. Nature. Feb. 15, 2012;482(7385):339-4. Review.
Halley et al., Natural antisense transcripts as therapeutic targets. Drug Discov Today Ther Strateg. 2013 Fall;10(3):e1 19-e125.
He et al., Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res. Feb. 3, 2012;110(3):406-15. doi: 10.1161/CIRCRESAHA.111.252205. Epub Dec. 8, 2011.
He, K. et al., Conjugation and Evaluation of Triazole-Linked Single Guide RNA for CRISPR-Cas9 Gene Editing, ChemBioChem, 2016, vol. 17, pp. 1809-1812.
Hendrich et al., Evolutionary conservation of possible functional domains of the human and murine XIST genes. Human Malec Gen. 1993;2(6):663-72.
Hernandez et al., Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma contaminated cell culture media. Nucleic Acid Ther. Feb. 2012;22(1):58-68. doi: 10.1089/nat.2011.0316. Epub Jan. 9, 2012.
Horike et al., Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome. Hum Mol Genet. Sep. 1, 2000;9(14):2075-83.
Huang et al., Non-encoding RNA and development of animals, Science China Life Science, Dec. 31, 2009; pp. 21-30 (with English abstract).
Inesi et al., Studies of Ca2+ ATPase (SERCA) inhibition. J Bioenerg Biomembr. Dec. 2005;37(6):365-8. Review.
Inoue et al., Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res. Aug. 11, 1987;15(15):6131-48.
Inouye, Antisense RNA: its functions and applications in gene regulation—a review. Gene. Dec. 10, 1988;72(1-2):25-34.
International Preliminary Report on Patentability for Application No. PCT/US2013/041461 dated Nov. 27, 2014.
International Search Report and Written Opinion for Application No. PCT/US2013/041461 dated Aug. 21, 2013, 13 pages.
Jackson et al., Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. Jun. 2003;21(6):635-7. Epub May 18, 2003.
Jayaprakash, K. N. et al., Non-nucleoside building blocks for copper-assisted and copper-free click chemistry for the efficient synthesis of RNA conjugates. Organic Letters, 2010, vol. 12, No. 23,pp. 5410-5413.
Jensen et al., Chapter 6: CLIP—Crosslinking and ImmunoPrecipitation of In Vivo RNA Targets of RNA-Binding Proteins. Methods in Molecular Biology. 2008;488:85-98.
Jeon et al., YY1 tethers Xist RNA to the inactive X nucleation center. Cell. Jul. 8, 2011;146(1):119-33. doi: 10.1016/j.cell.2011.06.026.
Jepsen et al., Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides. 2004; 14(2): 130-46. Review.
Jia et al., Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA Aug. 2010;16(8): 1478-87. doi: 10.1261/rna.1951310. Epub Jun. 29, 2010.
Johansson et al., Target-specific arrest of mRNAtranslation by antisense 2′-0-alkyloligoribonucleotides. Nucleic Acids Res. Nov. 11, 1994;22(22):4591-8.
Johnson, Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol Dis. 2012;46:245-54.
Kanduri et al., The length of the transcript encoded from the Kcnq1ot1 antisense promoter determines the degree of silencing. EMBO J. 2006;25:2096-106.
Kanhere et al., Short RN As are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. Mol Cell. Jun. 11, 2010;38(5):675-88. doi: 10.1016/j.molcel.2010.03.019.
Kao et al., Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med. Jan. 2010;38(1):217-22. doi: 10.1097/CCM.0b013e3181b4a854.
Kapranov et al., Genome-wide transcription and the implications for genomic organization. Nat Rev Genet. Jun. 2007;8(6):413-23.
Kapranov et al., RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. Jun. 8, 2007;316(5830):1484-8.
Kariya et al., Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. Hum Mol Genet. Aug. 1, 2012;21(15):3421-34. doi: 10.1093/hmg/ddsl 74. Epub May 11, 2012.
Keil et al., A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids. Jul. 8, 2014;3:el 74. doi: 10.1038/mtna.2014.23.
Khalil et al., Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA Jul. 14, 2009; 106(28): 11667-72.
Kierzek et al., The influence of locked nucleic acid residues on the thermodynamic properties of 2′-O-methyl RNA/RNA heteroduplexes. Nucleic Acids Res. Sep. 9, 2005;33(16):5082-93. Print 2005.
Kim et al., Identification of clustered YY1 binding sites in imprinting control regions. Genome Res. Jul. 2006; 16(7):901-11. Epub Jun. 7, 2006.
Kim et al., Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010; 465(7295):182-7. Epub Jan. 12, 2011. 15 pages.
Kiss, Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. Jul. 16, 2001;20(14):3617-22.
Klein et al., Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci. Dec. 2007;10(12):1513-4.
Krutzfeldt et al., Silencing of microRNAs in vivo with ‘antagomirs’. Nature. Dec. 1, 2005;438(7068):685-9. Epub Oct. 30, 2005.
Ku et al., Genomewide analysis of PR C1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. Oct. 2008;4(10):e1000242. doi: 10.1371/journal.pgen.1000242. Epub Oct. 31, 2008. 14 pages.
Kutyavin et al., Reduced aggregation and improved specificity of G-rich oligodeoxyribonucleotides containing pyrazolo[3,4-d]pyrimidine guanine bases. Nucleic Acids Res. Nov. 15, 2002;30(22):4952-9.
Lapointe et al., Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci US A Jan. 20, 2004;101(3):811-6. Epub Jan. 7, 2004.
Latorra et al., Design considerations and effects of LNA in PCR primers. Mol Cell Probes. Oct. 2003;1 7(5):253-9.
Lebedeva et al., Phosphorothioate Oligodeoxynucleotides as inhibitors of gene expression: antisense and non-antisense effects. 1991. 99-118.
Lee et al., A 450 kb Transgene Displays Properties of the Mammalian X-Inactivation Center. Cell. Jul. 12, 1996;86:83-94.
Lee et al., Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. Apr. 21, 2006;125(2):301-13.
Lee et al., Genetic analysis of the mouse X inactivation center defines an 80-kb multifunction domain. Proc Natl Acad Sci USA. Mar. 30, 1999;96(7):3836-41.
Lee et al., Homozygous SMN2 Deletion is a Major Risk Factor among Twenty-Five Korean Sporadic Amyotrophic Lateral Sclerosis Patients. Yonsei Med J. Jan. 2012;53(1):53-57.
Lee et al., Targeted Mutagenesis of Tsix Leads to Nomandom X Inactivation. Cell. Oct. 1, 1999;99:47-57.
Lee et al., Tsix, a gene antisense to Xist at the X-inactivation centre. Nat Genet. Apr. 1999;21:400-4.
Lee et al., Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene. 2012;31:116-27.
Lee, Disruption of Imprinted X Inactivation by Parent-of-Origin Effects at Tsix. Cell. Sep. 29, 2000; 103:17-27.
Lee, Epigenetic regulation by long noncoding RNAs. Science. Dec. 14, 2012;338(6113):1435-9. Review.
Lee, Homozygous Tsix mutant mice reveal a sex-ratio distortion and revert to random X inactivation. Nat Genet. Sep. 2002;32: 195-200.
Lee, Lessons from X-chromosome inactivation: long ncRNA as guides and tethers to the epigenome. Genes Dev. Aug. 15, 2009;23(16):1831-42. doi: 10.1101/gad.1811209.
Lee, The X as a Model for RN A's Niche in Epigenomic Regulation. Cold Spring Harb Perspect Biol. 2010;2:A003749. 12 pages.
Lennox et al., Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids. Aug. 27, 2013;2:e1 17. doi: 10.1038/mtna.2013.46.
Li et al., CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. Oct. 2008;28(20):6473-82. doi: 10.1128/MCB.00204-08. Epub Jul. 28, 2008.
Li et al., Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. Feb. 15, 2010;24(4):368-80. doi: 10.1101/gad.1886410. Epub Feb. 1, 2010.
Liang et al., B1-induced caspase-independent apoptosis in MCF-7 cells is mediated by downregulation of Bcl-2 via p53 binding to P2 promoter TATA box. Toxicol Appl Pharmacol. Oct. 1, 2011;256(1):52-61. doi: 10.1016/j.taap.2011.07.010. Epub Jul. 23, 2011.
Lim et al., Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem. Nov. 30, 2001;276(48):45476-83. Epub Oct. 2, 2001.
Lima et al., Single-stranded siRNAs activate RNAi in animals. Cell. Aug. 31, 2012;150(5):883-94. doi: 10.1016/j.cell.2012.08.014.
Lin et al., An in-depth map of polyadenylation sites in cancer. Nucleic Acids Res. Sep. 1, 2012;40(17):8460-71. Epub Jun. 29, 2012.
Lin et al., Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet. Sep. 2003;35(1):97-102. Epub Aug. 24, 2003.
Lipovich et al., MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim Biophys Acta. Sep. 2010;1 799(9):597-615. Review.
Margueron et al., The Polycomb complex PRC2 and its mark in life. Nature. Jan. 20, 2011;469(7330):343-9. Review.
Matsuda, S. et al., siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes., ACS Chemical Biology, 2015, vol. 10, pp. 1181-1187.
Mencia et al., Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat Genet. May 2009;41(5):609-13. doi: 10.1038/ng.355. Epub Apr. 12, 2009.
Mendenhall et al., GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet. Dec. 9, 2010;6(12):e1001244. doi: 10.1371/journal.ogen.1001244.
Mercer et al., Long non-coding RNAs: insights into functions. Nat Rev Genet. Mar. 2009;10(3):155-9. Review.
Mercer et al., Structure and function of long noncoding RNAs in epigenetic regulation. Mar. 5, 2013;20:300-7.
Merienne et al., SCA8 CAG/CTG expansions, a tale of two TOXICities: a unique or common case? PLoS Genet. Aug. 2009;5(8):e1000593. doi: 10.1371/journal.pgen.1000593. Epub Aug. 14, 2009.
Mikkelsen et al., Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. Aug. 2, 2007;448(7153):553-60. doi:10.1038/nature06008. Epub Aug. 13, 2010.
Miremadi et al., Cancer genetics of epigenetic genes. Hum Mol Genet. Apr. 15, 2007; 16 Spec No. 1:R28-49. Review.
Mirguet et al., From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg Med Chem Lett. Apr. 15, 2012;22(8):2963-7. doi:10.1016/j.bmcl.2012.01.125. Epub Feb. 8, 2012.
Miura et al., Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol Med. Mar. 2006;12(3):122-9. Epub Jan. 27, 2006.
Miyajima et al., Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem. Jun. 28, 2002;277(26):23271-7. Epub Apr. 15, 2002.
Modarresi et al., Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol. Mar. 25, 2012;30(5):453-9. doi: 10.1038/nbt.2158. 21 pages.
Modarresi et al., Natural Antisense Inhibition Results in Transcriptional De-Repression and Gene Upregulation. Nat Biotechnol. Mar. 25, 2012;30(5):453-9. doi: 10.1038/nbt.2158. 21 pages.
Montgomery et al., The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol. May 24, 2005;15(10):942-7.
Morris et al., Small interfering RNA-induced transcriptional gene silencing in human cells. Science. Aug. 27, 2004;305(5688):1289-92. Epub Aug. 5, 2004.
Morris, RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbial Immunol. 2008;320:211-24. Review.
Morse et al., Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Ther. Jan. 2012;19(1):30-7. doi: 10.1038/cgt.2011.63.
Mortazavi et al., Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. Jul. 2008;5(7):621-8.
Munroe, Antisense RNA inhibits splicing of pre-mRNA in vitro. EMBO J. Aug. 1988; 7(8):2523-32.
Nagano et al., The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science. Dec. 12, 2008;322(5908): 1717-20.
Nair, J. K. et al., Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing, Journal of the American Chemical Society, 2014, vol. 136, pp. 16958-16961.
Nakao, Gene Cluster control through epigenetic mechanisms and cytopathology. Uehara memorial life science foundation research report collection. 23;2009: 1-4.
Nie et al., Long non-coding RN As: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res. 2012;4(2):127-50. Epub Apr. 8, 2012.
Nishida et al., Synthesis, RNA selective hybridization and high nuclease resistance of an oligonucleotide containing novel bridged nucleic acid with cyclic urea structure. Chem Commun (Camb). Aug. 7, 2010;46(29):5283-5. doi: 10.1039/c0cc00154f. Epub Jun. 22, 2010.
Niwano et al., Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. Jun. 2008; 16(6): 1026-32. doi: 10.1038/rnt.2008.61. Epub Mar. 25, 2008.
Numata et al., Comparative analysis of cis-encoded antisense RNAs in eukaryotes. Gene. May 1, 2007;392(1-2):134-41.
Numata et al., Identification of novel endogenous antisense transcripts by DNA microarray analysis targeting complementary strand of annotated genes. BMC Genomics. Aug. 22, 2009;10:392. doi: 10.1186/1471-2164-10-392.
Office Action in Chinese Appln. No. 201380037614.0, dated Dec. 14, 2016, 14 pages.
Office Action in Chinese Appln. No. 201380037614.0, dated Jan. 26, 2016, 17 pages.
Office Action in European Appln. No. 13791546.8, dated Jun. 19, 2017, 11 pages.
Office Action in European Appln. No. 13791546.8, dated Nov. 9, 2018, 7 pages.
Office Action in Japanese Appln. No. 2015-512847, dated Jun. 1, 2017, 14 pages.
Okada et al., Comparative expression analysis uncovers novel features of endogenous antisense transcription. Hum Mol Genet. Jun. 1, 2008;17(11):1631-40. doi: 10.1093/hmg/ddn051. Epub Feb. 18, 2008.
Orom et al., LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. May 10, 2006;372:137-41. Epub Feb. 24, 2006.
Ozsolak et al., Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Cell. Dec. 10, 2010;143(6): 1018-29. doi: 10.1016/j.cell.2010.11.020.
Pandey et al., Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell. Oct. 24, 2008;32(2):232-46. doi: 10.1016/j.molcel.2008.08.022.
Paro et al., Extending the frontiers of epigenetic regulation. Curr Opin Genet Dev. Apr. 2010;20(2):107-9. doi: 10.1016/j.gde.2010.03.011.
Pasini et al., Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. Oct. 13, 2004;23(20):4061-71. Epub Sep. 23, 2004.
Pedersen et al., Identification and classification of conserved RNA secondary structures in the human genome. PLoS Comput Biol. Apr. 2006;2(4):e33. Epub Apr. 21, 2006.
Peng et al., Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell. Dec. 24, 2009;139(7):1290-302. doi: 10.1016/j.cell.2009.12.002. Epub Jul. 29, 2010. 24 pages.
Penny et al., Requirement for Xist in X chromosome inactivation. Nature. Jan. 11, 1996 ;379(6561): 131-7.
Pereira et al., Ezh2, the histone methyltransferase of PRC2, regulates the balance between self renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A Sep. 7, 2010;107(36):15957-62. doi: 10.1073/pnas.1002530107. Epub Aug. 23, 2010.
Petersen et al., LNA: a versatile tool for therapeutics and genomics. Trends Biotech. Feb. 2003;21(2):74-81. Review.
Pietersen et al., Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol. Apr. 2008;20(2):201-7. doi: 10.1016/j.ceb.2008.01.004. Epub Mar. 4, 2008. Review.
Plath et al., Role of Histone H3 Lysine 27 Methylation in X Inactivation. Science. Apr. 4, 2003;300:131-5. doi: 10.1126/science.1084274.
Ponting et al., Evolution and functions of long noncoding RNAs. Cell. Feb. 20, 2009;136(4):629-41. doi: 10.1016/j.cell.2009.02.006. Review.
Prensner et al., Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. Jul. 31, 2011 ;29(8):742-9. doi: 10.1038/nbt.1914.
Qi et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. Feb. 28, 2013;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022.
Rader, Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. Dec. 2006;1 16(12):3090-100.
Rajasekhar et al., Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells. Oct. 2007;25(10):2498-510. Epub Jun. 28, 2007. Review.
Redrup et al., The long noncoding RNA Kcnq1ot1 organises a lineage-specific nuclear domain for epigenetic gene silencing. Development. Feb. 2009; 136( 4 ):525-30. doi: 10.1242/dev.031328. Epub Jan. 14, 2009. 14 pages.
Reyon et al., FLASH assembly of TALEN s for high-throughput genome editing. Nat Biotechnol. May 2012;30(5):460-5. doi: 10.1038/nbt.2170.
Ringrose et al., Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet. 2004;38:413-43. Review.
Rinn et al., Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. Jun. 29, 2007;129(7):1311-23.
Rinn et al., Genome Regulation by Long Noncoding RN As. Annu Rev Biochem. 2012;81:145-66.
Rosok et al., Systematic identification of sense-antisense transcripts in mammalian cells. Nat Biotechnol. Jan. 2004;22(1):104-8. Epub Dec. 14, 2003.
Rozen et al., Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-86.
Sankaran et al., MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA Jan. 25, 2011;108(4):1519-24.
Sankaran, Targeted therapeutic strategies for fetal hemoglobin induction. Hematol Am Soc Hematol Educ Program. 2011;2011:459-65.
Sarma et al., Locked nucleic acids (LNAs) reveal sequence requirements and kinetics of Xist RNA localization to the X chromosome. Proc Natl Acad Sci USA. Dec. 21, 2010;107(51):22196-201. doi: 10.1073/pnas.1009785107. Epub Dec. 6, 2010.
Saxena et al., Long non-coding RNA modifies chromatin. Bioessays. 2011 ;33:830-9. Review.
Schadt et al., An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. Jul. 2005;37(7):710-7. Epub Jun. 19, 2005.
Schlesinger et al., Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. Feb. 2007;39(2):232-6. Epub Dec. 31, 2006.
Schoeftner et al., Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J. Jul. 12, 2006;25(13):3110-22, Epub Jun. 8, 2006.
Schuettengruber et al., Genome regulation by polycomb and trithorax proteins. Cell. Feb. 23, 2007;128(4):735-45.
Schultz et al., Enhancers compete with a long non-coding RNA for regulation of the Kcnq1 domain, Nucl Acids Res. 2015;43(2):745-59.
Schwartz et al., Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nat Genet. Jun. 2006;38(6):700-5.
Schwartz et al., Polycomb complexes and epigenetic states. Curr Opin Cell Biol. 2008;20:266-73. doi: 10.1016/j.ceb.2008.03.002.
Schwartz et al., Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet. Jan. 2007;8(1):9-22.
Sciabola et al., Improved nucleic acid descriptors for siRNA efficacy prediction. Nucleic Acids Res. Feb. 1, 2013;41(3):1383-94. doi: 10.1093/nar/gks1191. Epub Dec. 14, 2012.
Seila et al., Divergent transcription from active promoters. Science. Dec. 19, 2008;322(5909):1849-51. doi: 10.1126/science.1162253. Epub Dec. 4, 2008.
Seong et al., Huntingtin facilitates polycomb repressive complex 2. Hum Mol Genet. Feb. 15, 2010;19(4):573-83. doi: 10.1093/hmg/ddp524. Epub Nov. 23, 2009.
Shaver et al., Origin of the polycomb repressive complex 2 and gene silencing by an E(z) homolog in the unicellular alga Chlamydomonas. Epigenetics. May 16, 2010;5(4):301-12. Epub May 24, 2010.
Shen et al,. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. Nov. 21, 2008;32(4):491-502. doi: 10.1016/j.molcel.2008.10.016.
Shen et al., Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell. Dec. 24, 2009;139(7):1303-14. doi: 10.1016/j.cell.2009.12.003. Epub Jun. 24, 2010. 26 pages.
Shiraki et al., Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc Natl Acad Sci U S A Dec. 23, 2003; 100(26):15776-81. Epub Dec. 8, 2003.
Shore et al., Pregnancy-induced noncoding RNA (PINC) associates with polycomb repressive complex 2 and regulates mammary epithelial differentiation. PLoS Genet. 2012;8(7):e1002840. doi: 10.1371/journal.ogen.1002840. Epub Jul. 26, 2012.
Simon et al., High-resolution Xist binding maps reveal two-step spreading during X-chromosome inactivation. Nature. Dec. 19, 2013;504(7480):465-9. doi: 10.1038/nature12719. Epub Oct. 27, 2013.
Simon et al., Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. Dec. 1, 2008;647(1-2):21-9. Review.
Sing et al., A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell. Sep. 4, 2009;138(5):885-97. doi: 10.1016/j.cell.2009.08.020.
Singh et al., A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol. Jul.-Aug. 2009;6(3):341-50. Epub Jul. 14, 2009.
Singh et al., Splicing of a Critical Exon of Human Survival Motor Neuron is Regulated by a Unique Silencer Element Located in the Last Intron. Mol Cell Biol. Feb. 2006;26(4):1333-46. doi: 10.1128/MCB.26.4.1333-1346.2006.
Sirchia et al., Misbehaviour of XIST RNA in breast cancer cells. PLoS One. 2009;4(5):e5559. doi: 10,1371/journal.pone.0005559. Epub May 15, 2009.
Skordis et al., antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A Apr. 1, 2003; 100(7):4114-9. Epub Mar. 17, 2003.
Sparmann et al., Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. Nov. 2006;6(11):846-56. Review.
Submission. EBI Accession No. ADH50651. Baker et al. Mar. 25, 2004.
Submission. EBI Accession No. EMBL:GC092872. Palma et al. Aug. 31, 2008.
Summerton, Morpholino antisense oligomers: the case for an Rnase H-independent structural type. Biochim Biophys Acta. Dec. 10, 1999;1489(1):141-58.
Summons to Attend Oral Proceedings in European Appln. No. 13791546.8, dated Apr. 18, 2018, 9 pages.
Sun et al., Evidence for a preferential targeting of 3′-UTRs by cis-encoded natural antisense transcripts. Nucleic Acids Res. Oct. 4, 2005;33(17):5533-43. Print 2005.
Sun et al., SNPs in human miRNA genes affect biogenesis and function. RNA. Sep. 2009;15(9): 1640-51. doi: 10.1261/rna.1560209. Epub Jul. 17, 2009.
Tae et al., Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional repression of their target genes. Nucleic Acids Res. Jul. 2011;39(13):5424-38. doi: 10.1093/nar/gkr170.
Taft et al., Non-coding RN As: regulators of disease. J Pathol. Jan. 2010;220(2): 126-39. doi: 10.1002/path.2638. Review.
Taft et al., Tiny RN As associated with transcription start sites in animals. Nat Genet. May 2009;41(5):572-8. doi: 10.1038/ng.312. Epub Apr. 19, 2009. Erratum in: Nat Genet. Jul. 2009;41(7):859.
Takagi et al., Role of Sp 1 in transcription of human ATP2A2 gene in keratinocytes. J Invest Dermatol. Jan. 2008;128(1):96-103. Epub Jun. 28, 2007.
Takahashi et al., Deletion of Gtl2, imprinted non-coding RNA, with its differentially methylated region induces lethal parent-origin-dependent defects in mice. Hum Mol Genet. May 15, 2009;18(10):1879-88. doi: 10.1093/hmg/ddp108. Epub Mar. 4, 2009.
Tano et al., MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEES Lett. Nov. 19, 2010;584(22):4575-80. doi: 10.1016/j.febslet.2010.10.008. Epub Oct. 13, 2010.
Taylor et al. Drug Discovery Today 1999, vol. 4, pp. 562-567.
Thomas et al., Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep. Jan. 2010;12(1):58-65. doi: 10.1007 /s1 1883-009-0078-7.
Thorvaldsen et al., A YY1 bridge for X inactivation. Cell. Jul. 8, 2011;146(1): 11-3. doi: 10.1016/j.cell.2011.06.029.
Thorvaldsen et al., SnapShot: imprinted gene clusters. Cell. Sep. 7, 2007;130(5):958.
Tian et al., The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. Cell. Oct. 29, 2010;143(3):390-403. doi: 10.1016/j.cell.2010.09.049. 21 pages.
Torarinsson et al., Thousands of corresponding human and mouse genomic regions unalignable in primary sequence contain common RNA structure. Genome Res. Jul. 2006;16(7):885-9. Epub Jun. 2, 2006. Erratum in: Genome Res. Nov. 2006;16(11): 1439.
Tsai et al., Higher order chromatin structure at the X-inactivation center via looping DNA Dev Biol. Jul. 15, 2008;319(2):416-25. doi: 10.1016/j.ydbio.2008.04.010. Epub Apr. 18, 2008. 22 pages.
Tsai et al., Long noncoding RNA as modular scaffold of histone modification complexes. Science. Aug. 6, 2010;329(5992):689-93. doi: 10.1126/science.1192002. Epub Nov. 2, 2010. 9 pages.
Tsuiji et al., Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med. Feb. 2013;5(2):221-34. doi: 10.1002/emmm.201202303. Epub Jan. 25, 2013.
Turner et al., Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis. Jun. 2009;34(3):511-7. doi: 10.1016/j.nbd.2009.03.005. Epub Mar. 28, 2009.
Ule et al., CLIP Identifies Nova-Regulated RNA Networks in the Brain. Science. 2003;302: 1212-5. doi: 10.1126/science.1090095.
Ule et al., CLIP: A method for identifying protein-RNA interaction sites in living cells. Methods. 2005;37:376-86.
Valen et al., Genome-wide detection and analysis of hippocampus core promoters using DeepCAGE. Genome Res. Feb. 2009;19(2):255-65. doi: 10.1101/gr.084541.108. Epub Dec. 11, 2008.
Van Peer et al., miRBase Tracker: keeping track of microRNA annotation changes. Database (Oxford). Aug. 25, 2014;2014. pii:bau080. doi: 10.1093/database/bau080. Print 2014.
Varela et al., Natural Antisense Makes Sense for Gene-specific Activation in Brain. Mol Ther Nucleic Acids. May 15, 2012;1:e24. doi: 10.1038/mtna.2012.17.
Veldink et al., SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology. Sep. 27, 2005;65(6):820-5. Epub Aug. 10, 2005.
Venter et al., The sequence of the human genome. Science. Feb. 16, 2001;291(5507): 1304-51. Erratum in: Science Jun. 5, 2001;292(5523): 1838.
Vickers et al., Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. Mar. 15, 2001;29(6):1293-9.
Wahlestedt, Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today. Jun. 2006;1 1(11-12):503-8.
Wahlestedt, Targeting long non-coding RNA to therapeutically upregulate gene expression. Nature Rev Drug Disc. Jun. 2013;12:433-46. Review.
Wan et al., Regulation of imprinting in clusters: noncoding RNAs versus insulators. Adv Genet. 2008;61:207-23. Review.
Wang et al., Correlation between Dnase I hypersensitive site distribution and gene expression in HeLa S3 cells. PLoS One. 2 012;7(8):e42414. doi: 10.1371/journal.pone.0042414. Epub Aug. 10, 2012.
Wang et al., Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. Jul. 2012;41(1):276-84.
Wang et al., Molecular mechanisms of long noncoding RNAs. Cell Press. Sep. 16, 2011; 43(6):904-14.
Wang et al., Multifunctional transcription factor YY1: a therapeutic target in human cancer? Expert Opin Ther Targets. 2006;10(2):253-66.
Whitehead et al., Variation in tissue-specific gene expression among natural populations. Genome Biol. 2005;6(2):R13. Epub Jan. 26, 2005.
Williams et al., Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci. Jun. 17, 2009;29(24):7633-8. doi: 10.1523/JNEUROSCI.0950-09.2009.
Williamson et al., Identification of an imprinting control region affecting the expression of all transcripts in the Gnas cluster. Nat Genet. Mar. 2006;38(3):350-5.
Wilusz et al., A triple helix stabilizes the 3′ ends of long noncoding RNAs that lack poly(A) tails. Genes Dev. Nov. 1, 2012;26(21):2392-407. doi: 10.1101/gad.204438.112. Epub Oct. 16, 2012.
Wilusz et al., Long noncoding RN As: functional surprises from the RNA world. Genes Dev. Jul. 1, 2009;23(13):1494-504. doi: 10.1101/gad.1800909.
Woo et al., A Region of the Human HOXD Cluster that Confers Polycomb-Group Responsiveness. Cell. Jan. 8, 2010;140:99-110.
Woo et al., Gene activation of SMN by selective disruption of IncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy. Proc Natl Acad Sci US A. Feb. 21, 2017;114(8):E1509-E1518. doi:10.1073/pnas.1616521114. Epub Feb. 13, 2017.
Wu et al., Binding interactions between long noncoding RNA Hot Air and PRC2 proteins. Biochemistry, Dec. 31, 2013;52(52):9519-27. doi: 10.1021/bi401085h.
Wutz et al., A Shift from Reversible to Irreversible X Inactivation Is Triggered during ES Cell Differentiation. Malec Cell. Apr. 2000;5:695-705.
Xiong et al., Polycomb antagonizes p300/CREB-binding protein associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner. J Biol Chem. Oct. 5, 2012;287(41):34372-85. doi: 10.1074/jbc.M1 11.325332. Epub Aug. 15, 2012.
Yakali et al., Supramolecular chirality-sensing DNA-mimicry of a norbornane derivative decorated with isoxazoline and methylpyrolidine-2,5-dione ring. J Mol Structure. Jun. 10, 2013;1041: 164-174.
Yamazaki et al., FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep. Oct. 25, 2012;2(4):799-806. doi:10.1016/j.celrep.2012.08.025. Epub Sep. 27, 2012.
Yang et al., High fidelity PCR with an off/on switch mediated by proofreading polymerases combining with phosphorothioate-modified primer. Biochem Biophys Res Commun. Mar. 4, 2005;328(1):265-72. Erratum in: Biochem Biophys Res Commun. Jun. 3, 2005;331(2):682. Zhang, Jia [removed]; Li, Kai [removed].
Yang et al., Long noncoding RN As: fresh perspectives into the RNA world. Trends Biochem Sci. Jan. 2014;39(1):35-43. doi: 10.1016/j.tibs.2013.10.002. Epub Nov. 27, 2013. Review.
Yang et al., The histone code regulating expression of the imprinted mouse Igf2r gene. Endocrinology. Dec. 2003;144(12):5658-70.
Yap et al., Molecular interplay of the noncoding RNA ANRIL and methylated his tone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. Jun. 11, 2010 ;38(5):662-74. doi: 10.1016/j.molcel.2010.03.021. Epub Jun. 11, 2011. 23 pages.
Yatsuki et al., Sequence-based structural features between Kvlqt1 and Tapa1 on mouse chromosome 7F4/F5 corresponding to the Beckwith-Wiedemann syndrome region on human 11p15.5: long-stretches of unusually well conserved intronic sequences of kvlqt1 between mouse and human. DNA Res. Jun. 30, 2000;7(3): 195-206.
Yu et al., Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. Aug. 31, 2012;150(5):895-908. doi: 10.1016/j.cell.2012.08.002.
Zara Vinos et al., Yin yang 1 expression in human tumors. Cell Cycle. Feb. 1, 2010;9(3):512-22.
Zhang et al., Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. J Cell Biol. 2014;204(1):61-75.
Zhang et al., NATsDB: Natural Antisense Transcripts DataBase. Nucleic Acids Res. Jan. 2007;35(Database issue):D156-61. Epub Nov. 1, 2006.
Zhang et al., Perinucleolar Targeting of the Inactive X during S Phase: Evidence for a Role in the Maintenance of Silencing. Cell. May 18, 2007; 129:693-706.
Zhao et al., Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell. Dec. 22, 2010;40(6):939-53.
Zhao et al., Polycomb proteins targeted by a short repeat RNA to the mouse X-chromosome. Science. 2008; 322(5902):750-756. doi:10.1126/science.1163045. E-pub version.
Zhou et al., Targeting RNA-splicing for SMA treatment. Mol Cells. Mar. 2012;33(3):223-8. doi: 10.1007 /s10059-012-0005-6.

Also Published As

Publication number Publication date
CA2873779A1 (en) 2013-11-21
EP2850190A4 (en) 2016-02-10
AU2013262709A1 (en) 2015-01-22
US10655128B2 (en) 2020-05-19
EP2850190A1 (en) 2015-03-25
WO2013173608A1 (en) 2013-11-21
EA201492116A1 (en) 2015-05-29
US20210102203A1 (en) 2021-04-08
EP2850190B1 (en) 2020-07-08
US20150152410A1 (en) 2015-06-04
US20180223282A1 (en) 2018-08-09
JP2015518712A (en) 2015-07-06
CN104583402A (en) 2015-04-29

Similar Documents

Publication Publication Date Title
US11788089B2 (en) Compositions and methods for modulating MECP2 expression
US10058623B2 (en) Compositions and methods for modulating UTRN expression
US10174323B2 (en) Compositions and methods for modulating ATP2A2 expression
US10174315B2 (en) Compositions and methods for modulating hemoglobin gene family expression
US10059941B2 (en) Compositions and methods for modulating SMN gene family expression
US20150159161A1 (en) Compositions and methods for modulating pten expression
US20150191722A1 (en) Compositions and methods for modulating apoa1 and abca1 expression
US20160122760A1 (en) Compositions and methods for modulating foxp3 expression
EP2849800A1 (en) Compositions and methods for modulating bdnf expression
US10837014B2 (en) Compositions and methods for modulating SMN gene family expression

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: HOWARD HUGHES MEDICAL INSTITUTE, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEE, JEANNIE T.;REEL/FRAME:053511/0465

Effective date: 20130514

Owner name: THE GENERAL HOSPITAL CORPORATION D/B/A/ MASSACHUSETTS GENERAL HOSPITAL, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOWARD HUGHES MEDICAL INSTITUTE;REEL/FRAME:053511/0469

Effective date: 20130514

Owner name: RANA THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRIEG, ARTHUR M.;SUBRAMANIAN, ROMESH;MCSWIGGEN, JAMES;REEL/FRAME:053511/0442

Effective date: 20130423

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSLATE BIO MA, INC;REEL/FRAME:055419/0935

Effective date: 20210206

AS Assignment

Owner name: RANA DEVELOPMENT, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:RANA THERAPEUTICS, INC.;REEL/FRAME:056062/0179

Effective date: 20161110

Owner name: TRANSLATE BIO MA, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RANA DEVELOPMENT, INC.;REEL/FRAME:056062/0195

Effective date: 20170626

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction